OA18664A - Methods for treating conditions associated with masp-2 dependent complement activation - Google Patents
Methods for treating conditions associated with masp-2 dependent complement activation Download PDFInfo
- Publication number
- OA18664A OA18664A OA1201800171 OA18664A OA 18664 A OA18664 A OA 18664A OA 1201800171 OA1201800171 OA 1201800171 OA 18664 A OA18664 A OA 18664A
- Authority
- OA
- OAPI
- Prior art keywords
- masp
- antibody
- complément
- seq
- inhibitory
- Prior art date
Links
- 230000001419 dependent Effects 0.000 title claims abstract description 52
- 108009000280 Complement Activation Proteins 0.000 title abstract description 4
- 230000024203 complement activation Effects 0.000 title abstract description 4
- 101700062311 MASP2 Proteins 0.000 claims abstract description 543
- 102100011108 MASP2 Human genes 0.000 claims abstract description 543
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 351
- 241000282414 Homo sapiens Species 0.000 claims abstract description 142
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims abstract description 13
- 102000004965 antibodies Human genes 0.000 claims description 438
- 108090001123 antibodies Proteins 0.000 claims description 438
- 230000037361 pathway Effects 0.000 claims description 203
- 230000004913 activation Effects 0.000 claims description 189
- 239000000203 mixture Substances 0.000 claims description 103
- 230000027455 binding Effects 0.000 claims description 86
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 81
- 239000000427 antigen Substances 0.000 claims description 67
- 102000038129 antigens Human genes 0.000 claims description 67
- 108091007172 antigens Proteins 0.000 claims description 67
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 66
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 66
- 210000001772 Blood Platelets Anatomy 0.000 claims description 25
- 230000002829 reduced Effects 0.000 claims description 23
- 108091006028 chimera Proteins 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000002085 persistent Effects 0.000 claims description 9
- 102000003855 L-lactate dehydrogenases Human genes 0.000 claims description 6
- 108091000084 L-lactate dehydrogenases Proteins 0.000 claims description 6
- 102100009596 HP Human genes 0.000 claims description 4
- 108050005077 Haptoglobin Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 30
- 239000003795 chemical substances by application Substances 0.000 description 153
- 239000002523 lectin Substances 0.000 description 134
- 101710015954 HVA1 Proteins 0.000 description 126
- 101700065814 LEA2 Proteins 0.000 description 126
- 101700021338 LEC Proteins 0.000 description 126
- 101700077545 LECC Proteins 0.000 description 126
- 101700028499 LECG Proteins 0.000 description 126
- 101700063913 LECT Proteins 0.000 description 126
- 101710034340 Os04g0173800 Proteins 0.000 description 126
- 101700036391 lecA Proteins 0.000 description 126
- 101700001016 mbhA Proteins 0.000 description 126
- 208000006303 Thrombotic Microangiopathy Diseases 0.000 description 84
- 206010043645 Thrombotic microangiopathy Diseases 0.000 description 75
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 63
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 62
- 102100012590 C3 Human genes 0.000 description 55
- 102100013834 SLC3A2 Human genes 0.000 description 54
- 101710007458 SLC3A2 Proteins 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 51
- 201000009910 diseases by infectious agent Diseases 0.000 description 50
- 238000005755 formation reaction Methods 0.000 description 50
- 206010022114 Injury Diseases 0.000 description 48
- 210000004027 cells Anatomy 0.000 description 47
- 201000010099 disease Diseases 0.000 description 47
- 239000003112 inhibitor Substances 0.000 description 45
- 230000035492 administration Effects 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 230000035772 mutation Effects 0.000 description 37
- 102000016550 Complement Factor H Human genes 0.000 description 35
- 108010053085 Complement Factor H Proteins 0.000 description 35
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 35
- 229920001184 polypeptide Polymers 0.000 description 33
- 238000003776 cleavage reaction Methods 0.000 description 32
- 238000002616 plasmapheresis Methods 0.000 description 32
- 241000700159 Rattus Species 0.000 description 30
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 30
- 230000002949 hemolytic Effects 0.000 description 30
- 229960000060 monoclonal antibodies Drugs 0.000 description 30
- 230000015271 coagulation Effects 0.000 description 28
- 206010043554 Thrombocytopenia Diseases 0.000 description 27
- 102100006780 ADAMTS13 Human genes 0.000 description 26
- 230000001404 mediated Effects 0.000 description 26
- 238000005345 coagulation Methods 0.000 description 25
- 230000035693 Fab Effects 0.000 description 24
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 23
- 238000004166 bioassay Methods 0.000 description 23
- 238000001990 intravenous administration Methods 0.000 description 23
- 201000010874 syndrome Diseases 0.000 description 23
- 210000002381 Plasma Anatomy 0.000 description 22
- 210000003734 Kidney Anatomy 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 21
- 210000004369 Blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 238000002512 chemotherapy Methods 0.000 description 20
- 101700007095 C5 Proteins 0.000 description 19
- 102100007517 C5 Human genes 0.000 description 19
- 102000012479 Serine Proteases Human genes 0.000 description 19
- 108010022999 Serine Proteases Proteins 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 230000004083 survival Effects 0.000 description 19
- 102000018358 Immunoglobulins Human genes 0.000 description 18
- 108060003951 Immunoglobulins Proteins 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000004044 response Effects 0.000 description 16
- 101700060586 FCN2 Proteins 0.000 description 15
- 102100007697 FCN2 Human genes 0.000 description 15
- 230000001154 acute Effects 0.000 description 15
- 230000002792 vascular Effects 0.000 description 15
- 108091005662 ADAMTS13 Proteins 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000002054 transplantation Methods 0.000 description 14
- 108010093881 ADAMTS13 Protein Proteins 0.000 description 13
- 210000004408 Hybridomas Anatomy 0.000 description 13
- 241000588650 Neisseria meningitidis Species 0.000 description 13
- 108010079723 Shiga Toxin Proteins 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000008506 pathogenesis Effects 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 108090000056 Complement Factor B Proteins 0.000 description 12
- 102000003712 Complement Factor B Human genes 0.000 description 12
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 description 12
- 206010018364 Glomerulonephritis Diseases 0.000 description 12
- 210000001519 tissues Anatomy 0.000 description 12
- 229920002676 Complementary DNA Polymers 0.000 description 11
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 11
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000003247 decreasing Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 238000009093 first-line therapy Methods 0.000 description 11
- 230000002068 genetic Effects 0.000 description 11
- 230000001965 increased Effects 0.000 description 11
- 238000001361 intraarterial administration Methods 0.000 description 11
- 238000007918 intramuscular administration Methods 0.000 description 11
- 230000000630 rising Effects 0.000 description 11
- 108060007110 rnpA Proteins 0.000 description 11
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 11
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 10
- 108090000206 Autoantibodies Proteins 0.000 description 10
- 102000003852 Autoantibodies Human genes 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 10
- 229920000057 Mannan Polymers 0.000 description 10
- LUEWUZLMQUOBSB-GFVSVBBRSA-N Mannan Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 10
- 230000000977 initiatory Effects 0.000 description 10
- 210000000056 organs Anatomy 0.000 description 10
- 230000001575 pathological Effects 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 229960004072 thrombin Drugs 0.000 description 10
- 102100009045 AGTPBP1 Human genes 0.000 description 9
- 101710003107 AGTPBP1 Proteins 0.000 description 9
- 108010089414 Anaphylatoxins Proteins 0.000 description 9
- 101710012938 CAGL0K08184g Proteins 0.000 description 9
- 101710041907 CCP1 Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 101710014161 GZMB Proteins 0.000 description 9
- 102000004851 Immunoglobulin G Human genes 0.000 description 9
- 108090001095 Immunoglobulin G Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 206010061255 Ischaemia Diseases 0.000 description 9
- 102000004856 Lectins Human genes 0.000 description 9
- 108090001090 Lectins Proteins 0.000 description 9
- 101700086739 MASP1 Proteins 0.000 description 9
- 102100011109 MASP1 Human genes 0.000 description 9
- 101000357597 MASP2 Proteins 0.000 description 9
- 230000003115 biocidal Effects 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 229940079593 drugs Drugs 0.000 description 9
- 102000036608 human MASP2 protein Human genes 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000001732 thrombotic Effects 0.000 description 9
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 102100019144 CD46 Human genes 0.000 description 8
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 8
- -1 H-ficolin Proteins 0.000 description 8
- 229940027941 Immunoglobulin G Drugs 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 8
- 210000000440 Neutrophils Anatomy 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 206010037549 Purpura Diseases 0.000 description 8
- 241001672981 Purpura Species 0.000 description 8
- 210000003324 RBC Anatomy 0.000 description 8
- 206010040070 Septic shock Diseases 0.000 description 8
- 102100019017 VWF Human genes 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 238000002716 delivery method Methods 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 108010063231 eculizumab Proteins 0.000 description 8
- 229960002224 eculizumab Drugs 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000000099 in vitro assay Methods 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 230000036303 septic shock Effects 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 108010047303 von Willebrand Factor Proteins 0.000 description 8
- 229960001134 von Willebrand factor Drugs 0.000 description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 7
- 101710027020 CD46 Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 229920000392 Zymosan Polymers 0.000 description 7
- 230000000903 blocking Effects 0.000 description 7
- 230000001413 cellular Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001684 chronic Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000035939 shock Effects 0.000 description 7
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 6
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 6
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 6
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 6
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 6
- 206010060945 Bacterial infection Diseases 0.000 description 6
- 230000036880 Cls Effects 0.000 description 6
- 229940088598 Enzyme Drugs 0.000 description 6
- 101700036859 FCN1 Proteins 0.000 description 6
- 102100000193 FCN1 Human genes 0.000 description 6
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 108010005662 Membrane Cofactor Protein Proteins 0.000 description 6
- 241000529648 Neisseria meningitidis MC58 Species 0.000 description 6
- 108009000578 Oxidative Stress Proteins 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- 210000003491 Skin Anatomy 0.000 description 6
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000000295 complement Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229940079866 intestinal antibiotics Drugs 0.000 description 6
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 230000001717 pathogenic Effects 0.000 description 6
- 230000002263 peptidergic Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 230000000451 tissue damage Effects 0.000 description 6
- 231100000827 tissue damage Toxicity 0.000 description 6
- 102100020197 CFP Human genes 0.000 description 5
- 210000001736 Capillaries Anatomy 0.000 description 5
- 210000002421 Cell Wall Anatomy 0.000 description 5
- 108010034358 Classical Pathway Complement C3 Convertase Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 5
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 5
- 102000005919 Membrane Cofactor Protein Human genes 0.000 description 5
- 206010062198 Microangiopathy Diseases 0.000 description 5
- 229920000272 Oligonucleotide Polymers 0.000 description 5
- 102000035443 Peptidases Human genes 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 108010005642 Properdin Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 description 5
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
- 231100000494 adverse effect Toxicity 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 244000052769 pathogens Species 0.000 description 5
- 230000003389 potentiating Effects 0.000 description 5
- 230000002797 proteolythic Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 150000007970 thio esters Chemical group 0.000 description 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 4
- 210000004204 Blood Vessels Anatomy 0.000 description 4
- 210000000988 Bone and Bones Anatomy 0.000 description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 4
- 230000037250 Clearance Effects 0.000 description 4
- 206010009802 Coagulopathy Diseases 0.000 description 4
- 208000003576 Complement Factor H Deficiency Diseases 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 229920000665 Exon Polymers 0.000 description 4
- 102100015239 F2 Human genes 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 210000000224 Granular leucocyte Anatomy 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 210000004379 Membranes Anatomy 0.000 description 4
- 229960004857 Mitomycin Drugs 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 229940039716 Prothrombin Drugs 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 241000607768 Shigella Species 0.000 description 4
- 206010040550 Shigella infection Diseases 0.000 description 4
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 4
- 101700069556 VCO3 Proteins 0.000 description 4
- 230000003213 activating Effects 0.000 description 4
- 230000000735 allogeneic Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000035512 clearance Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 201000008286 diarrhea Diseases 0.000 description 4
- 230000003292 diminished Effects 0.000 description 4
- 238000010448 genetic screening Methods 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 230000001771 impaired Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002757 inflammatory Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000000968 intestinal Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000000813 microbial Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108091008117 polyclonal antibodies Proteins 0.000 description 4
- 230000003331 prothrombotic Effects 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001960 triggered Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 3
- 108090000866 Antiphospholipid Antibodies Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 210000001367 Arteries Anatomy 0.000 description 3
- 229960001230 Asparagine Drugs 0.000 description 3
- 101700049499 C5AR1 Proteins 0.000 description 3
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 3
- 229960001334 Corticosteroids Drugs 0.000 description 3
- 229940119017 Cyclosporine Drugs 0.000 description 3
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 3
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010018987 Haemorrhage Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 229960000310 ISOLEUCINE Drugs 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 102000004854 Immunoglobulin M Human genes 0.000 description 3
- 108090001096 Immunoglobulin M Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 208000005777 Lupus Nephritis Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 229960005190 Phenylalanine Drugs 0.000 description 3
- 206010039447 Salmonellosis Diseases 0.000 description 3
- 206010053879 Sepsis syndrome Diseases 0.000 description 3
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 3
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 210000000264 Venules Anatomy 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 3
- 201000003126 anuria Diseases 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000001747 exhibiting Effects 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940020899 hematological Enzymes Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001524 infective Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 3
- 230000003990 molecular pathway Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 244000045947 parasites Species 0.000 description 3
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000000090 phagocyte Effects 0.000 description 3
- 238000005375 photometry Methods 0.000 description 3
- 230000001737 promoting Effects 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 230000002685 pulmonary Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002269 spontaneous Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 200000000020 tissue injury Diseases 0.000 description 3
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 2
- 108010055216 Anti-Idiotypic Antibodies Proteins 0.000 description 2
- 229960005261 Aspartic Acid Drugs 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010003885 Azotaemia Diseases 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- 210000002469 Basement Membrane Anatomy 0.000 description 2
- 241000219430 Betula pendula Species 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 102100003281 CD59 Human genes 0.000 description 2
- 101700073334 CD59 Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 241000434299 Cinchona officinalis Species 0.000 description 2
- 206010053567 Coagulopathy Diseases 0.000 description 2
- 102000004405 Collectins Human genes 0.000 description 2
- 108090000909 Collectins Proteins 0.000 description 2
- 210000004351 Coronary Vessels Anatomy 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 2
- 102100015487 GLRA2 Human genes 0.000 description 2
- 108060004409 GLRA2 Proteins 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 206010069440 Henoch-Schonlein purpura nephritis Diseases 0.000 description 2
- 206010053317 Hydrophobia Diseases 0.000 description 2
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 208000002554 MASP2 Deficiency Diseases 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 101000357599 Mannan-binding lectin serine protease 2 Proteins 0.000 description 2
- 210000000138 Mast Cells Anatomy 0.000 description 2
- 210000004088 Microvessels Anatomy 0.000 description 2
- 206010028154 Multi-organ failure Diseases 0.000 description 2
- 208000004221 Multiple Trauma Diseases 0.000 description 2
- 206010028224 Multiple injury Diseases 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010063834 Oversensing Diseases 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 230000036823 Plasma Levels Effects 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229960000948 Quinine Drugs 0.000 description 2
- 101710029124 RPS3A Proteins 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 229940003641 Rituxan Drugs 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 208000006666 Shwartzman Phenomenon Diseases 0.000 description 2
- 231100000702 Shwartzman phenomenon Toxicity 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N Ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 229960005001 Ticlopidine Drugs 0.000 description 2
- 208000009852 Uremia Diseases 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 208000010019 Vascular System Injury Diseases 0.000 description 2
- 206010027701 Vascular injury Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial Effects 0.000 description 2
- 230000002429 anti-coagulation Effects 0.000 description 2
- 230000001494 anti-thymocyte Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002506 anticoagulant protein Substances 0.000 description 2
- 230000001640 apoptogenic Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated Effects 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 201000002393 blood protein disease Diseases 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 102000026868 carbohydrate binding proteins Human genes 0.000 description 2
- 108091007726 carbohydrate binding proteins Proteins 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001066 destructive Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 108010071253 factor H-related protein 1 Proteins 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000002489 hematologic Effects 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001861 immunosuppresant Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000002045 lasting Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 230000002101 lytic Effects 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 230000000921 morphogenic Effects 0.000 description 2
- 230000000269 nucleophilic Effects 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 230000001662 opsonic Effects 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 230000003571 opsonizing Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000000770 pro-inflamatory Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 230000002485 urinary Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- 101710006043 24 Proteins 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical group OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 108010083822 Alternative Pathway Complement C5 Convertase Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 229940114079 Arachidonic Acid Drugs 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 206010003997 Bacteraemia Diseases 0.000 description 1
- 210000003651 Basophils Anatomy 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010064913 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102100013391 CD55 Human genes 0.000 description 1
- 101710006195 CD55 Proteins 0.000 description 1
- 101700036312 CONA Proteins 0.000 description 1
- 101700068333 CR1L Proteins 0.000 description 1
- 101710036000 CUB1 Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 210000003917 Chromosomes, Human Anatomy 0.000 description 1
- 108010078804 Classical Pathway Complement C5 Convertase Proteins 0.000 description 1
- 229960003009 Clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229960003624 Creatine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- WQZGKKKJIJFFOK-SVZMEOIVSA-N D-galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 101700053597 FCER2 Proteins 0.000 description 1
- 102100014608 FCER2 Human genes 0.000 description 1
- 229950003499 FIBRIN Drugs 0.000 description 1
- 206010053172 Fatal outcome Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002024 GDNA Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017903 Gastroenteritis Escherichia coli Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 210000000585 Glomerular Basement Membrane Anatomy 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 229940030482 HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 206010020578 Hyperbilirubinaemia Diseases 0.000 description 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- 208000002370 Immune Complex Disease Diseases 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- 108090001122 Immunoglobulin A Proteins 0.000 description 1
- 108010043156 Immunoglobulin D Proteins 0.000 description 1
- 108090001124 Immunoglobulin E Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 206010022822 Intravascular haemolysis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 101700038420 MVP Proteins 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010066453 Mesangioproliferative glomerulonephritis Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 208000007201 Myocardial Reperfusion Injury Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-ACETYL-D-GALACTOSAMINE Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 description 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 description 1
- 210000000885 Nephrons Anatomy 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 108010039593 Opsonin Proteins Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M Phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010061353 Pneumococcal infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N RIFAMPICIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 229940081190 Rifampin Drugs 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 101700068732 VEGFA Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 201000011326 acute poststreptococcal glomerulonephritis Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004931 aggregating Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 201000006647 atypical hemolytic-uremic syndrome Diseases 0.000 description 1
- 230000000468 autoproteolytic Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 201000004532 bilirubin metabolic disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003399 chemotactic Effects 0.000 description 1
- 239000002820 chemotaxin Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 108010070043 complement 4 nephritic factor Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine zwitterion Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 1
- 230000000254 damaging Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002074 deregulated Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 108090000062 ficolin Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 102000034448 gene-regulatory proteins Human genes 0.000 description 1
- 108091006088 gene-regulatory proteins Proteins 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 201000003943 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000002132 lysosomal Effects 0.000 description 1
- 108091022076 maltose binding proteins Proteins 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 101700003655 orf7 Proteins 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 200000000002 platelet activation Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002947 procoagulant Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000000304 vasodilatating Effects 0.000 description 1
- 101710030641 vegfaa Proteins 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Abstract
In one aspect, the invention provides methods of inhibiting the effects of MASP-2dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
Description
METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
CROSS-REFERENCE TO RELATED APPLICATIONS
This application daims the benefit of Provisional Application No 62/406,726, filed October 11, 2016, and daims the benefit of Provisional Application No. 62/252,814, filed November 9, 2015, both of which are hereby incorporated by référencé in their entirety.
STATEMENT REGARDING SEQUENCE LISTING
The sequence listing associated with this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference into the spécification. The name of the text file containing the sequence listing is
MP_l_0248_PCTJSequence_Listing_as_Filed_20161109.txt. The text file is 115 KB, was created on November 8, 2016 and is being submitted via EFS-Web with the filing of the spécification.
BACKGROUND
The complément system provides an early acting mechanism to initiale, amplify and orchestrale the immune response to microbial infection and other acute insults (M.K. Liszewski and J.P. Atkinson, 1993, in Fundamental Immunology, Third Edition, edîted by W.E. Paul, Raven Press, Ltd., New York), in humans and other vertebrates. While complément activation provides a valuable first-line defense against potential pathogens, the activities of complément that promote a protective immune response can also represent a potential threat to the host (K.R. Kalli, et al., Springer Semin. Immunopathol. 75:417-431, 1994; B.P. Morgan, Eur. J. Clinical Investig. 24:219-228, 1994). For example, C3 and C5 proteolytic products recruit and activate neutrophils. While indispensable for host defense, activated neutrophils are indiscriminate in their release of destructive enzymes and may cause organ damage. In addition, complément activation may cause the déposition of lytic complément components on nearby host cells as well as on microbial targets, resulting in host cell lysis.
i
....................... -...........- -.....- .......... . __________________________________ )
Ο 2
The complément System has also been implicated in the pathogenesis of numerous acute and chronic disease States, including: myocardial infarction, stroke, ARDS, reperfusion injury, septic shock, capillary leakage following thermal bums, postcardiopulmonary bypass inflammation, transplant rejection, rheumatoid arthritis, 5 multiple sclerosis, myasthenia gravis, and Alzheimer’s disease. In almost ail of these conditions, complément is not the cause but is one of several factors involved in pathogenesis. Nevertheless, complément activation may be a major pathological mechanism and represents an effective point for clinical control in many of these disease States. The growing récognition of the importance of complement-mediated tissue injury 10 in a variety of disease States underscores the need for effective complément inhibitory drugs. To date, Eculizumab (Solaris®), an antibody against C5, is the only complementtargeting drug that has been approved for human use. Yet, C5 is one of several effector molécules located “downstream” in the complément System, and blockade of C5 does not inhibit activation of the complément System. Therefore, an inhibitor of the initiation 15 steps of complément activation would hâve significant advantages over a “downstream” complément inhibitor.
Currently, it is widely accepted that the complément System can be activated through three distinct pathways: the classical pathway, the lectin pathway, and the alternative pathway. The classical pathway is usually triggered by a complex composed 20 of host antibodies bound to a foreign particle (i.e., an antigen) and thus requîtes prior exposure to an antigen for the génération of a spécifie antibody response. Since activation of the classical pathway dépends on a prior adaptive immune response by the host, the classical pathway is part of the acquired immune System. In contrast, both the lectin and alternative pathways are independent of adaptive immunity and are part of the 25 innate immune System.
The activation of the complément System results in the sequential activation of serine protease zymogens. The first step in activation of the classical pathway is the binding of a spécifie récognition molécule, Clq, to antigen-bound IgG and IgM molécules. Clqis associated with the Clr andCls serine protease proenzymes as a 30 complex called Cl. Upon binding ofClq to an immune complex, autoproteolytic cleavage of the Arg-Ile site of Clr is followed by Clr-mediated cleavage and activation of Cls, which thereby acquires the ability to cleave C4 and C2. C4 is cleaved into two fragments, designated C4a and C4b, and, similarly, C2 is cleaved into C2a and C2b. C4b fragments are able to form covalent bonds with adjacent hydroxyl or amino groups and generate the C3 convertase (C4b2a) through noncovalent interaction with the C2a fragment of activated C2, C3 convertase (C4b2a) activâtes C3 by proteolytic cleavage 5 into C3a and C3b subcomponents leading to génération of the C5 convertase (C4b2a3b), which, by cleaving C5 leads to the formation of the membrane attack complex (C5b combined with C6, C7, C8 and C-9, also referred to as “MAC”) that can disrupt cellular membranes leading to cell lysis. The activated forms of C3 and C4 (C3b and C4b) are covalently deposited on the foreign target surfaces, which are recognized by complément 10 receptors on multiple phagocytes.
Independently, the first step in activation of the complément System through the lectin pathway is also the binding of spécifie récognition molécules, which is followed by the activation of associated serine protease proenzymes. However, rather than the binding of immune complexes by Clq, the récognition molécules in the lectin pathway 15 comprise a group of carbohydrate-binding proteins (mannan-binding lectin (MBL), H-ficolin, M-ficolin, L-ficolin and C-type lectin CL-11), collectively referred to as lectins. See J. Lu et al., Biochim. Biophys. Acta 2572:387-400, (2002); Holmskov et al., Annu. Rev. Immunol. 21:547-578 (2003); Teh étal., Immunology 101:225-232 (2000)), See also J. Luet et al., Biochim Biophys Acta 1572:387-400 (2002); Holmskov et al, Annu 20 Rev Immunol 21:547-578 (2003); Teh et al., Immunology 101:225-232 (2000); Hansen et al, J. Immunol 185(10):6096-6104 (2010).
Ikeda et al. first demonstrated that, like Clq, MBL could activate the complément System upon binding to yeast mannan-coated érythrocytes in a C4-dependent manner (Ikeda et al., J. Biol. Chem. 262:7451-7454, (1987)). MBL, a member of the collectin 25 protein family, is a calcium-dependent lectin that binds carbohydrates with 3- and 4-hydroxy groups oriented in the équatorial plane of the pyranose ring. Prominent ligands for MBL are thus D-mannose and N-acetyl-D-glucosamine, while carbohydrates not fitting this steric requirement hâve undetectable affinity for MBL (Weis et al., Nature 360:127-134, (1992)). The interaction between MBL and monovalent sugars is 30 extremely weak, with dissociation constants typically in the single-digit millimolar range. MBL achieves tight, spécifie binding to glycan ligands by avidity, i.e., by interacting simultaneously with multiple monosaccharide residues located in close proximity to each other (Lee et al., Archiv. Biochem. Biophys. 299:129-136, (1992)). MBL recognizes the carbohydrate patterns that commonly decorate microorganisms such as bacteria, yeast, parasites and certain viruses. In contrast, MBL does not recognize D-galactose and sialic acid, the penultimate and ultimate sugars that usually decorate mature complex glycoconjugates présent on mammalian plasma and cell surface glycoproteins. This binding specificity is thought to promote récognition of “foreign” surfaces and help protect from “self-activation.” However, MBL does bind with high affinity to clusters of high-mannose precursor glycans on N-linked glycoproteins and glycolipids sequestered in the endoplasmic réticulum and Golgi of mammalian cells (Maynard et al., J. Biol. Chem. 257:3788-3794, (1982)). Therefore, damaged cells are potential targets for lectin pathway activation via MBL binding.
The ficolins possess a different type of lectin domain than MBL, called the fibrinogen-like domain. Ficolins bind sugar residues in a Ca++-independent manner. In humans, three kinds of ficolins (L-ficolin, M-ficolin and H-ficolin) hâve been identified. The two sérum ficolins, L-ficolin and H-ficolin, hâve in common a specificity for N-acetyl-D-glucosamine; however, H-ficolin also binds N-acetyl-D-galactosamine. The différence in sugar specificity of L-ficolin, H-ficolin, CL-11, and MBL means that the different lectins may be complementary and target different, though overlapping, glycoconjugates. This concept is supported by the recent report that, of the known lectins in the lectin pathway, only L-ficolin binds specifically to lipoteichoic acid, a cell wall glycoconjugate found on ail Gram-positive bacteria (Lynch et al., J. Immunol. 772:1198-1202, (2004)). The collectins (i.e., MBL) and the ficolins bear no significant similarity in amino acid sequence. However, the two groups of proteins hâve similar domain organizations and, like Clq, assemble into oligomeric structures, which maximize the possibility of multisite binding.
The sérum concentrations of MBL are highly variable in healthy populations and this is genetically controlled by polymorphisms/mutations in both the promoter and coding régions of the MBL gene. As an acute phase protein, the expression of MBL is further upregulated during inflammation. L-ficolin is présent in sérum at concentrations similar to those of MBL. Therefore, the L-ficolin branch of the lectin pathway is potentially comparable to the MBL arm in strength. MBL and ficolins can also function as opsonins, which allow phagocytes to target MBL- and ficolin-decorated surfaces (see
Jack et al., J Leukoc Biol., 77(3):328-36 (2004), Matsushita and Fujita, Immunobiology, 205(4-5):490-7 (2002), Aoyagi et al., J Immunol, 174(1):418-25(2005). This opsonization requires the interaction of these proteins with phagocyte receptors (Kuhlman étal., J. Exp. Med. 169:1133, (1989); Matsushita et al., J. Biol. Chem. 277:2448-54, 5 (1996)), the indentity of which has not been established.
Human MBL forms a spécifie and high-affinity interaction through its collagen-like domain with unique Clr/Cls-like serine proteases, termed MBL-assocîated serine proteases (MASPs). To date, three MASPs hâve been described. First, a single enzyme MASP was identified and characterized as the enzyme responsible for the 10 initiation of the complément cascade (i.e., cleaving C2 and C4) (Matsushita et al., J Exp Med 176(6):1497-1502 (1992); Ji et al., J. Immunol. 750:571-578, (1993)). It was subsequently determined that the MASP activity was, in fact, a mixture of two proteases: MASP-1 and MASP-2 (Thiel étal., Nature 356:506-510, (1997)). However, it was demonstrated that the MBL-MASP-2 complex alone is sufficient for complément 15 activation (Vorup-Jensen et al., J. Immunol. 765:2093-2100, (2000)). Furthermore, only MASP-2 cleaved C2 and C4 at high rates (Ambrus étal., J. Immunol. 770:1374-1382, (2003)). Therefore, MASP-2 is the protease responsible for activating C4 and C2 to generate the C3 convertase, C4b2a. This is a signifîcant différence from the Cl complex of the classical pathway, where the coordinated action of two spécifie serine proteases 20 (Clr and Cls) leads to the activation of the complément System. In addition, a third novel protease, MASP-3, has been isolated (Dahl, M.R., et al., Immunity 75:127-35, 2001). MASP-1 and MASP-3 are alternatively spliced products of the same gene.
MASPs share identical domain organizations with those of Clr and Cls, the enzymatic components of the Cl complex (Sim étal., Biochem. Soc. Trans. 25:545, 25 (2000)). These domains include an N-terminal Clr/Cls/sea urchin VEGF/bone morphogenic protein (CUB) domain, an epidermal growth factor-like domain, a second CUB domain, a tandem of complément control protein domains, and a serine protease domain. As in the Cl proteases, activation of MASP-2 occurs through cleavage of an Arg-Ile bond adjacent to the serine protease domain, which splits the enzyme into 30 disulfide-linked A and B chains, the latter consisting of the serine protease domain.
MBL can also associate with an alternatively sliced form of MASP-2, known as MBL-associated protein of 19kDa (MApl9) or small MBL-associated protein (sMAP), which lacks the catalytic acivity of MASP2. (Stover, J. Immunol. 762:3481-90, (1999); Takahashi et al., Int. Immunol. 77:859-863, (1999)). MApl9 comprises the first two domains of MASP-2, followed by an extra sequence of four unique amino acids. The function of Mapl9 is unclear (Degn et al., J Immunol. Methods, 2011). The MASP-1 and MASP-2 genes are located on human chromosomes 3 and 1, respectively (Schwaeble et al., Immunobiology 205:455-466, (2002)).
Several Unes of evidence suggest that there are different MBL-MASP complexes and a large fraction of the MASPs in sérum is not complexed with MBL (Thiel, et ah, J. Immunol. 765:878-887, (2000)). Both H- and L-ficolin bind to ail MASPs and activate the lectin complément pathway, as does MBL (Dahl et al., Immunity 15:127-35, (2001); Matsushita étal., J. Immunol. 765:3502-3506, (2002)). Both the lectin and classical pathways form a common C3 convertase (C4b2a) and the two pathways converge at this step.
The lectin pathway is widely thought to hâve a major rôle in host defense against infection in the naïve host. Strong evidence for the involvement of MBL in host defense cornes from analysis of patients with decreased sérum levels of functîonal MBL (Kilpatrick, Biochim. Biophys. Acta 7572:401-413, (2002)). Such patients display susceptibility to récurrent bacterial and fungal infections. These symptoms are usually évident early in life, during an apparent window of vulnerability as matemally derived antibody titer wanes, but before a full répertoire of antibody responses develops. This syndrome often results from mutations at several sites in the collagenous portion of MBL, which interfère with proper formation of MBL oligomers. However, since MBL can function as an opsonin independent of complément, it is not known to what extent the increased susceptibility to infection is due to impaired complément activation.
In contrast to the classical and lectin pathways, no initiators of the alternative pathway hâve been found to fulfill the récognition fonctions that Clq and lectins perforai in the other two pathways. Currently it is widely accepted that the alternative pathway spontaneously undergoes a low level of turnover activation, which can be readily amplified on foreign or other abnormal surfaces (bacteria, yeast, virally infected cells, or damaged tissue) that lack the proper molecular éléments that keep spontaneous complément activation in check. There are four plasma proteins directly involved in the activation of the alternative pathway: C3, factors B and D, and properdin.
Although there is extensive evidence implicating both the classical and alternative complément pathways in the pathogenesis of non-infectious human diseases, the rôle of the lectin pathway is just beginning to be evaluated. Recent studies provide evidence that activation of the lectin pathway can be responsible for complément activation and related 5 inflammation in ischemia/reperfusion injury. Collard et al. (2000) reported that cultured endothélial cells subjected to oxidative stress bind MBL and show déposition of C3 upon exposure to human sérum (Collard et al., Am. J. Pathol. /56:1549-1556, (2000)). In addition, treatment of human sera with blocking anti-MBL monoclonal antibodies inhibited MBL binding and complément activation. These findings were extended to a 10 rat model of myocardial ischemia-reperfusion in which rats treated with a blocking antibody directed against rat MBL showed significantly less myocardial damage upon occlusion of a coronary artery than rats treated with a control antibody (Jordan et al., Circulation 104:1413-1418, (2001)). The molecular mechanism of MBL binding to the vascular endothélium after oxidative stress is unclear; a recent study suggests that 15 activation of the lectin pathway after oxidative stress may be mediated by MBL binding to vascular endothélial cytokeratins, and not to glycoconjugates (Collard et al., Am. J. Pathol. 759:1045-1054, (2001)). Other studies hâve implicated the classical and alternative pathways m the pathogenesis of ischemia/reperfusion injury and the rôle of the lectin pathway in this disease remains controversial (Riedermann, N.C., et al., Am. J. 20 Pathol. 762:363-367, 2003).
A recent study has shown that MASP-1 (and possibly also MASP-3) is required to couvert the alternative pathway activation enzyme Factor D from its zymogen form into its enzymatically active form (see Takahashi M. et al., J Exp Med 207(1):29-37 (2010)). The physiological importance of this process is underlined by the absence of alternative 25 pathway functional activity in plasma of MASP-l/3-deficient mice. Proteolytic génération of C3b from native C3 is required for the alternative pathway to function. Since the alternative pathway C3 convertase (C3bBb) contains C3b as an essential subunit, the question regarding the origin of the first C3b via the alternative pathway has presented a puzzling problem and has stimulated considérable research.
C3 belongs to a family of proteins (along with C4 and a-2 macroglobulin) that contain a rare posttranslational modification known as a thioester bond. The thioester group is composed of a glutamine whose terminal carbonyl group forms a covalent thioester hnkage with the sulfhydryl group of a cysteine three amino acids away, This bond is unstable and the electrophilic glutamyl-thioester can react with nucleophilic moieties such as hydroxyl or amino groups and thus form a covalent bond with other molécules. The thioester bond is reasonably stable when sequestered within a hydrophobie pocket of intact C3. However, proteolytic cleavage of C3 to C3a and C3b results in exposure of the highly reactive thioester bond on C3b and, following nucleophilic attack by adjacent moieties comprising hydroxyl or amino groups, C3b becomes covalently linked to a target. In addition to its well-documented rôle in covalent attachment of C3b to complément targets, the C3 thioester is also thought to hâve a pivotai rôle in triggering the alternative pathway. According to the widely accepted tick-over theory, the alternative pathway is initiated by the génération of a fluid-phase convertase, iC3Bb, which is formed from C3 with hydrolyzed thioester (iC3; C3(H2O)) and factor B (Lachmann, P.J., et al., Springer Semin. Immunopathol. 7:143-162, (1984)). The C3b-like C3(H2O) is generated from native C3 by a slow spontaneous hydrolysis of the internai thioester in the protein (Pangbum, M.K., étal., J. Exp. Med. 754:856-867, 1981). Through the activity of the C3(H2O)Bb convertase, C3b molécules are deposited on the target surface thereby initiating the alternative pathway.
Ver y little is known about the initiators of activation of the alternative pathway. Activators are thought to include yeast cell walls (zymosan), many pure polysaccharides, rabbit érythrocytes, certain immunoglobulins, viruses, fungi, bacteria, animal tumor cells, parasites, and damaged cells. The only feature common to these activators is the présence of carbohydrate, but the complexity and variety of carbohydrate structures has made it difficult to establish the shared molecular déterminants which are recognized. It has been widely accepted that alternative pathway activation is controlled through the fine balance between inhibitory regulatory components of this pathway, such as Factor H, Factor I, DAF, and CRI, and properdin, which is the only positive regulator of the alternative pathway (see Schwaeble W.J. and Reid K.B., Immunol Today 20(1):17-21 (1999)).
In addition to the apparently unregulated activation mechanism described above, the alternative pathway can also provide a powerful amplification loop for the lectin/classical pathway C3 convertase (C4b2a) silice any C3b generated can participate with factor B in forming additional alternative pathway C3 convertase (C3bBb). The alternative pathway C3 convertase is stabilized by the binding of properdin. Properdin extends the alternative pathway C3 convertase half-life six to ten fold. Addition of C3b to the alternative pathway C3 convertase leads to the formation of the alternative pathway C5 convertase.
Ail three pathways (i.e., the classical, lectin and alternative) hâve been thought to converge at C5, which is cleaved to form products with multiple proinflammatory effects. The converged pathway has been referred to as the terminal complément pathway. C5a is the most potent anaphylatoxin, inducing alterations in smooth muscle and vascular tone, as well as vascular permeability. It is also a powerful chemotaxin and activator of both ncutrophils and monocytes. C5a-mediated cellular activation can significantly amplify inflammatory responses by inducing the release of multiple additional inflammatory mediators, including cytokines, hydrolytic enzymes, arachidonic acid métabolites, and reactive oxygen species. C5 cleavage leads to the formation of C5b-9, also known as the membrane attack complex (MAC). There is now strong evidence that sublytic MAC déposition may play an important rôle in inflammation in addition to its rôle as a lytic pore-forming complex.
In addition to its essential rôle in immune defense, the complément system contributes to tissue damage in many clinical conditions. Thus, there is a pressing need to develop therapeutically effective complément inhibitors to prevent these adverse effects.
SUMMARY
This summary is provided to introduce a sélection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
In one aspect, the présent invention provîdes a method of inhibiting microvascular endothélial cell injury and/or thrombus formation in a subject suffering from a thrombotic microangiopathy (TMA) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2dependent complément activation. In some embodiments, the subject is suffering from, or at risk for developing a TMA selected from the group consîsting of hemolytic urémie syndrome (aHUS), thrombotic thrombocytopénie purpura (TTP) and atypical hemolytic urémie syndrome (HUS). In some embodiments, prior to administration of the composition the subject is determined to exhibit one or more symptoms selected from the group consisting of (i) anémia, (ii) thrombocytopenia (iii) rénal insufficiency and (iv) rising créatinine, and the composition is administered in an effective amount and for a 5 sufficient time period to improve said one or more symptoms. In some embodiments, the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof. In some embodiments, the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In some embodiments, the MASP-2 inhibitory agent inhibits microvascular endothélial cell injury.
In another aspect, the invention provides a method of inhibiting MASP-2dependent complément activation in a subject suffering from or at risk for developing atypical hemolytic urémie syndrome (aHUS), comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dépendent complément activation. In one embodiment, prior to administration 15 of the composition the subject is determined to exhibit one or more symptoms selected from the group consisting of (i) anémia, (ii) thrombocytopenia (iii) rénal insufficiency and (iv) rising créatinine, and the composition is administered in an effective amount and for a sufficient time period to improve said one or more symptoms. In one embodiment, the subject is suffering from or at risk for developing non-Factor H-dependent aHUS. In 20 one embodiment, the subject is suffering from aHUS associated with factor I, factor B, or membrane cofactor CD46. In one embodiment, the MASP-2 inhibitory agent is an antiMASP-2 antibody, or fragment thereof, such as an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent inhibits microvascular endothélial cell injury.
In one embodiment, the MASP-2 inhibitory agent inhibits thrombus formation.
In another aspect, the invention provides a method for reducing the likelihood that a subject at risk for developing atypical hemolytic urémie syndrome (aHUS) will suffer clinical symptoms associated with aHUS. The method according to this aspect of the invention comprises (a) determining the presence of a genetic marker in the subject 30 known to be associated with aHUS; (b) periodically monitoring the subject to détermine the presence or absence of at least one symptom selected from the group consisting of anémia, thrombocytopenia, rénal insufficiency and rising créatinine; and (c) administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complément activation upon the détermination of the presence of at least one of anémia, thrombocytopenia, rénal insufficiency or rising créatinine, wherein the composition is administered in an effective 5 amount and for a sufficient time period to improve said one or more symptoms. In one embodiment, the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof, such as an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO: 6. In one embodiment of the method, step (a) comprises performing a genetic screening test on a sample obtained from the subject 10 and identifying the presence of at least one genetic marker associated with aHUS in a gene selected from the group consisting of complément factor H (CFH), factor I (CFI), factor B (CFB), membrane cofactor CD46, C3, complément factor H-related protein (CFHR1), anticoagulant protein thrombodulin (THBD), complément factor H-related protein 3 (CFHR3) and complément factor H-related protein 4 (CFHR4). In one 15 embodiment, the method further comprises monitoring the subject for the occurrence of an event known to be associated with triggering aHUS clinical symptoms and administering to the subject the composition comprising the MASP-2 inhibitory agent prior to, during, or after the occurrence of the triggering event. In one embodiment, the event associated with triggering aHUS clinical symptoms is selected from the group 20 consisting of drug exposure, infection, malignancy, injury, organ or tissue transplant and pregnancy. In one embodiment, the infection is a bacterial infection. In one embodiment, the composition is administered subcutaneously. In one embodiment, the MASP-2 inhibitory agent inhibits microvascular endothélial cell injury. In one embodiment, the MASP-2 inhibitory agent inhibits thrombus formation.
In another aspect, the invention provides a method of inhibiting MASP-2dependent complément activation in a subject suffering from, or at risk for developing, atypical hemolytic urémie syndrome (aHUS) secondary to an infection, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 complément activation. In one embodiment, the 30 subject is suffering from, or at risk for developing non-enteric aHUS associated with an 5.
pneumonia infection. In one embodiment, the MASP-2 inhibitory agent is an anti-MASP2 antibody, or fragment thereof, such as an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent inhibits microvascular endothélial cell injury. In one embodiment, the MASP-2 inhibitory agent inhibits thrombus formation.
In another aspect, the invention provides a method of treating a subject suffering from atypical hemolytic urémie syndrome (aHUS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to înhibit MASP-2 dépendent complément activation, wherein the administration of the MASP-2 inhibitory agent is administered via an intravenous cathéter or other cathéter delivery method. In one embodiment, the method further comprises treating the patient with plasmapheresis. In one embodiment, the composition comprising the MASP-2 inhibitory agent is administered in the absence of plasmapheresis. In one embodiment, the composition comprising the MASP-2 inhibitory agent is administered via a cathéter for a first time period, further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time period, wherein the composition is administered subcutaneously during the second time period. In one embodiment, the method further comprises periodîcally determining the level of at least one complément factor, wherein the détermination of a reduced level of the at least one complément factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition. In one embodiment, the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof, such as an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent inhibits microvascular endothélial cell injury. In one embodiment, the MASP-2 inhibitory agent inhibits thrombus formation.
In another aspect, the invention provides a method of treating a subject suffering from thrombotic thrombocytopénie purpura (TTP), or exhibiting symptoms consistent with a diagnosis of TTP, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2dependent complément activation, wherein the administration of the MASP-2 inhibitory agent is administered to the subject via an intravenous cathéter or other cathéter delivery method. In one embodiment, the subject exhibits at least one or more symptoms selected from the group consisting of central nervous System involvement, thrombocytopenia, severe cardiac involvement, severe pulmonary involvement, gastro-intestinal infarction and gangrené. In one embodiment, the subject tests positive for the presence of an inhibitor of ADAMTS13, 5 and the method further comprises administering an immunosuppressant to the subject. In one embodiment, the composition comprising the MASP-2 inhibitory agent is administered for a first time period in the absence of plasmapheresis. In one embodiment, the subject tests positive for the presence of an inhibitor of ADAMTS-13, and the method further comprises administering ADAMTS-13. In one embodiment, the 10 method further comprises treating the patient with plasmapheresis. In one embodiment, the composition comprising the MASP-2 inhibitory agent is administered in the presence of plasmapheresis. In one embodiment, the composition comprising the MASP-2 inhibitory agent is administered via a cathéter for a first time period, further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time 15 period, wherein the composition is administered subcutaneously during the second time period. In one embodiment, the method further comprises periodically determining the level of at least one complément factor, wherein the détermination of a reduced level of the at least one complément factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition. In one 20 embodiment, the MASP-2 inhibitory agent is an anti-MASP-2 antibody, or fragment thereof, such as an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent inhibits microvascular endothélial cell injury. In one embodiment, the MASP-2 inhibitory agent inliibits thrombus formation.
In another aspect, the invention provides a method of treating a subject suffering from refractory thrombotic thrombocytopénie purpura (TTP) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dépendent complément activation. In one embodiment, the composition is administered subcutaneously. In one embodiment, the method further 30 comprises periodically determining the level of at least one complément factor, wherein the détermination of a reduced level of the at least one complément factor in comparison to a standard value or a healthy subject is indicative of the need for continued treatment with the composition. In one embodiment, the MASP-2 inhibitory agent is an antiMASP-2 antibody, or fragment thereof, such as an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent inhibits microvascular endothélial cell injury.
In one embodiment, the MASP-2 inhibitory agent inhibits thrombus formation.
In another aspect, the présent invention provides a method of inhibiting MASP-2dependent complément activation in a subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA), wherein the TMA is at least one of (i) a TMA secondary to cancer; (ii) a TMA secondary to chemotherapy, or (iii) a TMA secondary to 10 transplantation, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complément activation. In some embodiments, the subject is suffering from, or is at risk for developing a TMA secondary to cancer, and the MASP-2 inhibitory agent is administered systemically to the subject in an amount effective to reduce the risk of 15 developing TMA, or reduce the severity of TMA. In some embodiments, the subject is suffering from, or is at risk for developing a TMA secondary to chemotherapy, and the MASP-2 inhibitory agent is administered systemically to the subject prior to, during, or after chemotherapy, in an amount effective to reduce the risk of developing TMA, or reduce the severity of TMA. In some embodiments, the subject is suffering from, or is at 20 risk for developing a TMA secondary to transplantation and the MASP-2 inhibitory agent is administered systemically to the subject prior to, during, or after the transplant procedure, in an amount effective to reduce the risk of developing TMA, or reduce the severity of TMA. In some embodiments the transplant procedure is an allogeneic hematopoietic stem cell transplant. In some embodiments, the subject has previously 25 undergone, or is currently undergoing, treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the method further comprises administering to the subject a terminal complément inhibitor that inhibits cleavage of complément protein C5, such as a humanized anti-C5 antibody or antigen-binding fragment thereof, such as eculizumab.
In another aspect, the invention provides a method of inhibiting MASP-2dependent complément activation in a subject suffering from or at risk for developing Upshaw-Schulman Syndrome (USS) comprising administering to the subject a
Ο 15 composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dépendent complément activation. In some embodiments, the method comprises treating a subject at risk for developing USS, wherein the method comprises administerîng an amount of a MASP-2 inhibitory agent for a time period effective to ameliorate or prevent one of more clinical symptoms associated with TTP. In some embodiments, the method further comprises periodically monitoring the subject and administerîng the MASP-2 inhibitory agent upon the presence of an event known to be associated with triggering TTP clinical symptoms. In some embodiments, the method further comprises periodically monitoring the subject and administerîng the MASP-2 inhibitory agent upon the détermination of the presence of anémia, thrombocytopenia or rising creatine. In some embodiments, the subject has previously undergone, or is currently undergoing, treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the method further comprises administerîng to the subject a terminal complément inhibitor that inhibits cleavage of complément protein C5, such as a humanized anti-C5 antibody or antigenbinding fragment thereof, such as eculizumab.
hi another aspect, the invention provides a method of inhibiting MASP-2dependent complément activation in a subject suffering from Degos disease, comprising administerîng to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complément activation. In some embodiments, the subject has previously undergone, or is currently undergoing, treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the method further comprises administerîng to the subject a terminal complément inhibitor that inhibits cleavage of complément protein C5, such as a humanized anti-C5 antibody or antigen-binding fragment thereof, such as eculizumab.
In another aspect, the invention provides a method of inhibiting MASP-2dependent complément activation in a subject suffering from Catastrophic Antiphospholipid Syndrome (CAPS), comprising administerîng to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit
MASP-2-dependent complément activation. In some embodiments, the subject has previously undergone, or is currently undergoing, treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the method further comprises administering to the subject a terminal complément inhibitor that inhibits cleavage of complément protein C5, such as a humanized anti-C5 antibody or antigen-binding fragment thereof, such as eculizumab.
In some embodiments of any of the disclosed methods of the invention, the MASP-2 inhibitory agent is a MASP-2 inhibitory antibody or fragment thereof. In some embodiments, the MASP-2 inhibitory antibody has reduced effector function. In some embodiments, the MASP-2 inhibitory antibody does not substantîally inhibit the classical pathway. In some embodiments, the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In some embodiments, the anti-MASP-2 antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody. In some embodiments, the MASP-2 inhibitory antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F(ab')2. hi some embodiments, the MASP-2 inhibitory antibody is a single-chain molécule. In some embodiments, the MASP-2 inhibitory antibody is selected from the group consisting of an IgGl molécule, an IgG2 and an IgG4 molécule. In some embodiments, the MASP-2 inhibitory antibody is an IgG4 molécule comprising a S228P mutation. In some embodiments, the MASP-2 inhibitory antibody binds human MASP-2 with a KD of 10 nM or less. In some embodiments, the MASP-2 inhibitory antibody binds an epitope in the CCP1 domain of MASP-2. In some embodiments, the MASP-2 inhibitory antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5q of 10 nM or less. In some embodiments, the MASP-2 inhibitory antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM or less.
In some embodiments of any of the disclosed methods of the invention the MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof, comprises: (a) a heavy-chain variable région comprising: i) a heavy chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and (b) a light-chain variable région comprising: i) a light-chain CDR-L1
comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70. In some embodiments, the MASP-2 inhibitory monoclonal antibody comprises a heavy5 chain variable région set forth as SEQ ID NO:67 and a light-chain variable région set forth as SEQ ID NO:70. In some embodiments, the MASP-2 inhibitory antibody or antigen binding-fragment thereof specifically recognizes at least part of an epitope recognized by a reference antibody comprising a heavy chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
In another aspect of the invention, methods are provided for inhibiting thrombus formation in a subject suffering from atypical hemolytic urémie syndrome (aHUS), comprising administering to the subject an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, effective to inhibit MASP-2-dependent complément activation. In some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from aHUS by at least 40% as compared to untreated sérum. In some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from aHUS at a level of at least 20% greater (e.g., at least 30% greater, at least 40% greater, or at least 50% greater) than its inhibitory effect on C5b-9 déposition in the sérum from the same subject. In some embodiments, the subject is in the acute phase of aHUS. In some embodiments, the subject is in the remission phase of aHUS. In some embodiments, the MASP-2 inhibitory antibody is a monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In some embodiments, the MASP-2 inhibitory antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody. In some embodiments, the MASP-2 inhibitory antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F(ab')2. In some embodiments, the MASP-2 inhibitory antibody is a single-chain molécule. In some embodiments, the MASP-2 inhibitory antibody is selected from the group consisting of an IgGl molécule, an IgG2 and an IgG4 molécule. In some embodiments, the MASP-2 inhibitory antibody is an IgG4 molécule comprising a S228P mutation. In some embodiments, the MASP-2 inhibitory antibody binds human MASP-2 with a KD of 10 nM or less. In some embodiments, the MASP-2 inhibitory antibody binds an epitope in the CCP1 domain of MASP-2. In some embodiments, the MASP-2 inhibitory antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an ICgg of 10 nM or less. In some embodiments, the MASP-2 inhibitory antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM or less. In some embodiments the MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof, comprises: (a) a heavy-chain variable région comprising: i) a heavy chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and (b) a light-chain variable région comprising: i) a light-chain CDR-L1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70. In some embodiments, the MASP-2 inhibitory monoclonal antibody comprises a heavy-chain variable région set forth as SEQ ID NO:67 and a light-chain variable région set forth as SEQ ID NO:70. In some embodiments, the MASP-2 inhibitory antibody or antigen binding-fragment thereof specifically recognizes at least part of an epitope recognized by a référencé antibody comprising a heavy chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
In another aspect, the présent invention provides a method of treating a subject suffering from plasma therapy-resistant aHUS comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complément activation. In one embodiment, the MASP-2 inhibitory antibody is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to human MASP-2. In one embodiment, the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody, and a human antibody. In one embodiment, the subject has previously undergone, or is currently undergoing, treatment with a terminal complément inhibitor that inhibits cleavage of
complément protein C5, such as wherein the terminal complément inhibitor is a humanized anti-C5 antibody or antigen-binding fragment thereof. In one embodiment, the method further comprises treating the patient with plasmapheresis. In one embodiment, the composition comprising the MASP-2 inhibitory antibody is administered in the absence of plasmapheresis.
In another aspect, the présent invention provides a method of treating a subject suffering from TMA associated with hematopoietic stem cell transplant comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complément activation. In one embodiment, the MASP-2 inhibitory antibody is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to human MASP-2. In one embodiment, the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody, and a human antibody. In one embodiment, the subject has previously undergone, or is currently undergoing, treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In one embodiment, the subject is suffering from a TMA associated with hematopoietic stem cell transplant that is résistant to treatment with a platelet transfusion and/or résistant to treatment with plasmapheresis. In one embodiment, the MASP-2 inhibitory antibody is administered in an amount effective to improve at least one or more clinical parameters associated with TMA associated with hematopoietic stem cell transplant, such as an increase in platelet count (e.g., at least double, at least triple, at least quadmple the platelet count prior to treatment), an increase in haptoglobin, and/or a decrease in lactate dehydrogenase.
In another aspect, the présent invention provides a method of treating a human subject suffering from persistent TMA associated with hematopoietic stem cell transplant (HSCT-TMA) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complément activation. In one embodiment, the method further comprises identifying a human subject having persistent TMA associated with hematopoietic stem cell transplant prior to the step of administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complément activation. Tn one embodiment, the MASP-2 inhibitory antibody is a monoclonal antibody, or fragment thereof that specifically binds to human MASP-2. In one embodiment, the antibody or 5 antigen-binding fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody, and a human antibody. In one embodiment, the MASP-2 inhibitory antibody does not substantially inhibit the classical pathway. In one embodiment, the MASP-2 inhibitory antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM 10 or less. In one embodiment, the MASP-2 inhibitory antibody or antigen-binding fragment thereof, comprises a heavy chain variable région comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable région comprising CDR-L1, CDR-L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO:70. In one embodiment, the MASP-2 inhibitory antibody is 15 administered to the patient in the absence of plasmapheresis. In one embodiment, the subject has previously undergone, or is currently undergoing, treatment with a humanized anti-C5 antibody or antigen-binding fragment thereof, such as wherein the terminal complément inhibitor is a humanized anti-C5 antibody or antigen-binding fragment thereof. In one embodiment, the MASP-2 inhibitory antibody is delivered to the subject 20 systemically. In one embodiment, the MASP-2 inhibitory antibody or antigen-binding fragment thereof is administered in an amount effective to improve at least one or more of the following clinical parameters associated with persistent TMA associated with hematopoietic stem cell transplant: (i) an increase in platelet count (e.g., at least double, at least triple, at least quadruple the platelet count prior to treatment)); (ii) an increase in 25 haptoglobin; (iii) a decrease in lactate dehydrogenase (LDH); and/or (iv) a decrease in créatinine.
In another aspect, the présent invention provides compositions for inhibiting the adverse effects of MASP-2-dependent complément activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent, such as a MASP-2 30 inhibitory antibody and a pharmaceutically acceptable carrier. Methods are also provided for manufacturing a médicament for use in inhibiting the adverse effects of MASP-2-dependent complément activation in lîving subjects in need thereof, comprising a therapeutically effective amount of a MASP-2 inhibitory agent in a pharmaceutical carrier. Methods are also provided for manufacturing médicaments for use in inhibiting MASP-2-dependent complément activation for treatment of each of the conditions, diseases and disorders described herein below.
The methods, compositions and médicaments of the invention are useful for inhibiting the adverse effects of MASP-2-dependent complément activation in vivo in mammalian subjects, including humans suffering from or at risk for developing a thrombotic micro angiopathy (TMA) as further described herein.
DESCRIPTION OF THE DRAWINGS
The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
FIGURE 1 is a diagram illustrating the genomic structure of human MASP-2;
FIGURE 2A is a schematic diagram illustrating the domain structure of human MASP-2 protein;
FIGURE 2B is a schematic diagram illustrating the domain structure of human MApl9 protein;
FIGURE 3 is a diagram illustrating the murine MASP-2 knockout strategy;
FIGURE 4 is a diagram illustrating the human MASP-2 mînigene construct;
FIGURE 5A présents results demonstrating that MASP-2-deficiency leads to the loss of lectin-pathway-mediated C4 activation as measured by lack of C4b déposition on mannan, as described in Example 2;
FIGURE 5B présents results demonstrating that MASP-2-deficiency leads to the loss of lectin-pathway-mediated C4 activation as measured by lack of C4b déposition on zymosan, as described in Example 2;
FIGURE 5C présents results demonstrating the relative C4 activation levels of sérum samples obtained from MASP-2+/-; MASP-2-/- and wild-type strains as measure by C4b déposition on mannan and on zymosan, as described in Example 2;
FIGURE 6 présents results demonstrating that the addition of murine recombinant MASP-2 to MASP-2-/- sérum samples recovers lectin-pathway-mediated C4 activation in a protein concentration dépendant manner, as measured by C4b déposition on mannan, as described in Example 2;
FIGURE 7 présents results demonstrating that the classical pathway is functional in the MASP-2-/- strain, as described in Example 8;
FIGURE 8A présents results demonstrating that anti-MASP-2 Fab2 antibody #11 inhibits C3 convertase formation, as described in Example 10;
FIGURE 8B présents results demonstrating that anti-MASP-2 Fab2 antibody #11 binds to native rat MASP-2, as described in Example 10;
FIGURE 8C présents results demonstrating that anti-MASP-2 Fab2 antibody #41 10 inhibits C4 cleavage, as described in Example 10;
FIGURE 9 présents results demonstrating that ail of the anti-MASP-2 Fab2 antibodies tested that inhibited C3 convertase formation also were found to inhibit C4 cleavage, as described in Example 10;
FIGURE 10 is a diagram illustrating the recombinant polypeptides derived from 15 rat MASP-2 that were used for epitope mapping of the anti-MASP-2 blocking Fab2 antibodies, as described in Example 11 ;
FIGURE 11 présents results demonstrating the binding of anti-MASP-2 Fab2 #40 and #60 to rat MASP-2 polypeptides, as described in Example 11;
FIGURE 12 présents results demonstrating the blood urea nitrogen clearance for 20 wild type (+/+) and MASP-2 (-/-) mice at 24 and 48 hours after reperfusion in a rénal ischemia/reperfusion injury model, as described in Example 12;
FIGURE 13A présents results showing the baseline VEGF protein levels in RPE-choroid complex isolated from wild type (+/+) and MASP-2 (-/-) mice, as described in Example 13;
FIGURE 13B présents results showing the VEGF protein levels in RPE-choroid complex at day 3 in wild type (+/+) and MASP-2 (-/-) mice following laser induced injury in a macular degeneration model, as described in Ex ample 13;
FIGURE 14 présents results showing the mean choroidal neovascularization (CNV) volume at day seven following laser induced injury in wild type (+/+) and 30 MASP-2 (-/-) mice, as described in Example 13;
FIGURES 15A and 15B présent dose response curves for the inhibition of C4b déposition (FIG. 15A) and the inhibition of thrombin activation (FIG 15B) following the administration of a MASP-2 Fab2 antibody in normal rat sérum, as described in Example 14;
FIGURES 16A and 16B présent measured platelet aggregation (expressed as aggregate area) in MASP-2 (-/-) mice (FIG. 16B) as compared to platelet aggregation in untreated wild type mice and wild type mice in which the complément pathway is inhibited by depletory agent cobra venom factor (CVF) and a terminal pathway inhibitor (C5aR antagonist) (FIGURE 16A) in a localized Schwartzman reaction model of disseminated intravascular coagulation, as described in Example 15;
FIGURE 17 graphically illustrâtes the blood urea nitrogen (BUN) levels measured in either WT (+/+) (B6) or MASP-2 (-/-) transplant récipient mice of WT (+/+) donor kidneys, as described in Example 16;
FIGURE 18 graphically illustrâtes the percentage survival of WT (+/+) and MASP-2 (-/-) mice as a function of the number of days after microbial infection in the cecal ligation and puncture (CLP) model, as described in Example 17;
FIGURE 19 graphically illustrâtes the number of bacteria measured in WT (+/+) and MASP-2 (-/-) after microbial infection in the cecal ligation and puncture (CLP) model, as described in Example 17;
FIGURE 20 is a Kaplan-Mayer plot illustrating the percent survival of WT (+/+), MASP-2 (-/-) and C3 (-/-) mice six days after challenge with intranasal administration of Pseudomonas aeruginosa, as described in Example 18;
FIGURE 21 graphically illustrâtes the level of C4b déposition, measured as % of control, in samples taken at various time points after subcutaneous dosing of either 0.3 mg/kg or 1.0 mg/kg of mouse anti-MASP-2 monoclonal antibody in WT mice, as described in Example 19;
FIGURE 22 graphically illustrâtes the level of C4b déposition, measured as % of control, in samples taken at various time points after ip dosing of 0.6 mg/kg of mouse anti-MASP-2 monoclonal antibody in WT mice, as described in Example 19;
FIGURE 23 graphically illustrâtes the mean choroidal neovascularization (CNV) volume at day seven following laser induced injury in WT (+/+) mice pre-treated with a single ip injection of 0.3 mg/kg or 1.0 mg/kg mouse anti-MASP-2 monoclonal antibody; as described in Example 20;
FIGURE 24A graphically illustrâtes the percent survival of MASP-2 (-/-) and WT (+/+) mice after infection with 5χ1Ο8/1ΟΟ μΐ cfu N. meningitidis, as described in Example 21;
FIGURE 24B graphically illustrâtes the log cfu/ml of N. meningitidis recovered at 5 different time points in blood samples taken from the MASP-2 KO (-/-) and WT (+/+) mice infected with 5x108 cfu/100 μΐ N. meningitidis, as described in Example 21;
FIGURE 25A graphically illustrâtes the percent survival of MASP-2 KO (-/-) and WT (+/+) mice after infection with 2x108 cfu/100 μΐ N. meningitidis, as described in Example 21;
FIGURE 25B graphically illustrâtes the log cfu/ml of N. meningitidis recovered at different time points in blood samples taken from the WT (+/+) mice infected with 2xl08 cfu/100 μΐ N. meningitidis, as described in Example 21;
FIGURE 25C graphically illustrâtes the log cfu/ml of N. meningitidis recovered at different time points in blood samples taken from the MASP-2 (-/-) mice infected with 15 2xl08 cfu/100 μΐ N. meningitidis, as described in Example 21;
FIGURE 26A graphically illustrâtes the results of a C3b déposition assay demonstrating that MASP-2 (-/-) mice retain a functional classical pathway, as described in Example 22;
FIGURE 26B graphically illustrâtes the results of a C3b déposition assay on 20 zymosan coated plates, demonstrating that MASP-2 (-/-) mice retain a functional alternative pathway, as described in Example 22;
FIGURE 27A graphically illustrâtes myocardial ischemia/reperfusion injury (MIRI)-induced tissue loss following ligation of the left anterior descending branch of the coronary artery (LAD) and reperfusion in C4 (-/-) mice (n=6) and matching WT 25 littermate Controls (n=7), showing area at risk (AAR) and infarct size (INF) as described in Example 22;
FIGURE 27B graphically illustrâtes infarct size (INF) as a function of area at risk (AAR) in C4 (-/-) and WT mice treated as describe in FIGURE 42A, demonstrating that C4 (-/-) mice are as susceptible to MIRI as WT Controls (dashed line), as described in 30 Example 22;
FIGURE 28A graphically illustrâtes the results of a C3b déposition assay using sérum from WT mice, C4 (-/-) mice and sérum from C4 (-/-) mice pre-incubated with mannan, as described in Example 22;
FIGURE 28B graphically illustrâtes the results of a C3b déposition assay on sérum from WT, C4 (-/-), and MASP-2 (-/-) mice mixed with various concentrations of an anti-murine MASP-2 mAb (mAbMl 1), as described in Example 22;
FIGURE 28C graphically illustrâtes the results of a C3b déposition assay on human sérum from WT (04 sufficient) and C4 déficient sérum, and sérum from C4 déficient subjects pre-incubated with mannan, as described in Example 22;
FIGURE 28D graphically illustrâtes the results of a C3b déposition assay on human sérum from WT (C4 sufficient) and C4 déficient subjects mixed with anti-human MASP-2 mAb (mAbH3), as described in Example 22;
FIGURE 29A graphically illustrâtes a comparative analysis of C3 convertase activity in plasma from various complément déficient mouse strains tested either under 15 lectin activation pathway spécifie assay conditions, or under classical activation pathway spécifie assay conditions, as described in Example 22;
FIGURE 29 B graphically illustrâtes the time-resolved kinetics of C3 convertase activity in plasma from various complément déficient mouse strains tested under lectin activation pathway spécifie conditions, as described in Example 22;
FIGURE 30 illustrâtes the results of a Western blot analysis showing activation of human C3, shown by the presence of the a' chain, by thrombin substrates FXIa and FXa, as described in Example 23;
FIGURE 31 shows the results of the C3 déposition assay on sérum samples obtained from WT, MASP-2 (-/-), Fl 1(7-), Fll(-/-)/C4 (-/-) and C4 (-/-), as described in 25 Example 23;
FIGURE 32A is a Kaplain-Meier survival plot showing the percent survival over time after exposure to 7.0 Gy radiation in control mice and in mice treated with antimurine MASP-2 antibody (mAbMll) or anti-human MASP-2 antibody (mAbH6) as described in Example 29;
FIGURE 32B is a Kaplain-Meier survival plot showing the percent survival over time after exposure to 6.5 Gy radiation in control mice and in mice treated with anti| i i !
i ! ........................................................................................................................ ........J murine MASP-2 antibody (mAbMll) or anti-human MASP-2 antibody (mAbH6), as described in Example 29;
FIGURE 33 is a Kaplan-Meyer plot graphically illustrating the percent survival of MASP-2 KO and WT mice after administration of an infective dose of 2.6 x 107 cfu of N. meningitidis serogroup A Z2491, demonstrating that MASP-2 déficient mice are protected from N. meningitidis induced mortality, as described in Example 30;
FIGURE 34 is a Kaplan-Meyer plot graphically illustrating the percent survival of MASP-2 KO and WT mice after administration of an infective dose of 6 x 106 cfu of N. meningitidis serogroup B strain MC58, demonstrating that MASP-2-deficient mice are protected from N. meningitidis serogroup B strain MC58 induced mortality, as described in Example 30;
FIGURE 35 graphically illustrâtes the log cfu/ml of N. meningitidis serogroup B strain MC 5 8 recovered at different time points in blood samples taken from the MASP-2 KO and WT mice after i.p. infection with 6x10^ cfu of N. meningitidis serogroup B strain MC58 (n=3 at different time points for both groups of mice, results are expressed as Means±SEM) demonstrating that although the MASP-2 KO mice were infected with the same dose of N. meningitidis serogroup B strain MC58 as the WT mice, the MASP-2 KO mice hâve enhanced clearance of bacteraemia as compared to WT, as described in Example 30;
FIGURE 36 graphically illustrâtes the average illness score of MASP-2 and WT mice at 3, 6, 12 and 24 hours after infection with 6x106 cfu/100 μΐ N. meningitidis Serogroup Serogroup B strain MC58, demonstrating that the MASP-2 déficient mice showed high résistance to the infection, with much lower illness scores at 6 hours, as described in Example 30;
FIGURE 37 is a Kaplan-Meyer plot graphically illustrating the percent survival of mice after administration of an infective dose of 4 x 106/100 μΐ cfu N. meningitidis Serogroup B strain MC58, followed by administration 3 hours post infection of either inhibitory anti-MASP-2 antibody (1 mg/kg) or control isotype antibody, demonstrating that anti-MASP-2 antibody is effective to treat and improve survival in subjects infected with N. meningitidis, as described in Example 31;
Ο 27
FIGURE 38 graphically illustrâtes the log cfu/ml of viable counts of TV. meningitidis serogroup B-MC58 recovered at different time points in 20% human sérum concentration after i.p, infection with 6.5x106 cfu/100 μΐ N. meningitidis serogroup B strain MC58 at 0, 30, 60 and 90 minutes after incubation in the presence of: (A) normal 5 human sérum (NHS) plus human anti-MASP-2 antibody; (B) normal human sérum (NHS) plus isotype control antibody; (C) MBL-/- human sérum; (D) normal human sérum (NHS) and (E) heat inactivated normal human sérum (NHS), showing that complément dépendent killing of N. meningitidis in human sérum was significantly enhanced by the addition of the human anti-MASP-2 antibody, as described in Example 10 32;
FIGURE 39 graphically illustrâtes the log cfu/ml of viable counts of N. meningitidis serogroup B-MC58 recovered at different time points in the mouse sera samples, demonstrating MASP-2 -/- mouse sera has a higher level of bactericidal activity for Al. meningitidis than WT mouse sera, as described in Example 32;
FIGURE 40 graphically illustrâtes hemolysis (as measured by hemoglobin release of lysed mouse érythrocytes (Crry/C3-/-) into the supernatant measured by photometry) of mannan-coated murine érythrocytes by human sérum over a range of sérum concentrations The sera tested included heat-inactivated (HI) NHS, MBL-/-, NHS 4-antiMASP-2 antibody and NHS control, as described in Example 33;
FIGURE 41 graphically illustrâtes hemolysis (as measured by hemoglobin release of lysed WT mouse érythrocytes into the supernatant measured by photometry) of noncoated murine érythrocytes by human sérum over a range of sérum concentrations. The sera tested included heat-inactivated (HI) NHS, MBL-/-, NHS +anti-MASP-2 antibody and NHS control, demonstrating that inhibiting MASP-2 inhibits complement-mediated 25 lysis of non-sensitized WT mouse érythrocytes, as described in Example 33;
FIGURE 42 graphically illustrâtes hemolysis (as measured by hemoglobin release of lysed mouse érythrocytes (CD55/59 -/-) into the supernatant measured by photometry) of non-coated murine érythrocytes by human sérum over a range of sérum concentrations. The sera tested included heat-inactivated (HI) NHS, MBL-/-, NHS +anti-MASP-2 30 antibody and NHS control, as described in Ex ample 33;
FIGURE 43 graphically illustrâtes the percent survival over time (days) after exposure to 8.0 Gy radiation in control mice and in mice treated with anti-human MASP2 antibody (mAbH6), as described in Example 34;
FIGURE 44 graphically illustrâtes the time to onset of microvascular occlusion 5 following LPS injection in MASP-2 -/- and WT mice, showing the percentage of mice with thrombus formation measured over 60 minutes, demonstrating that thrombus formation is detected after 15 minutes in WT mice, with up to 80% of the WT mice demonatrated thrombus formation at 60 minutes; in contrast, noue of the MASP-2 -fmice showed any thrombus formation during the 60 minute period (log rank: p=0.0005), 10 as described in Ex ample 35;
FIGURE 45 graphically illustrâtes the percent survival of saline treated control mice (n=5) and anti-MASP-2 antibody treated mice (n=5) in the STX/LPS-induced model of HUS over time (hours), demonstrating that ail of the control mice died by 42 hours, whereas, in contrast, 100 % of the anti-MASP-2 antibody-treated mice survived 15 throughout the time course of the experiment, as described in Example 36;
FIGURE 46 graphically illustrâtes, as a function of time after injury induction, the percentage of mice with microvascular occlusion in the FITC/Dextran UV model after treatment with isotype control, or human MASP-2 antibody mAbH6 (lOmg/kg) dosed at 16 hours and 1 hour prior to injection of FITC/Dextran, as described in Example 37;
FIGURE 47 graphically illustrâtes the occlusion time in minutes for mice treated with the human MASP-2 antibody (mAbH6) and the isotype control antibody, wherein the data are reported as scatter-dots with mean values (horizontal bars) and standard eixor bars (vertical bars). The statistical test used for analysis was the unpaired t test; wherein the Symbol indicates p=0.0129, as described in Example 37; and
FIGURE 48 graphically illustrâtes the time until occlusion in minutes for wildtype mice, MASP-2 KO mice, and wild-type mice pre-treated with human MASP-2 antibody (mAbH6) administered i.p. at lOmg/kg 16 hours before, and again 1 hour prior to the induction of thrombosis in the FITC-dextran/light induced endothélial cell injury model of thrombosis with low light intensity (800-1500), as described in Example 37;
FIGURE 49 is a Kaplan-Meier plot showing the percentage of mice with thrombi as a function of time in FITC-Dextran induced thiOmbotic microangiopathy in mice treated with increasing doses of human MASP-2 inhibitory antibody (mAbH6) or an isotype control antibody, as described in Example 39;
FIGURE 50 graphically illustrâtes the médian time to onset (minutes) of thrombus formation as a function of mAbH6 dose (*p<0.01 compared to control), as described in Example 39;
FIGURE 51 is a Kaplan-Meier plot showing the percentage of mice with microvascular occlusion as a function of time in FITC-Dextran induced thrombotic microangiopathy in mice treated with imcreasing doses of human MASP-2 inhibitory antibody (mAbH6) or an isotype control antibody, as described in Example 39;
FIGURE 52 graphically illustrâtes the médian time to microvascular occlusion as a function of mAbH6 dose (*p<0.05 compared to control), as described in Example 39;
FIGURE 53A graphically illustrâtes the level of MAC déposition in the presence or absence of human MASP-2 monoclonal antibody (OMS646) under lectin pathwayspecific assay conditions, demonstrating that OMS646 inhibits lectin-mediated MAC déposition with an IC50 value of approximately 1 nM, as described in Example 40;
FIGURE 53 B graphically illustrâtes the level of MAC déposition in the presence or absence of human MASP-2 monoclonal antibody (OMS646) under classical pathwayspecific assay conditions, demonstrating that OMS646 does not inhibit classical pathwaymediated MAC déposition, as described in Example 40;
FIGURE 53C graphically illustrâtes the level of MAC déposition in the presence or absence of human MASP-2 monoclonal antibody (OMS646) under alternative pathway-spécifie assay conditions, demonstrating that OMS646 does not inhibit alternative pathway-mediated MAC déposition, as described in Example 40;
FIGURE 54 graphically illustrâtes the pharmacokinetic (PK) profile of human MASP-2 monoclonal antibody (OMS646) in mice, showing the OMS646 concentration (mean of n=3 animals/groups) as a function of time after administration at the indicated dose, as described in Example 40;
FIGURE 55A graphically illustrâtes the pharmacodynamie (PD) response of human MASP-2 monoclonal antibody (OMS646), measured as a drop in systemic lectin pathway activity in mice foliowing intravenous administration, as described in Example 40;
Ο 30
FIGURE 55Β graphically illustrâtes the pharmacodynamie (PD) response of human MASP-2 monoclonal antibody (OMS646), measured as a drop in systemic lectin pathway activity in mice following subeutaneous administration, as described in Example 40;
FIGURE 56 graphically illustrâtes the inhibitory effect of MASP-2 antibody (OMS646) as compared to sCRl on aHUS sérum-induced C5b-9 déposition on ADPactivated HMEC-1 cells, as described in Example 41;
FIGURE 57 graphically illustrâtes the inhibitory effect of MASP-2 antibody (OMS646) as compared to sCRl on aHUS serum-induced thrombus formation on ADP10 activated HMEC-1 cells, as described in Example 42;
FIGURE 58 graphically illustrâtes the mean change in platelet count from baseline over time (weeks) in subjects suffering from persistent hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) after treatment with MASP-2 inhibitory antibody (OMS646), as described in Example 46;
FIGURE 59 graphically illustrâtes the mean change in LDH from baseline over time (weeks) in subjects suffering from persistent (HSCT-TMA) after treatment with MASP-2 inhibitory antibody (OMS646), as described in Example 46; and
FIGURE 60 graphically illustrâtes the mean change in haptoglobin from baseline over time (weeks) in subjects suffering from persistent (HSCT-TMA) after treatment with 20 MASP-2 inhibitory antibody (OMS646), as described in Example 46.
DESCRIPTION OF THE SEQUENCE LISTING
SEQ ID NO:1 human MApl9 cDNA
SEQ ID NO:2 human MApl9 protein (with leader)
SEQ ID NO:3 human MApl9 protein (mature)
SEQ ID NO:4 human MASP-2 cDNA
SEQ ID NO:5 human MASP-2 protein (with leader)
SEQ ID NO: 6 human MASP-2 protein (mature)
SEQ ID NO:7 human MASP-2 gDNA (exons 1-6)
Ο 31
ANTIGENS: (IN REFERENCE TO THE MASP-2 MATURE PROTEIN)
SEQ ID N0:8 CUBI sequence (aa 1-121)
SEQ ID N0:9 CUBEGF sequence (aa 1-166)
SEQ ID NO: 10 CUBEGFCUBII (aa 1-293)
SEQ ID NO: 11 EGF région (aa 122-166)
SEQ ID NO: 12 serine protease domain (aa 429 - 671)
SEQ ID NO:13 serine protease domain inactive (aa 610-625 with Ser618 to Ala mutation)
SEQ ID NO: 14 TPLGPKWPEPVFGRL (CUB1 peptide)
SEQ ID NO: 15
TAPPGYRLRLYFTHFDLELSHLCEYDFVKLSSGAKVLATLC GQ (CUBI peptide)
SEQ ID NO: 16 TFRSDYSN (MBL binding région core)
SEQ ID NO: 17 FYSLGSSLDITFRSDYSNEKPFTGF (MBL binding région)
SEQ ID NO: 18 IDECQVAPG (EGF PEPTIDE)
SEQ ID NO: 19 ANMLCAGLESGGKDSCRGDSGGALV (serine protease binding core)
PEPTIDE INHIBITORS:
SEQ ID NO:20 MBL full length cDNA
SEQ ID NO:21 MBL full length protein
SEQ ID NO:22 OGK-X-GP (consensus binding)
SEQ ID NO:23 OGKLG
SEQ ID NO:24 GLR GLQ GPO GKL GPO G
SEQ ID NO:25 GPO GPO GLR GLQ GPO GKL GPO GPO GPO
SEQ ID NO:26 GKDGRDGTKGEKGEPGQGLRGLQGPOGKLGPOG
SEQ ID NO:27 GAOGSOGEKGAOGPQGPOGPOGKMGPKGEOGDO (human h-ficolin)
SEQ ID NO:28
GCOGLOGAOGDKGEAGTNGKRGERGPOGPOGKAGPOGPN
GAOGEO (human ficolin p35)
SEQ ID NO:29 LQRALEILPNRVTIKANRPFLVFI (C4 cleavage site)
EXPRESSION INHIBITORS:
SEQ ID NO:30 cDNA of CUBI-EGF domain (nucléotides 22-680 of SEQ
ID NO:4)
SEQIDNO:31
5' CGGGCACACCATGAGGCTGCTGACCCTCCTGGGC 3’ Nucléotides 12-45 of SEQ ID NO:4 including the MASP-2 translation start site (sense)
SEQ ID NO;32
5GACATTACCTTCCGCTCCGACTCCAACGAGAAG3’
Nucléotides 361-396 of SEQ ID NO:4 encoding a région comprising the MASP-2 MBL binding site (sense)
SEQ ID NO:33
5AGCAGCCCTGAATACCCACGGCCGTATCCCAAA3’
Nucléotides 610-642 of SEQ ID NO:4 encoding a région comprising the CUB II domain
CLONING PRIMERS:
SEQ ID NO:34 CGGGATCCATGAGGCTGCTGACCCTC (5’ PCR for CUB)
SEQ ID NO:35 GGAATTCCTAGGCTGCATA (3' PCR FOR CUB)
SEQ ID NO:36 GGAATTCCTACAGGGCGCT (3' PCR FOR CUBIEGF)
SEQ ID NO:37 GGAATTCCTAGTAGTGGAT (3' PCR FOR CUBIEGFCUBII)
SEQ ID NOS:38-47 are cloning primers for humanized antibody
SEQ ID NO:48 is 9 aa peptide bond
EXPRESSION VECTOR:
SEQ ID NO:49 is the MASP-2 minigene insert
SEQ ID NO: 50 is the murine MASP-2 cDNA
SEQ ID NO: 51 is the murine MASP-2 protein (w/leader)
SEQ ID NO: 52 is the mature murine MASP-2 protein
SEQ ID NO: 53 the rat MASP-2 cDNA
SEQ ID NO: 54 is the rat MASP-2 protein (w/ leader)
SEQ ID NO: 55 is the mature rat MASP-2 protein
SEQ ID NO: 56-59 are the oligonucleotides for site-directed mutagenesis of human MASP-2 used to generate human MASP-2A
SEQ ID NO: 60-63 are the oligonucleotides for site-directed mutagenesis of murine MASP-2 used to generate murine MASP-2A
SEQ ID NO: 64-65 are the oligonucleotides for site-directed mutagenesis of rat MASP-2 used to generate rat MASP-2A
SEQ ID NO: 66 DNA encoding 17D20_dc35VH21NllVL (OMS646) heavy chain variable région (VH) (without signal peptide)
SEQ ID NO: 67 17D20_dc35VH21NllVL (OMS646) heavy chain variable région (VH) polypeptide
SEQ ID NO: 68 17N16mc heavy chain variable région (VH) polypeptide
SEQ ID NO: 69: DNA encoding 17D20_dc35VH21NllVL (OMS646) light chain variable région (VL)
SEQ ID NO: 70: 17D20_dc35VH21NHVL (OMS646) light chain variable région (VL) polypeptide
SEQ ID NO: 71: 17N16_dcl7N9 light chain variable région (VL) polypeptide
DETAILED DESCRIPTION
The présent invention is based upon the surprising discovery by the présent inventors that it is possible to inhibit the lectin mediated MASP-2 pathway while leaving the classical pathway intact. The présent invention also describes the use of MASP-2 as a therapeutic target for inhibiting cellular injury associated with lectin-mediated complément pathway activation while leaving the classical (Clq-dependent) pathway component of the immune System intact.
I. DEFINITIONS
Unless specifically defined herein, ail tenus used herein hâve the same meaning as would be understood by those of ordinary skill in the art of the présent invention. The following définitions are provided in order to provide clarity with respect to the terms as they are used in the spécification and daims to describe the présent invention.
As used herein, the terni “MASP-2-dépendent complément activation” comprises MASP-2- dépendent activation of the lectin pathway, which occurs under physiological conditions (Le., in the presence of Ca++) leading to the formation of the lectin pathway C3 convertase C4b2a and upon accumulation of the C3 cleavage product C3b subsequently to the C5 convertase C4b2a(C3b)n, which has been determined to primarily cause opsonization.
As used herein, the term alternative pathway refers to complément activation that is triggered, for example, by zymosan from fungal and yeast cell walls, lipopolysaccharide (LPS) from Gram négative outer membranes, and rabbit érythrocytes, as well as from many pure polysaccharides, rabbit érythrocytes, viruses, bacteria, animal tumor cells, parasites and damaged cells, and which has traditionally been thought to arise from spontaneous proteolytic génération of C3b from complément factor C3.
As used herein, the term lectin pathway refers to complément activation that occurs via the spécifie binding of sérum and non-serum carbohydrate-binding proteins including mannan-binding lectin (MBL), CL-11 and the ficolins (H-ficolin, M-ficolin, or L-ficolin).
As used herein, the term classical pathway refers to complément activation that is triggered by antibody bound to a foreign particle and requires binding of the récognition molécule Clq.
As used herein, the term MASP-2 inhibitory agent refers to any agent that binds to or directly interacts with MASP-2 and effectively inhibits MASP-2-dependent complément activation, including anti-MASP-2 antibodies and MASP-2 binding fragments thereof, natural and synthetic peptides, small molécules, soluble MASP-2 receptors, expression inhibitors and isolated natural inhibitors, and also encompasses peptides that compete with MASP-2 for binding to another récognition molécule (e.g., MBL, H-ficolin, M-ficolin, or L-ficolin) in the lectin pathway, but does not encompass antibodies that bind to such other récognition molécules. MASP-2 inhibitory agents useful in the method of the invention may reduce MASP-2-dépendent complément activation by greater than 20%, such as greater than 50%, such as greater than 90%. In one embodiment, the MASP-2 inhibitory agent reduces MASP-2-dépendent complément activation by greater than 90% (i.e., resulting in MASP-2 complément activation of only 10% or less).
As used herein, the term antibody encompasses antibodies and antibody fragments thereof, derived from any antibody-producing mammal (e.g., mouse, rat, rabbit, and primate including human), or from a hybridoma, phage sélection, recombinant expression or transgénie animais (or other methods of producing antibodies or antibody 5 fragments”), that specifically bind to a target polypeptide, such as, for example, MASP-2, polypeptides or portions thereof. It is not intended that the term “antibody” limited as regards to the source of the antibody or the manner in which it is made (e.g., by hybridoma, phage sélection, recombinant expression, transgenic animal, peptide synthesis, etc). Exemplary antibodies include polyclonal, monoclonal and recombinant 10 antibodies; pan-specific, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies); humanized antibodies; murine antibodies; chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies; and anti-idiotype antibodies, and may be any intact antibody or fragment thereof. As used herein, the term “antibody” encompasses not only intact polyclonal or monoclonal antibodies, but also fragments 15 thereof (such as dAb, Fab, Fab', F(ab')2, Fv), single chain (ScFv), synthetic variants thereof, naturally occurring variants, fusion proteins comprising an antibody portion with an antigen-binding fragment of the required specificity, humanized antibodies, chimeric antibodies, and any other modified configuration of the immunoglobulin molécule that comprises an antigen-binding site or fragment (epitope récognition site) of the required 20 specificity.
A “monoclonal antibody refers to a homogeneous antibody population wherein the monoclonal antibody is comprised of amino acids (naturally occurring and nonnaturally occurring) that are involved in the sélective binding of an epitope. Monoclonal antibodies are highly spécifie for the target antigen. The term monoclonal antibody 25 encompasses not only intact monoclonal antibodies and full-length monoclonal antibodies, but also fragments thereof (such as Fab, Fab', F(ab')2, Fv), single chain (ScFv), variants thereof, fusion proteins comprising an antigen-binding portion, humanized monoclonal antibodies, chimeric monoclonal antibodies, and any other modified configuration of the immunoglobulin molécule that comprises an antigen30 binding fragment (epitope récognition site) of the required specificity and the ability to bind to an epitope. It is not intended to be limited as regards the source of the antibody or the manner in which it is made (e.g., by hybridoma, phage sélection, recombinant expression, transgenic animais, etc.). The term includes whole immunoglobulins as well as the fragments etc. described above under the définition of antibody.
As used herein, the term antibody fragment refers to a portion derived from or related to a full-length antibody, such as, for example, an anti-MASP-2 antibody, 5 generally including the antigen binding or variable région thereof. Illustrative examples of antibody fragments include Fab, Fab', F(ab)2, F(ab')2 and Fv fragments, scFv fragments, diabodies, linear antibodies, single-chain antibody molécules and multispecific antibodies formed from antibody fragments.
As used herein, a single-chain Fv or scFv antibody fragment comprises the 10 Vjq and Vl domains of an antibody, wherein these domains are présent in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the Vjq and Vl domains, which enables the scFv to form the desired structure for antigen binding.
As used herein, a chimeric antibody is a recombinant protein that contains the 15 variable domains and complementarity-determining régions derived from a non-human species (e.g., rodent) antibody, while the remainder of the antibody molécule is derived from a human antibody.
As used herein, a humanized antibody is a chimeric antibody that comprises a minimal sequence that conforms to spécifie complementarity-determining régions derived 20 from non-human immunoglobulin that is transplanted into a human antibody framework. Humanized antibodies are typically recombinant proteins in which only the antibody complementarity-determining régions are of non-human origin.
As used herein, the term mannan-binding lectin (MBL) is équivalent to mannan-binding protein (MBP).
As used herein, the membrane attack complex (MAC) refers to a complex of the terminal five complément components (C5b combîned with C6, C7, C8 and C-9) that inserts into and disrupts membranes (also referred to as C5b-9).
As used herein, a subject includes ail mammals, including without limitation humans, non-human primates, dogs, cats, horses, sheep, goats, cows, rabbits, pigs and 30 rodents.
As used herein, the amino acid residues are abbreviated as follows: alanine (Ala;A), asparagine (Asn;N), aspartic acid (Asp;D), arginine (Arg;R), cysteine (Cys;C), glutamic acid (GIu;E), glutamine (Gln;Q), glycine (Gly;G), histidine (His;H), isoleucine (Ile;I), leucine (Leu;L), lysine (Lys;K), méthionine (Met;M), phenylalanine (Phe;F), proline (Pro;P), serine (Ser;S), threonine (Thr;T), tryptophan (Trp;W), tyrosine (Tyr;Y), and valine (Val;V).
In the broadest sense, the naturally occurring amino acids can be divided into groups based upon the Chemical characteristic of the side chain of the respective amino acids. By hydrophobie amino acid is meant either Ile, Leu, Met, Phe, Trp, Tyr, Val, Ala, Cys or Pro. B y hydrophilic amino acid is meant either Gly, Asn, Gin, Ser, Thr, Asp, Glu, Lys, Arg or His. This grouping of amino acids can be further subclassed as follows. By uncharged hydrophilic amino acid is meant either Ser, Thr, Asn or Gin. By acidic amino acid is meant either Glu or Asp. By basic amino acid is meant either Lys, Arg or His.
As used herein the term conservative amino acid substitution is illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine,
The term oligonucleotide as used herein refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term also covers those oligonucleobases composed of naturally-occurring nucléotides, sugars and covalent intemucleoside (backbone) linkages as well as oligonucleotides having non-naturally- occurring modifications.
As used herein, an epitope refers to the site on a protein (e.g., a human MASP-2 protein) that is bound by an antibody. Overlapping epitopes include at least one (e.g., two, three, four, five, or six) common amino acid residue(s), including linear and nonlinear epitopes.
As used herein, the tenus polypeptide, peptide, and protein are used interchangeably and mean any peptide-linked chain of amino acids, regardless of length or post-translational modification. The MASP-2 protein described herein can contain or be wild-type proteins or can be variants that hâve not more than 50 (e.g., not more than one, two, three, four, five, six, seven, eight, nine, ten, 12, 15, 20, 25, 30, 35, 40, or 50) conservative amino acid substitutions. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and phenylalanine and tyrosine.
In some embodiments, the human MASP-2 protein can hâve an amino acid sequence that is, or is greater than, 70 (e.g., 71, 72, 73, 74, 75, 76, ΊΊ, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100) % identical to the human MASP-2 protein having the amino acid sequence set forth in SEQ ID NO: 5.
In some embodiments, peptide fragments can be at least 6 (e.g., at least 7, 8, 9,10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, or 600 or more) amino acid residues in length (e.g., at least 6 contiguous amino acid residues of SEQ ID NO: 5). In some embodiments, an antigenic peptide fragment of a human MASP-2 protein is fewer than 500 (e.g., fewer than 450, 400, 350, 325, 300, 275, 250, 225, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or 6) amino acid residues in length (e.g., fewer than 500 contiguous amino acid residues in any oneofSEQIDNOS: 5).
Percent (%) amino acid sequence identity is defined as the percentage of amino acids in a candidate sequence that are identical to the amino acids in a reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent sequence identity can be achieved in varions ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the fulllength of the sequences being compared can be determined by known methods.
II. OverView of the Invention
Lectins (MBL, M-ricolin, H-ficolin, L-ficolin and CL-11) are the spécifie récognition molécules that trigger the innate complément System and the System includes the lectin initiation pathway and the associated terminal pathway amplification loop that amplifies lectin-initiated activation of terminal complément effector molécules. Clq is the spécifie récognition molécule that triggers the acquired complément System and the System includes the classical initiation pathway and associated terminal pathway amplification loop that amplifies Clq-initiated activation of terminal complément effector molécules. We refer to these two major complément activation Systems as the lectin-dependent complément System and the Clq-dependent complément System, respectively.
In addition to its essential rôle in immune defense, the complément System contributes to tissue damage in many clinical conditions. Thus, there is a pressing need to develop therapeutically effective complément inhibitors to prevent these adverse effects. With the récognition that it is possible to inhibit the lectin mediated MASP-2 pathway while leaving the classical pathway intact cornes the realization that it would be highly désirable to specifically inhibit only the complément activation System causing a particular pathology without completely shutting down the immune defense capabilities of complément. For example, in disease States in which complément activation is mediated predominantly by the lectin-dependent complément system, it would be advantageous to specifically inhibit only this System. This would leave the Clq-dependent complément activation System intact to handle immune complex Processing and to aid in host defense against infection.
The preferred protein component to target in the development of therapeutic agents to specifically inhibit the lectin-dependent complément system is MASP-2. Of ail the known protein components of the lectin-dependent complément System (MBL, H-ficolin, M-ficolin, L-ficolin, MASP-2, C2-C9, Factor B, Factor D, and properdin), only MASP-2 is both unique to the lectin-dependent complément system and required for the system to function. The lectins (MBL, H-ficolin, M-ficolin,L-ficolin and CL-11) are also unique components in the lectin-dependent complément system. However, loss of any one of the lectin components would not necessarily inhibit activation of the system due to lectin redundancy. It would be necessary to inhibit ail five lectins in order to guarantee inhibition of the lectin-dependent complément activation System. Furthermore, since
MBL and the ficolins are also known to hâve opsonic activity independent of complément, inhibition of lectin function. would resuit in the loss of this bénéficiai host defense mechanism against infection. In contrast, this complement-independent lectin opsonic activity would remain intact if MASP-2 was the inhibitory target. An added benefit of MASP-2 as the therapeutic target to inhibit the lectin-dependent complément activation System is that the plasma concentration of MASP-2 is among the lowest of any complément protein (~ 500 ng/ml); therefore, correspondingly low concentrations of high-affinity inhibitors of MASP-2 may be sufficient to obtain full inhibition (Moller-Kristensen, M., et al., J. Immunol Methods 282:159-167, 2003).
III. THE ROLE OF MASP-2 IN THROMBOTIC MICROANGIOPATHIES AND
THERAPEUTIC METHODS USING MASP-2 INHIBITORY AGENTS
OverView
Thrombotic microangiopathy (TMA) is a pathology characterized by blood clots in small blood vessels (Benz, K.; et al., Curr Opin Nephrol Hypertens 19(3):242-7 (2010)). Stress or injury to the underlying vascular endothélium is believed to be a primary driver. Clinical and laboratory findings of TMA include thrombocytopenia, anémia, purpura, and rénal failure. The classic TMAs are hemolytic urémie syndrome (HUS) and thrombotic thrombocytopénie purpura (TTP). The characteristic underlying pathological feature of TMAs are platelet activation and the formation of microthrombi in the small artérioles and venules. Complément activation initiated, at least in part, by an injury or stress to microvascular endothélium, is also implicated in other TMAs including catastrophic antiphospholipid syndrome (CAPS), systemic Degos disease, and TMAs secondary to cancer, cancer chemotherapy and transplantation.
Direct evidence for a pathological rôle of complément in a host of nephritides is provided by studies of patients with genetic deficiencies in spécifie complément components. A number of reports hâve documented an association of rénal injury with deficiencies of complément regulatory factor H (Ault, B.H., Nephrol. 74:1045-1053, 2000; Levy, M., et al., Kidney Int. 50:949-56, 1986; Pickering, M.C., et al., Nat. Genet. 57:424-8, 2002). Factor H deficiency results in low plasma levels of factor B and C3 due to activation-related consumption of these components. Circulating levels of C5b-9 are also elevated m the sérum of these patients, rmplying complément activation. Membranoproliferative glomerulonephritis (MPGN) and idiopathic hemolytic urémie syndrome (HUS) are associated with factor H deficiency or mutations of factor H. Factor H-deficient pigs (Jansen, J.H., et al., Kidney Int. 55:331-49, 1998) and factor-H knockout mice (Pickering, M.C., 2002) display MPGN-like symptoms, confirming the importance of factor H in complément régulation. Deficiencies of other complément components are associated with rénal disease, secondary to the development of systemic lupus erythematosus (SLE) (Walport, M.J., Davies, et al., Ann. N.Y. Acad. Sci. 575:267-81, 1997). Deficiency for Clq, C4 and C2 prédisposé strongly to the development of SLE via mechanisms relating to defective clearance of immune complexes and apoptotic material. In many of these SLE patients lupus nephritis occurs, characterized by the déposition of immune complexes throughout the glomerulus.
aHUS
Atypical hemolytic urémie syndrome (aHUS) is part of a group of conditions termed “Thrombotic microangiopathies.” In the atypical form of HUS (aHUS), the disease is associated with defective complément régulation and can be either sporadic or familial. Familial cases of aHUS are associated with mutations in genes coding for complément activation or complément regulatory proteins, including complément factor H, factor I, factor B, membrane cofactor CD46 as well as complément factor H-related protein 1 (CFHR1) and complément factor H-related protein 3 (CFHR3). (Zipfel, P.F., et al., PloS Genetics 5(3):e41 (2007)). The unifying feature of this diverse array of genetic mutations associated with aHUS is a prédisposition to enhanced complément activation on cellular or tissue surfaces. Therefore, one aspect of the présent invention comprises treating a patient suffering with aHUS that is associated with a factor H defiency by administering an effective amount of a MASP-2 inhibitory agent. Another aspect of the présent invention comprises treating a patient suffering with HUS that is associated with a factor I, factor B, membrane cofactor CD46, CFHR1 or CFHR3 deficiency by administering an effective amount of a MASP-2 inhibitory agent.
Signifïcant progress has been made recently toward the understanding of the molecular pathophysiology underlying enhanced complément activation in aHUS caused b y the diverse set of mutant complément factors. This mechanism is best understood for factor H mutations. Factor H is an abundant sérum protein comprising 20 short consensus repeat (SCR) domains that acts as a négative regulator of complément activation both in solution as well as on host cell surfaces. It targets the activated form of C3 and, together with factor I and other cofactors, promotes its inactivation, forestalling further complément activation. To effectively control complément activation on host cell 5 surfaces, factor H needs to interact with host cells, which is mediated by SCR domains
16-20. Ail factor H mutations associated with aHUS described to date are clustered in the C-terminal région encompassing (SCR) domains 16-20. These mutant factor H proteins are fully functional in controlling C3 activation in solution, but are unable to interact with host cell surfaces and consequently cannot control C3 activation on cellular surfaces (Exp 10 Med 204(6):1249-56 (2007)). Thus, certain mutations of factor H are associated with aHUS because the mutant factor H protein fails to interact with host cell surfaces and thus cannot effectively down modulate complément activation on host cell surfaces, including the microvascular endothélium. As a resuit, once initial C3 activation has occurred, subséquent complément activation on microvascular endothélial surfaces proceeds 15 unabated in patients with factor H mutations. This uncontrolled activation of complément ultimately leads to progressive injury to the vascular endothélium, subséquent platelet aggregation and microvascular coagulation, and hemolysis caused by sheer stress of RBC passage through partially occluded microvessels. Thus, aHUS disease manifestations and clinical and laboratory findings are directly linked to a defect in the négative régulation of 20 complément on the surface of the microvascular endothélium.
Analogous to factor H mutation, loss-of-function mutations in the négative complément modulators factor I and membrane cofactor protein (CD46) are also linked to aHUS. The opposite has been observed for factor B the C3 protein in that aHUS was found to be associated with gain-of-function mutations in these proteins (Pediatr Nephrol 25 25(12):2431-42 (2010)). Thus, a host of converging data implicates complément activation in aHUS pathogenesis. This notion is most convincingly supported by the therapeutic efficacy ofeculizumab, a monoclonal antibody that blocks the terminal complément protein C5 in the treatment of aHUS.
While the central rôle of complément as an effector mechanism in aHUS is widely 30 accepted, the triggers initiating complément activation and the molecular pathways involved are unresolved. Not ail individuals carrying the above described mutations develop aHUS. In fact, familial studies hâve suggested that the penetrance of aHUS is only -50% (Ann Hum Genet 74(1):17-26 (2010)). The natural history of the disease suggests that aHUS most often develops after an initiating event such as an infections épisode or an injury. Infections agents are well known to activate the complément System. In the absence of pre-existing adaptive immunity, complément activation by 5 infections agents may be primarily initiated via the lectin pathway. Thus, lectin pathway activation triggered by an infection may represent the initiating trigger for subséquent pathological amplification of complément activation in aHUS-predisposed individuals, which may ultimately lead to disease progression. Accordingly, another aspect of the présent invention comprises treating a patient suffering with aHUS secondary to an 10 infection by administering an effective amount of a MASP-2 inhibitory agent.
Other forms of injury to host tissue will activate complément via the lectin pathway, in particular injury to the vascular endothélium. Human vascular endothélial cells subject to oxidative stress for example respond b y expressing surface moieties that bind lectins and activate the lectin pathway of complément (Am J. Pathol 156(6):1549-56 15 (2000)). Vascular injury following ischemia/reperfusion also activâtes complément via the lectin pathway in vivo (Scand J Immunol 61(5):426-34 (2005)). Lectin pathway activation in this setting has pathological conséquences for the host, and inhibition of the lectin pathway by blocking MASP-2 prevents further host tissue injury and adverse outcomes (Schwaeble PNAS 2011).
Thus, other processes that precipitate aHUS are also known to activate the lectin pathway of complément. It is therefore likely that the lectin pathway may represent the initial complément activating mechanism that is inappropriately amplified in a deregulated fashion in individuals genetically predisposed to aHUS, thus initiating aHUS pathogenesis. By inference, agents that block activation of complément via the lectin 25 pathway, including anti-MASP-2 antibodies, aie expected to prevent disease progression or reduce exacerbations in aHUS susceptible individuals.
In further support of this concept, recent studies hâve identified S. pneumonia as an important etiological agent in pédiatrie cases of aHUS. (Nephrology (Carlton), 17:4852 (2012); Pedîatr Infect Dis J. 30(9):736-9 (2011)). This particular etiology appears to 30 hâve an unfavorable prognosis, with significant mortality and long-term morbidity.
Notably, these cases involved non-enteric infections leading to manifestations of microangiopathy, uremia and hemolysis without evidence of concurrent mutations in complément genes known to prédisposé to aHUS. It is important to note that S. pneumonia is particularly effective at activating complément, and does so predominantly through the lectin pathway. Thus, in cases of non-enteric HUS associated with pneumococcal infection, manifestations of microangiopathy, uremia and hemolysis are 5 expected to be driven predominantly by activation of the lectin pathway, and agents that block the lectin pathway, including anti-MASP-2 antibodies, are expected to prevent progression of aHUS or reduce disease severity in these patients. Accordingly, another aspect of the présent invention comprises treating a patient suffering with non-enteric aHUS that is associated with S. pneumonia infection by administering an effective 10 amount of a MASP-2 inhibitory agent.
In accordance with the foregoing, in some embodiments, in the setting of a subject at risk for developing rénal failure associated with aHUS, a method is provided for decreasing the likelihood of developing aHUS, or of developing rénal failure associated with aHUS, comprising administering an amount of an MASP-2 inhibitory agent for a 15 time period effective to ameliorate or prevent rénal failure in the subject. In some embodiments, the method further comprises the step of determining whether a subject is at risk for developing aHUS prior to the onset of any symptoms associated with aHUS. In other embodiments, the method comprises determining whether a subject is a risk for developing aHUS upon the onset of at least one or more symptoms indicative of aHUS 20 (e.g., the presence of anémia, thrombocytopenia and/or rénal insufficiency) and/or the presence of thrombotic microangiopathy in a biopsy obtained from the subject. The détermination of whether a subject is at risk for developing aHUS comprises determining whether the subject has a genetic prédisposition to developing aHUS, which may be carried out by assessing genetic information (e.g. from a database containing the 25 génotype of the subject), or performing at least one genetic screening test on the subject to déterminé the presence or absence of a genetic marker associated with aHUS (i.e., determining the presence or absence of a genetic mutation associated with aHUS in the genes encoding complément factor H (CFH), factor I (CFI), factor B (CFB), membrane cofactor CD46, C3, complément factor H-related protein 1 (CFHR1), or THBD (encoding 30 the anticoagulant protein thrombodulin) or complément factor H-related protein 3 (CFHR3), or complément factor H-related protein 4 (CFHR4)) either via genome sequencing or gene-specific analysis (e.g., PCR analysis), and/or determining whether the subject has a family history of aHUS. Methods of genetic screening for the presence or absence of a genetic mutation associated with aHUS are well established, for ex ample, see Noris M et al. “Atypical Hemolytic-Uremic Syndrome,” 2007 Nov 16 [Updated 2011 Mar 10]. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews™, Seattle 5 (WA): University of Washington, Seattle.
For example, overall the penetrance of the disease in those with mutations of complément factor H (CFH) is 48%, and the penetrance for mutations in CD46 is 53%, for mutations in CFI is 50%, for mutations in C3 is 56% and for mutations in THBD is 64% (Caprioli J. et al., Blood, 108:1267-79 (2006); Noris et al., Clin J Am Soc Nephrol 10 5:1844-59 (2010)). As described in Caprioli et al., (2006), supra, a substantial number of individuals with a mutation in complément Factor H (CFH) never develop aHUS, and it is postulated that suboptimal CFH activity in these individuals is sufficient to protect the host from the effects of complément activation in physiological conditions, however, suboptimal CFH activity is not sufficient to prevent C3b from being deposited on 15 vascular endothélial cells when exposure to an agent that activâtes complément produces higher than normal amounts of C3b.
Accordingly, in one embodiment, a method is provided for inhibiting MASP-2dependent complément activation in a subject suffering from, or at risk for developing non-Factor H-dependent atypical hemolytic urémie syndrome, comprising administering 20 to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complément activation. In another embodiment, a method is provided for inhibiting MASP-2-dependent complément activation in a subject at risk for developing Factor H-dependent atypical hemolytic urémie syndrome, comprising periodically monitoring the subject to détermine the presence or absence of 25 anémia, thrombocytopenia or rising créatinine, and treating with a MASP-2 inhibitory agent upon the détermination of the presence of anémia thrombocytopenia, or rising créatinine. In another embodiment, a method is provided for reducing the likelihood that a subject at risk for developing Factor H-dependent aHUS will suffer clinical symptoms associated with aHUS, comprising administering a MASP-2 inhibitory agent prior to, or 30 during, or after an event known to be associated with triggering aHUS clinical symptoms, for example, drug exposure (e.g., chemotherapy), infection (e.g., bacterial infection), malignancy, an injury, organ or tissue transplant, or pregnancy.
Ο 46
In one embodiment, a method is provided for reducing the likelihood that a subject at risk for developing aHUS will suffer clinical symptoms associated with aHUS, comprising periodically monitoring the subject to détermine the presence or absence of anémia, thrombocytopenia or rising créatinine, and treating with a MASP-2 inhibitory 5 agent upon the détermination of the presence of anémia, thrombocytopenia, or rising créatinine.
In another embodiment, a method is provided for reducing the likelihood that a subject at risk for developing aHUS will suffer clinical symptoms associated with aHUS comprising administering a MASP-2 inhibitory agent prior to, or during, or after an event 10 known to be associated with triggering aHUS clinical symptoms, for example, drug exposure (e.g., chemotherapy), infection (e.g., bacterial infection), malignancy, an injury, organ or tissue transplant, or pregnancy.
In some embodiments, the MASP-2 inhibitory agent is administered for a time period of at least one, two, three, four days, or longer, prior to, during, or after the event 15 associated with triggering aHUS clinical symptoms and may be repeated as determined by a physîcian until the condition has been resolved or is controlled. In a pre-aHUS setting, the MASP-2 inhibitory agent may be administered to the subject systemically, such as by intra-arterial, intravenous, intramuscular, inhalational, nasal, subcutaneous or other parentéral administration.
In some embodiments, in the setting of initial diagnosis of aHUS, or in a subject exhibiting one or more symptoms consistent with a diagnosis of aHUS (e.g., the presence of anémia, thrombocytopenia and/or rénal insufficiency), the subject is treated with an effective amount of a MASP-2 inhibitory agent (e.g., an anti-MASP-2 antibody) as a first line therapy in the absence of plasmapheresis, or in combination with plasmapheresis. As 25 a first line therapy, the MASP-2 inhibitory agent may be administered to the subject systemically, such as by intra-arterial, intravenous, intramuscular, inhalational, nasal, subcutaneous or other parentéral administration. In some embodiments, the MASP-2 inhibitory agent is administered to a subject as a first line therapy in the absence of plasmaphersis to avoid the potential complications of plasmaphersis including 30 hemorrhage, infection, and exposure to disorders and/or allergies inhérent in the plasma donor, or in a subject otherwise averse to plasmapheresis, or in a setting where plasmapheresis is unavailable.
In some embodiments, the method comprises administering a MASP-2 inhibitory agent to a subject suffering from aHUS via a cathéter (e.g., intravenously) for a first time period (e.g., at least one day to a week or two weeks) followed by administering a MASP-2 inhibitory agent to the subject subcutaneously for a second time period (e.g., a 5 chronic phase of at least two weeks or longer). In some embodiments, the administration in the first and/or second time period occurs in the absence of plasmapheresis. In some embodiments, the method further comprises determining the level of at least one complément factor (e.g., C3, C5) in the subject prior to treatment, and optionally during treatment, wherein the détermination of a reduced level of at least one complément factor 10 in comparison to a standard value or healthy control subject is indicative of the need for continued treatment with the MASP-2 inhibitory agent.
In some embodiments, the method comprises administering a MASP-2 inhibitory agent, such as an anti-MASP-2 antibody, to a subject suffering from, or at risk for developing, aHUS either intravenously, intramuscularly, or preferably, subcutaneously. 15 Treatment may be chronic and administered daily to monthly, but preferably every two weeks. The anti-MASP-2 antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
HUS
Like atypical HUS, the typical form of HUS displays ail the clinical and laboratory findings of a TMA. Typical HUS, however, is often a pédiatrie disease and usually has no familial component or direct association with mutations in complément genes. The etiology of typical HUS is tightly linked to infection with certain intestinal pathogens. The patients typically présent with acute rénal failure, hemoglobinuria, and 25 thrombocytopenia, which typically follows an épisode of bloody diarrhea. The condition is caused by an enteric infection with Shigella dissenteria, Salmonella or shiga toxin-like producing enterohemorrhagic strains of E. Coll, such as E.Coli Ο157Ή7. The pathogens are acquired from contaminated food or water supply. HUS is a medical emergency and carries a 5-10% mortality. A significant portion of survivors develop chronic kidney 30 disease (Corrigan and Boineau, Pediatr Rev 22 (11): 365-9 (2011)) and may require kidney transplantation.
The microvascular coagulation in typical HUS occurs predominantly, though not exclusively, in the rénal microvasculature. The underlying pathophysiology is mediated by Shiga toxin (STX). Excreted by enteropathic microbes into the intestinal lumen, STX crosses the intestinal barrier, enters the bloodstream and binds to vascular endothélial cells via the blobotriaosyl ceramide receptor CD77 (Boyd and Lingwood Nephron 51:207 (1989)), which is preferentially expressed on glomerular endothélium and médiates the toxic effect of STX. Once bound to the endothélium, STX induces a sériés of events that damage vascular endothélium, activate leukocytes and cause vWF-dependent thrombus formation (Forsyth et al., Lancet 2: 411-414 (1989); Zoja et al., Kidney Int. 62: 846-856 (2002); Zanchi et al., J. Immunol. 181:1460-1469 (2008); Morigi et al., Blood 98: 18281835 (2001); Guessou et al., Infect. Immun., 73: 8306-8316 (2005)). These microthrombi obstmct or occlude the artérioles and capillaries of the kidney and other organs. The obstruction of blood flow in artérioles and capillaries by microthrombi increases the shear force applied to RBCs as they squeeze through the narrowed blood vessels. This can resuit in destruction of RBC by shear force and the formation of RBC fragments called schistocytes. The presence of schistocytes is a characteristic finding in HUS. This mechanism is known as microangiopathic hemolysis. In addition, obstruction of blood flow results in ischemia, initiating a complcmcnt-mcdiatcd inflammatory response that causes additional damage to the affected organ.
The lectin pathway of complément contribuas to the pathogenesis of HUS by two principle mechanisms: 1) MASP-2-mediated direct activation of the coagulation cascade caused by endothélial injury, and 2) lectin-mediated subséquent complément activation induced by the ischemia resulting from the initial occlusion of microvascular blood flow.
STX injures microvascular endothélial cells, and injured endothélial cells are known to activate the complément System. As detailed above, complément activation folio wing endothélial cell injury is driven predominantly b y the lectin pathway. Human vascular endothélial cells subject to oxidative stress respond by expressing surface moieties that bind lectins and activate the lectin pathway of complément (Collard et al., Am J Pathol. 156(5): 1549-56 (2000)). Vascular injury following ischemia reperfusion also activâtes complément via the lectin pathway in vivo (Scand J Immunol 61(5):426-34 (2005)).Lectin pathway activation in this setting has pathological conséquences for the host, and inhibition of the lectin pathway b y blockade of MASP-2 prevents further host tissue injury and adverse outcomes (Schwaeble et al., PNAS (2011)). In addition to complément activation, lectin-dependent activation of MASP-2 has been shown to resuit in cleavage of prothrombin to form thrombin and to promote coagulation. Thus, activation of the lectin pathway of complément by injured endothélial cells can directly activate the coagulation System. The lectin pathway of complément, b y virtue of MASP2-mediated prothombin activation, therefore is likely the dominant molecular pathway linking the initial endothélial injury by STX to the coagulation and microvascular thrombosis that occurs in HUS. It is therefore expected that lectin pathway inhibitors, including, but not limited to, antibodies that block MASP-2 function, will prevent or mitigate microvascular coagulation, thrombosis and hemolysis in patients suffering from HUS. Indeed, administration of anti-MASP-2 antibody profoundly protects mice in a model of typical HUS. As described in Example 36 and shown in FIGURE 45, ail control mice exposed to STX and LPS developed severe HUS and became moribund or died within 48 hours. On the other hand, as further shown in FIGURE 45, ail mice treated with an anti-MASP-2 antibody and then exposed to STX and LPS survived (Fisher’s exact p<0.01; N=5). Thus, anti-MASP-2 therapy profoundly protects mice in this model of HUS. It is expected that administration of a MASP-2 inhibitory agent, such as a MASP-2 antibody, will be effective in the treatment of HUS patients and provide protection from microvascular coagulation, thrombosis, and hemolysis caused by infection with enteropathic E. coli or other STX-producing pathogens.
While shown here for HUS caused by STX, it is expected that anti-MASP-2 therapy will also be bénéficiai for HUS-like syndromes due to endothélial injury caused by other toxic agents. This includes agents such as mitomycin, ticlopidine, cycplatin, quinine, cyclosporine, bleomycin as well as other chemotherapy drugs and immunosuppresssive drugs. Thus, it is expected that anti-MASP-2 antibody therapy, or other modalities that inhibit MASP-2 activity, will effectively prevent or limit coagulation, thrombus formation, and RBC destruction and prevent rénal failure in HUS and other TMA related diseases (i.e., aHUS and TTP).
Patients suffering from HUS often présent with diarrhea and vomiting, their platelet counts are usually reduced (thrombocytopenia), and RBCs are reduced (anémia). A pre-HUS diarrhea phase typically lasts for about four days, during which subjects at risk for developing HUS typically exhibit one or more of the following symptoms in addition to severe diarrhea: a hematocrit level below 30% with smear evidence of intravascular érythrocyte destruction, thrombocytopenia (platelet count <150 x 103/mm3), and/or the presence of impaired rénal function (sérum créatinine concentration greater than the upper limit of reference range for âge). The presence of oligoanuria (urine 5 output <0.5 mL/kg/h for >1 day) can be used as a measure for progression towards developing HUS (see C. Hickey et al., Arch Pediatr Adolesc Med 165(10):884-889 (2011)). Testing is typically caiTied out for the presence of infection with E. coli bacteria (E.coli O157:H7), or Shigella or Salmonella species. In a subject testing positive for infection with enterogenic E. coli (e.g., E. coli 0157:H7), the use of antibiotics is contra10 indicated because the use of antibiotics may increase the risk of developing HUS through increased STX production (See Wong C. et al., N Engl J. Med 342:1930-1936 (2000). For subjects testing positive for Shigella or Salmonella, antibiotics are typically administered to clear the infection. Other well established first-line therapy for HUS includes volume expansion, dialysis and plasmapheresis.
In accordance with the foregoing, in some embodiments, in the setting of a subject suffering from one or more symptoms associated with a pre-HUS phase and at risk for developing HUS (i.e., the subject exhibits one or more of the following: diarrhea, a hematocrit level less than 30% with smear evidence of intravascular érythrocyte destruction, thrombocytopenia (platelet count less than 150 x 103/mm3), and/or the 20 presence of impaired rénal function (sérum créatinine concentration greater than the upper limit of reference range for âge)), a method is provided for decreasing the risk of developing HUS, or of decreasing the likelihood of rénal failure in the subject, comprising administering an amount of an MASP-2 inhibitory agent for a time period effective to ameliorate or prevent impaired rénal function. In some embodiments, the 25 MASP-2 inhibitory agent is administered for a time period of at least one, two, three, four or more days, and may be repeated as determined by a physician until the condition has been resolved or is controlled. In a pre-HUS setting, the MASP-2 inhibitory agent may be administered to the subject systemically, such as by intra-arterîal, întravenous, intramuscular, inhalational, nasal, oral, subcutaneous or other parentéral administration.
The treatment of E. coli 0157:H7 infection with bactericidal antibiotics, particularly β-lactams, has been associated with an increased risk of developing HUS (Smith et al., Pediatr Infect Dis J 31(1):37-41 (2012).In some embodiments, in the setting of a subject suffering from symptoms associated with a pre-HUS phase, wherein the subject is known to hâve an infection with enterogenic E. coli for which the use of antibiotics is contra-indicated (e.g., E. coli 0157Ή7), a method is provided for decreasing the risk of developing HUS, or of decreasing the likelihood of rénal failure in the subject, comprising administerîng an amount of a MASP-2 inhibitory agent for a first time period effective to inhibit or prevent the presence of oligoanuria in the subject (e.g., at least one, two, three or four days), wherein the administration of the MASP-2 inhibitory agent during the first time period occurs in the absence of an antibiotic. In some embodiments, the method further comprises administerîng the MASP-2 inhibitory agent to the subject in combination with an antibiotic for a second time period (such as at least one to two weeks).
hi other embodiments, in the setting of a subject suffering from symptoms associated with a pre-HUS phase, wherein the subject is known to hâve an infection with Shigella or Salmonella, a method is provided for decreasing the risk of developing HUS, or of decreasing the likelihood of rénal failure in the subject, comprising administerîng an amount of a MASP-2 inhibitory agent and for a time period effective to inhibit or prevent the presence of oligoanuria in the subject, wherein the administration of the MASP-2 inhibitory agent is either in the presence or in the absence of a suitable antibiotic.
In some embodiments, in the setting of an initial diagnosis of HUS, or in a subject exhibîting one or more symptoms consistent with a diagnosis of HUS (e.g., the presence of rénal failure, or microangiopathic hemolytic anémia in the absence of low fibrinogen, or thrombocytopenia) the subject is treated with an effective amount of a MASP-2 inhibitory agent (e.g. a anti-MASP-2 antibody) as a first-line therapy in the absence of plasmapheresis, or in combination with plasmapheresis. As a first-line therapy, the MASP-2 inhibitory agent may be administered to the subject systemically, such as by intra-arterial, intravenous, intramuscular, inhalational, nasal, subcutaneous or other parentéral administration. In some embodiments, the MASP-2 inhibitory agent is administered to a subject as a first line therapy in the absence of plasmapheresis to avoid the complications of plasmapheresis such as hemorrhage, infection, and exposure to disorders and/or allergies inhérent in the plasma donor, or in a subject otherwise averse to plasmaphoresis, or in a setting where plasmapheresis is unavailable.
In some embodiments, the method comprises administering a MASP-2 inhibitory agent to a subject suffering from HUS via a cathéter (e.g., intravenously) for a first time period (e.g., an acute phase lasting at least one day to a week or two weeks) followed by administering a MASP-2 inhibitory agent to the subject subcutaneously for a second time period (e.g., a chronic phase of at least two weeks or longer). In some embodiments, the administration in the first and/or second time period occurs in the absence of plasmapheresis. In some embodiments, the method further comprises determining the level of at least one complément factor (e.g., C3, C5) in the subject prior to treatment, and optionally during treatment, wherein the détermination of a reduced level of the at least one complément factor in comparison to a standard value or healthy control subject is indicative of the need for treatment, and wherein the détermination of a normal level is indicative of improvement.
In some embodiments, the method comprises administering a MASP-2 inhibitory agent, such as an anti-MASP-2 antibody, to a subject suffering from, or at risk for developing, HUS either subcutaneously or intravenously. Treatment is preferably daily, but can be as infrequent as weekly or monthly. Treatment will continue for at least one week and as long as 3 months. The anti-MASP-2 antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
Thrombotic thrombocytopénie purpura (TTP) is a life threatening disorder of the blood-coagulation system, caused by autoimmune or hereditary dysfunctions that activate the coagulation cascade or the complément system (George, JN, N Engl J Med, 354:1927-35 (2006)). This results in numerous microscopie clots, or thomboses, in small blood vessels throughout the body. Red blood cells are subjected to shear stress which damages their membranes, leading to intravascular hemolysis. The resulting reduced blood flow and endothélial injury results in organ damage, including brain, heart, and kidneys. TTP is clinically characterized by thrombocytopenia, microangiopathic hemolytic anémia, neurological changes, rénal failure and fever. In the era before plasma exchange, the fatality rate was 90% during acute épisodes. Even with plasma exchange, survival at six months is about 80%.
Ο
TTP may arise from genetic or acquired inhibition of the enzyme ADAMTS-13, a metalloprotease responsable for cleaving large multimers of von Willebrand factor (vWF) into smaller units. ADAMTS-13 inhibition or deficiency ultimately results in increased coagulation (Tsai, H. J Am Soc Nephrol 14: 1072-1081, (2003)). ADAMTS-13 régulâtes 5 the activity of vWF; in its absence, vWF forms large multimers which are more likely to bind platelets and prédisposés patients to platelet aggregation and thrombosis in the microvasculature.
Upshaw-Schulman syndrome (USS, also described as congénital TTP) is a congénital deficiency of ADAMTS13 activity due to ADAMTS13 gene mutations 10 (Schulman et al., Blood, 16(1):943-57, 1960; Upshaw et al., New Engl. J. Med, 298 (24):1350-2, 1978). Numerous mutations in ADAMTS13 hâve been identifïed in indîviduals with congénital TTP (Kinoshita et al., International Journal of Hematology, 74:101-108 (2001); Levy et al., Nature, 413 (6855):488-494 (2001); Kokame et al., PNAS 99(18):11902-11907 (2002); Savasan et al., Blood, 101:4449-4451 (2003); Matsumoto et 15 al., Blood, 103:1305-1310 (2004) and Fujimura et al., Brit. J. Haemat 144:742-754 (2008)). Subjects with USS typically hâve 5-10% of normal ADAMTS13 activity (Kokame et al., PNAS 99(18):11902-11907, 2002). Although acquired TTP and USS hâve some similarities, USS has some important différences in clinical features. USS usually présents in infancy or childhood and is characterized by severe 20 hyperbilirubinemia with négative Coombs test soon after birth, response to fresh plasma infusion, and frequent relapses (Savasan et al., Blood, 101:4449-4451, 2003). In some cases, patients with this inheritcd ADAMTS13 deficiency hâve a mild phenotype at birth and only develop symptoms associated with TTP in clinical situations with increased von Willebrand factor levels, such as infection or pregnancy. For example, Fujimura et al. 25 reported 9 Japanese women from 6 familles with genetically confirmed USS who were diagnosed with the disorder during their first pregnancy. Thrombocytopenia occurred during the second to third trimesters in each of their 15 pregnancies, often foliowed by TTP. Ail of these women were found to be severely déficient in ADAMTS13 activity (Fujimura et al., Brit. J. Haemat 144:742-754, 2008).
In accordance with the foregoing, in some embodiments, in the setting of a subject with Upshaw-Schulman syndrome (USS) (i.e., the subject is known to be déficient in ADAMTS13 activity and/or the subject is known to hâve one or more ADAMTS13 gene
Ο 54 mutation(s)), a method is provided for decreasing the likelihood of developing clinical symptoms associated with congénital TTP (e.g., thrombocytopenia, anémia, fever, and/or rénal faîlure ) comprising administering an amount of a MASP-2 inhibitory agent (e.g., a MASP-2 antibody) for a time period effective to ameliorate or prevent one or more 5 clinical symptoms associated with TTP. In some embodiments, the method further comprises the step of determining whether a subject is at risk for developing symptoms associated with congénital TTP prior to the onset of any symptoms associated with TTP, or upon the onset of at least one or more symptoms indicative of TTP (e.g., the presence of anémia, thrombocytopenia and/or rénal insufficiency). The détermination of whether a subject is at risk for developing symptoms associated with congénital TTP (i.e., the subject has USS), comprises determining whether the subject has a mutation in the gene encoding ADAMTS13, and/or determining whether the subject is déficient in ADAMTS13 activity, and/or determining whether the subject has a family history of USS. Methods of genetic screening for the presence or absence of a genetic mutation associated with USS aie well established, for example see Kinoshita et al., International Journal of Hematology, 74:101-108 (2001); Levy et al., Nature, 413 (6855):488-494 (2001); Kokame et ah, ftVAS 99(18):11902-11907 (2002); Savasan et al., Blood, 101:4449-4451 (2003); Matsumoto et al., Blood, 103:1305-1310 (2004) and Fujimura et al., Brit. J. Haemat 144:742-754 (2008).
In one embodiment, a method is provided for reducing the likelihood that a subject diagnosed with USS will suffer clinical symptoms associated with TTP comprising periodically monitoring the subject to détermine the presence or absence of anémia, thrombocytopenia or rising créatinine, and treating with a MASP-2 inhibitory agent (e.g., a MASP-2 antibody) upon the détermination of the presence of anémia, 25 thrombocytopenia or rising créatinine, or upon the presence of an event known to be associated with triggering TTP clinical symptoms, for example, drug exposure (e.g., chemotherapy), infection (e.g. bacterial infection), malignancy, injury, transplant, or pregnancy.
In another embodiment, a method is provided for treating a subject with USS and 30 suffering from clinical symptoms associated with TTP comprising administering an amount of a MASP-2 inhibitory agent (e.g., a MASP-2 antibody) for a time period effective to ameliorate or prevent one or more clinical symptoms associated with TTP.
Ο
ΤΤΡ can also develop due to auto-antibodies against ADAMTS-13. In addition, TTP can develop during breast, gastrointestinal tract, or prostate cancer (George JN., Oncology (Williston Park). 25:908-14 (2011)), pregnancy (second trimester or postpartum), George JN., Curr Opin Hematol 10:339-344 (2003)), or is associated with 5 diseases, such as HIV or autoimmune diseases like systemic lupus erythematosis (Hamasaki K, et al., Clin Rheumatol.22:355-8 (2003)). TTP can also be caused by certain drug thérapies, including heparin, Quinine, immunemediated ingrédient, cancer chemotherapeutic agents (bleomycin, cisplatin, cytosine arabinoside, daunomycin gemcitabine, mitomycin C, and tamoxifen), cyclosporine A, oral contraceptives, 10 penicillin, rifampin and anti-platelet drugs including ticlopidine and clopidogrel (Azarm, T. et al., J Res Med Sci., 16: 353-357 (2011)). Other factors or conditions associated with TTP are toxins such as bee venoms, sepsis, splenic séquestration, transplantation, vasculitis, vascular surgery, and infections like Streptococcus pneumonia and cytomégalovirus (Moake JL., N Engl J Med., 347:589-600 (2002)). TTP due to transient 15 functional ADAMTS-13 deficiency can occur as a conséquence of endothélial cell injury associated with S. pneumonia infection (Pediatr Nephrol., 26:631-5 (2011)).
Plasma exchange is the standard treatment for TTP (Rock GA, et al., N Engl J Med 325:393-397 (1991)). Plasma exchange replaces ADAMTS-13 activity in patients with genetic defects and removes ADAMTS-13 autoantibodies in those patients with 20 acquired autoimmune TTP (Tsai, H-M, Hematol Oncol Clin North Am., 21(4): 609-v (2007)). Additional agents such as immunosuppressive drugs are routinely added to therapy (George, JN, N Engl J Med, 354:1927-35 (2006)). However, plasma exchange is not successful for about 20% of patients, relapse occurs in more than a third of patients, and plasmapheresis is costly and technically demanding. Furthermore, many patients are 25 unable to tolerate plasma exchange. Consequently there remains a critical need for additional and better treatments for TTP.
Because TTP is a disorder of the blood coagulation cascade, treatment with antagonists of the complément System may aid in stabilizing and correcting the disease. While pathological activation of the alternative complément pathway is linked to aHUS, 30 the rôle of complément activation in TTP is less clear. The functional deficiency of ADAMTS13 is important for the susceptibility of TTP, however it is not sufficient to cause acute épisodes. Environmental factors and/or other genetic variations may contribute to the manifestation of TTP. For example, genes encoding proteins involved in the régulation of the coagulation cascade, vWF, platelet function, components of the endothélial vessel surface, or the complément System may be implicated in the development of acute thrombotic microangiopathy (Galbusera, M. et al., Haematologica,
94: 166-170 (2009)). In particular, complément activation has been shown to play a critical rôle; sérum from thrombotic microangiopathy associated with ADAMTS-13 deficiency has been shown to cause C3 and MAC déposition and subséquent neutrophil activation which could be abrogated by complément inactivation (Ruiz-Torres MP, et al., Thromb Haemost, 93:443-52 (2005)). In addition, it has recently been shown that during 10 acute épisodes of TTP there are increased levels of C4d, C3bBbP, and C3a (M. Réti et al., J Thromb Haemost. Feb 28.(2012) doi: 10.1111/j.l538-7836.2012.04674.x. [Epub ahead of print]), consistent with activation of the classical/lectin and alternative pathways. This increased amount of complément activation in acute épisodes may initiate the terminal pathway activation and be responsîble for further exacerbation of TTP.
The rôle of ADAMTS-13 and vWF in TTP clearly is responsîble for activation and aggregation of platelets and their subséquent rôle in shear stress and déposition in microangiopathies. Activated platelets interact with and trigger both the classical and alternative pathways of complément. Platelet mediated complément activation increases the inflammatory mediators C3a and C5a (Peerschke E et al., Mol Immunol, 47:2170-5 20 (2010)). Platelets may thus serve as targets of classical complément activation in inherited or autoimmune TTP.
As described above, the lectin pathway of complément, by virtue of MASP-2 mediated prothombin activation, is the dominant molecular pathway linking endothélial injury to the coagulation and microvascular thrombosis that occurs in HUS. Similarly, 25 activation of the lectin pathway of complément may directly drive the coagulation System in TTP. Lectin pathway activation may be initiated in response to the initial endothélium injury caused by ADAMTS-13 deficiency in TTP. It is therefore expected that lectin pathway inhibitors, including but not limited to antibodies that block MASP-2 function, will mitigate the microangiopathies associated with microvascular coagulation, 30 thrombosis, and hemolysis in patients suffering from TTP.
Patients suffering from TTP typically présent in the emergency room with one or more of the following: purpura, rénal failure, low platelets, anémia and/or thrombosis,
Ο including stroke. The current standard of care for TTP involves intra-cathéter delivery (e.g., intravenous or other form of cathéter) of replacement plasmapheresis for a period of two weeks or longer, typically three times a week, but up to daily. If the subject tests positive for the presence of an inhibitor of ADAMTS13 (i.e., an endogenous antibody 5 against ADAMTS13), then the plasmapheresis may be carried out in combination with immunosuppressive therapy (e.g., corticosteroids, rituxan, or cyclosporine). Subjects with refractory TTP (approximately 20% of TTP patients) do not respond to at least two weeks of plasmapheresis therapy.
In accordance with the foregoing, in one embodiment, in the setting of an initial 10 diagnosis of TTP or in a subject exhibiting one or more symptoms consistent with a diagnosis of TTP (e.g., central nervous System involvement, severe thrombocytopenia (a platelet count of less that or equal to 5000/pL if off aspirin, less than or equal to 20,000/pL if on aspirin), severe cardiac involvement, severe pulmonary involvement, gastro-intestinal infarction or gangrené), a method is provided for treating the subject 15 with an effective amount of a MASP-2 inhibitory agent (e.g., a anti-MASP-2 antibody) as a first line therapy in the absence of plasmapheresis, or in combination with plasmapheresis. As a first-line therapy, the MASP-2 inhibitory agent may be administered to the subject systemically, such as by intra-arterial, intravenous, intramuscular, inhalational, nasal, subeutaneous or other parentéral administration. In 20 some embodiments, the MASP-2 inhibitory agent is administered to a subject as a firstline therapy in the absence of plasmapheresis to avoid the potential complications of plasmapheresis, such as hemorrhage, infection, and exposure to disorders and/or allergies inhérent in the plasma donor, or in a subject otherwise averse to plasmapheresis, or in a setting where plasmapheresis is unavailable. In some embodiments, the MASP-2 25 inhibitory agent is administered to the subject suffering from TTP in combination (including co-administration) with an immunosuppressive agent (e.g., corticosteroids, rituxan or cyclosporine) and/or in combination with concentrated ADAMTS-13.
In some embodiments, the method comprises administering a MASP-2 inhibitory agent to a subject suffering from TTP via a cathéter (e.g., intravenously) for a first time 30 period (e.g., an acute phase lasting at least one day to a week or two weeks) followed by administering a MASP-2 inhibitory agent to the subject subcutaneously for a second time period (e.g., a chronic phase of at least two weeks or longer). In some embodiments, the administration in the first and/or second time period occurs in the absence of plasmapheresis. In some embodiments, the method is used to maintain the subject to prevent the subject from suffering one or more symptoms associated with TTP.
In another embodiment, a method is provîded for treating a subject suffering from refractory TTP (i.e., a subject that has not responded to at least two weeks of plasmaphoresis therapy), by administering an amount of a MASP-2 inhibitor effective to reduce one or more symptoms of TTP. In one embodiment, the MASP-2 inhibitor (e.g., an anti-MASP-2 antibody) is administered to a subject with refractory TTP on a chronic basis, over a time period of at least two weeks or longer via subcutaneous or other 10 parentéral administration. Administration may be repeated as determined by a physician until the condition has been resolved or is controlled.
In some embodiments, the method further comprises determining the level of at least one complément factor (e.g., C3, C5) in the subject prior to treatment, and optionally during treatment, wherein the détermination of a reduced level of the at least 15 one complément factor in comparison to a standard value or healthy control subject is indicative of the need for continued treatment with the MASP-2 inhibitory agent.
In some embodiments, the method comprises administering a MASP-2 inhibitory agent, such as an anti-MASP-2 antibody, to a subject suffering from, or at risk for developing, TTP either subcutaneously or intravenously. Treatment is preferably daily, 20 but can be as infrequent as biweekly. Treatment is continued until the subject’s platelet count is greater than 150,000/ml for at least two consecutive days. The anti-MASP-2 antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
In one embodiment, the MASP-2 inhibitory antibody exhibits at least one or more 25 of the following characteristics: said antibody binds human MASP-2 with a Kp of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC50 of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC^q of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting 30 of Fv, Fab, Fab', F(ab)2 and F(ab')2> wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation, and/or wherein the antibody does not substantîally inhibit the classical pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantîally inhibit the alternative pathway. In one 5 embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantîally inhibit the classical pathway or the alternative pathway (i.e., inhibits the lectin pathway while leaving the classical and alternative complément pathways intact).
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation 10 in sérum from a subject suffering from TTP by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum, hi some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from TTP at a level of at least 20 percent or 15 greater, (such as at least 30%, at least 40%, at least 50%) more than the inhibitory effect on C5b-9 déposition in sérum.
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a TTP patient by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such 20 as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the subject via an intravenous cathéter or other cathéter delivery method.
In one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from TTP comprising administering to the subject a 25 composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavychain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 30 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDRL1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a lightchain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ 5 ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding 10 fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized b y reference antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID 20 NO:70.
Degos Disease
Degos disease, also known as malignant atrophie papulosis, is a very rare TMA affecting the endothélium of small vessels of skin, gastrointestînal tract, and CNS. This 25 vasculopathy causes occlusion of venules and articles, resulting in skin lésions, bowel ischemia, and CNS disorders including strokes, epilepsy and cognitive disorders. In the skin, connective tissue necrosis is due to thrombotic occlusion of the small arteries. However, the cause of Degos disease is unknown. Vasculitis, coagulopathy, or primary dysfonction of the endothélial cells hâve been implicated. Degos disease has a 50% 30 survival of only two to three years. There is no effective treatment for Degos disease although antiplatelet drugs, anticoagulants, and immunosuppressants are utilized to alleviate symptoms.
While the mechanism of Degos disease is unknown, the complément pathway has been implîcated. Margo et al., identified prominent C5b-9 deposits in skin, gastrointestinal tract and brain vessels of four terminal patients with Degos disease (Margo et al., Am J Clin Pathol 135(4):599-610, 2011). Experimental treatment with 5 eculizumab was initially effective in the treatment of skin and intestinal lésions, but did not prevent the progression of systemic disease (see Garrett-Bakelman F. et al., “C5b-9 is a potential effector in the pathophysiology of Degos disease; a case report of treatment with eculizumab” (Abstract), Jérusalem: International Society of Hematology; 2010, Poster #156; and Polito J. et al, “Early détection of systemic Degos disease (DD) or 10 malignant atrophie papulosis (MAP) may increase survival” (Abstract), San Antonio, TX: American College of Gastroenterology; 2010, Poster #1205).
Many patients suffering from Degos disease hâve defects of blood coagulation. Thrombotic occlusion of small arteries in the skin is characteristic of the disease. Because the complément pathway is implîcated in this disease, as described herein for 15 other TMAs, it is expected that lectin pathway inhibitors, including but not limited to antibodies that block MASP-2 function, will be bénéficiai in treating patients suffering from Degos disease.
Accordingly, in another embodiment, the invention provides methods for treating Degos disease by administering a composition comprising a therapeutically effective 20 amount of a MASP-2 inhibitory agent, such as a MASP-2 antibody, in a pharmaceutical carrier to a subject suffering from Degos disease or a condition resulting from Degos disease. The MASP-2 inhibitory agent is administered systemically to the subject suffering from Degos disease or a condition resulting from Degos disease, such as by intra-arterial, intravenous, intramuscular, inhalational, subcutaneous or other parentéral 25 administration, or potentially b y oral administration for non-peptidergic agents. The antiMASP-2 antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
In one embodiment, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a KD of 10 nM 30 or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5q of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation, and/or wherein the antibody does not substantially inhibit the classical pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the alternative pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway 10 and does not substantially inhibit the classical pathway or the alternative pathway (i.e., inhibits the lectin pathway while leaving the classical and alternative complément pathways intact).
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from Degos disease by at least 30%, such as at least 15 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum. In some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from Degos disease at a level of at least 20 percent or greater, (such as at least 30%, at least 40%, at least 50%) more than 20 the inhibitory effect on C5b-9 déposition in sérum.
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a Degos disease patient by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated 25 sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the subject via an intravenous cathéter or other cathéter delivery method.
In one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from Degos disease comprising administering to the 30 subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light5 chain CDR-L1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at 10 least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a 15 composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région 20 comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by reference antibody OMS646 comprising a heavy-chain variable région as 25 set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
Catastrophic antiphospholipid syndrome (CAPS)
Catastrophic antiphospholipid syndrome (CAPS) is an extreme variant of the antiphospholipid antibody (APLA) syndrome. CAPS is characterized by venons and arterial thrombosis due to pathogenic antibodies. CAPS is a TM A with multiple organ
Ο 64 thrombosis, ischemia, and organ failure. Like other TMAs, occlusion of small vessels in varions organs is characteristic. There is a high mortality rate in CAPS of about 50% and often it is associated with infection or trauma. Patients hâve antiphospholipid antibodies, generally IgG.
Clinically, CAPS involves at least three organs or tissues with histopathological evidence of small vessel occlusion. Peripheral thrombosis may involve veins and arteries in the CNS, cardiovascular, rénal, or pulmonary Systems. Patients are treated with antibiotics, anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin. Nevertheless, death may resuit from multiple organ failure.
The complément pathway has been implicated in CAPS. For example, studies in animal models indicate that complément inhibition may be an effective means to prevent thrombosis associated with CAPS (Shapira L. et al., Arthrîtîs Rheum 64(8):2719-23, 2012). Moreover, as further reported by Shapira et al., administration of eculizumab to a subject suffering from CAPS at doses that blocked complément pathway aborted acute 15 progressive thrombotic events and reversed thrombocytopenia (see also Lim W., Curr Opin Hematol 18(5):361-5, 2011). Therefore, as described herein for other TMAs, it is expected that lectin pathway inhibitors, including but not limited to antibodies that block MASP-2 function, will be bénéficiai in treating patients suffering from CAPS.
Accordingly, in another embodiment, the invention provides methods for treating 20 CAPS by administering a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent, such as a MASP-2 antibody, in a pharmaceutical carrier to a subject suffering from CAPS or a condition resulting from CAPS. The MASP-2 inhibitory agent is administered systemically to the subject suffering from CAPS or a condition resulting from CAPS, such as by intra-arterial, intravenous, intramuscular, 25 inhalational, subcutaneous or other parentéral administration, or potentially by oral administration for non-peptidergic agents. The anti-MASP-2 antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
In one embodiment, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a Kp of 10 nM 30 or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC50 of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an ICjq of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab1, F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation, and/or wherein the antibody does not substantially inhibit the classical pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the alternative pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the classical pathway or the alternative pathway (i.e., inhibits the lectin pathway while leaving the classical and alternative complément pathways intact).
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from CAPS by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum. In some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from CAPS at a level of at least 20 percent or greater, (such as at least 30%, at least 40%, at least 50%) more than the inhibitory effect on C5b-9 déposition in sérum.
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a CAPS patient by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the subject via an intravenous cathéter or other cathéter delivery method.
ht one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from CAPS comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavychain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDRL1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light- chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ
ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding 15 fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
hi some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by reference antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID 25 NO:70.
TMA Secondary to Cancer
Systemic malignancies of any type can lead to clinical and pathologie manifestations of TMA (see e.g., Batts and Lazarus, Bone Marrow Transplantation 40:709-719, 2007). Cancer-associated TMA is often found in the lungs and appears to be associated with tumor emboli (Francis KK et al., Commun Oncol 2:339-43, 2005).
Tumor emboli can reduce blood flow and thus lead to a hypo-perfused State in the affected artérioles and venules. The resulting tissue stress and injury is expected to activate the lectin pathway of complément in a localized fashion. The activated lectin pathway in turn can activate the coagulation cascade via MASP-2 dépendent cleavage of 5 prothrombin to thrombin, leading to a pro-thrombotic State characteristic of TMA.
MASP-2 inhibition in this setting is expected to reduce the localized activation of thrombin and thereby alleviate the pro-thrombotic State.
Therefore, as described herein for other TM As, it is expected that lectin pathway inhibitors, including, but not limited to, antibodies that block MASP-2 function, will be 10 bénéficiai in treating patients suffering from TMA secondary to cancer.
Accordingly, in another embodiment, the invention provides methods for treating or preventing TMA secondary to cancer by administering a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent, such as a MASP-2 antibody, in a pharmaceutical carrier to a subject suffering from, or at risk for developing, 15 a TMA secondary to cancer. The MASP-2 inhibitory agent is administered systemically to the subject suffering from, or at risk for developing, a TMA secondary to cancer, such as by intra-arterial, intravenous, intramuscular, inhalational, subcutaneous or other parentéral administration, or potentially by oral administration for non-peptidergic agents. The anti-MASP-2 antibody may be administered alone, or in combination with a C5 20 inhibitor, such as eculizamab.
In one embodiment, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a Kp of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5Q of 10 nM or 25 less, said antibody inhibits C3b déposition in 90% human sérum with an Ι05θ of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F/ab1^ wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a 30 S228P mutation, and/or wherein the antibody does not substantially inhibit the classical pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantîally inhibit the alternative pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantîally inhibit the classical pathway or the alternative pathway (i.e., inhibits the lectin pathway while leaving the classical and alternative complément 5 pathways intact).
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from TMA secondary to cancer by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as 10 compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a patient suffering TMA secondary to cancer by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as 15 compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the subject via an intravenous cathéter or other cathéter delivery method.
In one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from TMA secondary to cancer comprising administering 20 to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid 25 sequence from 95-102 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDR-L1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable 30 région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding 5 fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by reference antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID 15 NO:70.
TMA Secondary to Cancer Chemotherapy
Chemotherapy-associated TMA is a condition involving thrombocytopenia, microangiopathic hemolytic anémia, and rénal dysfunction that develops in 2-10% of 20 patients with a history of malignant neoplasms treated with chemotherapeutic agents such as gemcytabin, mitomycin, oxaliplatin and others. Chemotherapy-associated TMA is associated with high mortality poor clinical outcomes (see, e.g., Blake-Haskins et al., Clin Cancer Res 17(18):5858-5866, 2011).
The etiology of chemotherapy-associated TMA is thought to encompass a non25 spécifie, toxîc insult to the microvascular endothélium. A direct injury to endothélial cells has been shown in an animal model of mitomycin-induced TMA (Dlott J. et al., Ther Apher Dial 8:102-11, 2004). Endothélial cell injury through a variety of mechanisms has been shown to activate the lectin pathway of complément. For example, Stahl et al. hâve shown that endothélial cells exposed to oxidative stress activate the 30 lectin pathway of complément both in vitro and in vivo (Collard et al., Am J Pathol. 156(5):1549-56, 2000; La Bonte et al, J Immunol. 15;188(2):885-91, 2012). In vivo, this process leads to thombosis, and inhibition of the lectin pathway has been shown to prevent thrombosis (La Bonte et al. J Immunol. 15; 188(2):885-91, 2012), Futhermore, as demonstrated in Examples 37-39 herein, in the mouse model of TMA where localized photoexcitation of FITC-Dex was used to induce localized injury to the microvasculature with subséquent development of a TMA response, the présent inventer s hâve shown that 5 inhibition of MASP-2 can prevent TMA. Thus, microvascular endothélium injury by chemotherapeutic agents may activate the lectin pathway of complément which then créâtes a localized pro-thrombotic State and promûtes a TMA response. Since activation of the lectin pathway and the création of a pro-thombotic State is MASP-2-dependent, it is expected that MASP-2 inhibitors, including, but not limited to, antibodies that block 10 MASP-2 function, will alleviate the TMA response and reduce the risk of cancer chemotherapy-associated TMA..
Accordingly, in another embodiment, the invention provides methods for treating or preventing TMA secondary to chemotherapy by administerîng a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent, such as a 15 MASP-2 antibody, in a pharmaceutical carrier to a subject suffering from, or at risk for developing, a TMA secondary to chemotherapy. The MASP-2 inhibitory agent is administered systemically to a subject that has undergone, is undergoing, or will undergo chemotherapy, such as by intra-arterial, intravenous, intramuscular, inhalational, subcutaneous or other parentéral administration, or potentially by oral administration for 20 non-peptidergic agents. The anti-MASP-2 antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
In one embodiment, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a KD of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody 25 inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5Q of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC5q of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, 30 wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation, and/or wherein the antibody does not substantially inhibit the classical pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the alternative pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the classical pathway or the alternative pathway (i.e., 5 inhibits the lectin pathway while leaving the classical and alternative complément pathways intact).
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from TMA secondary to cancer chemotherapy by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 10 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a patient suffering TMA secondary to cancer chemotherapy by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 15 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the subject via an intravenous cathéter or other cathéter delivery method.
In one embodiment, the invention provides a method of inhibiting thrombus 20 formation in a subject suffering from TMA secondary to cancer chemotherapy comprising administering to the subject a composition comprising an amount of a MASP2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavychain variable région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the 25 amino acid sequence from 50-65 of SEQ ID NO:67; and iîi) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ED NO:67 and b) a light-chain variable région comprising: i) a light-chain CDR-L1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the 30 amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, that specifically recognizes at least paît of an epitope on human MASP-2 recognized by reference antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
TMA Secondary to Transplantation
Transplantation-associated TMA (TA-TMA) is a devastating syndrome that can occur in transplant patients, such as allogeneic hematopoietic stem cell transplant récipients (see e.g., Batts and Lazarus, Bone Marrow Transplantation 40:709-719, 2007). The pathogenesis of this condition is poorly understood, but likely involves a confluence of responses that culminate in endothélial cell injury (Laskin B.L. et al., Blood 118(6):1452-62, 2011). As discussed above, endothélial cell injury is a prototypic stimulus for lectin pathway activation and the génération of a pro-thrombotic environment.
Recent data further support the rôle of complément activation via the lectin pathway in the pathogenesis TA-TMA. Laskin et al., hâve demonstrated that rénal arteriolar C4d déposition was much more common in subjects with histologie TA-TMA (75%) compared with Controls (8%) (Laskin B.L., et al., Transplantation, 27; 96(2):21723, 2013). Thus, C4d may be a pathologie marker of TA-TMA, implicating localized complément fixation via the lectin or classical pathway.
Since activation of the lectin pathway and the création of a pro-thombotic State is MASP-2-dependent, it is expected that MASP-2 inhibitors, including, but not limited to, antibodies that block MASP-2 function, will alleviate the TMA response and reduce the risk of transplantation-associated TMA (TA-TMA).
Accordingly, in another embodiment, the invention provides methods for treating or preventing a TMA secondary to transplantation by administering a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent, such as a MASP-2 antibody, in a pharmaceutical carrier to a subject suffering from, or at risk for developing a TMA secondary to transplantation. The MASP-2 inhibitory agent is 10 adminîstered systemically to a subject that has undergone, is undergoing, or will undergo a transplant procedure, such as by intra-arterial, intravenous, intramuscular, inhalational, subeutaneous or other parentéral administration, or potentially b y oral administration for non-peptidergic agents. The anti-MASP-2 antibody may be adminîstered alone, or in combination with a C5 inhibitor, such as eculizamab. In some embodiments, the 15 invention provides methods for treating or preventing a TMA secondary to allogeneic stem cell transplant comprising administering a composition comprising an amount of a MASP-2 inhibitory agent, such as a MASP-2 inhibitory antibody, to a subject prior to, during or after undergoing an allogeneic stem cell transplant.
In one embodiment, the MASP-2 inhibitory antibody exhibits at least one or more 20 of the following characteristics: said antibody binds human MASP-2 with a Κθ of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5Q of 10 11M or less, said antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting 25 of Fv, Fab, Fab', F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein tire IgG4 molécule comprises a S228P mutation, and/or wherein the antibody does not substantially inhibit the classical pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the 30 lectin pathway and does not substantially inhibit the alternative pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the classical pathway or the alternative pathway (i.e., inhibits the lectin pathway while leaving the classical and alternative complément pathways intact).
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation 5 in sérum from a subject suffering from TMA secondary to transplant by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation 10 in sérum from a patient suffering TMA secondary to transplant by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the 15 subject via an intravenous cathéter or other cathéter delivery method.
In one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from TMA secondary to transplant comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable 20 région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDR-L1 comprising the amino acid sequence from 24-34 of 25 SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavychain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 30 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises 5 administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment 10 thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by référencé antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
IV. THE ROLE OF MASP-2 IN OTHER DISEASES AND CONDITIONS AND
THERAPEUTIC METHODS USING MASP-2 INHIBITORY AGENTS
RENAL CONDITIONS
Activation of the complément System has been implicated in the pathogenesis of a 20 wide variety of rénal diseuses; including, mesangioproliferative glomerulonephritis (IgA-nephropathy, Berger's disease) (Endo, M.,etal., Clin. Nephrology 55:185-191, 2001), membranous glomerulonephritis (Kerjashki, D., Arch B Cell Pathol. 58:253-71, 1990; Brenchley, P.E., étal., Kidney Int., 41:933-1, 1992; Salant, D.J., étal., Kidney Int. 55:976-84, 1989), membranoproliferative glomerulonephritis (mesangiocapillary 25 glomerulonephritis) (Bartlow, B.G., et al., Kidney Int. 75:294-300, 1979; Meri, S., et al., J. Exp. Med. 775:939-50, 1992), acute postinfectious glomerulonephritis (poststreptococcal glomerulonephritis), cryoglobulinémie glomerulonephritis (Ohsawa, I., étal., Clin Immunol. 101:59-66, 2001), lupus nephritis (Gatenby, P.A., Autoimmunity 77:61-6, 1991), and Henoch-Schonlein purpura nephritis (Endo, M., et al., 30 Am. J. Kidney Dis. 55:401-407, 2000). The involvement of complément in rénal disease has been appreciated for several décades but there is still a major discussion on its exact rôle in the onset, the development and the resolution phase of rénal disease. Under normal conditions the contribution of complément is bénéficiai to the host, but inappropriate activation and déposition of complément may contribute to tissue damage.
There is substantial evidence that glomerulonephritis, inflammation of the glomeruli, is often initiated by déposition of immune complexes onto glomerular or 5 tubular structures which then triggers complément activation, inflammation and tissue damage. Kahn and Sinniah demonstrated increased déposition of C5b-9 in tubular basement membranes in biopsies taken from patients with varions forms of glomerulonephritis (Kahn, T.N., et al., Histopath. 26:351-6, 1995). In a study of patients with IgA irephrology (Alexopoulos, A., étal., Nephrol. Dial. Transplant 70:1166-1172, 10 1995), C5b-9 déposition in the tubular epithelial/basement membrane structures correlated with plasma créatinine levels. Another study of membranous nephropathy demonstrated a relationship between clinical outcome and urinary sC5b-9 levels (Kon, S.P., et al., Kidney Int. 48:1953-58, 1995). Elevated sC5b-9 levels were correlated positively with poor prognosis. Lehto et al., measured elevated levels of CD59, a 15 complément regulatory factor tirât inhibits the membrane attack complex in plasma membranes, as well as C5b-9 in urine from patients with membranous glomerulonephritis (Lehto, T., étal., Kidney Int. 47:1403-11, 1995). Histopathological analysis of biopsy samples taken from these same patients demonstrated déposition of C3 and C9 proteins in the glomeruli, whereas expression of CD59 in these tissues was diminished compared to 20 that of normal kidney tissue. These various studies suggest that ongoing complement-mediated glomerulonephritis results in urinary excrétion of complément proteins that correlate with the degree of tissue damage and disease prognosis.
Inhibition of complément activation in various animal models of glomerulonephritis has also demonstrated the importance of complément activation in the 25 etiology of the disease. In a model of membranoproliferative glomerulonephritis (MPGN), infusion of anti-Thyl antiserum in C6-deficient rats (that cannot form C5b-9) resulted in 90% less glomerular cellular prolifération, 80% réduction in platelet and macrophage infiltration, diminished collagen type IV synthesis (a marker for mesangial matrix expansion), and 50% less proteinuria than in C6+ normal rats (Brandt, J., et al., 30 Kidney Int. 49:335-343, 1996). These results implicate C5b-9 as a major mediator of tissue damage by complément in this rat anti-thymocyte sérum model. In another model of glomerulonephritis, infusion of graded dosages of rabbit anti-rat glomerular basement membrane produced a dose-dependent influx of polymorphonuclear leukocytes (PMN) that was attenuated by prior treatment with cobra venom factor (to consume complément) (Scandrett, A.L., et al., Am. J. Physiol. 26S:F256-F265, 1995). Cobra venom factor-treated rats also showed diminished histopathology, decreased long-term proteinuria, and lower créatinine levels than control rats. Employing three models of GN in rats (anti-thymocyte sérum, Con A anti-Con A, and passive Heymann nephritis), Couseretal., demonstrated the potential therapeutic efficacy of approaches to inhibit complément by using the recombinant sCRl protein (Couser, W.G., et al., J. Am. Soc. Nephrol. 5:1888-94, 1995). Rats treated with sCRl showed significantly diminished PMN, platelet and macrophage influx, decreased mesangiolysis, and proteinuria versus control rats. Further evidence for the importance of complément activation in glomerulonephritis has been provided by the use of an anti-C5 MoAb in the NZB/W Fl mouse model. The anti-C5 MoAb inhibits cleavage of C5, thus blocking génération of C5a and C5b-9. Continuons therapy with anti-C5 MoAb for 6 months resulted in significant amelioration of the course of glomerulonephritis. A humanized anti-C5 Mo Ab monoclonal antibody (5G1.1) that prevents the cleavage of human complément component C5 into its pro-inflammatory components is under development by Alexion Pharmaceuticals, Inc., New Haven, Connecticut, as a potential treatment for glomerulonephritis.
Direct evidence for a pathological rôle of complément in rénal injury is provided by studies of patients with genetic deficiencies in spécifie complément components. A number of reports hâve documented an association of rénal disease with deficiencies of complément regulatory factor H (Ault, B.H., Nephrol. /4:1045-1053, 2000; Levy, M., et al., Kidney Int. 50:949-56, 1986; Pickering, M.C., et al., Nat. Genet. 57:424-8, 2002). Factor H deficiency results in low plasma levels of factor B and C3 and in consumption of C5b-9. Both atypical membranoproliferative glomerulonephritis (MPGN) and idiopathîc hemolytic urémie syndrome (HUS) are associated with factor H deficiency. Factor H déficient pigs (Jansen, J.H., et al., Kidney Int. 55:331-49, 1998) and factor H knockout mice (Pickering, M.C., 2002) display MPGN-like symptoms, confirming the importance of factor H in complément régulation. Deficiencies of other complément components are associated with rénal disease, secondary to the development of systemic lupus erythematosus (SLE) (Walport, M.J., Davies, et al., Ann. N.Y. Acad.
Sci. 815:261-31, 1997). Deficiency for Clq, C4 and C2 prédisposé strongly to the development of SLE via mechanisms relating to defective clearance of immune complexes and apoptotic material. In many of these SLE patients lupus nephritis occurs, characterized by the déposition of immune complexes throughout the glomerulus.
Further evidence linkîng complément activation and rénal disease has been provided by the identification in patients of autoantibodies directed against complément components, some of which hâve been directly related to rénal disease (Trouw, L,A., et ah, Mol. Immunol. 35:199-206, 2001). A number of these autoantibodies show such a high degree of corrélation with rénal disease that the term nephritic factor (NeF) 10 was introduced to indicate this activity. In clinical studies, about 50% of the patients positive for nephritic factors developed MPGN (Spitzer, R.E., et al., Clin. Immunol. Immunopathol. 64:111-33, 1992). C3NeF is an autoantîbody directed against the alternative pathway C3 convertase (C3bBb) and it stabilizes this convertase, thereby promoting alternative pathway activation (Daha, M.R., et ah, 7. Immunol. 116:1-1, 1976).
Likewise, autoantîbody with a specificity for the classical pathway C3 convertase (C4b2a), called C4NeF, stabilizes this convertase and thereby promotes classical pathway activation (Daha, M.R. étal., 7. Immunol. /25:2051-2054, 1980; Halbwachs, L., et al., 7. Clin. Invest. 65:1249-56, 1980). Anti-Clq autoantibodies hâve been described to be related to nephritis in SLE patients (Hovath, L., et al., Clin. Exp. Rheumatol. 19:661-12, 20 2001; Siegert, C., et al., 7. Rheumatol. 18:230-34, 1991; Siegert, C., et al., Clin. Exp.
Rheumatol. 70:19-23, 1992), and a rise in the titer of these anti-Clq autoantibodies was reported to predict a flare of nephritis (Corenians, LE., et al., Am. J. Kidney Dis. 26:595-601, 1995). Immune deposits eluted from postmortem kidneys of SLE patients revealed the accumulation of these anti-Clq autoantibodies (Mannick, M., et al., 25 Arthritis Rheumatol. 40:1504-11, 1997). Ail these facts point to a pathological rôle for these autoantibodies. However, not ail patients with anti-Clq autoantibodies develop rénal disease and also some healthy indîviduals hâve low titer anti-Clq autoantibodies (Siegert, C.E., et al., Clin. Immunol. Immunopathol. 67:204-9,1993).
In addition to the alternative and classical pathways of complément activation, the 30 lectin pathway may also hâve an important pathological rôle in rénal disease. Elevated levels of MBL, MBL-associated serine protease and complément activation products hâve been detected by immunohistochemical techniques on rénal biopsy material obtained from patients diagnosed with several different rénal diseases, including Henoch-Schonlein purpura nephritis (Endo, M., étal., Am. J. Kidney Dis. 35:401-407, 2000), cryoglobulinémie glomerulonephritis (Ohsawa, L, et al., Clin. Immunol. 701:59-66, 2001) and IgA neuropathy (Endo, M., etaL, Clin.
Nephrology 55:185-191, 2001). Therefore, despite the fact that an association between complément and rénal diseases has been known for several décades, data on how complément exactly influences these rénal diseases is far from complété.
BLOOD DISORDERS
Sepsis is caused by an overwhelming reaction of the patient to invading microorganisms. A major function of the complément System is to orchestrale the inflammatory response to invading bacteria and other pathogens. Consistent with this physiological rôle, complément activation has been shown in numerous studies to hâve a major rôle in the pathogenesis of sepsis (Bone, R.C., Annals. Internai. Med. 115:45!-469, 1991). The définition of the clinical manifestations of sepsis is ever evolving. Sepsis is usually defined as the systemic host response to an infection. However, on many occasions, no clinical evidence for infection (e.g., positive bacterial blood cultures) is found in patients with septic symptoms. This discrepancy was first taken into account at a Consensus Conférence in 1992 when the term systemic inflammatory response syndrome (SIRS) was established, and for which no definable presence of bacterial infection was required (Bone, R.C., et al., Crit. Care Med. 20:124-126, 1992). There is now general agreement that sepsis and SIRS are accompanied by the inability to regulate the inflammatory response. For the purposes of this brief review, we will consider the clinical définition of sepsis to also include severe sepsis, septic shock, and SIRS.
The prédominant source of infection in septic patients before the late 1980s was Gram-negative bacteria. Lipopolysaccharide (LPS), the main component of the Gram-negative bacterial cell wall, was known to stimulate release of inflammatory mediators from varions cell types and induce acute infections symptoms when injected into animais (Haeney, M.R., étal., Antimicrobial Chemotherapy 41 (Suppl. A):41-6, 1998). Interestingly, the spectrum of responsîble microorganisms appears to hâve shifted from predominantly Gram-negative bacteria in the late 1970s and 1980s to predominantly Gram-positive bacteria at présent, for reasons that are currently unclear (Martin, G.S., et al., N. Eng. J. Med. 348:1546-54, 2003).
Many studies hâve shown the importance of complément activation in mediating inflammation and contributing to the features of shock, particularly septic and hémorrhagie shock. Both Gram-negative and Gram-positive organisms commonly precipitate septic shock. LPS is a potent activator of complément, predominantly via the 5 alternative pathway, although classical pathway activation mediated by antibodies also occurs (Fearon, D.T., et al., N. Engl. J. Med. 292:937-400, 1975). The major components of the Gram-positive cell wall are peptidoglycan and lipoteichoic acid, and both components are potent activators of the alternative complément pathway, although in the presence of spécifie antibodies they can also activaie the classical complément pathway 10 (Joiner, K.A., et al., Ann. Rev. Immunol. 2:461-2, 1984).
The complément System was initially implicated in the patliogenesis of sepsis when it was noted by researchers that anaphylatoxins C3a and C5a médiate a variety of inllaminalory reactions that might also occur during sepsis. These anaphylatoxins evoke vasodilation and an increase in microvascular permeability, events that play a central rôle 15 in septic shock (Schumacher, W.A., étal., Agents Actions 34:345-349, 1991). In addition, the anaphylatoxins induce bronchospasm, histamine release from mast cells, and aggregation of platelets. Moreover, they exert numerous effects on granulocytes, such as chemotaxis, aggregation, adhesion, release of lysosomal enzymes, génération of toxic super oxide anion and formation of leukotrienes (Shin, H.S., et al., Science 162:361-363, 20 1968; Vogt, W., Complément 3:177-86, 1986). These biologie effects are thought to play a rôle in development of complications of sepsis such as shock or acute respiratory distress syndrome (ARDS) (Hammerschmidt, D.E., étal., Lancet 1:947-949, 1980; Slotman, G.T., étal., Surgery 99:144-50, 1986). Furthermore, elevated levels of tire anaphylatoxin C3a is associated with a fatal outcome in sepsis (Hack, C.E., et al., Am. J. 25 Med. 86:20-26, 1989). In some animal models of shock, certain complement-deficient strains (e.g., C5-deficient ones) are more résistant to the effects of LPS infusions (Hseuh, W., et al., Immunol. 70:309-14,1990).
Blockade of C5a génération with antibodies during the onset of sepsis in rodents has been shown to greatly improve survival (Czermak, B.J., étal., Nat. Med. 5:788-792, 30 1999). Similar findings were made when the C5a receptor (C5aR) was blocked, either with antibodies or with a small molecular inhibitor (Huber-Lang, M.S., et al., FASEB J. 76:1567-74, 2002; Riedemann, N.C., étal., J. Clin. Invest. 270:101-8, 2002). Earlier experimental studies in monkeys hâve suggested that antibody blockade of C5a attenuated E. co/ï-induced septic shock and adult respiratory distress syndrome (Hangen, D.H., et al., J. Surg. Res. 46:195-9, 1989; Stevens, J.H., et al., J. Clin. Invest. 77:1812-16, 1986). In humans with sepsis, C5a was elevated and associated with significantly 5 reduced survival rates together with multiorgan failure, when compared with that in less severely septic patients and survivors (Nakac, H., et al., Res. Commun. Chem. Pathol. Pharmacol. 84:189-95, 1994; Nakae, étal., Surg. Today 26:225-29, 1996; Bengtson, A., et al., Arch. Surg. 725:645-649, 1988). The mechanisms by which C5a exerts its harmful effects during sepsis are yet to be investigated in greater detail, but recent data suggest the 10 génération of C5a during sepsis significantly compromises innate immune fonctions of blood neutrophils (Huber-Lang, M.S., et al., J. Immunol. 769:3223-31, 2002), their ability to express a respiratory burst, and their ability to generate cytokines (Riedemann, N.C., et al., Immunity 79:193-202, 2003). In addition, C5a génération during sepsis appears to hâve procoagulant effects (Laudes, I.J., étal., Am. J. Pathol. 760:1867-75, 2002). The 15 complement-modulating protein CI INH has also shown efficacy in animal models of sepsis and ARDS (Dickneite, G., Behring Ins. Mitt. 93:299-305,1993).
The lectin pathway may also hâve a rôle in pathogenesis of sepsis. MBL has been shown to bind to a range of clinically important microorganisms including both Gram-negative and Gram-positive bacteria, and to activate the lectin pathway (Neth, O., 20 et al., Infect. Immun. 68:688, 2000). Lipoteichoic acid (LTA) is increasingly regarded as the Gram-positive counterpart of LPS. It is a potent immunostimulant that induces cytokine release from mononuclear phagocytes and whole blood (Morath, S., et al., J. Exp. Med. 795:1635, 2002; Morath, S„ et al„ Infect. Immun. 70:938, 2002). Recently it was demonstrated that L-ficolin specifically binds to LTA isolated from numerous 25 Gram-positive bacteria species, including Staphylococcus aureus, and activâtes the lectin pathway (Lynch, N.J., et al., J. Immunol. 772:1198-02, 2004). MBL also has been shown to bind to LTA from Enterococcus spp in which the polyglycerophosphate chain is substituted with glycosyl groups), but not to LTA from nine other species including 5. aureus (Polotsky, V.Y., et al., Infect. Immun. 64:380, 1996).
An aspect of the invention thus provides a method for treating sepsis or a condition resulting from sepsis, by administering a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent in a pharmaceutical
Ο 82 carrier to a subject suffering from sepsis or a condition resulting from sepsis including without limitation severe sepsis, septic shock, acute respiratory dîstress syndrome resulting from sepsis, and systemic inflammatory response syndrome. Related methods are provided for the treatment of other blood disorders, including hémorrhagie shock, 5 hemolytic anémia, autoimmune thrombotic thrombocytopénie purpura (TTP), hemolytic urémie syndrome (HUS), atypical hemolytic urémie syndrome (aHUS), or other marrow/blood destructive conditions, by administering a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent in a pharmaceutical carrier to a subject suffering from such a condition. The MASP-2 inhibitory agent is 10 administered to the subject systemically, such as by intra-arterial, intravenous, intramuscular, inhalational (particularly in the case of ARDS), subeutaneous or other parentéral administration, or potentially by oral administration for non-peptidergic agents. The MASP-2 inhibitory agent composition may be combined with one or more additional therapeutic agents to combat the sequelae of sepsis and/or shock. For advanced sepsis or 15 shock or a distress condition resulting therefrom, the MASP-2 inhibitory composition may suitably be administered in a fast-acting dosage form, such as by intravenous or intra-arterial delivery of a bolus of a solution containing the MASP-2 inhibitory agent composition. Repeated administration may be carried out as determined by a physician until the condition has been resolved.
COAGULOPATHIES
Evidence has been developed for the rôle of the complément System in disseminated intravascular coagulation (DIC), such as DIC secondary to significant bodily trauma.
Previous studies hâve shown that C4-Z- mice are not protected from rénal 25 reperfusion injury. (Zhou, W., et al, Prédominant rôle for C5b-9 in rénal ischemia/reperfusion injury, J Clin Invest 105:1363-1371 (2000)) In order to investigate whether C4-/- mice may still be able to activate complément via either the classical or the lectin pathway, C3 turn-over in C4-/- plasma was measured in assays spécifie for either the classical, or the lectin pathway activation route. While no C3 cleavage could be 30 observed when triggering activation via the classical, a highly efficient lectin pathwaydependent activation of C3 in C4 déficient sérum was observed (FIGURE 30). It can be seen that C3b déposition on mannan and zymosan is severely corapromised in MASP-2-/ mice, even under experimental conditions, that accordîng to many previously published papers on alternative pathway activation, should be permissive for ail three pathways. When using the same sera in wells coated with immunoglobulin complexes instead of mannan or zymosan, C3b déposition and Factor B cleavage are seen in MASP-2+/+ 5 mouse sera and MASP-2-/- sera, but not in Clq depleted sera. This indicates that alternate pathway activation is facilitated in MASP-2-/- sera when the initial C3b is provided via classical activity. FIGURE 30C depicts the surprising finding that C3 can efficiently be activated in a lectin pathway-dépendent fashion in C4 déficient plasma.
This C4 bypass is abolished by the inhibition of lectin pathway-activation 10 through preincubation of plasma with soluble mannan or mannose.
Aberrant, non-immune, activation of the complément System is potentially hazardous to man and may also play an important rôle in hematological pathway activation, particularly in severe trauma situations wherein both inflammatory and hematological pathways are activated. In normal health, C3 conversion is <5% of the 15 total plasma C3 protein. In rampant infection, including septicaemia and immune complex disease, C3 conversion re-establishes itself at about 30% with complément levels frequently lower than normal, due to increased utilization and changes in pool distribution. Immédiate C3 pathway activation of greater than 30% generally produces obvious clinical evidence of vasodilatation and of fluid loss to the tissues. Above 30% C3 20 conversion, the initiatîng mechanisms are predominantly non-immune and the resulting clinical manifestations are harmful to the patient. Complément C5 levels in health and in controlled disease appear much more stable than C3. Significant decreases and or conversion of C5 levels are associated with the patient's response to abnormal polytrauma (e.g., road traffic accidents) and the likely development of shock lung syndromes. Thus, 25 any evidence of either complément C3 activation beyond 30% of the vascular pool or of any C5 involvement, or both, may be considered likely to be a harbinger of a harmful pathological change in the patient.
Both C3 and C5 liberate anaphylatoxins (C3a and C5a) that act on mast cells and basophils releasing vasodilatory Chemicals. They set up chemotactic gradients to guide 30 polymorphonuclear cells (PMN) to the center of îmmunological disturbances (a bénéficiai response), but here they differ because C5a has a spécifie dumping (aggregating) effect on these phagocytîc cells, preventing their random movement away from the reaction site.
Ο 84
In normal control of infection, C3 activâtes C5. However, in polytrauma, C5 appears to be widely activated, generating C5a anaphylatoxins systemically. This uncontrolled activity causes polymorphe to clump within the vascular System, and these clumps are then swept into the capillaries of tire lungs, which they occlude and generate local 5 damaging effects as a resuit of superoxide libération. While not wishing to be limited by theory, the mechanism is probably important in the pathogenesis of acute respiratory distress syndrome (ARDS), although this view has recently been challenged. The C3a anaphylatoxins in vitro can be shown to be potent platelet aggregators, but their involvement in vivo is less defined and the release of platelet substances and plasmîn in 10 wound repair may only secondarily involve complément C3. It is possible that prolonged élévation of C3 activation is necessary to generate DIC.
In addition to cellular and vascular effects of activated complément component outlined above that could explain the link between trauma and DIC, emerging scientific discoveries hâve identified direct molecular links and functîonal cross-talk between 15 complément and coagulation Systems. Supporting data has been obtained from studies in C3 déficient mice. Because C3 is the shared component for each of the complément pathways, C3 déficient mice are predicted to lack ail complément function. Surprisingly, however, C3 déficient mice are perfectly capable of activatîng terminal complément components. (Huber-Lang, M., et al., Génération of C5a in the absence of C3: a new 20 complément activation pathway, Nat. Med 72:682-687 (2006)) In depth studies revealed that C3-independent activation of terminal complément components is mediated by thrombin, the rate limiting enzyme of the coagulation cascade. (Huber et al., 2006) The molecular components mediating thrombin activation following initial complément activation remained elusive.
The présent inventors hâve elucidated what is believed to be the molecular basis for cross-talk between complément and clotting cascades and identified MASP-2 as a central control point linking the two Systems. Biochemical studies into the substrate specificity of MASP-2 hâve identified prothrombin as a possible substrate, in addition to the well known C2 and C4 complément proteins. MASP-2 specifically cleaves 30 prothrombin at functionally relevant sites, generating thrombin, the rate limiting enzyme of the coagulation cascade. (Krarup, A., et al., Simultaneous Activation of Complément and Coagulation by MBL-Associated Serine Protease 2, PLoS. ONE. 2:e623 (2007))
MASP-2-generated thrombin is capable of promoting fibrin déposition in a defined reconstituted in vitro System, demonstrating the functional relevance of MASP-2 cleavage. (Krarup et al., 2007) As discussed in the examples herein below, the inventors hâve further corroborated the physiological significance of this discovery by documenting thrombin activation in normal rodent sérum following lectin pathway activation, and demonstrated that this process is blocked by neutralizing MASP-2 monoclonal antibodies.
MASP-2 may represent a central branch point in the lectin pathway, capable of promoting activation of both complément and coagulation Systems. Because lectin pathway activation is a physiologie response to many types of traumatic injury, the présent inventors believe that concurrent systemic inflammation (mediated by complément components) and disseminated coagulation (mediated via the clotting pathway) can be explained by the capacity of MASP-2 to activate both pathways. These findings clearly suggest a rôle for MASP-2 in DIC génération and therapeutic benefit of MASP-2 inhibition in treating or preventing DIC. MASP-2 may provide the molecular link between complément and coagulation System, and activation of the lectin pathway as it occurs în settings of trauma can directly initiate activation of the clotting System via the MASP-2-thrombin axis, providing a mechanistic link between trauma and DIC. In accordance with an aspect of the présent invention, inhibition of MASP-2 would inhibit lectin pathway activation and reduce the génération of both anaphylatoxins C3a and C5a. It is believed that prolonged élévation of C3 activation is necessary to generate DIC.
Microcirculatory coagulation (blot clots in capillaries and small blood vessels) occurs in settings such a septic shock. A rôle of the lectin pathway in septic shock is established, as evidenced by the protected phenotype of MASP-2 (-/-) mouse models of sepsis, described in Example 17 and FIGURES 18 and 19. Furthermore, as demonstrated in Example 15 and FIGURES 16A and 16B, MASP-2 (-/-) mice are protected in the localized Schwartzman reaction model of disseminated intravascular coagulation (DIC), a model of localized coagulation in microvessels.
V. MASP-2 INHIBITORY AGENTS
In one aspect, the présent invention provides methods of inhibiting MASP-2-dependent complément activation in a subject suffering from, or at risk for developing a thrombotic microangiopathy. MASP-2 inhibitory agents are administered in an amount effective to inhibit MASP-2-dependent complément activation in a living subject. In the practice of this aspect of the invention, représentative MASP-2 inhibitory agents include: molécules that inhibit the biological activity of MASP-2 (such as small molécule inhibitors, anti-MASP-2 antibodies or blocking peptides which internet with MASP-2 or interfère with a protein-protein interaction), and molécules that decrease the expression of MASP-2 (such as MASP-2 antisense nucleic acid molécules, MASP-2 spécifie RNAi molécules and MASP-2 ribozymes), thereby preventing MASP-2 from activating the lectin complément pathway. The MASP-2 inhibitory agents can be used alone as a primary therapy or in combination with other therapeutics as an adjuvant therapy to enhance the therapeutic benefits of other medical treatments.
The inhibition of MASP-2-dependent complément activation is characterized b y at least one of the following changes in a component of the complément system that occurs as a resuit of administration of a MASP-2 inhibitory agent in accordance with the methods of the invention: the inhibition of the génération or production of MASP-2-dependent complément activation system products C4b, C3a, C5a and/or C5b-9 (MAC) (measured, for example, as described in Example 2), the réduction of complément activation assessed in a hemolytic assay using unsensitized rabbit or guinea pig red blood cells (measured, for example as described in Example 33), the réduction of C4 cleavage and C4b déposition (measured, for example as described in Example 2), or the réduction of C3 cleavage and C3b déposition (measured, for example, as described in Example 2).
According to the présent invention, MASP-2 inhibitory agents are utilized that are effective in inhibitmg the MASP-2-dependent complément activation system. MASP-2 inhibitory agents useful in the practice of this aspect of the invention include, for example, anti-MASP-2 antibodies and fragments thereof, MASP-2 inhibitory peptides, small molécules, MASP-2 soluble receptors and expression inhibitors. MASP-2 inhibitory agents may inhibit the MASP-2-dependent complément activation system by blocking the biological function of MASP-2. For example, an inhibitory agent may effectively block MASP-2 protein-to-protein interactions, interfère with MASP-2 dimerization or assembly, block Ca2+ binding, interfère with the MASP-2 serine protease active site, or may reduce MASP-2 protein expression.
In some embodiments, the MASP-2 inhibitory agents selectively inhibit MASP-2 complément activation, leaving the Clq-dependent complément activation System functionally intact.
In one embodiment, a MASP-2 inhibitory agent useful in the methods of the 5 invention is a spécifie MASP-2 inhibitory agent that specifically binds to a polypeptide comprising SEQ ID NO:6 with an affinity of at least ten times greater than to other antigens in the complément System. In another embodiment, a MASP-2 inhibitory agent specifically binds to a polypeptide comprising SEQ ID NO:6 with a binding affinity of at least 100 times greater than to other antigens in the complément System. The binding 10 affinity of the MASP-2 inhibitory agent can be determined using a suitable binding assay.
The MASP-2 polypeptide exhibits a molecular structure similar to MASP-1, MASP-3, and Clr and Cls, the proteases of the Cl complément System. The cDNA molécule set forth in SEQ ID NO:4 encodes a représentative example of MASP-2 (consisting of the amino acid sequence set forth in SEQ ID NO:5) and provides the 15 human MASP-2 polypeptide with a leader sequence (aa 1-15) that is cleaved after sécrétion, resulting in the mature form of human MASP-2 (SEQ ID NO:6). As shown in FIGURE 2, the human MASP 2 gene encompasses twelve exons. The human MASP-2 cDNA is encoded by exons B, C, D, F, G, H, I, J, K AND L. An alternative splice results in a 20 kDa protein termed MBL-associated protein 19 (MApl9, also referred to as 20 sMAP) (SEQ ID NO:2), encoded by (SEQ ID NO: 1) arising from exons B, C, D and E as shown in FIGURE 2. The cDNA molécule set forth in SEQ ID NO:50 encodes the murine MASP-2 (consisting of the amino acid sequence set forth in SEQ ID NO:51) and provides the murine MASP-2 polypeptide with a leader sequence that is cleaved after sécrétion, resulting in the mature form of murine MASP-2 (SEQ ID NO:52). The cDNA 25 molécule set forth in SEQ ID NO:53 encodes the rat MASP-2 (consisting of the amino acid sequence set forth in SEQ ID NO: 54) and provides the rat MASP-2 polypeptide with a leader sequence that is cleaved after sécrétion, resulting in the mature form of rat MASP-2 (SEQ ID NO:55).
Those skilled in the art will recognize that the sequences disclosed in SEQ ID 30 NO:4, SEQ ID NO:50 and SEQ ID NO:53 represent single alleles of human, murine and rat MASP-2 respectively, and that allelic variation and alternative splicing are expected to occur. Allelic variants of the nucléotide sequences shown in SEQ ID NO:4, SEQ ID
NO:50 and SEQ ID NO:53, including those containing silent mutations and those in which mutations resuit in amino acid sequence changes, are within the scope of the présent invention. Allelic variants of the MASP-2 sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures.
The domains of the human MASP-2 protein (SEQ ID NO:6) are shown in
FIGURE 1 and 2A and include an N-terminal Clr/Cls/sea urchin Vegf/bone morphogenic protein (CUBI) domain (aa 1-121 of SEQ ID NO:6), an epidermal growth factor-Iike domain (aa 122-166), a second CUBI domain (aa 167-293), as well as a tandem of complément control protein domains and a serine protease domain. 10 Alternative splicing of the MASP 2 gene results in MApl9 shown in FIGURE 1. MApl9 is a nonenzymatic protein containing the N-terminal CUBI-EGF région of MASP-2 with four additional residues (EQSL) derived from exon E as shown in FIGURE 1.
Several proteins hâve been shown to bind to, or interact with MASP-2 through protein-to-protein interactions. For example, MASP-2 is known to bind to, and form 15 Ca2+ dépendent complexes with, the lectin proteins MBL, H-ficolin and L-ficolin. Each MASP-2/lectin complex has been shown to activate complément through the MASP-2-dependent cleavage of proteins C4 and C2 (Ikeda, K., étal., J. Biol. Chem. 262:7451-7454, 1987; Matsushita, M., étal., J. Exp. Med. 776:1497-2284, 2000; Matsushita, M., et al., J. Immunol. 765:3502-3506, 2002). Studies hâve shown that the 20 CUB1-EGF domains of MASP-2 are essential for the association of MASP-2 with MBL (Thîelens, N.M., étal., J. Immunol. 766:5068, 2001). It has also been shown that the CUB1EGFCUBII domains médiate dimerization of MASP-2, which is required for formation of an active MBL complex (Wallis, R., et al., J. Biol. Chem. 275:30962-30969, 2000). Therefore, MASP-2 inhibitory agents can be identified that bind to or interfère 25 with MASP-2 target régions known to be important for MASP-2-dependent complément activation.
ANTI-MASP-2 ANTIBODIES
In some embodiments of this aspect of the invention, the MASP-2 inhibitory agent comprises an anti-MASP-2 antibody that inhibits the MASP-2-dependent 30 complément activation System. The anti-MASP-2 antibodies useful in this aspect of the invention include polyclonal, monoclonal or recombinant antibodies derived from any antibody producing mammal and may be multispecific, chimeric, humanized, anti-idiotype, and antibody fragments. Antibody fragments include Fab, Fab', F(ab)2, F(ab')2, Fv fragments, scFv fragments and single-chain antibodies as further described herein.
Several anti-MASP-2 antibodies hâve been described in the literature, some of 5 which are listed below in TABLE 1. These previously described anti-MASP-2 antibodies can be screened for the ability to inhibit the MASP-2-dependent complément activation System using the assays described herein. For example, anti rat MASP-2 Fab2 antibodies hâve been identified that block MASP-2 dépendent complément activation, as described in more detail in Examples 10 and 11 herein. Once an anti-MASP-2 antibody is 10 identified that functions as a MASP-2 inhibitory agent, it can be used to produce anti-idiotype antibodies and used to identify other MASP-2 binding molécules as further described below.
TABLE 1: MAS! | >-2 SPECIFIC ANTIBODIES FROM THE LITERATURE | |
ANTIGEN | ANTIBODY type | REFERENCE |
Recombinant MASP-2 | Rat Polyclonal | Peterson, S.V., et al., Mol. Immunol. 37:803-811, 2000 |
Recombinant human CCP1/2-SP fragment (MoAb 8B5) | Rat MoAb (subclass IgGl) | Moller-Kristensen, M., et al., J. of Immunol. Methods 282:159-167, 2003 |
Recombinant human MApl9 (MoAb 6G12) (cross reacts with MASP-2) | Rat MoAb (subclass IgGl) | Moller-Kristensen, M., et al., J. of Immunol. Methods 282:159-167, 2003 |
hMASP-2 | Mouse MoAb (S/P) Mouse MoAb (N-term) | Peterson, S.V., et al., Mol. Immunol. 35:409, April 1998 |
hMASP-2 (CCP1-CCP2-SP domain | rat MoAb: NimoablOl, produced by hybridoma cell line 03050904 (ECACC) | WO 2004/106384 |
ANTIGEN | ANTIBODY TYPE | REFERENCE |
hMASP-2 (full length-his tagged) | murine MoAbs: NimoAbl04, produced by hybridoma cell line M0545YM035 (DSMZ) NimoAbl08, produced by hybridoma cell line M0545YM029 (DSMZ) NimoAbl09 produced by hybridoma cell line M0545YM046 (DSMZ) NimoAbllO produced by hybridoma cell line M0545YM048 (DSMZ) | WO 2004/106384 |
ANTI-MASP-2 ANTIBODIES WITH REDUCED EFFECTOR FUNCTION
In some embodiments of this aspect of the invention, the anti-MASP-2 antibodies hâve reduced effector function in order to reduce inflammation that may arise from the activation of the classical complément pathway. The ability of IgG molécules to trigger the classical complément pathway has been shown to résidé within the Fc portion of the molécule (Duncan, A.R., et al., Nature 352:738-740 1988). IgG molécules in which the Fc portion of the molécule has been removed by enzymatic cleavage are devoid of this effector function (see Harlow, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988). Accordingly, antibodies with reduced effector function can be generated as the resuit of lacking the Fc portion of the molécule by having a genetically engineered Fc sequence that minimizes effector function, or being of either the human IgG2 or IgGq isotype.
Antibodies with reduced effector function can be produced b y standard molecular biological manipulation of the Fc portion of the IgG heavy chains as described in Example 9 herein and also described in Jolliffe et al., Int'l Rev. Immunol. /0:241-250, 1993, and Rodrigues étal., J. Immunol. 757:6954-6961, 1998. Antibodies with reduced effector function also include human IgG2 and IgG4 isotypes that hâve a reduced ability to activate complément and/or internet with Fc receptors (Ravetch, J.V., et al., Annu. Rev. Immunol. 9:457-492, 1991; Isaacs, J.D., et al., J. Immunol. 745:3062-3071, 1992; van de
Winkel, J.G., étal., Immunol. Today 74:215-221, 1993). Humanized or fully human antibodies spécifie to human MASP-2 comprised of IgG2 or IgG4 isotypes can be produced b y one of several methods known to one of ordinary skilled in the art, as described in Vaughan, T.J., et al., Nature Biotechnical 76:535-539, 1998.
PRODUCTION OF ANTI-MASP-2 ANTIBODIES
Anti-MASP-2 antibodies can be produced using MASP-2 polypeptides (e.g., full length MASP-2) or using antigenic MASP-2 epitope-bearing peptides (e.g., a portion of the MASP-2 polypeptide). Immunogenic peptides may be as small as five amino acid residues. For example, the MASP-2 polypeptide including the entire amino acid sequence of SEQ ID NO:6 may be used to induce anti-MASP-2 antibodies useful in tire method of the invention. Particular MASP-2 domains known to be involved in protein-protein interactions, such as the CUBI, and CUBIEGF domains, as well as the région encompâssing the serine-protease active site, may be expressed as recombinant polypeptides as described in Example 3 and used as antigens. In addition, peptides comprising a portion of at least 6 amino acids of the MASP-2 polypeptide (SEQ ID NO:6) are also useful to induce MASP-2 antibodies. Additional examples of MASP-2 derived antigens useful to induce MASP-2 antibodies are provided below in TABLE 2. The MASP-2 peptides and polypeptides used to raise antibodies may be isolated as natural polypeptides, or recombinant or synthetic peptides and catalytically inactive recombinant polypeptides, such as MASP-2A, as further described in Examples 5-7. In some embodiments of this aspect of the invention, anti-MASP-2 antibodies are obtained using a transgenic mouse strain as described in Examples 8 and 9 and further described below.
Antigens useful for producing anti-MASP-2 antibodies also include fusion polypeptides, such as fusions of MASP-2 or a portion thereof with an immunoglobulin polypeptide or with maltose-binding protein. The polypeptide immunogen may be a full-length molécule or a portion thereof. If the polypeptide portion is hapten-like, such portion may be advantageously joîned or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine sérum albumin (BSA) or tetanus toxoid) for immunization.
TABLE 2: MASP-2 DERIVED ANTIGENS
SEQ ID NO: | Amino Acid Sequence |
SEQ ID NO:6 | Human MASP-2 protein |
SEQIDNO:51 | Murine MASP-2 protein |
SEQ ID NO:8 | CUBI domain of human MASP-2 (aa 1-121 ofSEQIDNO:6) |
SEQ ID NO:9 | CUBIEGF domains of human MASP-2 (aa 1-166 of SEQ ID NO:6) |
SEQ ID NO: 10 | CUBIEGFCUBII domains of human MASP-2 (aa 1-293 of SEQ ID NO:6) |
SEQID NO: 11 | EGF domain of human MASP-2 (aa 122-166 of SEQ ID NO:6) |
SEQ ID NO: 12 | Serine-Protease domain of human MASP-2 (aa 429-671 of SEQ ID NO:6) |
SEQID NO: 13 GKDSCRGDAGGALVFL | Serine-Protease inactivated mutant form (aa 610-625 of SEQ ID NO:6 with mutated Ser 618) |
SEQID NO: 14 TPLGPKWPEPVFGRL | Human CUBI peptide |
SEQID NO: 15: TAPPGYRLRLYFTHFDLEL SHLCEYDFVKLSSGAKVL ATLCGQ | Human CUBI peptide |
SEQID NO: 16: TFRSDYSN | MBL binding région in human CUBI domain |
SEQID NO: 17: FYSLGSSLDHFRSDYSNEK PFTGF | MBL binding région in human CUBI domain |
SEQID NO: 18 IDECQVAPG | EGF peptide |
SEQID NO: 19 ANMLCAGLESGGKDSCRG DSGGALV | Peptide from serine-protease active site |
POLYCLONAL ANTIBODIES
Polyclonal antibodies against MASP-2 can be prepared by immunizing an animal with MASP-2 polypeptide or an immunogenic portion thereof using methods well known to those of ordinary skill in the art. See, for example, Green étal., Production of
Polyclonal Antisera, in Immunochemical Protocols (Manson, ed.), page 105, and as further described in Example 6. The immunogenicity of a MASP-2 polypeptide can be increased through the use of an adjuvant, including minerai gels, such as aluminum hydroxide or Freund's adjuvant (complété or incomplète), surface active substances such as lysolecithin, pluronic polyols, polyanions, oil émulsions, keyhole limpet hemocyanin and dinitrophenol. Polyclonal antibodies are typically raised in animais such as horses, cows, dogs, chicken, rats, mice, rabbits, guinea pigs, goats, or sheep. Alternative!y, an anti-MASP-2 antibody useful in the présent invention may also be derived from a subhuman primate. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in Goldenberg et al., International Patent Publication No. WO 91/11465, and in Losman, M.J., étal., Int. J. Cancer 46:310, 1990. Sera containing immunologically active antibodies are then produced from the blood of such immunized animais using standard procedures well known in the ait.
MONOCLONAL ANTIBODIES
In some embodiments, the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody. Anti-MASP-2 monoclonal antibodies are highly spécifie, being directed against a single MASP-2 epitope. As used herein, the modifier monoclonal indicates the character of the antibody as being obtained from a substantially homogenous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. Monoclonal antibodies can be obtained using any technique that provides for the production of antibody molécules by continuons cell lines in culture, such as the hybridoma method described by Kohler, G., et al., Nature 256:495, 1975, or they may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567 to Cabilly). Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson, T., étal., Nature 552:624-628, 1991, and Marks, J.D., et al., J. Mol. Biol. 222:581-597, 1991. Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
For example, monoclonal antibodies can be obtained by injecting a suitable mammal (e.g., a BALB/c mouse) with a composition comprising a MASP-2 polypeptide or portion thereof. After a predetermined period of time, splénocytes are removed from the mouse and suspended in a cell culture medium. The splénocytes are then fused with an immortal cell line to form a hybridoma. The formed hybridomas are grown in cell culture and screened for their ability to produce a monoclonal antibody against MASP-2. An example further describing the production of anti-MASP-2 monoclonal antibodies is provided in Example 7. (See also Current Protocols in Immunology, Vol. 1., John Wiley & Sons, pages 2.5.1-2.6.7,1991.)
Human monoclonal antibodies may be obtained through the use of transgenic mice that hâve been engineered to produce spécifie human antibodies in response to antigenic challenge. In this technique, éléments of the human immunoglobulin heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous immunoglobulin heavy chain and light chain loci. The transgenic mice can synthesize human antibodies spécifie for human antigens, such as the MASP-2 antigens described herein, and the mice can be used to produce human MASP-2 antibody-secreting hybridomas by fusing B-cells from such animais to suitable myeloma cell lines using conventional Kohler-Milstein technology as further described in Example 7. Transgenic mice with a human immunoglobulin genome are commercially available (e.g., from Abgenix, Inc., Fremont, CA, and Medarex, hic., Annandale, N.J.). Methods for obtaining human antibodies from transgenic mice are described, for example, by Green, L.L., étal., Nature Genet. 7:13, 1994; Lonberg, N., et al., Nature 368:856, 1994; and Taylor, L.D., et al., Int. Immun. 6:519,1994.
Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines et al., Purification of Immunoglobulin G (IgG), in Methods in Molecular Biology, The Humana Press, Inc., Vol. 10, pages 79-104, 1992).
Once produced, polyclonal, monoclonal or phage-derived antibodies are first tested for spécifie MASP-2 binding. A variety of assays known to those skilled in the art may be utilized to detect antibodies which specifically bind to MASP-2. Exemplary assays include Western blot or immunoprécipitation analysis by standard methods (e.g., as described in Ausubel et al.), immunoelectrophoresis, enzyme-linked immuno-sorbent assays, dot blots, inhibition or compétition assays and sandwich assays (as described in
Hai’low and Land, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988). Once antibodies are identified that specifically bind to MASP-2, the anti-MASP-2 antibodies are tested for the abiiity to function as a MASP-2 inhibitory agent in one of several assays such as, for example, a lectin-specific C4 cleavage assay 5 (described in Example 2), a C3b déposition assay (described in Example 2) or a C4b déposition assay (described in Example 2).
The affinity of anti-MASP-2 monoclonal antibodies can be readily determined by one of ordinary skill in the art (see, e.g., Scatchard, A., NY Acad. Sci. 57:660-672, 1949). In one embodiment, the anti-MASP-2 monoclonal antibodies useful for the methods of 10 the invention bind to MASP-2 with a binding affinity of <100 nM, preferably <10 nM and most preferably <2 nM. In some embodiments, a MASP-2 inhibitory monoclonal antibody useful in the methods of the invention is a MASP-2 inhibitory monoclonal antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 15 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDR-L1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 20 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavychain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at 25 least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
CHIMERIC/HUMANIZED ANTIBODIES
Monoclonal antibodies useful in the method of the invention include chimeric 30 antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies (U.S. Patent No. 4,816,567, to Cabilly; and Momson, S.L., étal., Proc. Nat'IAcad. Sci. USA 57:6851-6855, 1984).
One form of a chimeric antibody useful in the invention is a humanized monoclonal anti-MASP-2 antibody. Humanized forms of non-human (e.g., murine) antibodies are chimeric antibodies, which contain minimal sequence derived from non-human immunoglobulin. Humanized monoclonal antibodies are produced by transferring the non-human (e.g., mouse) complementarity determining régions (CDR), 10 from the heavy and light variable chains of the mouse immunoglobulin into a human variable domain. Typically, residues of human antibodies are then substituted in the framework régions of the non-human counterparts. Furthermore, humanized antibodies may comprise residues that are not found in the récipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In 15 general, the humanized antibody will comprise substantially ail of at least one, and typically two variable domains, in which ail or substantially ail of the hypervariable loops correspond to those of a non-human immunoglobulin and ail or substantially ail of the Fv framework régions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant 20 région (Fc), typically that of a human immunoglobulin. For further details, see Jones, P.T., et al., Nature 321:522-525, 1986; Reichmann, L., et al., Nature 332:323-329, 1988; and Presta, Curr. Op. Struct. Biol. 2:593-596, 1992.
The humanized antibodies useful in the invention include human monoclonal antibodies including at least a MASP-2 binding CDR3 région. In addition, the Fc 25 portions may be replaced so as to produce IgA or IgM as well as human IgG antibodies. Such humanized antibodies will hâve particular clinical utility because they will specifically recognize human MASP-2 but will not evoke an immune response in humans against the antibody itself. Consequently, they are better suited for in vivo administration in humans, especially when repeated or long-term administration is necessary.
An example of the génération of a humanized anti-MASP-2 antibody from a murine anti-MASP-2 monoclonal antibody is provided herein in Example 6. Techniques for producing humanized monoclonal antibodies are also described, for example, by
Jones, P.T., étal., Nature 321:522, 1986; Carter, P., étal., Proc. Nat'l. Acad. Sel. USA 89:4285, 1992; Sandhu, J.S., Crit. Rev. Biotech. 12Ά3Ί, 1992; Singer, LL, et al., J. Immun. /50:2844, 1993; Sudhir (ed.), Antibody Engineering Protocole, Humana Press, Inc., 1995; Kelley, Engineering Therapeutic Antibodies, in Protein Engineering: Principles and Practice, Cleland et al. (eds.), John Wiley & Sons, Inc., pages 399-434, 1996; and by U.S. Patent No. 5,693,762, to Queen, 1997. In addition, there are commercial entities that will synthesize humanized antibodies from spécifie murine antibody régions, such as Protein Design Labs (Mountain View, CA).
RECOMBINANT ANTIBODIES
Anti-MASP-2 antibodies can also be made using recombinant methods. For example, human antibodies can be made using human immunoglobulin expression libraries (available for example, from Stratagene, Corp., La Jolla, CA) to produce fragments of human antibodies (Vj.j, Vp, Fv, Fd, Fab or F(ab')2). These fragments are then used to construct whole human antibodies using techniques similar to those for producîng chimeric antibodies.
ANTI-IDIOTYPE ANTIBODIES
Once anti-MASP-2 antibodies are identified with the desired inhibitory activity, these_antibodies can be used to generale anti-idiotype antibodies that resemble a portion of MASP-2 using techniques that are well known in the art. See, e.g., Greenspan, N.S., étal., FASEB J. 7:437, 1993. For example, antibodies that bind to MASP-2 and competitively inhibit a MASP-2 protein interaction required for complément activation can be used to generate anti-idiotypes that resemble the MBL binding site on MASP-2 protein and therefore bind and neutralize a binding ligand of MASP-2 such as, for example, MBL.
IMMUNOGLOBULIN FRAGMENTS
The MASP-2 inhibitory agents useful m the method of the invention encompass not only intact immunoglobulin molécules but also the well known fragments including Fab, Fab', F(ab)2, F(ab')2 and Fv fragments, scFv fragments, diabodies, linear antibodies, smgle-chain antibody molécules and multispecific antibodies formed from antibody fragments.
It is well known in the art that only a small portion of an antibody molécule, the paratope, is involved in the binding of the antibody to its epitope (see, e.g., Clark, W.R., The Experimental Foundations of Modem Immunology, Wiley & Sons, Inc., NY, 1986). The pFc' and Fc régions of the antibody are effectors of the classical complément pathway, but are not involved in antigen binding. An antibody from which the pFc' région has been enzymatically cleaved, or which has been produced without the pFc' région, is designated an F(ab')2 fragment and retains both of the antigen binding sites of an intact antibody. An isolated F(ab')2 fragment is referred to as a bivalent monoclonal fragment because of its two antigen binding sites. Similarly, an antibody from which the Fc région has been enzymatically cleaved, or which has been produced without the Fc région, is designated a Fab fragment, and retains one of the antigen binding sites of an intact antibody molécule.
Antibody fragments can be obtained by proteolytic hydrolysis, such as by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2· This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that resuit from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, U.S. Patent No. 4,331,647 to Goldenberg; Nisonoff, A., étal., Arch. Biochem. Biophys. 89:230, 1960; Porter, R.R., Biochem. J. 75:119, 1959; Edelman, et al., in Methods in Enzymology 7:422, Academie Press, 1967; and by Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.
In some embodiments, the use of antibody fragments lacking the Fc région are preferred to avoid activation of the classical complément pathway which is initiated upon binding Fc to the Fcy receptor. There are several methods by which one can produce a MoAb that avoids Fcy receptor interactions. For example, the Fc région of a monoclonal antibody can be removed chemically using partial digestion by proteolytic enzymes (such as frein digestion), thereby generating, for example, antigen-binding antibody fragments such as Fab or F(ab)2 fragments (Mariani, M., et ah, Mol. Immunol. 25:69-71, 1991). Altematively, the human γ4 IgG isotype, which does not bind Fcy receptors, can be used during construction of a humanized antibody as described herein. Antibodies, single chain antibodies and antigen-binding domains that lack the Fc domain can also be engineered using recombinant techniques described herein.
SINGLE-CHAIN ANTIBODY FRAGMENTS
Altematively, one can create single peptide chain binding molécules spécifie for 10 MASP-2 in which the heavy and light chain Fv régions are connected. The Fv fragments may be connected by a peptide linker to form a single-chain antigen binding protein (scFv). These single-chain antigen binding proteins are prepared by constructing a structural gene comprising DNA sequences encoding the Vjq and Vl domains which are connected by an oligonucleotide. The structural gene is inserted into an expression 15 vector, which is subsequently introduced into a host cell, such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing scFvs are described for example, by Whitlow, étal., Methods: A Companion to Methods in Enzymology 2:97, 1991; Bird, étal., Science242:423, 1988; U.S. Patent No. 4,946,778, to Ladner; Pack, P., étal., 20 Bio/Technology 77:1271, 1993.
As an illustrative example, a MASP-2 spécifie scFv can be obtained by exposing lymphocytes to MASP-2 polypeptide in vitro and selecting antibody display libraries in phage or similar vectors (for example, through the use of immobilized or labeled MASP-2 protein or peptide). Genes encoding polypeptides having potential MASP-2 25 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage or on bacteria such as E. coli. These random peptide display libraries can be used to screen for peptides which interact with MASP-2, Techniques for creating and screening such random peptide display libraries are well known in the ait (U.S. Patent No. 5,223,409, to Lardner; U.S. Patent No. 4,946,778, to Ladner; U.S. Patent 30 No. 5,403,484, to Lardner; U.S. Patent No. 5,571,698, to Lardner; and Kay et al., Phage Display of Peptides and Proteins Academie Press, Inc., 1996) and random peptide
100 display libraries and kits for screening such libraries are available comniercially, for instance from CLONTECH Laboratories, Inc. (Palo Alto, Calif.), Invitrogen Inc. (San Diego, Calif.), New England Biolabs, Inc. (Beverly, Mass.), and Pharmacia LKB Biotechnology hic. (Piscataway, N.J.).
Another form of an anti-MASP-2 antibody fragment useful in this aspect of the invention is a peptide coding for a single complementarity-determining région (CDR) that binds to an epitope on a MASP-2 antigen and inhibits MASP-2-dependent complément activation. CDR peptides (minimal récognition units) can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable région from RNA of antibody-producing cells (see, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2:1Q6, 1991; Courtenay-Luck, Genetic Manipulation of Monoclonal Antibodies, in Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), page 166, Cambridge University Press, 1995; and Ward et al., Genetic Manipulation and Expression of Antibodies, in Monoclonal Antibodies: Principles and Applications, Birch et al. (eds.), page 137, Wiley-Liss, hic., 1995).
The MASP-2 antibodies described herein are administered to a subject in need thereof to inhibit MASP-2-dependent complément activation. In some embodiments, the MASP-2 inhibitory agent is a high-affinity human or humanized monoclonal anti-MASP-2 antibody with reduced effector function.
PEPTIDE INHIBITORS
In some embodiments of this aspect of the invention, the MASP-2 inhibitory agent comprises isolated MASP-2 peptide inhibitors, including isolated natural peptide inhibitors and synthetic peptide inhibitors that inhibit the MASP-2-dependent complément activation system. As used herein, the terni isolated MASP-2 peptide inhibitors refers to peptides that inhibit MASP-2 dépendent complément activation by binding to, competing with MASP-2 for binding to another récognition molécule (e.g., MBL, H-ficolin, M-ficolin, or L-ficolin) in the lectin pathway, and/or directly interacting with MASP-2 to inhibit MASP-2-dependent complément activation that are substantially
101 pure and are essentially free of other substances with which they may be found in nature to an extent practical and appropriate for their intended use.
Peptide inhibitors hâve been used successfully in vivo to interfère with protein-protein interactions and catalytic sites. For example, peptide inhibitors to 5 adhesion molécules structurally related to LFA-1 hâve recently been approved for clinical use in coagulopathies (Ohman, E.M., étal., European Heart J. 7(5:50-55, 1995). Short linear peptides (<30 amino acids) hâve been described that pievent or interfère with integrin-dépendent adhesion (Murayama, O., étal., J. Biochem. 120:445-51, 1996). Longer peptides, ranging in length from 25 to 200 amino acid residues, hâve also been 10 used successfully to block integrin-dépendent adhesion (Zhang, L., étal., J. Biol.
Chem. 277(47):29953-57, 1996). In general, longer peptide inhibitors hâve higher affinities and/or slower off-rates than short peptides and may therefore be more potent inhibitors. Cyclic peptide inhibitors hâve also been shown to be effective inhibitors of integrins in vivo for the treatment of human inflammatory disease (Jackson, D.Y., et al., 15 J. Med. Chem. 40:3359-68, 1997). One method of producing cyclic peptides involves the synthesis of peptides in which the terminal amino acids of the peptide are cysteines, thereby al.lowing the peptide to exist in a cyclic form by disulfide bonding between the terminal amino acids, which has been shown to improve affinity and half-life in vivo for the treatment of hematopoietic neoplasms (e.g., U.S. Patent No. 6,649,592, to Larson).
SYNTHETIC MASP-2 PEPTIDE INHIBITORS
MASP-2 inhibitory peptides useful in the methods of this aspect of the invention are exemplified by amino acid sequences that mimic the target régions important for MASP-2 function. The inhibitory peptides useful in the practice of the methods of the 25 invention range in size from about 5 amino acids to about 300 amino acids. TABLE 3 provides a list of exemplary inhibitory peptides that may be useful in the practice of this aspect of the présent invention. A candidate MASP-2 inhibitory peptide may be tested for the ability to function as a MASP-2 inhibitory agent in one of several assays including, for example, a lectin spécifie C4 cleavage assay (described in Example 2), and 30 a C3b déposition assay (described in Example 2).
In some embodiments, the MASP-2 inhibitory peptides are derived from MASP-2 polypeptides and are selected from the full length mature MASP-2 protein (SEQ ID
102
NO:6), or from a particular domain of the MASP-2 protein such as, for example, the CUBI domain (SEQ ID NO:8), the CUBIEGF domain (SEQ ID NO:9), the EGF domain (SEQ ID NO: 11), and the serine protease domain (SEQ ID NO: 12). As previously described, the CUBEGFCUBII régions hâve been shown to be required for dimerization 5 and binding with MBL (Thielens et al., supra). In particular, the peptide sequence TFRSDYN (SEQ ID NO: 16) in the CUBI domain of MASP-2 has been shown to be involved in binding to MBL in a study that identified a human carrying a homozygous mutation at Asp 105 to Gly 105, resulting in the loss of MASP-2 from the MBL complex (Stengaard-Pedersen, K., et ah, New EnglandJ. Med. 349:554-560, 2003).
In some embodiments, MASP-2 inhibitory peptides are derived from the lectin proteins that bind to MASP-2 and are involved in the lectin complément pathway. Several different lectins hâve been identified that are involved in this pathway, including mannan-binding lectin (MBL), L-ficolin, M-ficolin and H-ficolin. (Ikeda, K., et al., J. Biol. Chem. 262:7451-7454, 1987; Matsushita, M., et al., J. Exp. Med. /76:1497-2284, 15 2000; Matsushita, M., et al., J. Immunol. /65:3502-3506, 2002). These lectins are présent in sérum as oligomers of homotrimeric subunits, each having N-terminal collagen-like fibers with carbohydrate récognition domains. These different lectins hâve been shown to bind to MASP-2, and the lectin/MASP-2 complex activâtes complément through cleavage of proteins C4 and C2. H-ficolin has an amino-terminal région of 24 amino 20 acids, a collagen-like domain with 11 Gly-Xaa-Yaa repeats, a neck domain of 12 amino acids, and a fibrinogen-like domain of 207 amino acids (Matsushita, M., et al., J. Immunol. 765:3502-3506, 2002). H-ficolin binds to GlcNAc and agglutinâtes human érythrocytes coated with LPS derived from 5. typhimurium, S. minnesota and E. coli. H-ficolin has been shown to be associated with MASP-2 and MApl9 and activâtes the 25 lectin pathway. Id. L-ficolin/P35 also binds to GlcNAc and has been shown to be associated with MASP-2 and MApl9 in human sérum and this complex has been shown to activate the lectin pathway (Matsushita, M.,etal., J. Immunol. 764:2281, 2000). Accordingly, MASP-2 inhibitory peptides useful in the présent invention may comprise a région of at least 5 amino acids selected from the MBL protein (SEQ ID NO:21), the 30 H-ficolin protein (Genbank accession number NM_173452), the M-ficolin protein (Genbank accession number 000602) and the L-ficolin protein (Genbank accession number NM_015838).
103
More specifically, scientists hâve identified the MASP-2 binding site on MBL to be within the 12 Gly-X-Y triplets GKD GRD GTK GEK GEP GQG LRG LQG POG KLG POG NOG PSG SOG PKG QKG DOG KS (SEQ ID NO:26) that lie between the hinge and the neck in the C-terminal portion of the collagen-like domain of MBP (Wallis, R., et al., J. Biol. Chem. 279:14065, 2004). This MASP-2 binding site région is also highly conserved in human H-ficolin and human L-ficolin. A consensus binding site has been described that is présent in ail three lectin proteins comprising the amino acid sequence OGK-X-GP (SEQ ID NO:22) where the letter O represents hydroxyproline and the letter X is a hydrophobie residue (Wallis et al., 2004, supra). Accordingly, in some embodiments, MASP-2 inhibitory peptides useful in this aspect of the invention are at least 6 amino acids in length and comprise SEQ ID NO:22. Peptides derived from MBL that include the amino acid sequence GLR GLQ GPO GKL GPO G (SEQ ID NO:24) hâve been shown to bind MASP-2 in vitro (Wallis, et al., 2004, supra). To enhance binding to MASP-2, peptides can be synthesized that are flanked by two GPO triplets at each end (GPO GPO GLR GLQ GPO GKL GPO GGP OGP O SEQ ID NO: 25) to enhance the formation of triple helices as found in the native MBL protein (as further described in Wallis, R., et al., J. Biol. Chem. 279:14065, 2004).
MASP-2 inhibitory peptides may also be derived from human H-ficolin that include the sequence GAO GSO GEK GAO GPQ GPO GPO GKM GPK GEO GDO (SEQ ID NO:27) from the consensus MASP-2 binding région in H-ficolin. Also included are peptides derived from human L-ficolin that include the sequence GCO GLO GAO GDK GEA GTN GKR GER GPO GPO GKA GPO GPN GAO GEO (SEQ ID NO:28) from the consensus MASP-2 binding région in L-ficolin. .
MASP-2 inhibitory peptides may also be derived from the C4 cleavage site such as LQRALEILPNRVTIKANRPFLVFI (SEQ ID NO:29) which is the C4 cleavage site linked to the C-terminal portion of antithrombin III (Glover, G.I., et al., Mol. Immunol. 25:1261 (1988)).
TABLE 3: EXEMPLARY MASP-2 INHIBITORY PEPTIDES
SEQ ID NO | Source |
SEQ ID NO:6 | Human MASP-2 protein |
104
SEQ ID NO | Source |
SEQ ID NO:8 | CUBI domain of MASP-2 (aa 1-121 of SEQ ID NO:6) |
SEQ ID NO:9 | CUBIEGF domains of MASP-2 (aa 1-166 of SEQ ID NO:6) |
SEQ ID NO: 10 | CUBIEGFCUBII domains of MASP-2 (aa 1-293 ofSEQIDNO:6) |
SEQ ID NO: 11 | EGF domain of MASP-2 (aa 122-166) |
SEQID NO: 12 | Serine-protease domain of MASP-2 (aa 429-671) |
SEQ ID NO: 16 | MBL binding région in MASP-2 |
SEQ ID NO:3 | Human MApl9 |
SEQ ID NO:21 | Human MBL protein |
SEQ ID NO:22 OGK-X-GP, Where 0 = hydroxyproline and X is a hydrophobie amino acid residue | Synthetic peptide Consensus binding site from Human MBL and Human ficolins |
SEQ ID NO:23 OGKLG | Human MBL core binding site |
SEQ ID NO:24 GLR GLQ GPO GKL GPOG | Human MBP Triplets 6-10- demonstrated binding to MASP-2 |
SEQ ID NO:25 GPOGPOGLRGLQGPO GKLGPOGGPOGPO | Human MBP Triplets with GPO added to enhance formation of triple helices |
SEQ ID NO:26 GKDGRDGTKGEKGEP GQGLRGLQGPOGKLG POGNOGPSGSOGPKG QKGDOGKS | Human MBP Triplets 1-17 |
SEQ ID NO:27 GAOGSOGEKGAOGPQ GPOGPOGKMGPKGEO GPO____________ | Human H-Ficolin (Hataka) |
105
SEQ ID NO | Source |
SEQ ID NO:28 GCOGLOGAOGDKGE AGTNGKRGERGPOGP OGKAGPOGPNGAOGE O | Human L-Ficolin P35 |
SEQ ID NO:29 LQRALEILPNRVTIKA NRPFLVFI | Human C4 cleavage site |
Note: The letter O represents hydroxyproline. The letter X is a hydrophobie residue. |
Peptides derived from the C4 cleavage site as well as other peptides that inhibit the MASP-2 serine protease site can be chemically modified so that they are irréversible protease inhibitors. For example, appropriate modifications may include, but are not necessarily limited to, halomethyl ketones (Br, Cl, I, F) at the C-terminus, Asp or Glu, or appended to functional side chains; haloacetyl (or other ot-haloacetyl) groups on amino groups or other functional side chains; epoxide or imine-containing groups on the amino or carboxy termini or on functional side chains; or imidate esters on the amino or carboxy termini or on functional side chains. Such modifications would afford the advantage of permanently inhibiting the enzyme by covalent attachment of the peptide. This could resuit in lower effective doses and/or tire need for less frequent administration of the peptide inhibitor.
In addition to the inhibitory peptides described above, MASP-2 inhibitory peptides useful in the method of the invention include peptides containing the MASP-2-binding CDR3 région of anti-MASP-2 MoAb obtained as described herein. The sequence of the CDR régions for use in synthesizing the peptides may be determined by methods known in the art. The heavy chain variable région is a peptide that generally ranges from 100 to 150 amino acids in length. The light chain variable région is a peptide that generally ranges from 80 to 130 amino acids in length. The CDR sequences within the heavy and light chain variable régions include only approximately 3-25 amino acid sequences that may be easily sequenced b y one of ordinary skill in the art.
Those skilled in the art will recognize that substantially homologous variations of the MASP-2 inhibitory peptides described above will also exhibit MASP-2 inhibitory
106 activity. Exemplary variations include, but are not necessarily limited to, peptides having insertions, délétions, replacements, and/or additional amino acids on the carboxy-terminus or amino-terminus portions of the subject peptides and mixtures thereof. Accordingly, those homologous peptides having MASP-2 inhibitory activity are considered to be useful in the methods of this invention. The peptides described may also include duplicating motifs and other modifications with conservative substitutions. Conservative variants are described elsewhere herein, and include the exchange of an amino acid for another of like charge, size or hydrophobicity and the like.
MASP-2 inhibitory peptides may be modified to increase solubility and/or to maximize the positive or négative charge in order to more closely resemble the segment in the intact protein. The dérivative may or may not hâve the exact primary amino acid structure of a peptide disclosed herein so long as the dérivative functionally retains the desired property of MASP-2 inhibition. The modifications can include amino acid substitution with one of the commonly known twenty amino acids or with another amino acid, with a derivatized or substituted amino acid with ancillary désirable characteristics, such as résistance to enzymatic dégradation or with a D-amino acid or substitution with another molécule or compound, such as a carbohydrate, which mimics the natural confirmation and function of the amino acid, amino acids or peptide; amino acid délétion; amino acid insertion with one of the commonly known twenty amino acids or with another amino acid, with a derivatized or substituted amino acid with ancillary désirable characteristics, such as résistance to enzymatic dégradation or with a D-amino acid or substitution with another molécule or compound, such as a carbohydrate, which mimics the natural confirmation and function of the amino acid, amino acids or peptide; or substitution with another molécule or compound, such as a carbohydrate or nucleic acid monomer, which mimics the natural conformation, charge distribution and function of the parent peptide. Peptides may also be modified by acétylation or amidation.
The synthesis of dérivative inhibitory peptides can rely on known techniques of peptide biosynthesis, carbohydrate biosynthesis and the like. As a starting point, the artisan may rely on a suitable computer program to déterminé the conformation of a peptide of interest. Once the conformation of peptide disclosed herein is known, then the artisan can détermine in a rational design fashion what sort of substitutions can be made at one or more sites to fashion a dérivative that retains the basic conformation and charge
107 distribution of the parent peptide but which may possess characteristics which are not présent or are enhanced over those found in the parent peptide. Once candidate dérivative molécules are identified, the dérivatives can be tested to détermine if they function as MASP-2 inhibitory agents using the assays described herein.
SCREENING FOR MASP-2 INHIBITORY PEPTIDES
One may also use molecular modeling and rational molecular design to generate and screen for peptides that mimic the molecular structures of key binding régions of MASP-2 and inhibit the complément activities of MASP-2. The molecular structures 10 used for modeling include the CDR régions of anti-MASP-2 monoclonal antibodies, as well as the target régions known to be important for MASP-2 function including the région required for dimerization, the région involved in binding to MBL, and the serine protease active site as previously described. Methods for identifying peptides that bind to a particular target are well known in the art. For example, molecular imprinting may be 15 used for the de novo construction of macromolecular structures such as peptides that bind to a particular molécule. See, for example, Shea, K.J., Molecular Imprinting of Synthetic Network Polymers: The De Novo synthesis of Macromolecular Binding and Catalytic Sties, TRIP 2(5) 1994.
As an illustrative example, one method of preparing mimics of MASP-2 binding 20 peptides is as follows. Functional monomers of a known MASP-2 binding peptide or the binding région of an anti-MASP-2 antibody that exhibits MASP-2 inhibition (the template) are polymerized. The template is then removed, followed by polymerization of a second class of monomers in the void left by the template, to provide a new molécule that exhibits one or more desired properties that are similar to the template. In addition to 25 preparing peptides in this manner, other MASP-2 binding molécules that are MASP-2 inhibitory agents such as polysaccharides, nucleosides, drugs, nucleoproteins, lipoproteins, carbohydrates, glycoproteins, steroid, lîpids and other biologically active materials can also be prepared. This method is useful for designing a wide variety of biological mimics that are more stable than their natural counterparts because they are 30 typically prepared by free radical polymerization of function monomers, resulting in a compound with a nonbiodegradable backbone.
108
PEPTIDE SYNTHESIS
The MASP-2 inhibitory peptides can be prepared using techniques well known in the art, such as the solid-phase synthetic technique initially described by Merrîfield, in J. Amer. Chem. Soc. 55:2149-2154, 1963. Automated synthesis may be achieved, for 5 example, using Applied Biosystems 431A Peptide Synthesizer (Foster City, Calif.) in accordance with the instructions provided by the manufacturer. Other techniques may be found, for example, in Bodanszky, M., et al., Peptide Synthesis, second édition, John Wiley & Sons, 1976, as well as in other reference works known to those skilled in the art.
The peptides can also be prepared using standard genetic engineering techniques 10 known to those skilled in the art. For example, the peptide can be produced enzymatically by inserting nucleic acid encoding the peptide into an expression vector, expressing the DNA, and translating the DNA into the peptide in the presence of the required amino acids. The peptide is then purified using chromatographie or electrophoretic techniques, or by encans of a carrier protein that can be fused to, and 15 subsequently cleaved from, the peptide by inserting into the expression vector in phase with the peptide encoding sequence a nucleic acid sequence encoding the carrier protein. The fusion protein-peptide may be isolated using chromatographie, electrophoretic or immunological techniques (such as binding to a resin via an antibody to the carrier protein). The peptide can be cleaved using Chemical methodology or enzymatically, as 20 by, for example, hydrolases.
The MASP-2 inhibitory peptides that are useful in the method of the invention can also be produced in recombinant host cells following conventîonal techniques. To express a MASP-2 inhibitory peptide encoding sequence, a nucleic acid molécule encoding the peptide must be operably linked to regulatory sequences that control transcriptional 25 expression in an expression vector and then introduced into a host cell. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene, which are suitable for sélection of cells that carry the expression vector.
Nucleic acid molécules that encode a MASP-2 inhibitory peptide can be 30 synthesized with gene machines using protocols such as the phosphoramidite method. If chemically synthesized double-stranded DNA is required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made
109 separately. The production of short genes (60 to 80 base pairs) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealmg them. For the production of longer genes, synthetic genes (double-stranded) are assembled in modulai form from single-stranded fragments that are from 20 to 100 nucléotides in length. For reviews on polynucleotide synthesis, see, for example, Glick and Pasternak, Molecular Biotechnology, Principles and Applications of Recombinant DNA, ASM Press, 1994; Itakura, K., et al., Annu. Rev. Biochem. 53:323, 1984; and Climie, S., et al., Proc. Nat'IAcad. Sci. USA 87:633, 1990.
SMALL MOLECULE INHIBITORS
In some embodiments, MASP-2 inhibitory agents are small molécule inhibitors including natural and synthetic substances that hâve a low molecular weight, such as for example, peptides, peptidomimetics and nonpeptide inhibitors (including oligonucleotides and organic compounds). Small molécule inhibitors of MASP-2 can be generated based on the molecular structure of the variable régions of the anti-MASP-2 antibodies.
Small molécule inhibitors may also be designed and generated based on the MASP-2 crystal structure using computational drug design (Kuntz I.D., et al., Science 257:1078, 1992). The crystal structure of rat MASP-2 has been described (Feinberg, H., et al., EMBO J. 22:2348-2359, 2003). Using the method described by Kuntz et al., the MASP-2 crystal structure coordinates are used as an input for a computer program such as DOCK, which outputs a list of small molécule structures that are expected to bind to MASP-2. Use of such computer programs is well known to one of skill in the art. For example, the crystal structure of the HIV-1 protease inhibîtor was used to identify unique nonpeptide ligands that are HIV-1 protease inhibitors by evaluating the fit of compounds found in the Cambridge Crystallographic database to the binding site of the enzyme using the program DOCK (Kuntz, I.D., et al., J. Mol. Biol. 767:269-288, 1982; DesJarlais, R.L., et al., PNAS 57:6644-6648,1990).
The list of small molécule structures that are identified by a computational method as potential MASP-2 inhibitors are screened using a MASP-2 binding assay such as described in Example 10. The small molécules that are found to bind to MASP-2 are then assayed in a functional assay such as described in Example 2 to détermine if they inhibit MASP-2-dependent complément activation.
110
MASP-2 SOLUBLE RECEPTORS
Other suitable MASP-2 inhibitory agents are believed to include MASP-2 soluble receptors, which may be produced using techniques known to those of ordinary skill in 5 the art.
EXPRESSION INHIBITORS OF MASP-2
In another embodiment of this aspect of the invention, the MASP-2 inhibitory agent is a MASP-2 expression inhibitor capable of inhibiting MASP-2-dependent complément activation. In the practice of this aspect of the invention, représentative 10 MASP-2 expression inhibitors include MASP-2 antisense nucleic acid molécules (such as antisense mRNA, antisense DNA or antisense oligonucleotides), MASP-2 ribozymes and MASP-2 RNAi molécules.
Anti-sense RNA and DNA molécules act to directly block the translation of MASP-2 mRNA by hybridizing to MASP-2 mRNA and preventing translation of 15 MASP-2 protein. An antisense nucleic acid molécule may be constructed in a number of different ways provided that it is capable of interfering with the expression of MASP-2. For example, an antisense nucleic acid molécule can be constructed by inverting the coding région (or a portion thereof) of MASP-2 cDNA (SEQ ID NO:4) relative to its normal orientation for transcription to allow for the transcription of its complément.
The antisense nucleic acid molécule is usually substantially identical to at least a portion of the target gene or genes. The nucleic acid, however, need not be perfectly identical to inhibit expression. Generally, higher homology can be used to compensate for the use of a shorter antisense nucleic acid molécule. The minimal percent identity is typically greater than about 65%, but a higher percent identity may exert a more effective repression of expression of the endogenous sequence. Substantially greater percent identity of more than about 80% typically is preferred, though about 95% to absolute identity is typically most preferred.
The antisense nucleic acid molécule need not hâve the saine intron or exon pattern as the target gene, and non-coding segments of the target gene may be equally effective in 30 achieving antisense suppression of target gene expression as coding segments. A DNA sequence of at least about 8 or so nucléotides may be used as the antisense nucleic acid molécule, although a longer sequence is préférable. In the présent invention, a
Ο 111 représentative example of a useful inhibitory agent of MASP-2 is an antisense MASP-2 nucleic acid molécule which is at least ninety percent identical to the complément of the MASP-2 cDNA consisting of the nucleic acid sequence set forth in SEQ ID NO:4, The nucleic acid sequence set forth in SEQ ID NO:4 encodes the MASP-2 protein consisting 5 of the amino acid sequence set forth in SEQ ID NO:5.
The targeting of antisense oligonucleotides to bind MASP-2 mRNA is another mechanism that may be used to reduce the level of MASP-2 protein synthesis. For example, the synthesis of polygalacturonase and the muscarine type 2 acétylcholine receptor is inhibited by antisense oligonucleotides directed to their respective mRNA 10 sequences (U.S. Patent No. 5,739,119, to Cheng, and U.S. Patent No. 5,759,829, to Shewmaker). Furthermore, examples of antisense inhibition hâve been demonstrated with the nuclear protein cyclin, the multiple drug résistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABAa receptor and human EGF (see, e.g., U.S. Patent No. 5,801,154, to Baracchini; U.S. Patent No. 5,789,573, to Baker; U.S. Patent 15 No. 5,718,709, to Considine; and U.S. Patent No. 5,610,288, to Reubenstein).
A System has been described that allows one of ordinary skill to détermine which oligonucleotides are useful in the invention, which involves probing for suitable sites in the target mRNA using Rnase H cleavage as an indicator for accessibility of sequences within the transcripts. Scherr, M., et al., Nucleic Acids Res. 26:5079-5085, 1998;
Lloyd, et al., Nucleic Acids Res. 29:3665-3673, 2001. A mixture of antisense oligonucleotides that are complementary to certain régions of the MASP-2 transcript is added to cell cxtracts expressing MASP-2, such as hépatocytes, and hybridized in order to create an RNAseH vulnérable site. This method can be combined with computer-assisted sequence sélection that can predict optimal sequence sélection for 25 antisense compositions based upon their relative ability to form dimers, hairpins, or other secondary structures that would reduce or prohibit spécifie binding to the target mRNA in a host cell. These secondary structure analysis and target site sélection considérations may be performed using the OLIGO primer analysis software (Rychlik, I., 1997) and the BLASTN 2.0.5 algorithm software (Altschul, S.F., et al., Nucl. Acids Res. 25:3389-3402, 30 1997). The antisense compounds directed towards the target sequence preferably comprise from about 8 to about 50 nucléotides in length. Antisense oligonucleotides comprising from about 9 to about 35 or so nucléotides are particularly preferred. The
Ο 112 inventors contemplate ail oligonucleotide compositions in the range of 9 to 35 nucléotides (i.e., those of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 or so bases in length) are highly preferred for the practice of antisense oligonucleotide-based methods of the invention. Highly preferred target 5 régions of the MASP-2 mRNA are those that are at or near the AUG translation initiation codon, and those sequences that are substantially complementary to 5' régions of the mRNA, e.g., between the -10 and +10 régions of the MASP-2 gene nucléotide sequence (SEQ ID NO:4). Exemplary MASP-2 expression inhibitors are provîded in TABLE 4.
TABLE 4: EXEMPLARY EXPRESSION INHIBITORS OF MASP-2
SEQ ID NO:30 (nucléotides 22-680 of SEQ ID NO:4) | Nucleic acid sequence of MASP-2 cDNA (SEQ ID NO:4) encoding CUBIEGF |
SEQIDNO:31 5'CGGGCACACCATGAGGCTGCTG ACCCTCCTGGGC3 | Nucléotides 12-45 of SEQ ID NO:4 including the MASP-2 translation start site (sense) |
SEQ ID NO:32 5'GACATTACCTTCCGCTCCGACTC CAACGAGAAG3' | Nucléotides 361-396 of SEQ ID NO:4 encoding a région comprising the MASP-2 MBL binding site (sense) |
SEQ ID NO:33 5'AGCAGCCCTGAATACCCACGGCC GTATCCCAAA3' | Nucléotides 610-642 of SEQ ID NO:4 encoding a région comprising the CUBII domain |
As noted above, the terni oligonucleotide as used herein refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term also covers those oligonucleobases composed of naturally occurring nucléotides, sugars and covalent intemucleoside (backbone) linkages as well as 15 oligonucleotides having non-naturally occurring modifications. These modifications allow one to introduce certain désirable properties that are not offered through naturally occurring oligonucleotides, such as reduced toxic properties, mcreased stability against nuclease dégradation and enhanced cellular uptake. In illustrative embodiments, the antisense compounds of the invention differ from native DNA by the modification of the 20 phosphodiester backbone to extend the life of the antisense oligonucleotide in which the phosphate substituents are replaced by phosphorothioates. Likewise, one or both ends of
113 the oligonucleotide may be substituted by one or more acridine dérivatives that intercalate between adjacent basepairs within a strand of nucleic acid.
Another alternative to antisense is the use of RNA interférence (RNAi). Double-stranded RNAs (dsRNAs) can provoke gene silencing in mammals in vivo. The natural fonction of RNAi and co-suppression appears to be protection of the genome against invasion by mobile genetic éléments such as retrotransposons and viruses that produce aberrant RNA or dsRNA in the host cell when they become active (see, e.g., Jensen, J., et al., Nat. Genet. 27:209-12, 1999). The double-stranded RNA molécule may be prepared by synthesizing two RNA strands capable of forming a double-stranded RNA molécule, each having a length from about 19 to 25 (e.g., 19-23 nucléotides). For example, a dsRNA molécule usefol in the methods of the invention may comprise the RNA corresponding to a sequence and its complément listed in TABLE 4. Preferably, at least one strand of RNA has a 3' overhang from 1-5 nucléotides. The synthesized RNA strands are combined under conditions that form a double-stranded molécule. The RNA sequence may comprise at least an 8 nucléotide portion of SEQ ID NO:4 with a total length of 25 nucléotides or less. The design of siRNA sequences for a given target is within the ordinary skill of one in the art. Commercial services are available that design siRNA sequence and guarantee at least 70% knockdown of expression (Qiagen, Valencia, Calif).
The dsRNA may be administered as a pharmaceutical composition and carried out by known methods, wherein a nucleic acid is introduced into a desired target cell. Commonly used gene transfer methods include calcium phosphate, DEAE-dextran, electroporation, microinjection and viral methods. Such methods are taught in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 1993.
Ribozymes can also be utilized to decrease the amount and/or biological activity of MASP-2, such as ribozymes that target MASP-2 mRNA. Ribozymes are catalytic RNA molécules that can cleave nucleic acid molécules having a sequence that is completely or partially homologous to the sequence of the ribozyme. It is possible to design ribozyme transgenes that encode RNA ribozymes that specifically pair with a target RNA and cleave the phosphodiester backbone at a spécifie location, thereby fonctionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molécules. The
114 inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the antisense constructs.
Ribozymes useful in the practice of the invention typically comprise a hybridizing région of at least about nine nucléotides, which is complementary in nucléotide sequence 5 to at least paît of the target MASP-2 mRNA, and a catalytic région that is adapted to cleave the target MASP-2 mRNA (see generally, EPA No. 0 321 201; W088/04300; Haseloff, J., étal., Nature 334:585-591, 1988; Fedor, M.J., étal., Proc. Natl. Acad. Sci. USA 37:1668-1672,1990; Cech, T.R., et al., Ann. Rev. Biochem. 55:599-629, 1986).
Ribozymes can either be targeted directly to cells in the form of RNA 10 oligonucleotides incorporating ribozyme sequences, or introduced into the cell as an expression vector encoding the desired ribozymal RNA. Ribozymes may be used and applied in much the same way as described for antisense polynucleotides.
Anti-sense RNA and DNA, ribozymes and RNAi molécules useful in the methods of the invention may be prepared by any method known in the art for the synthesis of 15 DNA and RNA molécules. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art, such as for example solid phase phosphoramidite Chemical synthesis. Alternatively, RNA molécules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molécule. Such DNA sequences may be incorporated into a wide variety 20 of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.
Varions well known modifications of the DNA molécules may be introduced as a 25 means of increasing stability and half-life. Useful modifications include, but are not limited to, the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molécule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.
115
VI. PHARMACEUTICAL COMPOSITIONS AND DELIVERY METHODS DOSING
In another aspect, the invention provides compositions for inhibiting the adverse effects of MASP-2-dependent complément activation in a subject suffering from a 5 disease or condition as disclosed herein, comprising administering to the subject a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. The MASP-2 inhibitory agents can be administered to a subject in need thereof, at therapeutically effective doses to treat or ameliorate conditions associated with MASP-2-dependent complément activation. A 10 therapeutically effective dose refers to the amount of the MASP-2 inhibitory agent sufficient to resuit in amelioration of symptoms associated with the disease or condition.
Toxicity and therapeutic efficacy of MASP-2 inhibitory agents can be determined by standard pharmaceutical procedures employing experimental animal models, such as the murine MASP-2 -/- mouse model expressing the human MASP-2 transgene described 15 in Example 1. Using such animal models, the NOAEL (no observed adverse effect level) and the MED (the minimally effective dose) can be determined using standard methods. The dose ratio between NOAEL and MED effects is the therapeutic ratio, which is expressed as the ratio NOAEL/MED. MASP-2 inhibitory agents that exhibit large therapeutic ratios or indices are most preferred. The data obtained from the cell culture 20 assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of the MASP-2 inhibitory agent preferably lies within a range of circulating concentrations that include the MED with little or no toxicity. The dosage may vary within this range dependîng upon the dosage form employed and the route of administration utilized.
For any compound formulation, the therapeutically effective dose can be estimated using animal models. For example, a dose may be formulated in an animal model to achieve a circulating plasma concentration range that includes the MED. Quantitative levels of the MASP-2 inhibitory agent in plasma may also be measured, for example, by high performance liquid chromatography.
In addition to toxicity studies, effective dosage may also be estimated based on the amount of MASP-2 protein présent in a living subject and the binding affinity of the MASP-2 inhibitory agent. It has been shown that MASP-2 levels in normal human
116 subjects is présent in sérum in low levels in the range of 500 ng/ml, and MASP-2 levels in a particular subject can be determined using a quantitative assay for MASP-2 described in Moller-Kristensen M., et al., J. Immunol. Methods 252:159-167, 2003.
Generally, the dosage of administered compositions comprising MASP-2 5 inhibitory agents varies depending on such factors as the subject's âge, weight, height, sex, general medical condition, and previous medical history. As an illustration, MASP-2 inhibitory agents, such as anti-MASP-2 antibodies, can be administered in dosage ranges from about 0.010 to 10.0 mg/kg, preferably 0.010 to 1.0 mg/kg, more preferably 0.010 to 0.1 mg/kg of the subject body weight. In some embodiments the composition comprises 10 a combination of anti-MASP-2 antibodies and MASP-2 inhibitory peptides.
Therapeutic efficacy of MASP-2 inhibitory compositions and methods of tire présent invention in a given subject, and appropriate dosages, can be determined in accordance with complément assays well known to those of skill in the art. Complément generates numerous spécifie products. During the last decade, sensitive and spécifie 15 assays hâve been developed and are available commercially for most of these activation products, including the small activation fragments C3 a, C4a, andC5a and the large activation fragments iC3b, C4d, Bb, and sC5b-9. Most of these assays utilize monoclonal antibodies that react with new antigens (neoantigens) exposed on the fragment, but not on the native proteins from which they are formed, making these assays very simple and 20 spécifie. Most rely on ELISA technology, although radioimmunoassay is still sometîmes used for C3a and C5a. These latter assays measure both the unprocessed fragments and their 'desArg' fragments, which are the major forms found in the circulation. Unprocessed fragments and C5adeSArg are rapidly cleared by binding to cell surface receptors and are hence présent in very low concentrations, whereas C3a<iesArg does not 25 bind to cells and accumulâtes in plasma. Measurement ofC3a provides a sensitive, pathway-independent indicator of complément activation. Alternative pathway activation can be assessed by measuring the Bb fragment. Détection of the fluid-phase product of membrane attack pathway activation, sC5b-9, provides evidence that complément is being activated to completion. Because both the lectin and classical pathways generate 30 the same activation products, C4a and C4d, measurement of these two fragments does not provide any information about which of these two pathways has generated the activation products.
117
The inhibition of MASP-2-dependent complément activation is characterized by at least one of the following changes in a component of the complément System that occurs as a resuit of administration of a MASP-2 inhibitory agent in accordance with the methods of the invention: the inhibition of the génération or production of 5 MASP-2-dependent complément activation System products C4b, C3a, C5a and/or C5b-9 (MAC) (measured, for example, as described in measured, for example, as described in Ex ample 2, the réduction of C4 cleavage and C4b déposition (measured, for example as described in Example 10), or the réduction of C3 cleavage and C3b déposition (measured, for example, as described in ExamplelO).
ADDITIONAL AGENTS
The compositions and methods comprising MASP-2 inhibitory agents may optionally comprise one or more additional therapeutic agents, which may augment the activity of the MASP-2 inhibitory agent or that provide related therapeutic functions in an 15 additive or synergistic fashion. For example, in the context of treating a subject suffering from TTP, wherein the subject is positive for an inhibitor of ADAM-TS13, one or more MASP-2 inhibitory agents may be administered in combination (including coadministration) with one or more immunosuppressive agents. Suitable immunosuppressive agents include: corticosteroids, rituxan, cyclosporine, and the like. 20 In the context of treating a subject suffering from, or at risk for developing, HUS or aHUS, one or more MASP-2 inhibitory agents may be administered in combination (including co-administration) with a suitable antibiotic. In the context of treating a subject suffering from, or at risk for developing aHUS, one or more MASP-2 inhibitory agents may be administered in combination (including co-administration) with other 25 complément inhibitory agents such as eculizumab (Soliris), TT-30, antibody to factor B, or other agents that inhibit terminal complément components or alternative pathway amplification.
The inclusion and sélection of additional agent(s) will be determined to achieve a desired therapeutic resuit. In some embodiments, the MASP-2 inhibitory agent may be 30 administered in combination with one or more anti-inflammatory and/or analgésie agents. Suitable anti-inflammatory and/or analgésie agents include: serotonin receptor antagonists; serotonin receptor agonists; histamine receptor antagonists; bradykinin
118 receptor antagoniste; kallikrein inhibitors; tachykinin receptor antagonists, including neurokinim and neurokiniite receptor subtype antagonists; calcitonin gene-related peptide (CGRP) receptor antagonists; interleukin receptor antagonists; inhibitors of enzymes active in the synthetic pathway for arachidonic acid métabolites, including phospholipase 5 inhibitors, including PLA? isoform inhibitors and PLCy isofonn inhibitors, cyclooxygenase (COX) inhibitors (which may be either COX-1, COX-2, or nonselective COX-1 and -2 inhibitors), lipooxygenase inhibitors; prostanoid receptor antagonists including eicosanoid EP-1 and EP-4 receptor subtype antagonists and thromboxane receptor subtype antagonists; leukotriene receptor antagonists including 10 leukotriene B4 receptor subtype antagonists and leukotriene D4 receptor subtype antagonists; opioid receptor agonists, including μ-opioid, δ-opioid, and κ-opioid receptor subtype agonists; purinoceptor agonists and antagonists including Pgx receptor antagonists and Pgy receptor agonists; adenosine triphosphate (ATP)-sensitive potassium channel openers; MAP kinase inhibitors; nicotinic acétylcholine inhibitors; and alpha 15 adrenergic receptor agonists (including alpha-1, alpha-2, and nonselective alpha-1 and 2 agonists).
The MASP-2 inhibitory agents of the présent invention may also be administered in combination with one or more other complément inhibitors, such as an inhibitor of C5. To date, Eculizumab (Solaris®), an antibody against C5, is the only complement20 targeting drug that has been approved for human use. However some pharmacological agents hâve been shown to block complément in vivo. K76COOH and nafamstat mesilate are two agents that hâve shown some effectiveness in animal models of transplantation (Miyagawa, S., et al., Transplant Proc. 24:483-484, 1992). Low molecular weight heparins hâve also been shown to be effective in regulating complément activity 25 (Edens, R.E., et al., Complément Today, pp. 96-120, Basel: Karger, 1993). It is believed that these small molécule inhibitors may be useful as agents to use in combination with the MASP-2 inhibitory agents of the présent invention.
Other naturally occurring complément inhibitors may be useful in combination with the MASP-2 inhibitory agents of the présent invention. Biological inhibitors of 30 complément include soluble complément factor 1 (sCRl). This is a naturally-occumng inhibitor that can be found on the outer membrane of human cells. Other membrane
119 inhibitors include DAF, MCP, and CD59. Recombinant forms hâve been tested for their anti-complement activity in vitro and in vivo. sCRl has been shown to be effective in xenotransplantation, wherein the complément System (both alternative and classical) provides the trigger for a hyperactive rejection syndrome within minutes of perfusing blood through the newly transplanted organ (Platt, J.L., et al., Immunol. Today 77:450-6, 1990; Marino, I.R., étal,, Transplant Proc. 1071:6, 1990; Johnstone, P.S., étal., Transplantation 54:573-6, 1992). The use of sCRl protects and extends the survival time of the transplanted organ, implicating the complément pathway in the pathogenesîs of organ survival (Leventhal, J.R., étal., Transplantation 55:857-66, 1993; Pruitt, S.K., et al., Transplantation 57:363-70, 1994).
Suitable additional complément inhibitors for use in combination with the compositions of the présent invention also include, by way of example, MoAbs such as an anti-C5 antibody (e.g., eculizumab) being developed by Alexion Pharmaceuticals, Inc., New Haven, Connecticut, and anti-properdin MoAbs.
PHARMACEUTICAL CARRIERS AND DELIVERY VEHICLES
In general, the MASP-2 inhibitory agent compositions of the présent invention, combined with any other selected therapeutic agents, are suitably contained in a pharmaceutically acceptable carrier. The carrier is non-toxic, biocompatible and is selected so as not to detrimentally affect the biological activity of the MASP-2 inhibitory agent (and any other therapeutic agents combined therewith). Exemplary pharmaceutically acceptable carriers for peptides are described in U.S. Patent No. 5,211,657 to Yamada. The anti-MASP-2 antibodies and inhibitory peptides useful in the invention may be formulated into préparations in solid, semi-solid, gel, liquid or gaseous forms such as tablets, capsules, powders, granules, ointments, solutions, depositories, inhalants and injections allowing for oral, parentéral or surgical administration. The invention also contemplâtes local administration of the compositions by coating medical de vices and tire like.
Suitable carriers for parentéral delivery via injectable, infusion or irrigation and topical delivery include distilled water, physiological phosphate-buffered saline, normal or lactated Ringer's solutions, dextrose solution, Hank's solution, or propanediol. In addition, stérile, fixed oils may be employed as a solvent or suspending medium. For this représentative example of a useful inhibitory agent of MASP-2 is an antisense MASP-2 nucleic acid molécule which is at least ninety percent identical to the complément of the MASP-2 cDNA consisting of the nucleic acid sequence set forth in SEQ ID NO:4. The nucleic acid sequence set forth in SEQ ID NO:4 encodes the MASP-2 protein consisting 5 of the amino acid sequence set forth in SEQ ID NO:5.
The targeting of antisense oligonucleotides to bind MASP-2 mRNA is another mechanism that may be used to reduce the level of MASP-2 protein synthesis. For example, the synthesis of polygalacturonase and the muscarine type 2 acétylcholine receptor is inhibited by antisense oligonucleotides directed to their respective mRNA 10 sequences (U.S. Patent No. 5,739,119, to Cheng, and U.S. Patent No. 5,759,829, to Shewmaker). Furthermore, examples pf antisense inhibition hâve been demonstrated with the nuclear protein cyclin, the multiple drug résistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABAa receptor and human EGF (see, e.g., U.S, Patent No. 5,801,154, to Baracchini; U.S. Patent No. 5,789,573, to Baker; U.S. Patent 15 No. 5,718,709, to Considine; and U.S. Patent No. 5,610,288, to Reubenstein).
A System has been described that allows one of ordinary skill to détermine which oligonucleotides are useful in the invention, which involves probing for suitable sites in the target mRNA using Rnase H cleavage as an indicator for accessibility of sequences within the transcripts. Scherr, M., et al., Nucleic Acids Res. 26:5079-5085, 1998; 20 Lloyd, étal., Nucleic Acids Res. 29:3665-3613, 2001. A mixture of antisense oligonucleotides that are complementary to certain régions of the MASP-2 transcript is added to cell extracts expressing MASP-2, such as hépatocytes, and hybridized in order to create an RNAseH vulnérable site. This method can be combined with computer-assisted sequence sélection that can predict optimal sequence sélection for 25 antisense compositions based upon their relative ability to form dimers, hairpins, or other secondary structures that would reduce or prohibit spécifie binding to the target mRNA in a host cell. These secondary structure analysis and target site sélection considérations may be performed using the OLIGO primer analysis software (Rychlik, L, 1997) and the BLASTN 2.0.5 algorithm software (Altschul, S.F., et al., Nucl. Acids Res. 25:3389-3402, 30 1997). The antisense compounds directed towards the target sequence preferably comprise from about 8 to about 50 nucléotides in length. Antisense oligonucleotides comprising from about 9 to about 35 or so nucléotides are particularly preferred. The
112 inventors contemplate ail oligonucleotide compositions in the range of 9 to 35 nucléotides (i.e., those of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 or so bases in length) are highly preferred for the practice of antisense oligonucleotide-based methods of the invention. Highly preferred target régions of the MASP-2 mRNA are those that are at or near the AUG translation initiation codon, and those sequences that are substantially complementary to 5' régions of the mRNA, e.g., between the -10 and +10 régions of the MASP-2 gene nucléotide sequence (SEQ ID NO:4). Exemplary MASP-2 expression inhibitors are provided in TABLE 4.
TABLE 4: EXEMPLARY EXPRESSION INHIBITORS OF MASP-2
SEQ ID NO:30 (nucléotides 22-680 of SEQ ID NO:4) | Nucleic acid sequence of MASP-2 cDNA (SEQ ID NO:4) encoding CUBIEGF |
SEQ ID NO:31 5'CGGGCACACCATGAGGCTGCTG ACCCTCCTGGGC3 | Nucléotides 12-45 of SEQ ID NO:4 including the MASP-2 translation start site (sense) |
SEQ ID NO:32 5'GACATTACCTTCCGCTCCGACTC CAACGAGAAG3' | Nucléotides 361-396 of SEQ ID NO:4 encoding a région comprising the MASP-2 MBL binding site (sense) |
SEQ ID NO:33 5'AGCAGCCCTGAATACCCACGGCC GTATCCCAAA3' | Nucléotides 610-642 of SEQ ID NO:4 encoding a région comprising the CUBII domain |
As noted above, the tenu oligonucleotide as used herein refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This terni also covers those oligonucleobases composed of naturally occurring nucléotides, sugars and covalent intemucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring modifications. These modifications allow one to introduce certain désirable properties that are not offered through naturally occurring oligonucleotides, such as reduced toxic properties, increased stability against nuclease dégradation and enhanced cellular uptake. In illustrative embodiments, the antisense compounds of the invention differ from native DNA b y the modification of the phosphodiester backbone to extend the life of the antisense oligonucleotide in which the phosphate substituents are replaced by phosphorothioates. Likewise, one or both ends of
113 the oligonucleotide may be substituted by one or more acridine dérivatives that intercalate between adjacent basepairs within a strand of nucleic acid.
Another alternative to antisense is the use of RNA interférence (RNAi). Double-stranded RNAs (dsRNAs) can provoke gene silencing in mammals in vivo. The natural function of RNAi and co-suppression appears to be protection of the genome against invasion by mobile genetic éléments such as retrotransposons and viruses that produce aberrant RNA or dsRNA in the host cell when they become active (see, e.g., Jensen, J., et al., Nat. Genet. 27:209-12, 1999). The double-stranded RNA molécule may be prepared by synthesizing two RNA strands capable of forming a double-stranded RNA molécule, each having a length from about 19 to 25 (e.g., 19-23 nucléotides). For example, a dsRNA molécule useful in the methods of the invention may comprise the RNA corresponding to a sequence and its complément listed in TABLE 4. Preferably, at least one strand of RNA has a 3' overhang from 1-5 nucléotides. The synthesized RNA strands are combined under conditions that form a double-stranded molécule. The RNA sequence may comprise at least an 8 nucléotide portion of SEQ ID NO:4 with a total length of 25 nucléotides or less. The design of siRNA sequences for a given target is within the ordinary skill of one in the art. Commercial services are available that design siRNA sequence and guarantee at least 70% knockdown of expression (Qiagen, Valencia, Calif).
The dsRNA may be administered as a pharmaceutical composition and carried out by known methods, wherein a nucleic acid is introduced into a desired target cell. Commonly used gene transfer methods include calcium phosphate, DEAE-dextran, electroporation, microinjection and viral methods. Such methods are taught in Ausubel et al., Carrent Protocols in Molecular Biology, John Wiley & Sons, Inc., 1993.
Ribozymes can also be utilized to decrease the amount and/or biological activity of MASP-2, such as ribozymes that target MASP-2 mRNA, Ribozymes are catalytic RNA molécules that can cleave nucleic acid molécules having a sequence that is completely or partially homologous to the sequence of the ribozyme. It is possible to design ribozyme transgenes that encode RNA ribozymes that specifically pair with a target RNA and cleave the phosphodiester backbone at a spécifie location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molécules. The
114 inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the antisense constructs.
Ribozymes useful in the practice of the invention typically comprise a hybridizing région of at least about nine nucléotides, which is complementary in nucléotide sequence 5 to at least paît of the target MASP-2 mRNA, and a catalytic région that is adapted to cleave the target MASP-2 mRNA (see generally, EPA No. 0 321 201; W088/04300; Haseloff, J., étal., Nature 334:585-591, 1988; Fedor, MJ., et al., Proc. Natl. Acad. Sci. USA 87:1668-1672, 1990; Cech, T.R., et al., Am. Rev. Biochem. 55:599-629, 1986).
Ribozymes can either be targeted directly to cells in the form of RNA 10 oligonucleotides incorporating ribozyme sequences, or introduced into the cell as an expression vector encoding the desired ribozymal RNA. Ribozymes may be used and applied in much the same way as described for antisense polynucleotides.
Anti-sense RNA and DNA, ribozymes and RNAi molécules useful in the methods of the invention may be prepared by any method known in the art for the synthesis of 15 DNA and RNA molécules. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art, such as for example solid phase phosphoramidite Chemical synthesis. Altematively, RNA molécules may be generated by in vitro and in vivo transcription of DNA sequences encoding tire antisense RNA molécule. Such DNA sequences may be incorporated into a wide variety 20 of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Altematively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.
Various well known modifications of the DNA molécules may be introduced as a 25 means of increasing stability and half-life. Useful modifications include, but are not limited to, the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/pr 3' ends of the molécule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.
115
VI. PHARMACEUTICAL COMPOSITIONS AND DELIVERY METHODS
DOSING
In another aspect, the invention provides compositions for inhibiting the adverse effects of MASP-2-dependent complément activation in a subject suffering from a disease or condition as disclosed herein, comprising administering to the subject a composition comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. The MASP-2 inhibitory agents can be administered to a subject in need thereof, at therapeutically effective doses to treat or ameliorate conditions associated with MASP-2-dependent complément activation. A therapeutically effective dose refers to the amount of the MASP-2 inhibitory agent sufficient to resuit in amelioration of symptoms associated with the disease or condition.
Toxicity and therapeutic efficacy of MASP-2 inhibitory agents can be determined by standard pharmaceutical procedures employing experimental animal models, such as the murine MASP-2 -/- mouse model expressing the human MASP-2 transgene described in Example 1. Using such animal models, the NOAEL (no observed adverse effect level) and the MED (the minimally effective dose) can be determined using standard methods. The dose ratio between NOAEL and MED effects is the therapeutic ratio, which is expressed as the ratio NOAEL/MED. MASP-2 inhibitory agents that exhibit large therapeutic ratios or indices are most preferred. The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of the MASP-2 inhibitory agent preferably lies within a range of circulating concentrations that include the MED with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
For any compound formulation, the therapeutically effective dose can be estimated using animal models. For example, a dose may be formulated in an animal model to achieve a circulating plasma concentration range that includes the MED. Quantitative levels of the MASP-2 inhibitory agent in plasma may also be measured, for example, by high performance liquid chromatography.
In addition to toxicity studies, effective dosage may also be estimated based on the amount of MASP-2 protein présent in a living subject and the binding affinity of the MASP-2 inhibitory agent. It has been shown that MASP-2 levels in normal human
116 subjects is présent in sérum in low levels in the range of 500 ng/ml, and MASP-2 levels in a particular subject can be determined using a quantitative assay for MASP-2 described in Moller-Kristensen M., et al., J. Immunol. Methods 282:159-167, 2003.
Generally, the dosage of administered compositions comprising MASP-2 inhibitory agents varies depending on such factors as the subject's age, weight, height, sex, general medical condition, and previous medical history. As an illustration, MASP-2 inhibitory agents, such as anti-MASP-2 antibodies, can be administered in dosage ranges from about 0.010 to 10.0 mg/kg, preferably 0.010 to 1.0 mg/kg, more preferably 0.010 to 0.1 mg/kg of the subject body weight. In some embodiments the composition comprises a combination of anti-MASP-2 antibodies and MASP-2 inhibitory peptides.
Therapeutic efficacy of MASP-2 inhibitory compositions and methods of the présent invention in a given subject, and appropriate dosages, can be determined in accordance with complément assays well known to those of skill in the art. Complément generates numerous spécifie products. During the last decade, sensitive and spécifie assays hâve been developed and are available commercially for most of these activation products, including the small activation fragments C3a, C4a, and C5a and the large activation fragments iC3b, C4d, Bb, and sC5b-9. Most of these assays utilize monoclonal antibodies that react with new antigens (neoantigens) exposed on the fragment, but not on the native proteins from which they are formed, making these assays very simple and spécifie. Most rely on ELISA technology, although radioimmunoassay is still sometimes used for C3a and C5a. These latter assays measure both the unprocessed fragments and their 'desArg' fragments, which are the major forms found in the circulation. Unprocessed fragments and C5adesArg are rapidly cleared by binding to cell surface receptors and are hence présent in very low concentrations, whereas C3adesArg does not bind to cells and accumulâtes in plasma. Measurement of C3a provides a sensitive, pathway-independent indicator of complément activation. Alternative pathway activation can be assessed by measuring the Bb fragment. Détection of the fluid-phase product of membrane attack pathway activation, sC5b-9, provides evidence that complément is being activated to completion. Because both the lectin and classical pathways generate the same activation products, C4a and C4d, measurement of these two fragments does not provide any information about which of these two pathways has generated the activation products.
117
The inhibition of MASP-2-dependent complément activation is characterized by at least one of the following changes in a component of the complément System that occurs as a resuit of administration of a MASP-2 inhibitory agent in accordance with the methods of the invention: the inhibition of the génération or production of 5 MASP-2-dependent complément activation System products C4b, C3a, C5a and/or C5b-9 (MAC) (measured, for example, as described in measured, for example, as described in Example 2, the réduction of C4 cleavage and C4b déposition (measured, for example as described in Example 10), or the réduction of C3 cleavage and C3b déposition (measured, for example, as described in ExamplelO).
ADDITIONAL AGENTS
The compositions and methods comprising MASP-2 inhibitory agents may optionally comprise one or more additional therapeutic agents, which may augment the activity of the MASP-2 inhibitory agent or that provide related therapeutic functions in an 15 additive or synergistic fashion. For example, in the context of treating a subject suffering from TTP, wherein the subject is positive for an inhibitor of ADAM-TS13, one or more MASP-2 inhibitory agents may be administered in combination (including coadministration) with one or more immunosuppressive agents. Suitable immunosuppressive agents include: corticosteroids, rituxan, cyclosporine, and the like. 20 In the context of treating a subject suffering from, or at risk for developing, HUS or aHUS, one or more MASP-2 inhibitory agents may be administered in combination (including co-administration) with a suitable antibiotic. In the context of treating a subject suffering from, or at risk for developing aHUS, one or more MASP-2 inhibitory agents may be administered in combination (including co-administration) with other 25 complément inhibitory agents such as eculizumab (Soliris), TT-30, antibody to factor B, or other agents that inhibit terminal complément components or alternative pathway amplification.
The inclusion and sélection of additional agent(s) will be determined to achieve a desired therapeutic result. In some embodiments, the MASP-2 inhibitory agent may be 30 administered in combination with one or more anti-inflammatory and/or analgésie agents. Suitable anti-inflammatory and/or analgésie agents include: serotonin receptor antagonists; serotonin receptor agonists; histamine receptor antagonists; bradykinin
118 receptor antagonists; kallikrein inhibitors; tachykinin receptor antagonists, including neuiokinim and iieurokinin2 receptor subtype antagonists; calcitonin gene-related peptide (CGRP) receptor antagonists; interleukin receptor antagonists; inhibitors of enzymes active in the synthetic pathway for arachidonic acid métabolites, including phospholipase inhibitors, including PLA2 isoform inhibitors and PLCy isoform inhibitors, cyclooxygenase (COX) inhibitors (which may be either COX-1, COX-2, or nonselective COX-1 and -2 inhibitors), lipooxygenase inhibitors; prostanoid receptor antagonists including eicosanoid EP-1 andEP-4 receptor subtype antagonists and thromboxane receptor subtype antagonists; leukotriene receptor antagonists including leukotriene B 4 receptor subtype antagonists and leukotriene D4 receptor subtype antagonists; opioid receptor agonists, including μ-opioid, δ-opioid, and κ-opioid receptor subtype agonists; purinoceptor agonists and antagonists including P2X receptor antagonists and P2Y receptor agonists; adenosine triphosphate (ATP)-sensitive potassium charme! openers; MAP kinase inhibitors; nicotinic acétylcholine inhibitors; and alpha adrenergic receptor agonists (including alpha-1, alpha-2, and nonselective alpha-1 and 2 agonists),
The MASP-2 inhibitory agents of the présent invention may also be administered in combination with one or more other complément inhibitors, such as an inhibitor of C5. To date, Eculizumab (Solaris®), an antibody against C5, is the only complementtargeting drug that has been approved for human use. However some pharmacologîcal agents hâve been shown to block complément in vivo. K76COOH and nafamstat mesilate are two agents that hâve shown some effectiveness in animal models of transplantation (Miyagawa, S., et al., Transplant Proc. 24:483-484, 1992). Low molecular weight heparins hâve also been shown to be effective in regulating complément activity (Edens, R.E., et al., Complément Today, pp. 96-120, Basel: Karger, 1993). it is believed that these small molécule inhibitors may be useful as agents to use in combination with the MASP-2 inhibitory agents of the présent invention.
Other naturally occurring complément inhibitors may be useful 111 combination with the MASP-2 inhibitory agents of the présent invention. Biological inhibitors of complément include soluble complément factor 1 (sCRl). This is a naturally-occurring inhibitor that can be found on the outer membrane of human cells. Other membrane
119 inhibitors include DAF, MCP, and CD59. Recombinant forms hâve been tested for their anti-complement activity in vitro and in vivo. sCRl has been shown to be effective in xenotransplantation, wherein the complément System (both alternative and classical) provides the trigger for a hyperactive rejection syndrome within minutes of perfusing blood through the newly transplanted organ (Platt, J.L., et ah, Immunol. Today /7:450-6, 1990; Marino, I.R., et al., Transplant Proc. 1071:6, 1990; Johnstone, P.S., étal., Transplantation 54:573-6, 1992). The use of sCRl protects and extends the survival time of the transplanted organ, implicating the complément pathway in the pathogenesis of organ survival (Leventhal, J.R., étal., Transplantation 55:857-66, 1993; Pruitt, S.K., et al., Transplantation 57:363-70, 1994).
Suitable additional complément inhibitors for use in combination with the compositions of the présent invention also include, by way of example, MoAbs such as an anti-C5 antibody (e.g., eculizumab) being developed by Alexion Pharmaceuticals, Inc., New Haven, Connecticut, and anti-properdin MoAbs.
PHARMACEUTICAL CARRIERS AND DELIVERY VEHICLES hi general, the MASP-2 inhibitory agent compositions of the présent invention, combined with any other selected therapeutic agents, are suitably contained in a pharmaceutically acceptable carrier. The carrier is non-toxic, biocompatible and is selected so as not to detrimentally affect the biological activity of the MASP-2 inhibitory agent (and any other therapeutic agents combined therewith). Exemplary pharmaceutically acceptable carriers for peptides are described in U.S. Patent No. 5,211,657 to Yamada. The anti-MASP-2 antibodies and inhibitory peptides useful in the invention may be formulated into préparations in solid, semi-solid, gel, liquid or gaseous forms such as tablets, capsules, powders, granules, ointments, solutions, depositories, inhalants and injections allowing for oral, patenterai or surgical administration. The invention also contemplâtes local administration of the compositions by coating medical devices and tire like.
Suitable carriers for parentéral delivery via injectable, infusion or irrigation and topical delivery include distilled water, physiological phosphate-buffered saline, normal or lactated Ringer's solutions, dextrose solution, Hank's solution, or propanedioi. In addition, stérile, fixed oils may be employed as a solvent or suspending medium. For this
120 purpose any biocompatible oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the préparation of injectables. The carrier and agent may be compounded as a liquid, suspension, polymerizable or non-polymerizable gel, paste or salve.
The carrier may also comprise a delivery vehicle to sustain (i.e., extend, delay or regulate) the delivery of the agent(s) or to enhance the delivery, uptake, stability or pharmacokinetics of the therapeutic agent(s). Such a delivery vehicle may include, by way of non-limiting example, microparticles, microspheres, nanospheres or nanoparticles composed of proteins, liposomes, carbohydrates, synthetic organic compounds, inorganic compounds, polymeric or copolymerîc hydrogels and polymeric micelles. Suitable hydrogel and micelle delivery Systems include thePEO:PHB:PEO copolymers and copolymer/cyclodextrin complexes disclosed in WO 2004/009664 A2 and the PEO and PEO/cyclodextrin complexes disclosed in U.S. Patent Application Publication No. 2002/0019369 Al. Such hydrogels may be injected locally at the site of intended action, or subcutaneously or intramuscularly to form a sustained release depot.
For intra-articular delivery, the MASP-2 inhibitory agent may be carried in above-described liquid or gel carriers that are injectable, above-described sustained-release delivery vehicles that are injectable, or a hyaluronic acid or hyaluronic acid dérivative.
For oral administration of non-peptidergic agents, the MASP-2 inhibitory agent may be carried in an inert filler or diluent such as sucrose, cornstarch, or cellulose.
For topical administration, the MASP-2 inhibitory agent may be carried in ointment, lotion, cream, gel, drop, suppository, spray, liquid or powder, or in gel or microcapsular delivery Systems via a transdermal patch.
Varions nasal and pulmonary delivery Systems, including aérosols, metered-dose inhalers, dry powder inhalers, and nebulizers, are being developed and may suitably be adapted for delivery of the présent invention in an aérosol, inhalant, or nebulized delivery vehicle, respectively.
For intrathecal (IT) or intracerebroventricular (ICV) delivery, appropriately stérile delivery Systems (e.g., liquids; gels, suspensions, etc.) can be used to administer the présent invention.
121
The compositions of the présent invention may also include biocompatible excipients, such as dispersing or wetting agents, suspending agents, diluents, buffers, pénétration enhancers, emulsifiers, binders, thickeners, flavouring agents (for oral administration).
PHARMACEUTICAL CARRIERS FOR ANTIBODIES AND PEPTIDES
More specifically with respect to anti-MASP-2 antibodies and inhibitory peptides, exemplary formulations can be parenterally administered as injectable dosages of a solution or suspension of the compound in a physiologically acceptable diluent with a 10 pharmaceutical carrier that can be a stérile liquid such as water, oils, saline, glycerol or éthanol. Additionally, auxiliary substances such as wetting or emulsifying agents, surfactants, pH buffering substances and the like can be présent in compositions comprising anti-MASP-2 antibodies and inhibitory peptides. Additional components of pharmaceutical compositions include petroleum (such as of animal, vegetable or synthetic 15 origin), for example, soybean oïl and minerai oil. In general, glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers for injectable solutions.
The anti-MASP-2 antibodies and inhibitory peptides can also be administered in the form of a depot injection or implant préparation that can be formulated in such a manner as to permit a sustained or pulsatile release of the active agents.
PHARMACEUTICALLY ACCEPTABLE CARRIERS FOR EXPRESSION
INHIBITORS
More specifically with respect to expression inhibitors useful in the methods of the invention, compositions are provided that comprise an expression inhibitor as described above and a pharmaceutically acceptable carrier or diluent. The composition 25 may further comprise a colloïdal dispersion System.
Phannaceutical compositions that include expression inhibitors may include, but are not limited to, solutions, émulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. 30 The préparation of such compositions typically involves combining the expression inhibitor with one or more of the following: buffers, antioxidants, low molecular weight polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins,
122 chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with non-spécifie sérum albumin are examples of suitable dîluents.
In some embodiments, the compositions may be prepared and formulated as émulsions which are typically heterogeneous Systems of one liquid dispersed in another in the form of droplets (see, Idson, in Pharmaceutical Dosage Forms, Vol. 1, Rieger and Banker (eds.), Marcek Dekker, Inc., N.Y., 1988). Examples of naturally occurring emulsifiers used in émulsion formulations include acacia, beeswax, lanolin, lecithin and phosphatides.
hi one embodiment, compositions including nucleic acids can be formulated as microemulsions. A microemulsion, as used herein refers to a System of water, oil, and amphiphile, which is a single optically isotropie and thermodynamically stable liquid solution (see Rosoff in Pharmaceutical Dosage Forms, Vol. 1). The method of the invention may also use liposomes for the transfer and delivery of antisense oligonucleotides to the desired site.
Pharmaceutical compositions and formulations of expression inhibitors for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, as well as aqueous, powder or oily bases and thickeners and the like may be used.
MODES OF ADMINISTRATION
The pharmaceutical compositions comprising MASP-2 inhibitory agents may be adminîstered in a number of ways depending on whether a local or systernie mode of administration is most appropriate for the condition being treated. Additionally, as described herein above with respect to extracorporeal reperfusion procedures, MASP-2 inhibitory agents can be adminîstered via introduction of the compositions of the présent invention to recirculating blood or plasma. Further, the compositions of the présent invention can be delivered b y coating or incorporating the compositions on or into an implantable medical device.
123
SYSTEMIC DELIVERY
As used herein, the terms systemic delivery and systemic administration are întended to include but are not limited to oral and parentéral routes including intramuscular (IM), subcutaneous, intravenous (IV), intra-arterial, inhalational, 5 sublingual, buccal, topical, transdermal, nasal, rectal, vaginal and other routes of administration that effectively resuit in dispersement of the delivered agent to a single or multiple sites of întended therapeutic action. Preferred routes of systemic delivery for the présent compositions include intravenous, intramuscular, subcutaneous and inhalational. It will be appreciated that the exact systemic administration route for selected agents 10 utilized in particular compositions of the présent invention will be determined in part to account for the agent's susceptibility to metabolic transformation pathways associated with a given route of administration. For example, peptidergic agents may be most suitably administered by routes other than oral.
MASP-2 inhibitory antibodies and polypeptides can be delivered into a subject in 15 need thereof by any suitable means. Methods of delivery of MASP-2 antibodies and polypeptides include administration by oral, pulmonary, parentéral (e.g., intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), inhalation (such as via a fine powder formulation), transdermal, nasal, vaginal, rectal, or sublingual routes of administration, and can be formulated in dosage forms appropriate for each route of 20 administration.
By way of représentative example, MASP-2 inhibitory antibodies and peptides can be introduced into a living body b y application to a bodily membrane capable of absorbing the polypeptides, for example the nasal, gastrointestinal and rectal membranes. The polypeptides are typically applied to the absorptive membrane in conjunction with a 25 perméation enhancer. (See, e.g., Lee, V.H.L., Crit. Rev. Ther. Drug Carrier Sys. 5:69, 1988; Lee, V.H.L., J. Controlled Release 13:213, 1990; Lee, V.H.L., Ed., Peptide and Protein Drug Delivery, Marcel Dekker, New York (1991); DeBoer, A.G., et al., J. Controlled Release 75:241, 1990.) For example, STDHF is a synthetic dérivative of fusidic acid, a stéroïdal surfactant that is similar in structure to the bile salts, and has been 30 used as a perméation enhancer for nasal delivery. (Lee, W.A., Biopharm. 22, Nov./Dec. 1990.)
124
The MASP-2 inhibitory antibodies and polypeptides may be introduced in association with another molécule, such as a lipid, to protect the polypeptides from enzymatic dégradation. For example, the covalent attachment of polymers, especially polyethylene glycol (PEG), has been used to protect certain proteins from enzymatic 5 hydrolysis in the body and thus prolong half-life (Fuertges, F., et al., J. Controlled Release 77:139, 1990). Many polymer Systems hâve been reported for protein delivery (Bae, Y.H., et al., J. Controlled Release 9:271, 1989; Hori, R., et al., Pharm. Res. 6:813, 1989; Yamakawa, L, et al., J. Pharm. Sci. 79:505, 1990; Yoshihiro, L, et al., J. Controlled Release 70:195, 1989; Asano, M., et aL, J. Controlled Release 9:111, 1989; Rosenblatt, 10 J., étal., J. Controlled Release 9:195, 1989; Makino, K., J. Controlled Release 12:235,
1990; Takakura, Y., étal., J. Pharm. Sci. 75:117, 1989; Takakura, Y., étal., J. Pharm. Sci. 75:219, 1989).
Recently, liposomes hâve been developed with împroved sérum stability and circulation half-times (see, e.g., U.S. Patent No. 5,741,516, to Webb). Furthermore, 15 various methods of liposome and liposome-like préparations as potential drug can'iers hâve been reviewed (see, e.g., U.S. Patent No. 5,567,434, to Szoka; U.S. Patent No. 5,552,157, to Yagi; U.S. Patent No. 5,565,213, to Nakamori; U.S. Patent No. 5,738,868, to Shinkarenko; and U.S. Patent No. 5,795,587, to Gao).
For transdermal applications, the MASP-2 inhibitory antibodies and polypeptides 20 may be combined with other suitable ingrédients, such as carriers and/or adjuvants. There are no limitations on the nature of such other ingrédients, except that they must be pharmaceutically acceptable for their intended administration, and cannot dégradé the activity of the active ingrédients of the composition. Examples of suitable vehicles include ointments, creams, gels, or suspensions, with or without purified collagen. The 25 MASP-2 inhibitory antibodies and polypeptides may also be impregnated into transdermal patches, plasters, and bandages, preferably in liquid or semi-liquid form.
The compositions of the présent invention may be systemically administered on a periodic basis at întervals determined to maintam a desired level of therapeutic effect. For example, compositions may be administered, such as by subcutaneous injection, 30 every two to four weeks or at less frequent întervals. The dosage regimen will be determined by the physician considerîng various factors that may influence the action of the combination of agents. These factors will include the extent of progress of the
125 condition being treated, the patient's âge, sex and weight, and other clinical factors. The dosage for each individual agent will vary as a fonction, of the MASP-2 inhibitory agent that is included hi the composition, as well as the presence and nature of any drug delivery vehicle (e.g., a sustained release delivery vehicle). In addition, the dosage quantity may be adjusted to account for variation in the frequency of administration and the pharmacokinetic behavior of the delivered agent(s).
LOCAL DELivERY
As used herein, the term local encompasses application of a drug in or around a site of intended localized action, and may include for example topical delivery to the skin or other affected tissues, ophthalmic delivery, intrathecal (IT), intracerebroventricular (ICV), intra-articular, intracavity, intracranial or intravesicular administration, placement or irrigation. Local administration may be preferred to enable administration of a lower dose, to avoid systemic side effects, and for more accurate control of the timing of delivery and concentration of the active agents at the site of local delivery. Local administration provides a known concentration at the target site, regardless of interpatient variability in metabolism, blood flow, etc. Improved dosage control is also provided by the direct mode of delivery.
Local delivery of a MASP-2 inhibitory agent may be achieved in the context of surgical methods for treating a disease or condition, such as for example during procedures such as arterial bypass surgery, atherectomy, laser procedures, ultrasonic procedures, balloon angioplasty and stent placement. For example, a MASP-2 inhibitor can be administered to a subject in conjunction with a balloon angioplasty procedure. A balloon angioplasty procedure involves inserting a cathéter having a deflated balloon into an artery. The deflated balloon is positioned in proximity to the atherosclerotic plaque and is inflated such that the plaque is compressed against the vascular wall. As a resuit, tire balloon surface is in contact with the layer of vascular endothélial cells on the surface of the blood vessel. The MASP-2 inhibitory agent may be attached to the balloon angioplasty cathéter in a manner that permits release of the agent at the site of the atherosclerotic plaque. The agent may be attached to the balloon cathéter in accordance with standard procedures known in the art. For example, the agent may be stored in a compartment of the balloon cathéter until the balloon is inflated, at which point it is released into the local environment. Alternatively, the agent may be impregnated on the
126 balloon surface, such that it contacts the cells of the arterial wall as the balloon is inflated. The agent may also be delivered in a perforated balloon cathéter such as those disclosed in Flugelman, M.Y., étal., Circulation 35:1110-1117, 1992. See also published PCT Application WO 95/23161 for an exemplary procedure for attaching a therapeutic protein 5 to a balloon angioplasty cathéter. Likewise, the MASP-2 inhibitory agent may be included in a gel or polymeric coating applied to a stent, or may be incorporated into the material of the stent, such that the stent elutes the MASP-2 inhibitory agent after vascular placement.
MASP-2 inhibitory compositions used in the treatment of arthritides and other 10 musculoskeletal disorders may be locally delivered by intra-articulai' injection. Such compositions may suitably include a sustained release delivery vehicle. As a further example of instances in which local delivery may be desired, MASP-2 inhibitory compositions used in the treatment of urogénital conditions may be suitably instilled intravesically or within another urogénital structure.
COATINGS ON A MEDICAL DEVICE
MASP-2 inhibitory agents such as antibodies and inhibitory peptides may be immobilized onto (or within) a surface of an implantable or attachable medical device. The modified surface will typically be in contact with living tissue after implantation into 20 an animal body. B y implantable or attachable medical device is intended any device that is implanted into, or attached to, tissue of an animal body, during the normal operation of the device (e.g., stents and implantable drug delivery devices). Such implantable or attachable medical devices can be made from, for example, nitrocellulose, diazocellulose, glass, polystyrène, polyvinylchloride, polypropylene, polyethylene, 25 dextran, Sepharose, agar, starch, nylon, stainless Steel, titanium and biodégradable and/or biocompatible polymers. Linkage of the protein to a device can be accomplished by any technique that does not destroy the biological activity of the linked protein, for example by attaching one or both of the N- C-terminal residues of the protein to the device. Attachment may also be made at one or more internai sites in the protein. Multiple 30 attachments (both internai and at the ends of the protein) may also be used. A surface of an implantable or attachable medical device can be modified to include functional groups (e.g., carboxyl, amide, amino, ether, hydroxyl, cyano, nitrido, sulfanamido, acetylinic,
127 epoxide, silanic, anhydnc, succinimic, azido) for protein immobilization thereto. Coupling chemistries include, but are not limited to, the formation of esters, ethers, amides, azido and sulfanamido dérivatives, cyanate and other linkages to the functional groups available on MASP-2 antibodies or inhibitory peptides. MASP-2 antibodies or inhibitory fragments can also be attached non-covalently by the addition of an affinity tag sequence to the protein, such as GST (D.B. Smith and K.S. Johnson, Gene 67:3\, 1988), polyhistidines (E. Hochuli et al., J. Chromatog. 411:11, 1987), or biotin. Such affinity tags may be used for the réversible attachment of the protein to a device.
Proteins can also be covalently attached to the surface of a device body, for example, by covalent activation of the surface of the medical device. B y way of représentative example, matricellular protein(s) can be attached to the device body by any of the following pairs of reactive groups (one member of the pair being présent on the surface of the device body, and the other member of the pair being présent on the matricellular protein(s)): hydroxyl/carboxylic acid to yield an ester linkage; hydroxyl/anhydride to yield an ester linkage; hydroxyl/isocyanate to yield a urethane linkage. A surface of a device body that does not possess useful reactive groups can be treated with radio-frequency discharge plasma (RFGD) etching to generate reactive groups in order to allow déposition of matricellular protein(s) (e.g., treatment with oxygen plasma to introduce oxygen-containing groups; treatment with propyl amino plasma to introduce amine groups).
MASP-2 inhibitory agents comprising nucleic acid molécules such as antisense, RNAi-or DNA-encoding peptide inhibitors can be embedded in porous matrices attached to a device body. Représentative porous matrices useful for making the surface layer are those prepared from tendon or dermal collagen, as may be obtained from a variety of commercial sources (e.g., Sigma and Collagen Corporation), or collagen matrices prepared as described in U.S. Patent Nos. 4,394,370, to Jefferies, and 4,975,527, to Koezuka. One collagenous material is termed UltraFiber™ and is obtainable from Norian Corp. (Mountain View, California).
Certain polymeric matrices may also be employed if desired, and include acrylic ester polymers and lactîc acid polymers, as disclosed, for example, in U.S. Patent Nos. 4,526,909 and 4,563,489, to Urist. Particular examples of useful polymers are those of orthoesters, anhydrides, propylene-cofumarates, or a polymer of one or more
128 α-hydroxy carboxylic acid monomers, (e.g., α-hydroxy acetic acid (glycolic acid) and/or α-hydroxy propionic acid (lactic acid)).
TREATMENT REGIMENS
In prophylactic applications, the pharmaceutical compositions are administered to a subject susceptible to, or otherwise at risk of, a condition associated with MASP-2-dependent complément activation in an amount sufficient to eliminate or reduce the risk of developing symptoms of the condition. In therapeutic applications, the pharmaceutical compositions are administered to a subject suspected of, or already suffering from, a condition associated with MASP-2-dependent complément activation in a therapeutically effective amount sufficient to relieve, or at least partially reduce, the symptoms of the condition. In both prophylactic and therapeutic regimens, compositions comprising MASP-2 inhibitory agents may be administered in several dosages until a sufficient therapeutic outcome has been achieved in the subject. Application of the MASP-2 inhibitory compositions of the présent invention may be carried out by a single administration of the composition, or a limited sequence of administrations, for treatment of an acute condition, e.g., reperfusion injury or other traumatic injury. Altematively, the composition may be administered at periodic intervals over an extended period of time for treatment of chrome conditions, e.g., arthritides or psoriasis.
The methods and compositions of the présent invention may be used to inhibit inflammation and related processes that typically resuit from diagnostic and therapeutic medical and surgical procedures. To inhibit such processes, the MASP-2 inhibitory composition of the présent invention may be applied periprocedurally. As used herein periprocedurally refers to administration of the inhibitory composition preprocedurally and/or intraprocedurally and/or postprocedurally, i.e., before the procedure, before and during the procedure, before and after the procedure, before, during and after the procedure, during the procedure, during and after the procedure, or after the procedure. Periprocedural application may be carried out by local administration of the composition to the surgical or procédural site, such as by injection or continuons or intermittent irrigation of the site or by systemic administration. Suitable methods for local perioperative delivery of MASP-2 inhibitory agent solutions are disclosed in US Patent Nos. 6,420,432 to Demopulos and 6,645,168 to Demopulos. Suitable methods for local
129 delivery of chondroprotective compositions including MASP-2 inhibitory agent(s) are disclosed in International PCT Patent Application WO 01/07067 A2. Suitable methods and compositions for targeted systemic delivery of chondroprotective compositions including MASP-2 inhibitory agent(s) are disclosed in International PCT Patent Application WO 03/063799 A2.
In one aspect of the invention, the pharmaceutical compositions are administered to a subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA), In one embodiment, the TMA is selected from the group consisting of hemolytic urémie syndrome (HUS), thrombotic thrombocytopénie purpura (TTP) and atypical hemolytic urémie syndrome (aHUS). In one embodiment, the TMA is aHUS. In one embodiment, the composition is administered to an aHUS patient during the acute phase of the disease. In one embodiment, the composition is administered to an aHUS patient during the remission phase (i.e., in a subject that has recovered or partially recovered from an épisode of acute phase aHUS, such remission evidenced, for example, by increased platelet count and/or reduced sérum LDH concentrations, for example as described in Loirat C et al., Orphanet Journal of Rare Diseases 6:60, 2011, hereby incorporated herein by reference). In one embodiment, the subject is suffering from, or at risk for developing a TMA that is (i) a TMA secondary to cancer; (ii) a TMA secondary to chemotherapy; or (iii) a TMA secondary to transplantation (e.g., organ transplantation, such as kidney transplantation or allogeneic hematopoietic stem cell transplantation). In one embodiment, the subject is suffering from, or at risk for developing UpshawSchulman Syndrome (USS). In one embodiment, the subject is suffering from, or at risk for developing Degos disease. In one embodiment, the subject is suffering from, or at risk for developing Catastrophic Antiphospholipid Syndrome (CAPS). In therapeutic applications, the pharmaceutical compositions are administered to a subject suffering from, or at risk for developing a TMA in a therapeutically effective amount sufficient to inhibit thrombus formation, relieve, or at least partially reduce, the symptoms of the condition.
In both prophylactic and therapeutic regimens, compositions comprising MASP-2 inhibitory agents may be administered in several dosages until a sufficient therapeutic outcome has been achieved in the subject. In one embodiment of the invention, the MASP-2 inhibitory agent comprises an anti-MASP-2 antibody, which suitably may be
130 administered to an adult patient (e.g,, an average adult weight of 70 kg) in a dosage of from 0.1 mg to 10,000 mg, more suitably from 1.0 mg to 5,000 mg, more suitably 10.0 mg to 2,000 mg, more suitably 10.0 mg to 1,000 mg and still more suitably from 50.0 mg to 500 mg. For pédiatrie patients, dosage can be adjusted in proportion to the patient’s 5 weight. Application of the MASP-2 inhibitory compositions of the présent invention may be carried out by a single administration of the composition, or a limited sequence of administrations, for treatment of TMA. Alternatively, the composition may be administered at periodic intervals such as daily, biweekly, weekly, every other week, monthly or bimonthly over an extended period of time for treatment of TMA.
In some embodiments, the subject suffering from or at risk for developing a TMA has previously undergone, or is currently undergoing treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the method comprises administering to the subject a composition of the invention comprising a MASP-2 inhibitor and further administering to the subject a 15 terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the terminal complément inhibitor is a humanized anti-C5 antibody or antigen-bindîng fragment thereof. In some embodiments, the terminal complément inhibitor is eculizumab.
In one aspect of the invention, the pharmaceutical compositions are administered 20 to a subject susceptible to, or otherwise at risk of, aHUS in an amount sufficient to eliminate or reduce the risk of developing symptoms of the condition. In therapeutic applications, the pharmaceutical compositions are administered to a subject suspected of, or already suffering from, aHUS in a therapeutically effective amount sufficient to relieve, or at least paitially reduce, the symptoms of the condition. In one aspect of the 25 invention, prior to administration, the subject may be examined to déterminé whether the subject exhibits one or more symptoms of aHUS, including (i) anémia, (ii) thrombocytopenia (iii) rénal insufficiency and (iv) rising créatinine, and the composition of the présent invention is then administered in an effective amoimt and for a sufficient time period to improve these symptom(s).
In another aspect of the invention, the MASP-2 inhibitory compositions of the présent invention may be used to prophylactically treat a subject that has an elevated risk of developing aHUS and thereby reduce the likelihood that the subject will deliver aHUS.
131
The presence of a genetic marker in the subject known to be associated with aHUS is first determined by performing a genetic screening test on a sample obtained from the subject and identifying the presence of at least one genetic marker associated with aHUS, complément factor H (CFH), factor I (CFI), factor B (CFB), membrane cofactor CD46, 5 C3, complément factor H-related protein (CFHR1), anticoagulant protein thrombodulin (THBD), complément factor H-related protein 3 (CFHR3) or complément factor Hrelated protein 4 (CFHR4). The subject is then periodically monitored (e.g., monthly, quarterly, twice annually or annually) to détermine the presence or absence of at least one symptom of aHUS, such as anémia, thrombocytopenia, rénal insufficiency and rising 10 créatinine. Upon the détermination of the presence of at least one of these symptoms, the subject can be administered an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dépendent complément activation, in an effective amount and for a sufficient time period to improve said one or more symptoms. In a still further aspect of the présent invention, a subject at increased risk of developing aHUS due to having been screened 15 and determined to hâve one of the genetic markers associated with aHUS may be monitored for the occurrence of an event associated with triggering aHUS clinical symptoms, including drug exposure, infection (e.g., bacterial infection), malignancy, injury, organ or tissue transplant and pregnancy.
In a still further aspect of the présent invention, a composition comprising an 20 amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dépendent complément activation can be administered to a suffering from or at risk of developing atypical hemolytic urémie syndrome (aHUS) secondary to an infection. For example, a patient suffering from or at risk of developing non-enteric aHUS associated with an S. pneumonia infection may be treated with the compositions of the présent invention.
In a still further aspect of the présent invention, a subject suffering from aHUS may initially be treated with a MASP-2 inhibitory composition of the présent invention that is administered through a cathéter line, such as an intravenous cathéter line or a subeutaneous cathéter line, for a first period of time such as one hour, twelve hours, one day, two days or three days. The subject may then be treated for a second period of time 30 with the MASP-2 inhibitory composition administered through regular subeutaneous injections, such as daily, biweekly, weekly, every other week, monthly or bimonthly, injections.
132
In a still further aspect of the présent invention, a MASP-2 inhibitory composition of the présent invention may be administered to a subject suffering from aHUS in the absence of plasmapheresis (i.e., a subject whose aHUS symptoms hâve not been treated with plasmapheresis and are not treated with plasmapheresis at the time of treatment with 5 the MASP-2 inhibitory composition), to avoid the potential complications of plasmaphersis including hemorrhage, infection, and exposure to disorders and/or allergies inhérent in the plasma donor, or in a subject otherwise averse to plasmapheresis, or in a setting where plasmapheresis is unavailable.
In a still further aspect of the présent invention, a MASP-2 inhibitory composition 10 of the présent invention may be administered to a subject suffering from aHUS coincident with treating the patient with plasmapheresis. For example, a subject receiving plasmapheresis treatment can then be administered the MASP-2 inhibitory composition following or altemating with plasma exchange.
In a still fuither aspect of the présent invention, a subject suffering from or at risk 15 of developing aHUS and being treated with a MASP-2 inhibitory composition of the présent invention can be monitored by periodically determining, such as every twelve hours or on a daily basis, the level of at least one complément factor, wherein the détermination of a reduced level of the at least one complément factor in comparison to a standard value or to a healthy subject is indicative of the need for continued treatment 20 with the composition.
In both prophylactic and therapeutic regimens, compositions comprising MASP-2 inhibitory agents may be administered in several dosages until a sufficient therapeutic outcome has been achieved in the subject. In one embodiment of the invention, the MASP-2 inhibitory agent comprises an anti-MASP-2 antibody, which suitably may be 25 administered to an adult patient (e.g., an average adult weight of 70 kg) in a dosage of from 0.1 mg to 10,000 mg, more suitably from 1.0 mg to 5,000 mg, more suitably 10.0 mg to 2,000 mg, more suitably 10.0 mg to 1,000 mg and still more suitably from 50.0 mg to 500 mg. For pédiatrie patients, dosage can be adjusted in proportion to the patient’s weight. Application of the MASP-2 inhibitory compositions of the présent invention may 30 be carried out by a single administration of the composition, or a limited sequence of administrations, for treatment of aHUS. Alternative!y, the composition may be
133 administered at periodic intervals, such as daily, biweekly, weekly, every other week, monthly or bimonthly, over an extended period of time for treatment of aHUS.
In some embodiments, the subject suffering from aHUS has previously undergone, or is currently undergoing treatment with a terminal complément inhibitor 5 that inhibits cleavage of complément protein C5. In some embodiments, the method comprises administering to the subject a composition of the invention comprising a MASP-2 inhibitor and further administering to the subject a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the terminal complément inhibitor is a humanized anti-C5 antibody or antigen-binding 10 fragment thereof. In some embodiments, the terminal complément inhibitor is eculizumab.
In one aspect of the invention, the pharmaceutical compositions are administered to a subject susceptible to, or otherwise at risk of, HUS in an amount sufficient to eliminate or reduce the risk of developing symptoms of the condition. In therapeutic 15 applications, the pharmaceutical compositions are administered to a subject suspected of, or already suffering from, HUS in a therapeutically effective amount sufficient to relieve, or at least partially reduce, the symptoms of the condition.
In another aspect of the présent invention, the likelihood of developing impaired rénal function in a subject at risk for developing HUS can be reduced b y administering to 20 the subject a MASP-2 inhibitory composition of the présent invention in an amount effective to inhibit MASP-2 dépendent complément activation. For example, a subject at risk for developing HUS and to be treated with a MASP-2 inhibitory composition of the présent invention may exhibit one or more symptoms associated with HUS, including diarrhea, a hematocrit level of less than 30% with smear evidence of intravascular 25 érythrocyte destruction, thrombocytopenia and rising créatinine levels. As a further example, a subject at risk for developing HUS and to be treated with the MASP-2 inhibitory compositions of the présent invention may be infected with E. coli, shigella or salmonella. Such subjects infected with E. coli, shigella or Salmonella may be treated with a MASP-2 inhibitory composition of the présent invention concurrent with antibiotic 30 treatment, or alternately may be treated with a MASP-2 inhibitory composition without concurrent treatment with an antibiotic, particularly for enterogenic E. coli for which antibiotic treatment is contra-indicated. A subject infected with enterogenic E. coli that
134 has been treated with an antibiotic may be at elevated risk of developing HUS, and may be suitably treated with a MASP-2 inhibitory composition of the présent invention to reduce that risk. A subject infected with enterogenic E. coli may be treated for a first period of time with a MASP-2 inhibitory composition of the présent invention in the absence of an antibiotic and then for a second period of time with both a MASP-2 inhibitory composition of the présent invention and an antibiotic.
In a still further aspect of the présent invention, a subject suffering from HUS may initially be treated with a MASP-2 inhibitory composition of the présent invention that is administered through a cathéter line, such as an intravenous cathéter line or a subcutaneous cathéter line, for a first period of time such as one hour, twelve hours, one day, two days or three days. The subject may then be treated for a second period of time with the MASP-2 inhibitory composition administered through regular subcutaneous injections, such as daily, biweekly, weekly, every other week, monthly or bimonthly, injections.
In a still further aspect of the présent invention, a MASP-2 inhibitory composition of the présent invention may be administered to a subject suffering from HUS in the absence of plasmapheresis (i.e., a subject whose HUS symptoms hâve not been treated with plasmapheresis and are not treated with plasmapheresis at the time of treatment with the MASP-2 inhibitory composition), to avoid the potential complications of plasmaphersis including hemorrhage, infection, and exposure to disorders and/or allergies inhérent in the plasma donor, or in a subject otherwise averse to plasmapheresis, or in a setting where plasmapheresis is unavailable.
In a still further aspect of the présent invention, a MASP-2 inhibitory composition of the présent invention may be administered to a subject suffering from HUS coïncident with treating the patient with plasmapheresis. For example, a subject receiving plasmapheresis treatment can then be administered the MASP-2 inhibitory composition following or altemating with plasma exchange.
In a still further aspect of the présent invention, a subject suffering from or at risk of developing HUS and being treated with a MASP-2 inhibitory composition of the présent invention can be monitored by periodically determining, such as every twelve hours or on a daily basis, the level of at least one complément factor, wherein the détermination of a reduced level of the at least one complément factor in comparison to a
135 standard value or to a healthy subject is indicative of the need for continued treatment with die composition.
In both prophylactic and therapeutic regîmens, compositions comprising MASP-2 inhibitory agents may be administered in several dosages until a sufficient therapeutic outcome has been achieved in the subject. In one embodiment of the invention, the MASP-2 inhibitory agent comprises an anti-MASP-2 antibody, which suitably may be administered to an adult patient (e.g., an average adult weight of 70 kg) in a dosage of from 0.1 mg to 10,000 mg, more suitably from 1.0 mg to 5,000 mg, more suitably 10.0 mg to 2,000 mg, more suitably 10.0 mg to 1,000 mg and still more suitably from 50.0 mg to 500 mg. For pédiatrie patients, dosage can be adjusted in proportion to the patient’s weight. Application of the MASP-2 inhibitory compositions of the présent invention may be carried out by a single administration of the composition, or a limited sequence of administrations, for treatment of HUS. Alternatively, the composition may be administered at periodic intcrvals, such as daily, biweekly, weekly, every other week, monthly or bimonthly, over an extended period of time for treatment of HUS.
In some embodiments, die subject suffering from HUS has previously undergone, or is currently undergoing treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the mediod comprises administering to the subject a composition of the invention comprising a MASP-2 inhibitor and further administering to the subject a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the terminal complément inhibitor is a humanized anti-C5 antibody or antigen-binding fragment thereof. In some embodiments, the terminal complément inhibitor is eculizumab.
In one aspect of the invention, the pharmaceutical compositions are administered to a subject susceptible to, or otherwise at risk of, TTP in an amount sufficient to eliminate or reduce the risk of developing symptoms of the condition, hi therapeutic applications, the pharmaceutical compositions are administered to a subject suspected of, or already suffering from, TTP in a therapeutically effective amount sufficient to relieve, or at least partially reduce, the symptoms of the condition.
In another aspect of the présent invention, a subject exhibiting one or more of the symptoms of TTP, including central nervous System invol veinent, thrombocytopenia, severe cardiac involvement, severe pulmonary involvement, gastro-intestinal infarction
136 and gangrené, may be treated with a MASP-2 inhibitory composition of the présent invention. In another aspect of the présent invention, a subject determined to hâve a depressed level of ADAMTS13 and also testing positive for the presence of an inhibitor of (i.e., an antibody) ADAMTS13 may be treated with a MASP-2 inhibitory composition 5 of the présent invention, hi a still further aspect of the présent invention, a subject testing positive for the presence of an inhibitor of ADAMTS13 may be treated with an immunosupressant (e.g., corticosteroids, rituxan, or cyclosporine) concurrently with treatment with a MASP-2 inhibitory composition of the présent invention. In a still further aspect of the présent invention, a subject determined to hâve a reduced level of 10 ADAMTS13 and testing positive for the presence of an inhibitor of ADAMTS13 may be treated with ADAMTS13 concun'ently with treatment with a MASP-2 inhibitory composition of the présent invention.
In a still further aspect of the présent invention, a subject suffering from TTP may initially be treated with a MASP-2 inhibitory composition of the présent invention that is 15 administered through a cathéter line, such as an intravenous cathéter line or a subcutaneous cathéter line, for a first period of time such as one hour, twelve hours, one day, two days or three days. The subject may then be treated for a second period of time with the MASP-2 inhibitory composition administered through regular subcutaneous injections, such as daily, biweekly, weekly, every other week, monthly or bimonthly, 20 injections.
In a still further aspect of the présent invention, a MASP-2 inhibitory composition of the présent invention may be administered to a subject suffering from HUS in the absence of plasmapheresis (i.e., a subject whose TTP symptoms hâve not been treated with plasmapheresis and are not treated with plasmapheresis at the time of treatment with 25 the MASP-2 inhibitory composition), to avoid the potential complications of plasmaphersis including hemorrhage, infection, and exposure to disorders and/or allergies inhérent in the plasma donor, or in a subject otherwise averse to plasmapheresis, or in a setting where plasmapheresis is unavailable.
In a still further aspect of the présent invention, a MASP-2 inhibitory composition 30 of the présent invention may be administered to a subject suffering from TTP coïncident with treating the patient with plasmapheresis. For example, a subject receiving
137 plasmapheresis treatment can then be administered the MASP-2 inhibitory composition following or alternating with plasma exchange.
In a still further aspect of the présent invention, a subject suffering from refractory TTP, i.e., symptoms of TTP that hâve not responded adequately to other treatment such 5 as plasmapheresis, may be treated with a MASP-2 inhibitory composition of the présent invention, with or without additional plasmapheresis.
In a still further aspect of the présent invention, a subject suffering from or at risk of developing TTP and being treated with a MASP-2 inhibitory composition of the présent invention can be monitored by periodically determining, such as every twelve 10 hours or on a daily basis, the level of at least one complément factor, wherein the détermination of a reduced level of the at least one complément factor in comparison to a standard value or to a healthy subject is indicative of the need for continued treatment with the composition.
In both prophylactic and therapeutic regimens, compositions comprising MASP-2 15 inhibitory agents may be administered in several dosages until a sufficient therapeutic outcome has been achieved in the subject. In one embodiment of the invention, the MASP-2 inhibitory agent comprises an anti-MASP-2 antibody, which suitably may be administered to an adult patient (e.g., an average adult weight of 70 kg) in a dosage of from 0.1 mg to 10,000 mg, more suitably from 1.0 mg to 5,000 mg, more suitably 10.0 20 mg to 2,000 mg, more suitably 10.0 mg to 1,000 mg and still more suitably from 50.0 mg to 500 mg. For pédiatrie patients, dosage can be adjusted in proportion to the patient’s weight. Application of the MASP-2 inhibitory compositions of the présent invention may be carried out by a single administration of the composition, or a limited sequence of administrations, for treatment of TTP, Altematively, the composition may be 25 administered at periodic intervals, such as daily, biweekly, weekly, every other week, monthly or bîmonthly, over an extended period of time for treatment of TTP.
In some embodiments, the subject suffering from TTP has previously undergone, or is currently undergoing treatment with a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the method comprises 30 administering to the subject a composition of the invention comprising a MASP-2 inhibitor and further administering to the subject a terminal complément inhibitor that inhibits cleavage of complément protein C5. In some embodiments, the terminal
138 complément inhibitor is a humanized anti-C5 antibody or antigen-binding fragment thereof. In some embodiments, the terminal complément inhibitor is eculizumab.
VI. EXAMPLES
The following examples merely illustrate the best mode now contemplated for practicing the invention, but should not be construed to limit the invention. Ail literature citations herein are expressly incorporated by reference.
EXAMPLE 1
This example describes the génération of a mouse strain déficient in MASP-2 (MASP-2-/-) but sufficient of MApl9 (MApl9+/+).
Materials and Methods: The targeting vector pKO-NTKV 1901 was designed to disrupt the three exons coding for the C-terminal end of murine MASP-2, including the exon that encodes the serine protease domain, as shown in FIGURE 3. PKO-NTKV 1901 was used to transfect the murine ES cell lineE14.1a (SV 129 Ola). Neomycin-resistant and Thymidine Kinase-sensitive clones were selected. 600 ES clones were screened and, of these, four different clones were identified and verified by Southern blot to contain the expected sélective targeting and recombination event as shown in FIGURE 3. Chimeras were generated from these four positive clones by embryo transfer. The chimeras were then backcrossed in the genetic background C57/BL6 to create transgenic males. The transgenic males were crossed with females to generate Fis with 50% of the offspring showing heterozygosity for the disrupted MASP-2 gene. The heterozygous mice were intercrossed to generate homozygous MASP-2 déficient offspring, resulting in heterozygous and wild-type mice in the ration of 1:2:1, respectively.
Results and Phenotype: The resulting homozygous MASP-2-/- déficient mice were found to be viable and fertile and were verified to be MASP-2 déficient by southem blot to confirm the correct targeting event, by Northern blot to confirm the absence of MASP-2 mRNA, and by Western blot to confirm the absence of MASP-2 protein (data not shown). The presence of MApl9 mRNA and the absence of MASP-2 mRNA were further confirmed using time-resolved RT-PCR on a LightCycler machine. The MASP-2-/- mice do continue to express MApl9, MASP-1, and MASP-3 mRNA and
139 protein as expected (data not shown). The presence and abundance of mRNA in the MASP-2-/- mice for Properdin, Factor B, Factor D, C4, C2, and C3 was assessed by LightCycler analysis and found to be identical to that of the wild-type littermate Controls (data not shown). The plasma from homozygous MASP-2-/- mice is totally déficient of 5 lectin-pathway-mediated complément activation as further described in Example 2.
Génération of a MASP-2-/- strain on a pure C57BL6 Background: The MASP-2-/- mice were back-crossed with a pure C57BL6 line for nine générations prior to use of the MASP-2-/- strain as an experimental animal model.
A transgenic mouse strain that is murine MASP-2-/-, MApl9+/+ and that 10 expresses a human MASP-2 transgene (a murine MASP-2 knock-out and a human MASP-2 knock-in) was also generated as foliows:
Materials and Methods: A minigene encoding human MASP-2 called mini hMASP-2 (SEQ ID NO:49) as shown in FIGURE 4 was constructed which includes the promoter région of the human MASP 2 gene, including the first 3 exons (exon 1 to 15 exon 3) followed by the cDNA sequence that represents the coding sequence of the following 8 exons, thereby encoding the full-length MASP-2 protein driven by its endogenous promoter. The mini hMASP-2 construct was injected into fertilized eggs of MASP-2-/- in order to replace the déficient murine MASP 2 gene by transgenically expressed human MASP-2.
EXAMPLE 2
This example demonstrates that MASP-2 is required for complément activation via the lectin pathway.
Methods and Materials:
Lectin pathway spécifie C4 Cleavage Assay: A C4 cleavage assay has been described by Petersen, et al., J. Immunol. Methods 257:107 (2001) that measures lectin pathway activation resulting from lipoteichoic acid (LTA) from S. aureus, which binds L-ficolin. The assay described by Petersen et al., (2001) was adapted to measure lectin pathway activation via MBL by coating the plate with LPS and mannan or zymosan prior 30 to adding sérum from MASP-2 -/- mice as described below. The assay was also modified to remove the possibility of C4 cleavage due to the classical pathway. This was achîeved by using a sample dilution buffer containing 1 M NaCl, which permits high affinity
140 binding of lectin pathway récognition components to their ligands but prevents activation of endogenous C4, thereby excluding the participation of the classical pathway by dissociating the Cl complex. Briefly described, in the modified assay sérum samples (diluted in high sait (1 M NaCl) buffer) are added to ligand-coated plates, followed by the addition of a constant amount of purified C4 in a buffer with a physiological concentration of sait. Bound récognition complexes containing MASP-2 cleave the C4, resulting in C4b déposition.
Assay Methods:
1) Nunc Maxisorb microtiter plates (Maxisorb, Nunc, Cat. No. 442404, Fisher Scientific) were coated with 1 pg/ml mannan (M7504 Sigma) or any other ligand (e.g., such as those listed below) diluted in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6).
The following reagents were used in the assay:
a. mannan (1 pg/well mannan (M7504 Sigma) in 100 μΐ coating buffer):
b. zymosan (1 μg/well zymosan (Sigma) in 100 μΐ coating buffer);
c. LTA (1 pg/well in 100 μΐ coating buffer or 2 μg/well in 20 μΐ methanol)
d. 1 pg of the H-ficolin spécifie Mab 4H5 in coating buffer
e. PSA from Aerococcus viridans (2 pg/well in 100 μΐ coating buffer)
f. 100 μΐ/well of formalin-fixed S. aureus DSM20233 (OD35q=0.5) in coating buffer.
2) The plates were incubated ovemight at 4°C.
3) After ovemight incubation, the residual protein binding sites were saturated by incubated the plates with 0.1% HSA-TBS blocking buffer (0.1% (w/v) HSA in 10 mM Tris-CL, 140 mM NaCl, 1.5 mM NaN3, pH 7.4) for 1-3 hours, then washing the plates 3X with TBS/tween/Ca^+ (TBS with 0.05% Tween 20 and 5 mM CaCl2, 1 mM MgCl2, pH 7.4).
4) Sérum samples to be tested were diluted in MBL-binding buffer (1 M NaCl) and the diluted samples were added to the plates and incubated ovemight at 4°C. Wells receiving buffer only were used as négative Controls.
5) Following incubation ovemight at 4°C, the plates were washed 3X with TBS/tween/Ca2+. Human C4 (100 μΐ/well of 1 pg/ml diluted in BBS (4 mM barbital,
141
145 mM NaCl, 2 mM CaC12, 1 mM MgC12, pH 7.4)) was then added to the plates and incubated for 90 minutes at 37°C. The plates were washed again 3X with TBS/tween/Ca2+.
6) C4b déposition was detected with an alkaline phosphatase-conjugated 5 chicken anti-human C4c (diluted 1:1000 in TBS/tween/Ca2+), which was added to the plates and incubated for 90 minutes at room température. The plates were then washed again 3X with TBS/tween/Ca2+.
7) Alkaline phosphatase was detected by adding 100 μΐ of p-nitrophenyl phosphate substrate solution, incubating at room température for 20 minutes, and reading the OD4Q5 in a microtiter plate reader.
Results: FIGURES 5A-B show the amount of C4b déposition on mannan (FIGURE 5A) and zymosan (FIGURE 5B) in sérum dilutions from MASP-2+/+ (crosses), MASP-2+/- (closed circles) and MASP-2-/- (closed triangles). FIGURE 5C shows the relative C4 convertase activity on plates coated with zymosan (white bars) or 15 mannan (shaded bars) from MASP-2-/+ mice (n=5) and MASP-2-/- mice (n=4) relative to wild-type mice (n=5) based on measuring the amount of C4b déposition normalized to wild-type sérum. The error bars represent the standard déviation. As shown in
FIGURES 5A-C, plasma from MASP-2-/- mice is totally déficient in lectin-pathway-mediated complément activation on mannan and on zymosan coated 20 plates. These results clearly demonstrate that MASP-2 is an effector component of the lectin pathway.
Recombinant MASP-2 reconstitutes Lectin Pathway-Dependent C4 Activation in sérum from the MASP-2-/- mice
In order to establish that the absence of MASP-2 was the direct cause of the loss of lectin pathway-dependent C4 activation in the MASP-2-/- mice, the effect of adding recombinant MASP-2 protein to sérum samples was examined in the C4 cleavage assay described above. Functionally active murine MASP-2 and catalytically inactive murine MASP-2A (in which the active-site serine residue in the serine protease domain was 30 substituted for the alanine residue) recombinant proteins were produced and purified as described below in Example 3. Pooled sérum from 4 MASP-2 mice was
142 pre-incubated with increasing protein concentrations of recombinant murine MASP-2 or inactive recombinant murine MASP-2A and C4 convertase activity was assayed as described above.
Results: As shown in FIGURE 6, the addition of functionally active murine 5 recombinant MASP-2 protein (shown as open triangles) to sérum obtained from the MASP-2 -/- mice restored lectin pathway-dependent C4 activation in a protein concentration dépendent manner, whereas the catalytically inactive murine MASP-2A protein (shown as stars) did not restore C4 activation. The results shown in FIGURE 6 are normalized to the C4 activation observed with pooled wîld-type mouse sérum (shown 10 as a dotted line).
EXAMPLE 3
This example describes the recombinant expression and protein production of recombinant full-length human, rat and murine MASP-2, MASP-2 derived polypeptides, 15 and catalytically inactivated mutant forms of MASP-2
Expression of Full-length human, murine and rat MASP-2:
The full length cDNA sequence of human MASP-2 (SEQ ID NO: 4) was also subcloned into the mammalian expression vector pCI-Neo (Promega), which drives eukaryotic expression under the control of the CMV enhancer/promoter région (described 20 in Kaufman R.J. et al., Nucleic Acids Research 79:4485-90, 1991; Kaufman, Methods in Enzymology, 185:531-66 (1991)). The full length mouse cDNA (SEQ ID NO:50) and rat MASP-2 cDNA (SEQ ID NO:53) were each subcloned into the pED expression vector. The MASP-2 expression vectors were then transfected into the adhèrent Chinese hamster ovary cell line DXB1 using the standard calcium phosphate transfection procedure 25 described in Maniatis et al., 1989. Cells transfected with these constructs grew very slowly, implying that the encoded protease is cytotoxic.
In another approach, the minigene construct (SEQ ID NO:49) containing the human cDNA of MASP-2 driven by its endogenous promoter is transiently transfected into Chinese hamster ovary cells (CHO). The human MASP-2 protein is secreted into the 30 culture media and isolated as described below.
143
Expression of Full-length catalytically inactive MASP-2:
Rationale: MASP-2 is activated by autocatalytic cleavage after the récognition subcomponents MBL or ficolins (either L-ficolin, H-ficolin or M-ficolin) bind to their respective carbohydrate pattern. Autocatalytic cleavage resulting in activation of 5 MASP-2 often occurs during the isolation procedure of MASP-2 from sérum, or during the purification following recombinant expression. In order to obtain a more stable protein préparation for use as an antigen, a catalytically inactive form of MASP-2, desîgned as MASP-2A was created by replacing the serine residue that is présent in the catalytic triad of the protease domain with an alanine residue in rat (SEQ ED NO:55 10 Ser617 to Ala617); in mouse (SEQ ID NO:52 Ser617 to Ala617); or in human (SEQ ID NO:3 Ser618 to Ala618).
In order to generate catalytically inactive human and murine MASP-2A proteins, site-directed mutagenesis was carried out using the oligonucleotides shown in TABLE 5. The oligonucleotides in TABLE 5 were designed to anneal to the région of the human 15 and murine cDNA encoding the enzymatically active serine and oligonucleotide contain a mismatch in order to change the serine codon into an alanine codon. For example, PCR oligonucleotides SEQ ID NOS:56-59 were used in combination with human MASP-2 cDNA (SEQ ID NO:4) to amplify the région from the start codon to the enzymatically active serine and from the serine to the stop codon to generate the complété open reading 20 from of the mutated MASP-2A containing the Ser618 to Ala618 mutation. The PCR products were purified after agarose gel electrophoresis and band préparation and single adenosine overlaps were generated using a standard tailing procedure. The adenosine tailed MASP-2A was then cloned into the pGEM-T easy vector, transformed into E. coli.
A catalytically inactive rat MASP-2A protein was generated by kinasing and 25 annealing SEQ ID NO:64 and SEQ ID NO:65 by combining these two oligonucleotides in equal molar amounts, heating at 100°C for 2 minutes and slowly cooling to room température. The resulting annealed fragment has Pstl and Xbal compatible ends and was inserted in place of the Pstl-Xbal fragment of the wild-type rat MASP-2 cDNA (SEQ ID NO:53) to generate rat MASP-2A.
5 'GAGGTGACGCAGGAGGGGCATTAGTGTTT 3' (SEQ ID NO:64)
5' CTAGAAACACTAATGCCCCTCCTGCGTCACCTCTGCA 3’ (SEQ ID
NO:65)
144
The human, murine and rat MASP-2A were each further subcloned into either of the mammalian expression vectors pED or pCI-Neo and transfected into the Chinese Hamster ovary cell line DXB1 as described below.
In another approach, a catalytically inactive form of MASP-2 is constructed using 5 the method described in Chen et al., J. Biol. Chem., 276(28):25894-25902, 2001. Briefly, the plasmid containing the full-length human MASP-2 cDNA (described in Thiel et ah, Nature 356:506, 1997) is digested with Xhol and EcoRA and the MASP-2 cDNA (described herein as SEQ ID NO:4) is cloned into the corresponding restriction sites of the pFastBacl baculovîrus transfer vector (Life Technologies, NY). The MASP-2 serine 10 protease active site at Ser618 is then altered to Ala618 by substituting the double-stranded oligonucleotides encoding the peptide région amino acid 610-625 (SEQ ID NO: 13) with the native région amino acids 610 to 625 to create a MASP-2 full length polypeptide with an inactive protease domain. Construction of Expression Plasmîds Containing Polypeptide Régions Derived from Human Masp-2.
The following constructs are produced using the MASP-2 signal peptide (residues 1-15 of SEQ ID NO:5) to secrete various domains of MASP-2. A construct expressing the human MASP-2 CUBI domain (SEQ ID NO: 8) is made b y PCR amplifying the région encoding residues 1-121 of MASP-2 (SEQ ID NO:6) (corresponding to the N-terminal CUBI domain). A construct expressing the human 20 MASP-2 CUBIEGF domain (SEQ ID NO:9) is made by PCR amplifying the région encoding residues 1-166 of MASP-2 (SEQ ID NO:6) (corresponding to the N-terminal CUBIEGF domain). A construct expressing the human MASP-2 CUBIEGFCUBII domain (SEQ ID NO: 10) is made by PCR amplifying the région encoding residues 1-293 of MASP-2 (SEQ ID NO:6) (corresponding to the N-terminal CUBIEGFCUBII domain).
The above mentioned domains are amplified by PCR using VentR polymerase and pBS-MASP-2 as a template, according to establîshed PCR methods. The 5' primer sequence of the sense primer (51 -CGGGATCCATGAGGCTGCTGACCCTC- 3 ' SEQ ID NO:34) introduces a BomHI restriction site (underlincd) at the 5’ end of the PCR products. Antisense primers for each of the MASP-2 domains, shown below in 30 TABLE 5, are designed to introduce a stop codon (boldface) followed by an EcoRI site (underlîned) at the end of each PCR product. Once amplified, the DNA fragments are digested with BamHI and EcoRI and cloned into the corresponding sites of the pFastBacl
145 vector. The resulting constructs are characterized by restriction mapping and confirmed by dsDNA sequencing.
TABLE 5: MASP-2 PCR PRIMERS
MASP-2 domain | 5' PCR Primer | 3' PCR Primer |
SEQ ID NO:8 CUBI (aa 1-121 of SEQ ID NO:6) | 5'CGGGATCCATGA GGCTGCTGACCCT C-3' (SEQ ID NO:34) | 5'GGAATTCCTAGGCTGCAT A (SEQ ID NO:35) |
SEQ ID NO:9 CUBIEGF (aa 1-166 of SEQ ID NO:6) | 5'CGGGATCCATGA GGCTGCTGACCCT C-3' (SEQ ID NO:34) | 5'GGAATTCCTACAGGGCGC T-3' (SEQ ID NO:36) |
SEQ ID NO: 10 CUBIEGFCUB1I (aa 1-293 of SEQ ID NO:6) | 5’CGGGATCCATGA GGCTGCTGACCCT C-3' (SEQ ID NO:34) | 5’GGAATTCCTAGTAGTGGA T 3' (SEQ ID NO:37) |
SEQ ID NO:4 human MASP-2 | 5’ATGAGGCTGCTG ACCCTCCTGGGCC TTC 3' (SEQ ID NO: 56) hMASP-2_forward | 5TTAAAATCACTAATTATG TTCTCGATC 3' (SEQ ID NO: 59) hMASP-2 ...reverse |
SEQ ID NO:4 human MASP-2 cDNA | 5'CAGAGGTGACGC AGGAGGGGCAC 3' (SEQ ID NO: 58) hMASP-2_ala_forwar d | 5'GTGCCCCTCCTGCGTCAC CTCTG 3’ (SEQ ID NO: 57) hMASP-2_ala_reverse |
SEQ ID NO:50 Murine MASP-2 cDNA | 5'ATGAGGCTACTC ATCTTCCTGG3' (SEQ ID NO: 60) mMASP-2_forward | 5'TTAGAAATTACTTATTAT GTTCTCAATCC3’ (SEQ ID NO: 63) mMASP-2_reverse |
SEQ ID NO:50 Murine MASP-2 cDNA | 5'CCCCCCCTGCGT CACCTCTGCAG3' (SEQ ID NO: 62) mMASP-2_ala_forwa rd | 5’CTGCAGAGGTGACGCAG GGGGGG 3' (SEQ ID NO: 61) mM ASP-2_ala_re ver s e |
146
Recombinant eukaryotic expression of MASP-2 and protein production of enzymatically inactive mouse, rat, and human MASP-2A.
The MASP-2 and MASP-2A expression constructs described above were transfected into DXB1 cells using the standard calcium phosphate transfection procedure 5 (Maniatis et al., 1989). MASP-2A was produced in serum-free medium to ensure that préparations were not contaminated with other sérum proteins. Media was harvested from confluent cells every second day (four times in total). The level of recombinant MASP-2A averaged approximately 1.5 mg/liter of culture medium for each of the three species.
MASP-2A protein purification: The MASP-2A (Ser-Ala mutant described above) was purified by affinity chromatography on MBP-A-agarose columns. This strategy enabled rapid purification without the use of extraneous tags. MASP-2A (100-200 ml of medium diluted with an equal volume of loading buffer (50 mM Tris-Cl, pH 7.5, containing 150 mM NaCl and 25 mM CaCh) was loaded onto an MBP-agarose 15 affinity column (4 ml) pre-equilibrated with 10 ml of loading buffer. Following washing with a further 10 ml of loading buffer, protein was eluted in 1 ml fractions with 50 mM Tris-Cl, pH7.5, containing 1.25 M NaCl and 10 mM EDTA. Fractions containing the MASP-2A were identified by SDS-polyacrylamide gel electrophoresis. Where necessary, MASP-2A was purified further by ion-exchange chromatography on a MonoQ column 20 (HR 5/5). Protein was dîalysed with 50 mM Tris-Cl pH 7.5, containing 50 mM NaCl and loaded onto the column equilibrated in the same buffer. Following washing, bound MASP-2A was eluted with a 0.05-1 M NaCl gradient over 10 ml.
Results: Yields of 0.25-0.5 mg of MASP-2A protein were obtained from 200 ml of medium. The molecular mass of 77.5 kDa determined by MALDI-MS is greater than 25 the calculated value of the unmodified polypeptide (73.5 kDa) due to glycosylation. Attachaient of glycans at each of the /V-glycosylation sites accounts for the observed mass. MASP-2A migrâtes as a single band on SDS-polyacrylamide gels, demonstrating that it is not proteolytically processed during biosynthesis. The weight-average molecular mass determined by equilibrium ultracentrifugation is in agreement with the calculated 30 value for homodimers of the glycosylated polypeptide.
147
PRODUCTION OF RECOMBINANT HUMAN MASP-2 POLYPEPTIDES
Another method for producing recombinant MASP-2 and MASP2A derived polypeptides is described in Thielens, N.M., et al., J. Immunol. 166:5068-5077, 2001. Briefly, the Spodoptera frugiperda insect cells (Ready-Plaque Sf9 cells obtained from 5 Novagen, Madison, WI) are grown and maintained in Sf900II scrum-free medium (Life Technologies) supplemented with 50 lU/ml penicillin and 50 mg/ml streptomycin (Life Technologies). The Trichoplusia ni (High Five) insect cells (provided by Jadwiga Chroboczek, Institut de Biologie Structurale, Grenoble, France) are maintained in TC100 medium (Life Technologies) containing 10% FCS (Dominique Dutscher, Brumath, 10 France) supplemented with 50 lU/ml penicillin and 50 mg/ml streptomycin.
Recombinant baculoviruses are generated using the Bac-to-Bac System (Life Technologies). The bacmid DNA is purified using the Qiagen midîprep purification System (Qiagen) and is used to transfect Sf9 insect cells using cellfectin in Sf900 II SFM medium (Life Technologies) as described in the manufacturer's protocol. Recombinant 15 virus particles are collected 4 days later, titrated by virus plaque assay, and amplified as described by King and Possee, in The Baculovirus Expression System: A Laboratory Guide, Chapman and Hall Ltd., London, pp. 111-114, 1992.
High Five cells (1.75 x 107 cells/175-cm2 tissue culture flask) are infected with the recombinant viruses containing MASP-2 polypeptides at a multiplicity of infection of 2 in 20 Sf900 II SFM medium at 28°C for 96 h. The supernatants are collected by centrifugation and diisopropyl phosphorofluoridate is added to a final concentration of 1 mM.
The MASP-2 polypeptides are secreted in the culture medium. The culture supernatants are dialyzed against 50 mM NaCl, 1 mM CaCL, 50 mM triethanolamine hydrochloride, pH 8.1, and loaded at 1.5 ml/min onto a Q-Sepharose Fast Flow column 25 (Amersham Pharmacia Biotech) (2.8 x 12 cm) equilibrated in the saine buffer. Elution is conducted by applying al.21iter linear gradient to 350 mM NaCl in the same buffer. Fractions containing the recombinant MASP-2 polypeptides are identified by Western blot analysis, precipitated by addition of (NFL^SCU to 60% (w/v), and left overnight at 4°C. The pellets are resuspended in 145 mM NaCl, 1 mM CaCh, 50 mM 30 triethanolamine hydrochloride, pH 7.4, and applied onto a TSK G3000 SWG column (7.5 x 600 mm) (Tosohaas, Montgomeryville, PA) equilibrated in the same buffer. The
148 purified polypeptides are then concentrated to 0.3 mg/ml by ultrafiltration on Microsep microconcentrators (m.w. cut-off = 10,000) (Filtron, Karlstein, Germany).
EX AMPLE 4
This example describes a method of producing polyclonal antibodies against MASP-2 polypeptides.
Materials and Methods:
MASP-2 Antigens: Polyclonal anti-human MASP-2 antiserum is produced by immunizing rabbits with the following isolated MASP-2 polypeptides: human MASP-2 (SEQ ID NO:6) isolated from sérum; recombinant human MASP-2 (SEQ ID NO:6), MASP-2A containing the inactive protease domain (SEQ ID NO: 13), as described in Example 3; and recombinant CUBI (SEQ ID NO:8), CUBEGFI (SEQ ID NO:9), and CUBEGFCUBII (SEQ ID NO: 10) expressed as described above in Example 3.
Polyclonal antibodies: Six-week old Rabbits, primed with BCG (bacillus Calmette-Guerin vaccine) are immunized by injecting 100 pg of MASP-2 polypeptide at 100 pg/ml in stérile saline solution. Injections are done every 4 weeks, with antibody titer monitored by ELISA assay as described in Example 5. Culture supernatants are collected for antibody purification by protein A affinity chromatography.
EXAMPLE 5
This example describes a method for producing murine monoclonal antibodies against rat or human MASP-2 polypeptides.
Materials and Methods:
Male A/J mice (Harlan, Houston, Tex,),. 8-12 weeks old, are injected subcutaneously with 100 pg human or rat rMASP-2 or rMASP-2A polypeptides (made as described in Example 3) in complété Freund's adjuvant (Difco Laboratories, Detroit, Mich.) in 200 pl of phosphate buffered saline (PBS) pH 7.4. At two-week intervals the mice are twice injected subcutaneously with 50 pg of human or rat rMASP-2 or rMASP-2A polypeptide in incomplète Freund's adjuvant. On the fourth week the mice are injected with 50 pg of human or rat rMASP-2 or rMASP-2A polypeptide in PBS and are fused 4 days later.
149
For each fusion, single cell suspensions are prepared from the spleen of an immunized mouse and used for fusion with Sp2/0 myeloma cells. 5x10^ of the Sp2/0 and 5x10^ spleen cells are fused in a medium containing 50% polyethylene glycol (M.W. 1450) (Kodak, Rochester, N.Y.) and 5% dimethylsulfoxide (Sigma Chemical Co., 5 St. Louis, Mo.). The cells are then adjusted to a concentration of 1.5xl05 spleen cells per 200 μΐ of the suspension in Iscove medium (Gibco, Grand Island, N.Y.), supplemented with 10% fêtai bovine scrum, 100 units/ml of penicillin, 100 pg/ml of streptomycin, 0.1 mM hypoxanthine, 0.4 μΜ aminopterin and 16 μΜ thymidine. Two hundred microliters of the cell suspension are added to each well of about twenty 96-well 10 microculture plates. After about ten days culture supernatants are withdrawn for screening for reactivity with purified factor MASP-2 in an ELIS A assay.
ELISA Assay: Wells of Immulon 2 (Dynatech Laboratories, Chantilly, Va.) microtest plates are coated by adding 50 μΐ of purified hMASP-2 at 50 ng/ml or rat rMASP-2 (or rMASP-2A) overnight at room température. The low concentration of 15 MASP-2 for coating enables the sélection of high-affinity antibodies. After the coating solution is removed by flicking the plate, 200 μΐ of BLOTTO (non-fat dry milk) in PBS is added to each well for one hour to block the non-specific sites. An hour later, the wells are then washed with a buffer PBST (PBS containing 0.05% Tween 20). Fifty microliters of culture supernatants from each fusion well is collected and mixed with 50 μΐ of 20 BLOTTO and then added to the individual wells of the microtest plates. After one hour of incubation, the wells are washed with PBST. The bound murine antibodies are then detected by reaction with horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (Fc spécifie) (Jackson ImmunoResearch Laboratories, West Grave, Pa.) and diluted at 1:2,000 in BLOTTO. Peroxidase substrate solution containing 0.1% 3,3,5,5 tetramethyl 25 benzidine (Sigma, St. Louis, Mo.) and 0.0003% hydrogen peroxide (Sigma) is added to the wells for color development for 30 minutes. The reaction is terminated by addition of 50 μΐ of 2M H2SO4 per well. The Optical Density at 450 nm of the reaction mixture is read with a BioTek ELISA Reader (BioTek Instruments, Winooski, Vt.).
MASP-2 Binding Assay:
Culture supernatants that test positive in the MASP-2 ELISA assay described above can be tested in a binding assay to déterminé the binding affinity the MASP-2
150 inhibitory agents hâve for MASP-2. A similar assay can also be used to détermine if the inhibitory agents bind to other antigens in the complément System.
Polystyrène mîcrotiter plate wells (96-well medium binding plates, Corning Costar, Cambridge, MA) are coated with MASP-2 (20 ng/100 μΐ/well, Advanced 5 Research Technology, San Diego, CA) in phosphate-buffered saline (PBS) pH 7.4 overnight at 4°C. After aspirating the MASP-2 solution, wells are blocked with PBS containing 1% bovine sérum albumin (BSA; Sigma Chemical) for 2 h at room température. Wells without MASP-2 coating serve as the background Controls. Aliquots of hybridoma supernatants or purified anti-MASP-2 MoAbs, at varying concentrations in 10 blocking solution, are added to the wells. Following a 2 h incubation at room température, the wells are extensively rinsed with PBS. MASP-2-bound anti-MASP-2 MoAb is detected by the addition of peroxîdase-conjugated goat anti-mouse IgG (Sigma Chemical) in blocking solution, which is allowed to incubate for lh at room température. The plate is rinsed again thoroughly with PBS, and 100 pl of 3,3',5,5'-tetramethyl 15 benzidine (TMB) substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD) is added. The reaction of TMB is quenched by the addition of 100 pl of IM phosphoric acid, and the plate is read at 450 nm in a microplate reader (SPECTRA MAX 250, Molecular Devices, Sunnyvale, CA).
The culture supernatants from the positive wells are then tested for the ability to 20 inhibit complément activation in a functîonal assay such as the C4 cleavage assay as described in Example 2. The cells in positive wells are then cloned by limiting dilution. The MoAbs are tested again for reactivity with hMASP-2 in an ELISA assay as described above. The selected hybridomas are grown in spinner flasks and the spent culture supematant collected for antibody purification by protein A affinity chromatography.
EX AMPLE 6
This example describes the génération and production of humanized murine anti-MASP-2 antibodies and antibody fragments.
A murine anti-MASP-2 monoclonal antibody is generated in Male A/J mice as 30 described in Example 5. The murine antibody is then humanized as described below to reduce its immunogenicity by replacing the murine constant régions with their human counterparts to generate a chimeric IgG and Fab fragment of the antibody, which is useful
151 for inhibiting the adverse effects of MASP-2-dependent complément activation in human subjects in accordance with the présent invention.
1. Cloning of anti-MASP-2 variable région genes from murine hybridoma cells. Total RNA is isolated from the hybridoma cells secreting anti-MASP-2 MoAb (obtained as described in Example 7) using RNAzol following the manufacturées protocol (Biotech, Houston, Tex.). First strand cDNA is synthesized from the total RNA using oligo dT as the primer. PCR is performed using the immunoglobulin constant C région-derived 3' primers and degenerate primer sets derived from the leader peptide or the first framework région of murine Vfj or Vpç genes as the 5' primers.
Anchored PCR is carried out as described by Chen and Platsucas (Chen, P.F., Scand. J. Immunol. 35:539-549, 1992). For cloning the gene, double-stranded cDNA is prepared using a Notl-MAKl primer (5'-TGCGGCCGCTGTAGGTGCTGTCTTT-3' SEQ ID NO:38). Aimealed adaptors ADI (5'-GGAATTCACTCGTTATTCTCGGA-3' SEQ ID NO:39) and AD2 (5'-TCCGAGAATAACGAGTG-3' SEQ ID NO:40) aie ligated to both 5’ and 3' termini of the double-stranded cDNA. Adaptors at the 3' ends are removed by Notl digestion. The digested product is then used as tire template in PCR with the ADI oligonucleotide as the 5’ primer and MAK2 (5’-CATTGAAAGCTTTGGGGTAGAAGTTGTTC-3' SEQ ID NO:41) as the 3' primer. DNA fragments of approximately 500 bp are cloned into pUC19. Several clones are selected for sequence analysis to verify that the cloned sequence encompasses the expected murine immunoglobulin constant région. The Notl-MAKl and MAK2 oligonucleotides are derived from the Vjç région and are 182 and 84 bp, respectively, downstream from the first base pair of the C kappa gene. Clones are chosen that include the complété Vjç and leader peptide.
For cloning the Vjq gene, double-stranded cDNA is prepared using the Notl
MAG1 primer (5'-CGCGGCCGCAGCTGCTCAGAGTGTAGA-3r SEQ ID NO:42). Aimealed adaptors ADI and AD2 are ligated to both 5' and 3' termini of the double-stranded cDNA. Adaptors at the 3' ends are removed by Notl digestion. The digested product are used as the template in PCR with the ADI oligonucleotide and
MAG2 (5'-CGGTAAGCTTCACTGGCTCAGGGAAATA-3' SEQ ID NO:43) as primers.
DNA fragments of 500 to 600 bp in length are cloned into pUC19. The Notl-MAGl and
152
MAG2 oligonucleotides are derived from the murine Cy.7.1 région, and are 180 and 93 bp, respectively, downstream from the first bp of the murine Cy.7.1 gene. Clones are chosen that encompass the complété Vjq and leader peptide.
2. Construction of Expression Vectors for Chimeric MASP-2 IgG and
Fab. The cloned Vj-j and Vjç genes described above are used as templates in a PCR reaction to add the Kozak consensus sequence to the 5' end and the splice donor to the 3' end of the nucléotide sequence. After the sequences are analyzed to confirm the absence of PCR errors, the Vjq and Vg genes are înserted into expression vector cassettes containing human C.yl and C. kappa respectively, to give pSV2neoVyq-huCyl and pSV2neoV-huCy. CsCl gradient-purified plasmid DNAs of the heavy- and light-chain vectors are used to transfert COS cells b y electroporation. After 48 hours, the culture supernatant is tested by ELISA to confirm the presence of approximately 200 ng/ml of chimeric IgG. The cells are harvested and total RNA is prcparcd. First strand cDNA is synthesized from the total RNA using oligo dT as the primer. This cDNA is used as the template in PCR to generate the Fd and kappa DNA fragments. For the Fd gene, PCR is carried out using 5'-AAGAAGCTTGCCGCCACCATGGATTGGCTGTGGAACT-3' (SEQ ID NO:44) as the 5' primer and a CHl-derived 3' primer (5’-CGGGATCCTCAAACTTTCTTGTCCACCTTGG-3' SEQ ID NO:45). The DNA sequence is confirmed to contain the complété Vj j and the CH1 domain of human IgGl.
After digestion with the proper enzymes, the Fd DNA fragments are inserted at the HindlII and BamHI restriction sites of the expression vector cassette pSV2dhfr-TUS to give pSV2dhfrFd. The pSV2 plasmid is commercially available and consists of DNA segments from varions sources: pBR322 DNA (thin line) contains the pBR322 origin of DNA réplication (pBR ori) and the lactamase ampicillin résistance gene (Amp); SV40
DNA, represented by wider hatching and marked, contains the SV40 origin of DNA réplication (SV40 ori), early promoter (5' to the dhfr and neo genes), and polyadenylation signal (3' to the dhfr and neo genes). The SV40-derived polyadenylation signal (pA) is also placed at the 3' end of the Fd gene.
For the kappa gene, PCR is carried out using 5'30 AAGAAAGCTTGCCGCCACCATGTTCTCACTAGCTCT-3’ (SEQ ID NO:46) as the 5' primer and a CK-derived 3' primer (5'-CGGGATCCTTCTCCCTCTAACACTCT-3’ SEQ
153
ID NO:47). DNA sequence is confirmée! to contain the complété Vjç and human Cjç régions. After digestion with proper restriction enzymes, the kappa DNA fragments are inseited at the HindlII and BamHI restriction sites of the expression vector cassette pSV2neo-TUS to give pSV2neoK. The expression of both Fd and .kappa genes are 5 driven by the HCMV-derived enhancer and promoter éléments. Since the Fd gene does not include the cysteine amino acid residue involved in the inter-chain disulfide bond, this recombinant chimeric Fab contains non-covalently linked heavy- and light-chains. This chimeric Fab is designated as cFab.
To obtain recombinant Fab with an inter-heavy and light chain disulfide bond, the 10 above Fd gene may be extended to include the coding sequence for additional 9 amino acids (EPKSCDKTH SEQ ID NO:48) from the hinge région of human IgGl. The BstEII-BamHI DNA segment encoding 30 amino acids at the 3’ end of the Fd gene may be replaced with DNA segments encoding the extended Fd, resulting in pSV2dhfrFd/9aa.
3. Expression and Purification of Chimeric Anti-MASP-2 IgG
To generate cell lines secreting chimeric anti-MASP-2 IgG, NS O cells are transfected with purîfied plasmid DNAs of pSV2neoVpj-huC.yl and pSV2neoV-huC kappa by electroporation. Transfected cells are selected in the presence of 0.7 mg/ml G418. Cells are grown in a 250 ml spinner flask using serum-containing medium.
Culture supernatant of 100 ml spinner culture is loaded on a 10-ml PROSEP-A 20 column (Bioprocessing, Inc., Princeton, N.J.). The column is washed with 10 bed volumes of PBS. The bound antibody is eluted with 50 mM citrate buffer, pH 3.0. Equal volume of 1 M Hepes, pH 8.0 is added to the fraction containing the purified antibody to adjust the pH to 7.0. Residual salts are removed by buffer exchange with PBS by Millipore membrane ultrafiltration (M.W. cut-off: 3,000). The protein concentration of 25 the purified antibody is determined by the BCA method (Pierce).
4. Expression and purification of chimeric anti-MASP-2 Fab
To generate cell Unes secreting chimeric anti-MASP-2 Fab, CHO cells are transfected with purified plasmid DNAs of pSV2dhfrFd (or pSV2dhfrFd/9aa) and pSV2neokappa, by electroporation. Transfected cells are selected in the presence of 30 G418 and methotrexate. Selected cell lines are amplified in increasing concentrations of methotrexate. Cells are single-cell subcloned by limiting dilution. High-producing
154 single-cell subcloned cell lines are then grown in 100 ml spinner culture using serum-free medium.
Chimeric anti-MASP-2 Fab is purified by affinity chromatography using a mouse anti-idiotypic MoAb to the MASP-2 MoAb. An anti-idiotypic MASP-2 MoAb can be 5 made by immunizing mice with a murine anti-MASP-2 MoAb conjugated with keyhole limpet hemocyanin (KLH) and screening for spécifie MoAb binding that can be competed with human MASP-2. For purification, 100 ml of supematant from spinner cultures of CHO cells producing cFab or cFab/9aa are loaded onto the affinity column coupled with an anti-idiotype MASP-2 MoAb. The column is then washed thoroughly 10 with PBS before the bound Fab is eluted with 50 mM diethylamine, pH 11.5. Residual salts are removed by buffer exchange as described above. The protein concentration of the purified Fab is determined by the BCA method (Pierce).
The ability of the chimeric MASP-2 IgG, cFab, and cFAb/9aa to inhibit MASP-2-dependent complément pathways may be determined by using the inhibitory 15 assays described in Example 2 or Example 7.
EX AMPLE 7
This example describes an in vitro C4 cleavage assay used as a functional screen to identify MASP-2 inhibitory agents capable of blocking MASP-2-dépendent 20 complément activation via L-ficolin/P35, H-ficolin, M-ficolin or mannan.
C4 Cleavage Assay: A C4 cleavage assay has been described by Petersen, S.V., étal., J. Immunol. Methods 257:107, 2001, which measures lectin pathway activation resulting from lipoteichoic acid (LTA) from S. aureus which binds L-ficolin.
Reagents: Formalin-fixed 5. aureous (DSM20233) is prepared as follows: 25 bacteria is grown ovemight at 37°C in tryptic soy blood medium, washed three times with PBS, then fixed for 1 h at room température in PBS/0.5% formalin, and washed a further three times with PBS, before being resuspended in coating buffer (15 mM NagCog, 35 mMNaHC03, pH 9.6).
Assay: The wells of a Nunc MaxiSorb microtiter plate (Nalgene Nunc 30 International, Rochester, NY) are coated with: 100 μΐ of formalin-fixed 5. aureus DSM20233 (Οϋ35θ = 0.5) in coating buffer with 1 ug of L-ficolin in coating buffer.
155
After ovemight incubation, wells are blocked with 0.1% human sérum albumin (HSA) in TBS (10 mM Tris-HCl, 140 mM NaCl, pH7.4), then are washed with TBS containing 0.05% Tween 20 and 5 mM CaCl2 (wash buffer). Human sérum s amples are diluted in mM Tris-HCl, 1 M NaCl, lOmM CaCl2, 0.05% Triton X-100, 0.1% HSA, pH7.4, which prevents activation of endogenous C4 and dissociâtes the Cl complex (composed of Clq, Clr and Cls). MASP-2 inhibitory agents, including anti-MASP-2 MoAbs and inhibitory peptides are added to the sérum samples in varying concentrations. The diluted samples are added to the plate and incubated ovemight at 4°C. After 24 hours, the plates are washed thoroughly with wash buffer, then 0.1 pg of purified human C4 (obtained as described in Dodds, A.W., Methods Enzymol. 223:46, 1993) in 100 μΐ of 4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4 is added to each well. After 1.5 h at 37°C, the plates are washed again and C4b déposition is detected using alkaline phosphatase-conjugated chicken anti-human C4c (obtained from Immunsystem, Uppsala, Sweden) and measured using the colorimétrie substrate p-nitrophenyl phosphate.
C4 Assay on mannan: The assay described above is adapted to measure lectin pathway activation via MBL by coating the plate with LSP and mannan prior to adding sérum mixed with varions MASP-2 inhibitory agents.
C4 assay on H-ficolin (Hakata Ag): The assay described above is adapted to measure lectin pathway activation via H-ficolin by coating the plate with LPS and
H-ficolin prior to adding sérum mixed with varions MASP-2 inhibitory agents.
EXAMPLE 8
The following assay demonstrates the presence of classical pathway activation in wild-type and MASP-2-/- mice.
Methods: Immune complexes were generated in situ by coating microtiter plates (Maxisorb, Nunc, cat. No. 442404, Fisher Scientific) with 0.1% human sérum albumin in 10 mM Tris, 140 mM NaCl, pH 7.4 for 1 hours at room température followed by ovemight incubation at 4°C with sheep anti whole sérum antiserum (Scottish Antibody Production Unit, Carluke, Scotland) diluted 1:1000 in TBS/tween/Ca2+. Sérum samples were obtained from wild-type and MASP-2-/- mice and added to the coated plates. Control samples were prepared in which Clq was depleted from wild-type and
156
MASP-2-/- sérum samples. Clq-depleted mouse sérum was prepared using protein-A-coupled Dynabeads (Dynal Biotech, Oslo, Norway) coated with rabbit antî-human Clq IgG (Dako, Glostrup, Denmark), according to the supplier's instructions. The plates were incubated for 90 minutes at 37°C. Bound C3b was detected with a 5 polyclonal anti-human-C3c Antibody (Dako A 062) diluted in TBS/tw/ Ca++ at 1:1000. The secondary antibody is goat anti-rabbit IgG.
Results: FIGURE 7 shows the relative C3b déposition levels on plates coated with IgG in wild-type sérum, MASP-2-/- sérum, Clq-depleted wild-type and Clq-depleted MASP-2-/- sérum. These results demonstrate that the classical pathway is 10 intact in the MASP-2-/- mouse strain.
EXAMPLE 9
The following assay is used to test whether a MASP-2 inhibitory agent blocks the classical pathway b y analyzing the effect of a MASP-2 inhibitory agent under conditions 15 in which the classical pathway is initiated by immune complexes.
Methods: To test the effect of a MASP-2 inhibitory agent on conditions of complément activation where the classical pathway is initiated by immune complexes, triplicate 50 μΐ samples containing 90% NHS are incubated at 37°C in the presence of 10 Lig/ml immune complex (IC) or PB S, and parallel triplicate samples (+/-IC) are also 20 included which contain 200 nM anti-properdin monoclonal antibody during the 37°C incubation. After a two hour incubation at 37°C, 13 mM EDTA is added to ail samples to stop further complément activation and the samples are immediately cooled to 5°C. The samples are then stored at -70°C prior to being assayed for complément activation products (C3a and sC5b-9) using ELISA kits (Quidel, Catalog Nos. A015 and A009) 25 following the manufacturées instructions.
EXAMPLE 10
This example describes the identification of high affinity anti-MASP-2 Fab2 antibody fragments that block MASP-2 activity.
Background and rationale: MASP-2 is a complex protein with many separate functional domains, including: binding site(s) for MBL and ficolins, a serine protease catalytic site, a binding site for proteolytic substrate C2, a binding site for proteolytic
157 substrate C4, a MASP-2 cleavage site for autoactivation of MASP-2 zymogen, and two Ca++ binding sites. Fab2 antibody fragments were identified that bind with high affinity to MASP-2, and the identified Fab2 fragments were tested in a functional assay to détermine if they were able to block MASP-2 functional activity.
To block MASP-2 functional activity, an antibody or Fab2 antibody fragment must bind and interféré with a structural epitope on MASP-2 that is required for MASP-2 functional activity. Therefore, many or ail of the high affinity binding anti-MASP-2 Fab2s may not inhibit MASP-2 functional activity unless they bind to structural epitopes on MASP-2 that are directly involved in MASP-2 functional activity.
A functional assay that measures inhibition of lectin pathway C3 convertase formation was used to evaluate the blocking activity of anti-MASP-2 Fab2s. It is known that the primary physiological rôle of MASP-2 in the lectin pathway is to generate the next functional component of the lectin-mediated complément pathway, namely the lectin pathway C3 convertase. The lectin pathway C3 convertase is a critical enzymatic complex (C4bC2a) that proteolytically cleaves C3 into C3a and C3b. MASP-2 is not a structural component of the lectin pathway C3 convertase (C4bC2a); however, MASP-2 functional activity is required in order to generate the two protein components (C4b, C2a) that comprise the lectin pathway C3 convertase. Furthermore, ail of the separate functional activities of MASP-2 listed above appear to be required in order for MASP-2 to generate the lectin pathway C3 convertase. For these reasons, a preferred assay to use in evaluating the blocking activity of anti-MASP-2 Fab2s is believed to be a functional assay that measures inhibition of lectin pathway C3 convertase formation.
Génération, of High Affinity Fab2s: A phage display library of human variable light and heavy chain antibody sequences and automated antibody sélection technology 25 for identifying Fab2s that react with selected ligands of interest was used to create high affinity Fab2s to rat MASP-2 protein (SEQ ID NO:55). A known amount of rat MASP-2 (~1 mg, >85% pure) protein was utilized for antibody screening. Three rounds of amplification were utilized for sélection of the antibodies with the best affinity. Approximately 250 different hits expressing antibody fragments were picked for ELISA 30 screening. High affinity hits were subsequently sequenced to détermine uniqueness of the different antibodies.
158
Fifty unique anti-MASP-2 antibodies were purified and 250 pg of each purified Fab2 antibody was used for characterization of MASP-2 binding affinity and complément pathway functional testing, as described in more detail below.
Assays used to Evaluate the Inhibitory (blocking) Activity of Anti-MASP-2 5 Fab2s
1. Assay to Measure Inhibition of Formation of Lectin Pathway C3 Convertase:
Background: The lectin pathway C3 convertase is the enzymatic complex (C4bC2a) that proteolytically cleaves C3 into the two potent proinflammatory fragments, 10 anaphylatoxin C3a and opsonic C3b. Formation of C3 convertase appears to a key step in the lectin pathway in terms of mediating inflammation. MASP-2 is not a structural component of the lectin pathway C3 convertase (C4bC2a); therefore anti-MASP-2 antibodies (or Fab2) will not directly inhibit activity of preexisting C3 convertase. However, MASP-2 serine protease activity is required in order to generate the two protein 15 components (C4b, C2a) that comprise the lectin pathway C3 convertase. Therefore, anti-MASP-2 Fab2 which inhibit MASP-2 functional activity (i.e., blocking anti-MASP-2 Fab2) will inhibit de novo formation of lectin pathway C3 convertase. C3 contains an unusual and highly reactive thioester group as part of its structure. Upon cleavage of C3 by C3 convertase in this assay, the thioester group on C3b can form a covalent bond with 20 hydroxyl or amino groups on macromolecules immobilized on the bottom of the plastic wells via ester or amide linkages, thus facilitating détection of C3b in the ELIS A assay.
Yeast mannan is a known activator of the lectin pathway. In the following method to measure formation of C3 convertase, plastic wells coated with mannan were incubated for 30 min at 37°C with diluted rat sérum to activate the lectin pathway. The 25 wells were then washed and assayed for C3b immobilized onto the wells using standard ELISA methods. The amount of C3b generated in this assay is a direct reflection of the de novo formation of lectin pathway C3 convertase. Anti-MASP-2 Fab2s at selected concentrations were tested in this assay for their ability to inhibit C3 convertase formation and conséquent C3b génération.
Methods:
96-well Costar Medium Binding plates were incubated overnight at 5°C with mannan diluted in 50 mM carbonate buffer, pH 9.5 at 1 ug/50 Tl/well. After overnight
159 incubation, each well was washed three times with 200 Tl PBS. The wells were then blocked with 100 Tl/well of 1% bovine sérum albumin in PBS and incubated for one hour at room température with gentle mixing. Each well was then washed three times with 200 Tl of PBS. The anti-MASP-2 Fab2 samples were diluted to selected concentrations 5 in Ca++ and Mg++ containing GVB buffer (4.0 mM barbital, 141 mM NaCl, 1.0 mM MgCh, 2.0 mM CaCh, 0.1% gelatin, pH 7.4) at 5 C. A 0.5% rat sérum was added to the above samples at 5 C and 100 Tl was transferred to each well. Plates were covered and incubated for 30 minutes in a 37 C waterbath to allow complément activation. The reaction was stopped b y transferring the plates from the 37 C waterbath to a container 10 containing an ice-water mix. Each well was washed five times with 200 Tl with
PBS-Tween 20 (0.05% Tween 20 in PBS), then washed two times with 200 Tl PBS. A 100 ΊΊ/well of 1:10,000 dilution of the primary antibody (rabbit anti-human C3c, DAKO A0062) was added in PBS containing 2.0 mg/ml bovine sérum albumin and incubated 1 hr at room température with gentle mixing. Each well was washed 5 x 200 Tl PBS. 100 15 Tl/well of 1:10,000 dilution of the secondary antibody (peroxidase-conjugated goat anti-rabbit IgG, American Qualex A102PU) was added in PBS containing 2.0 mg/ml bovine sérum albumin and incubated for one hour at room température on a shaker with gentle mixing. Each well was washed five times with 200 Tl with PBS. 100 Tl/well of the peroxidase sub strate TMB (Kirkegaard & Perry Laboratories) was added and 20 incubated at room température for 10 min. The peroxidase reaction was stopped by adding 100 Tl/well of 1.0 Μ H3PO4 and the OD450. was measured.
2. Assay to Measure Inhibition of MASP-2-dependent C4 Cleavage
Background: The serine protease activity of MASP-2 is highly spécifie and only two protein substrates for MASP-2 hâve been identified; C2 and C4. Cleavage of C4 25 générâtes C4a and C4b. Anti-MASP-2 Fab2 may bind to structural epitopes on MASP-2 that are directly involved in C4 cleavage (e.g., MASP-2 binding site for C4; MASP-2 serine protease catalytic site) and thereby inhibit the C4 cleavage functional activity of MASP-2.
Yeast mannan is a known activator of the lectin pathway. In the following 30 method to measure the C4 cleavage activity of MASP-2, plastic wells coated with mannan were incubated for 30 minutes at 37 C with diluted rat sérum to activate the
160 lectin pathway. Since the primary antibody used in this ELISA assay only recognizes human C4, the diluted rat sérum was also supplemented with human C4 (1.0 Tg/ml). The wells were then washed and assayed for human C4b immobilized onto the wells using standard ELISA methods. The amount of C4b generated in this assay is a measure of MASP-2 dépendent C4 cleavage activity. Anti-MASP-2 Fab2 at selected concentrations were tested in this assay for their ability to inhibit C4 cleavage.
Methods: 96-well Costar Medium Binding plates were incubated ovemight at 5 C with mannan diluted in 50 mM carbonate buffer, pH 9.5 at 1.0 Tg/50 Tl/well. Each well was washed 3X with 200 Tl PBS, The wells were then blocked with 100 Tl/well of 1% bovine sérum albumin in PBS and incubated for one hour at room température with gentle mixing. Each well was washed 3X with 200 Tl of PBS. Anti-MASP-2 Fab2 samples were diluted to selected concentrations in Ca++ and Mg++ containing GVB buffer (4.0 mM barbital, 141 mM NaCl, 1.0 mM MgCl2, 2.0 mM CaCl2, 0.1% gelatin, pH 7.4) at 5 C. 1.0 Tg/ml human C4 (Quidel) was also included in these samples. 0.5% rat sérum was added to the above samples at 5 C and 100 Tl was transferred to each well. The plates were covered and incubated for 30 min in a 37 C waterbath to allow complément activation. The reaction was stopped by transferring the plates from the 37 C waterbath to a container containing an ice-water mix. Each well was washed 5 x 200 Tl with PBS-Tween 20 (0.05% Tween 20 in PBS), then each well was washed with 2X with 200 Tl PBS. 100 Tl/well of 1:700 dilution of biotîn-conjugated chicken anti-human C4c (Immunsystem AB, Uppsala, Sweden) was added in PBS containing 2.0 mg/ml bovine sérum albumin (BSA) and incubated one hour at room température with gentle mixing. Each well was washed 5x200 Tl PBS. 100 Tl/well of 0.1 Tg/ml of peroxidase-conjugated streptavidin (Pierce Chemical #21126) was added in PBS containing 2.0 mg/ml BSA and incubated for one hour at room température on a shaker with gentle mixing. Each well was washed 5 x 200 Tl with PBS. 100 Tl/well of the peroxidase substrate TMB (Kirkegaard & Perry Laboratories) was added and incubated at room température for 16 min. The peroxidase reaction was stopped b y adding 100 Tl/well of 1.0 Μ H3PO4 and the OD450 .was measured.
161
3. Binding Assay of anti-rat MASP-2 Fab2 to 'Native' rat MASP-2
Background: MASP-2 is usually présent in plasma as a MASP-2 dimer complex that also includes spécifie lectin molécules (mamiose-binding protein (MBL) and ficolins). Therefore, if one is înterested in studying the binding of anti-MASP-2 Fab2 to 5 the physiologically relevant form of MASP-2, it is important to develop a binding assay in which the interaction between the Fab2 and 'native1 MASP-2 in plasma is used, rather than purified recombinant MASP-2. In this binding assay the 'native' MASP-2-MBL complex from 10% rat sérum was first immobilized onto mannan-coated wells. The binding affinity of varions anti-MASP-2 Fab2s to the immobilized 'native' MASP-2 was 10 then studied using a standard ELISA methodology.
Methods: 96-well Costar High Binding plates were incubated ovemight at 5°C with mannan diluted in 50 mM carbonate buffer, pH 9.5 at 1 Tg/50 Tl/well. Each well was washed 3X with 200 Tl PBS. The wells were blocked with 100 Tl/well of 0.5% nonfat diy milk in PB ST (PBS with 0.05% Tween 20) and incubated for one hour at room 15 température with gentle mixing. Each well was washed 3X with 200 Tl of TBS/Tween/Ca++ Wash Buffer (Tris-buffered saline, 0.05% Tween 20, containing 5.0 mM CaCl2, pH 7.4. 10% rat sérum in High Sait Binding Buffer (20 mM Tris, 1.0 M NaCl, 10 mM CaCb, 0.05% Triton-X100, 0.1% (w/v) bovine sérum albumin, pH7.4) was prepared on ice. 100 Tl/well was added and incubated ovemight at 5°C. Wells were 20 washed 3X with 200 Ή of TBS/Tween/Ca++ Wash Buffer. Wells were then washed 2X with 200 Tl PBS. 100 Tl/well of selected concentration of anti-MASP-2 Fab2 diluted in Ca++ and Mg++ containing GVB Buffer (4.0 mM barbital, 141 mM NaCl, 1.0 mM MgCh, 2.0 mM CaCh, 0.1% gelatin, pH7.4) was added and incubated for one hour at room température with gentle mixing. Each well was washed 5 x 200 Tl PBS. 100 Tl/well of 25 HRP-conjugated goat anti-Fab2 (Biogenesis Cat No 0500-0099) diluted 1:5000 in 2.0 mg/ml bovine sérum albumin in PBS was added and incubated for one hour at room température with gentle mixing. Each well was washed 5 x 200 Tl PBS. 100 Ti/well of the peroxidase substrate TMB (Kirkegaard & Perry Laboratories) was added and incubated at room température for 70 min. The peroxidase reaction was stopped by 30 adding 100 Tl/well of 1.0 Μ H3PO4 and OD450. was measured.
162
RESULTS:
Approximately 250 different Fab2s that reacted with high affinity to the rat MASP-2 protein were picked for ELISA screening. These high affinity Fab2s were sequenced to détermine the uniqueness of the different antibodies, and 50 unique 5 anti-MASP-2 antibodies were purified for further analysis. 250 ug of each purified Fab2 antibody was used for characterization of MASP-2 binding affinity and complément pathway functional testing. The results of this analysis is shown below in TABLE 6.
TABLE 6: ANTI-MASP-2 FAB2 THAT BLOCK LECTIN PATHWAY
COMPLEMENT ACTIVATION
Fab2 antibody # | C3 Convertase (IC50(nM) | Kd | C4 Cleavage IC50 (nM) |
88 | 0.32 | 4.1 | ND |
41 | 0.35 | 0.30 | 0.81 |
11 | 0.46 | 0.86 | <2 nM |
86 | 0.53 | 1.4 | ND |
81 | 0.54 | 2.0 | ND |
66 | 0.92 | 4.5 | ND |
57 | 0.95 | 3.6 | <2nM |
40 | 1.1 | 7.2 | 0.68 |
58 | 1.3 | 2.6 | ND |
60 | 1.6 | 3.1 | ND |
52 | 1.6 | 5.8 | <2 nM |
63 | 2.0 | 6.6 | ND |
49 | 2.8 | 8.5 | <2 nM |
89 | 3.0 | 2.5 | ND |
71 | 3.0 | 10.5 | ND |
87 | 6.0 | 2.5 | ND |
67 | 10.0 | 7.7 | ND |
As shown above in TABLE 6, of the 50 anti-MASP-2 Fab2s tested, seventeen Fab2s were îdentified as MASP-2 blocking Fab2 that potently inhibit C3 convertase formation with IC50 equal to or less than 10 nM Fab2s (a 34% positive hit rate). Eight of
163 the seventeen Fab2s identified hâve IC5QS in the subnanomolar range. Furthermore, ail seventeen of the MASP-2 blocking Fab2s shown in TABLE 6 gave essentially complété inhibition of C3 convertase formation in the lectin pathway C3 convertase assay. FIGURE 8A graphically illustrâtes the results of the C3 convertase formation assay for 5 Fab2 antibody #11, which is représentative of the other Fab2 antibodies tested, the results of which are shown in TABLE 6. This is an important considération, since it is theoretically possible that a blocking Fab2 may only fractionally inhibit MASP-2 fonction even when each MASP-2 molécule is bound by the Fab2.
Although mannan is a known activator of the lectin pathway, it is theoretically 10 possible that the presence of anti-mannan antibodies in the rat sérum might also activate the classical pathway and generate C3b via the classical pathway C3 convertase. However, each of the seventeen blocking anti-MASP-2 Fab2s listed in this example potently inhibits C3b génération (>95 %), thus demonstrating the specificity of this assay for lectin pathway C3 convertase.
Binding assays were also performed with ail seventeen of the blocking Fab2s in order to calculate an apparent Kj for each. The results of the binding assays of anti-rat MASP-2 Fab2s to native rat MASP-2 for six of the blocking Fab2s are also shown in TABLE 6. FIGURE 8B graphically illustrâtes the results of a binding assay with the Fab2 antibody #11. Similar binding assays were also carried out for the other Fab2s, the results of which are shown in TABLE 6. In general, the apparent Kjs obtained for binding of each of the six Fab2s to 'native' MASP-2 corresponds reasonably well with the IC5Q for the Fab2 in the C3 convertase functional assay. There is evidence that MASP-2 undergoes a conformational change from an 'inactive' to an 'active' form upon activation of its protease activity (Feinberg et al., EMBO J 22:2348-59 (2003); Gai et al., J. Biol.
Chem. 280:33435-44 (2005)). In the normal rat plasma used in the C3 convertase formation assay, MASP-2 is présent primarily in the 'inactive' zymogen conformation. In contrast, in the binding assay, MASP-2 is présent as part of a complex with MBL bound to immobilized mannan; therefore, the MASP-2 would be in the 'active' conformation (Petersen et al., J. Immunol Methods 257:FD-\6, 2001). Consequently, one would not necessarily expect an exact correspondence between the IC5Q and Kj for each of the seventeen blocking Fab2 tested in these two functional assays since in each assay the
164
Fab2 would be binding a different conformational form of MASP-2. Never-the-less, with the exception of Fab2 #88, there appears to be a reasonably close correspondence between the IC5Q and apparent Kd for each of the other sixteen Fab2 tested in the two assays (see TABLE 6).
Several of the blocking Fab2s were evaluated for inhibition of MASP-2 mediated cleavage of C4. FIGURE 8C graphically illustrâtes the results of a C4 cleavage assay, showing inhibition with Fab2 #41, with an IC5q=0.81 nM (see TABLE 6). As shown in FIGURE 9, ail of the Fab2s tested were found to inhibit C4 cleavage with IC5QS similar to those obtained in the C3 convertase assay (see TABLE 6).
Although mannan is a known activator of the lectin pathway, it is theoretically possible that the presence of anti-mannan antibodies in the rat sérum might also activate the classical pathway and thereby generate C4b by Cls-mediated cleavage of C4. However, several anti-MASP-2 Fab2s hâve been identified which potently inhibit C4b génération (>95 %), thus demonstrating the specificity of this assay for MASP-2 mediated C4 cleavage. C4, like C3, contains an unusual and highly reactive thioester group as part of its structure. Upon cleavage of C4 by MASP-2 in this assay, the thioester group on C4b can form a covalent bond with hydroxyl or amino groups on macromolecules immobilized on the bottom of the plastic wells via ester or amide linkages, thus facilitating détection of C4b in the ELIS A assay.
These studies clearly demonstrate the création of high affinity FAB2s to rat
MASP-2 protein that functionally block both C4 and C3 convertase activity, thereby preventing lectin pathway activation.
EXAMPLE 11
This Example describes the epîtope mapping for several of the blocking anti-rat
MASP-2 Fab2 antibodies that were generated as described in Example 10.
Methods:j
As shown in FIGURE 10, the following proteins, ail with N-terminal 6X His tags were expressed in CHO cells using the pED4 vector:| rat MASP-2A, a full length MASP-2 protein, inactivated by altering the serine atI the active center to alanine (S613A);I t i
165 rat MASP-2K, a full-length MASP-2 protein altered to reduce autoactivation (R424K);
CUBI-II, an N-terminal fragment of rat MASP-2 that contains the CUBI, EGF-like and CUBII domains only; and
CUBI/EGF-like, an N-terminal fragment of rat MASP-2 that contains the CUBI and EGF-like domains only.
These proteins were purified from culture supernatants by nickel-affinity chromatography, as previously described (Chen et al., J. Biol. Chem. 276:25894-02 (2001)).
A C-terminal polypeptide (CCPII-SP), containing CCPII and the serine protease domain of rat MASP-2, was expressed in E. coli as a thîoredoxin fusion protein using pTrxFus (Invitrogen). Protein was purified from cell lysâtes using Thiobond affinity resin. The thîoredoxin fusion partner was expressed from empty pTrxFus as a négative control.
Ail recombinant proteins were dialyzed into TBS buffer and their concentrations determined by measuring the OD at 280 nm.
DOT BLOT ANALYSIS:
Serial dilutions of the five recombinant MASP-2 polypeptides described above and shown in FIGURE 10 (and the thîoredoxin polypeptide as a négative control for 20 CCPILserine protease polypeptide) were spotted onto a nitrocellulose membrane. The amount of protein spotted ranged from 100 ng to 6.4 pg, in five-fold steps. In later experiments, the amount of protein spotted ranged from 50 ng down to 16 pg, again in five-fold steps. Membranes were blocked with 5% skimmed milk powder in TBS (blocking buffer) then incubated with 1.0 pg/ml anti-MASP-2 Fab2s in blocking buffer 25 (containing 5.0 mM Ca2+). Bound Fab2s were detected using HRP-conjugated anti-human Fab (AbD/Serotec; diluted 1/10,000) and an ECL détection kit (Amersham). One membrane was incubated with polyclonal rabbit-anti human MASP-2 Ab (described in Stover et al., J Immunol 765:6848-59 (1999)) as a positive control. In this case, bound Ab was detected using HRP-conjugated goat anti-rabbit IgG (Dako; diluted 1/2,000).
MASP-2 Binding Assay
ELISA plates were coated with 1.0 pg/well of recombinant MASP-2A or CUBI-II polypeptide in carbonate buffer (pH 9.0) overnight at 4°C. Wells were blocked with 1%
166
BSA in TBS, then serial dilutions of the anti-MASP-2 Fab2s were added in TBS containing 5.0 mM Ca2+. The plates were incubated for one hour at RT. After washing three times with TBS/tween/Ca2+, HRP-conjugated anti-human Fab (AbD/Serotec) diluted 1/10,000 in TBS/ Ca2+ was added and the plates incubated for a further one hour 5 at RT. Bound antibody was detected using a TMB peroxidase substrate kit (Biorad).
RESULTS:
Results of the dot blot analysis demonstrating the reactivity of the Fab2s with varions MASP-2 polypeptides are provided below in TABLE 7. The numerical values provided in TABLE 7 indicate the amount of spotted protein required to give 10 approximately half-maximal signal strength. As shown, ail of the polypeptides (with the exception of the thioredoxin fusion partner alone) were recognized by the positive control Ab (polyclonal anti-human MASP-2 sera, raised in rabbits).
TABLE 7: REACTIVITY WITH VARIOUS RECOMBINANT RAT MASP-2 ________________ POLYPEPTIDES ON DOT BLOTS
Fab2 Antibody # | MASP-2A | CUBI-II | CUBI/EGF-like | CCPII-SP | Thioredoxin |
40 | 0.16 ng | NR | NR | 0.8 ng | NR |
41 | 0.16 ng | NR | NR | 0.8 ng | NR |
11 | 0.16 ng | NR | NR | 0.8 ng | NR |
49 | ___0-16 ng | NR | NR | >20 ng | NR |
52 | 0.16 ng | NR | NR | 0.8 ng | NR |
57 | 0.032 ng | NR | NR | NR | NR |
58 | 0.4 ng | NR | NR | 2.0 ng | NR |
60 | 0.4 ng | 0.4 ng | NR | NR | NR |
63 | 0.4 ng | NR | NR | 2-0 ng | NR |
66 | 0.4 ng | NR | NR | 2.0 ng | NR |
67 | 0.4 ng | NR | NR | 2.0 ng | NR |
71 | 0.4 ng | NR | NR | 2.0 ng | NR |
81 | 0.4 ng | NR | NR | 2.0 ng | NR |
86 | 0.4 ng | NR | NR | 10 ng | NR |
87 | 0.4 ng | NR | NR | 2-0 ng | NR |
167
Fab2 Antibody # | MASP-2A | CUBI-II | CUBI/EGF-like | CCPII-SP | Thioredoxin |
Positive Control | <0.032 ng | 0.16 ng | 0.16 ng | <0.032 ng | NR |
pathway activity was observed over the second and third weeks, with complété lectin pathway restoration in the mice by 17 days post anti-MASP-2 Mo Ab administration. NR = No reaction. The positive control antibody is polyclonal anti-human MASP-2 sera, raised in rabbits.
Ail of the Fab2s reacted with MASP-2A as well as MASP-2K (data not shown).
The majority of the Fab2s recognized the CCPII-SP polypeptide but not the N-terminal fragments. The two exceptions are Fab2 #60 and Fab2 #57. Fab2 #60 recognizes MASP-2A and the CUBI-II fragment, but not the CUBI/EGF-like polypeptide or the CCPII-SP polypeptide, suggesting it binds to an epitope in CUBII, or spanning the CUBII 10 and the EGF-like domain. Fab2 # 57 recognizes MASP-2A but not any of the MASP-2 fragments tested, indicating that this Fab2 recognizes an epitope in CCP1. Fab2 #40 and #49 bound only to complété MASP-2A. In the ELISA binding assay shown in FIGURE 11, Fab2 #60 also bound to the CUBI-II polypeptide, albeit with a slightly lower apparent affinity.
These finding demonstrate the identification of unique blocking Fab2s to multiple régions of the MASP-2 protein
EXAMPLE 12
This Example describes the analysis of MASP-2-/- mice in a Murine Rénal 20 Ischemia/Reperfusion Model.
Background/Rationale: Ischemia-Reperfusion (I/R) injury in kidney at body température has relevance in a number of clinical conditions, including hypovolaemic shock, rénal artery occlusion and cross-clamping procedures.
Kidney ischemia-reperfusion (I/R) is an important cause of acute rénal failure, 25 associated with a mortality rate of up to 50% (Levyetal., JAMA 275:1489-94, 1996; Thadhani et al., N. Engl. J. Med. 334:1448-60, 1996). Post-transplant rénal failure is a common and threatening complication after rénal transplantation (Nicholson et al., Kidney Int, 58:2585-91, 2000). Effective treatment for rénal I/R injury is currently not
168 available and hemodialysis is the only treatment available. The pathophysiology of rénal I/R injury is complicated. Recent studies hâve shown that the lectin pathway of complément activation may hâve an important rôle in the pathogenesis of rénal I/R injury (deVries étal., Am. J. Path. 765:1677-88, 2004).
Methods:
A MASP-2(-/-) mouse was generated as described in Example 1 and backcrossed for at least 10 générations with C57B1/6. Six male MASP-2(-/-) and six wildtype (+/+) mice weighing between 22-25 g were administered an intraperitoneal injection of Hypnovel (6.64 mg/kg; Roche products Ltd. Welwyn Garden City, UK), and 10 subsequently anaesthetized by inhalation of isoflurane (Abbott Laboratories Ltd., Kent, UK). Isoflurane was chosen because it is a mild inhalation anaesthetic with minimal liver toxicity; the concentrations are produced accurately and the animal recovers rapidly, even after prolonged anaesthesia. Hypnovel was administered because it produces a condition of neuroleptanalgesîa in the animal and means that less isoflurane 15 needs to be administered. A warm pad was placed beneath the animal in order to maintain a constant body température. Next, a midline abdominal incision was performed and the body cavity held open using a pair of retractors. Connective tissue was cleared above and below the rénal vein and artery of both right and left kidneys, and the rénal pedicle was clamped via the application of microaneurysm clamps for a period 20 of 55 minutes. This period of ischemia was based înitially on a préviens study performed in this laboratory (Zhouetal., J. Clin. Invest. 105:1363-71 (2000)). In addition, a standard ischémie time of 55 minutes was chosen following ischémie titration and it was found that 55 minutes gave consistent injury that was also réversible, with low mortality, less than 5%. After occlusion, 0.4 ml of warm saline (37°C) was placed in the abdominal 25 cavity and then the abdomen was closed for the period of ischemia. Following removal of the microaneurysm clamps, the kidneys were observed until color change, an indication of blood re-flow to the kidneys. A further 0.4 ml of warm saline was placed in the abdominal cavity and the opening was sutured, whereupon animais were returned to their cages. Tail blood samples were taken at 24 hours after removing the clamps, and at 30 48 hours the mice were sacrificed and an additional blood sample was collected.
Assessment of Rénal Injury: Rénal function was assessed at 24 and 48 hours after reperfusion in six male MASP-2(-/-) and six WT (+/+) mice. Blood créatinine
169 measurement was determined by mass spectrometry, which provides a reproducible index of rénal function (sensitivity <1.0 pmol/L). FIGURE 12 graphically illustrâtes the blood urea nitrogen clearance for wildtype C57B1/6 Controls and MASP-2 (-/-) at 24 hours and 48 hours after reperfusion. As shown in FIGURE 12, MASP-2(-/-) mice displayed a significant réduction in the amount of blood urea at 24 and 48 hours, in comparison to wildtype control mice, indicating a protective functional effect from rénal damage in the ischemia reperfusion injury model.
Overall, increased blood urea was seen in both the WT (+/+) and MASP-2 (-/-) mice at 24 and 48 hours following the surgical procedure and ischémie insult. Levels of blood urea in a non-ischemic WT (+/+) surgery animal was separately determined to be 5.8 mmol/L. In addition to the data presented in FIGURE 12, one MASP-2 (-/-) animal showed nearly complété protection from the ischémie insult, with values of 6.8 and 9.6 mmol/L at 24 and 48 hours, respectively. This animal was excluded from the group analysis as a potential outlier, wherein no ischémie injury may hâve been présent. Therefore, the final analysis shown in FIGURE 12 included 5 MASP-2(-/-) mice and 6 WT (+/+) mice and a statîstically significant réduction in blood urea was seen at 24 and 48 hours in the MASP-2 (-/-) mice (Student t-test p<0.05). These findings indicate inhibition of MASP-2 activity would be expected to hâve a protective or therapeutic effect from rénal damage due to ischémie injury.
EXAMPLE 13
This Example describes the results of MASP-2-/- in a Murine Macular Degeneration Model.
Background/Rationale: Age-related macular degeneration (AMD) is the leading cause of blindness after âge 55 in the industrialized world. AMD occurs in two major forms: neovascular (wet) AMD and atrophie (dry) AMD. The neovascular (wet) form accounts for 90% of severe visual loss associated with AMD, even though only -20% of individuals with AMD develop the wet form. Clinical hallmarks of AMD include multiple drusen, géographie atrophy, and choroidal neovascularization (CNV). In December, 2004, the FDA approved Macugen (pegaptanib), a new class of ophthalmic drugs to specifically target and block the effects of vascular endothélial growth factor (VEGF), for treatment of the wet (neovascular) form of AMD (Ng et al., Nat Rev. Drug
170
Discov 5:123-32 (2006)). Although Macugen représente a promising new therapeutic option for a subgroup of AMD patients, there remains a pressing need to develop additional treatments for this complex disease. Multiple, independent lines of investigation implicate a central rôle for complément activation in the pathogenesis of AMD. The pathogenesis of choroidal neovascularization (CNV), the most serions form of AMD, may in volve activation of complément pathways.
Over twenty-five years ago, Ryan described a laser-induced injury model of CNV in animais (Ryan, S.J., Tr. Am. Opth. Soc. LXXVIP.707-745, 1979). The model was initially developed using rhésus monkeys, however, the same technology has since been used to develop similar models of CNV in a variety of research animais, including the mouse (Tobe et al., Am. J. Pathol. 253:1641-46, 1998). In this model, laser photocoagulation is used to break Bruch's membrane, an act which results in the formation of CNV-like membranes. The laser-induced model captures many of the important features of the human condition (for a recent review, see Ambati et al., Survey Ophthalmology 48:257-293, 2003). The laser-induced mouse model is now well established, and is used as an experimental basis in a large, and ever increasîng, number of research projects. It is generally accepted that the laser-induced model shares enough biological similarity with CNV in humans that preclinical studies of pathogenesis and drug inhibition using this model are relevant to CNV in humans.
Methods:
A MASP-2-/- mouse was generated as described in Example 1 and backcrossed for 10 générations with C57B1/6. The current study compared the results when MASP-2 (-/-) and MASP-2 (+/+) male mice were evaluated in the course of laser-induced CNV, an accelerated model of neovascular AMD focusing on the volume of laser-induced CNV by scanning laser confocal microscopy as a measure of tissue injury and détermination of levels of VEGF, a potent angiogenic factor implicated in CNV, in the retinal pigment epithelium (RPE)/choroids by ELISA after laser injury.
Induction of choroidal neovascularization (CNV): Laser photocoagulation (532 nm, 200 mW, 100 ms, 75pm; Oculight GL, Iridex, Mountain View, CA) was performed on both eyes of each animal on day zéro by a single individual masked to drug group assignment. Laser spots were applied in a standardized fashion around the optic nerve, using a slit lamp delivery system and a coverslip as a contact lens. The
171 morphologie end point of the laser injury was the appearance of a cavitation bubble, a sign thought to correlate with the disruption of Bruch's membrane. The detailed methods and endpoints that were evaluated are as follows.
Fluorescein Angiography: Fluorescein angiography was performed with a 5 caméra and imaging System (TRC 50 IA caméra; ImageNet 2.01 System; Topcon, Paramus , NJ) at 1 week after laser photocoagulation. The photographs were captured with a 20-D lens in contact with the fundus caméra lens after intraperitoneal injection of 0.1 ml of 2.5% fluorescein sodium. A retina expert not involved in the laser photocoagulation or angiography evaluated the fluorescein angiograms at a single sitting 10 in masked fashion.
Volume of choroidal neovascularization (CNV): One week after laser injury, eyes were enucleated and fixed with 4% paraformaldéhyde for 30 min at 4°C. Eye cups were obtained by removing anterior segments and were washed three times in PBS, followed by déhydration and rehydration through a methanol sériés. After blocking twice 15 with buffer (PBS containing 1% bovine serumalbumin and 0.5% Triton X-100) for 30 minutes at room température, eye cups were incubated ovemight at 4°C with 0.5% FITC-isolectin B4 (Vector laboratories, Burlingame, CA), diluted with PBS containing 0.2% BSA and 0.1% Triton X-100, which binds terminal β-D-galactose residues on the surface of endothélial cells and selectively labels the murine vasculature. After two 20 washings with PBS containing 0.1% Triton X-100, the neurosensory retina was gently detached and severed from the optic nerve. Four relaxing radial incisions were made, and the remaining RPE -choroid-sclera complex was flatmounted in antifade medium (Immu-Mount Vectashield Mounting Medium; Vector Laboratories) and cover-slipped.
Flatmounts were examined with a scanning laser confocal microscope (TCS SP; 25 Leica, Heidelberg, Germany). Vessels were visualized by exciting with blue argon wavelength (488 nm) and capturing émission between 515 and 545 nm. A 40X oil-immersion objective was used for ail imaging studies. Horizontal optical sections (1 pm step) were obtained from the surface of the RPE-choroid-sclera complex. The deepest focal plane in which the surrounding choroidal vascular network connecting to 30 the lésion could be identified was judged to be the floor of the lésion. Any vessel in the laser-targeted area and superficial to this reference plane was judged as CNV. Images of each section were digitally stored. The area of CNV-related fluorescence was measured
172 by computenzed image analysis with the microscope software (TCS SP; Leica). The summation of whole fluorescent area in each horizontal section was used as an index for the volume of CNV, Imaging was performed by an operator masked to treatment group assignment.
Because the probability of each laser lésion developing CNV is influenced by the group to which it belongs (mouse, eye, and laser spot), the mean lésion volumes were compared using a linear mixed model with a split plot repeated-measures design, The whole plot factor was the genetic group to which the animal belongs, whereas the split plot factor was the eye, Statistical significance was determined at the 0.05 level. Post hoc comparisons of means were constructed with a Bonferronî adjustment for multiple comparisons.
VEGF ELISA. At three days after injury by 12 laser spots, the RPE-choroid complex was sonicated in lysis buffer (20 mM imidazole HCl, 10 mM KC1, 1 mM MgCLi, 10 mM EGTA, 1% Triton X-100, 10 mM NaF, 1 mM Na molybdate, and 1 mM EDTA with protease inhibitor) on ice for 15 min. VEGF protein levels in the supematant were determined by an ELISA kit (R&D Systems, Minneapolis, MN) that recognizes ail splice variants, at 450 to 570 nm (Emax; Molecular Devices, Sunnyvale, CA), and normalized to total protein. Duplicate measurements were performed in a masked fashion by an operator not involved in photocoagulation, imaging, or angiography. VEGF numbers were represented as the mean +/- S EM of at least three independent experiments and compared using the Mann-Whitney U test. The null hypothesis was rejected at P<0.05.
RESULTS:
Assessment of VEGF Levels:
FIGURE 13A graphically illustrâtes the VEGF protein levels in RPE-choroid complex isolated from C57B16 wildtype and MASP-2(-/-) mice at day zéro. As shown in FIGURE 13A, the assessment of VEGF levels indicate a decrease in baseline levels for VEGF in the MASP-2 (-/-) mice versus the C57bl wildtype control mice. FIGURE 13B graphically illustrâtes VEGF protein levels measured at day three following laser induced injury. As shown in FIGURE 13B VEGF levels were significantly increased in the wildtype (+/+) mice three days following laser induced injury, consistent with published
173 studies (Nozaki et al., Proc. Natl. Acad. Sci. USA 103:2328-33 (2006)). However, surprisingly very low levels of VEGF were seen in the MASP-2 (-/-) mice.
Assessment of choroidal neovascularization (CNV):
hi addition to the réduction in VEGF levels following laser induced maculai degeneration, CNV area was determined before and after laser injury. FIGURE 14 graphically illustrâtes the CNV volume measured in C57bl wildtype mice and MASP-2(-/-) mice at day seven following laser induced injury. As shown in FIGURE 14, the MASP-2 (-/-) mice displayed about a 30% réduction in the CNV area following laser induced damage at day seven in comparison to the wildtype control mice.
These findings indicate a réduction in VEGF and CNV as seen in the MASP (-/-) mice versus the wildtype (+/+) control and that blockade of MASP-2 with an inhibitor would hâve a préventive or therapeutic effect in the treatment of macular degeneration.
EXAMPLE 14
This Example demonstrates that thrombin activation can occur following lectin pathway activation under physiological conditions, and demonstrates the extent of MASP-2 involvement. hi normal rat sérum, activation of the lectin pathway leads to thrombin activation (assessed as thrombin déposition) concurrent with complément activation (assessed as C4 déposition). As can be seen in FIGURES 15A and 15B, thrombin activation in this System is inhibited by a MASP-2 blocking antibody (Fab2 format), exhibiting an inhibition concentration-response curve (FIGURE 15B) that parallels that for complément activation (FIGURE 15A). These data suggest that activation of the lectin pathway as it occurs in trauma will lead to activation of both complément and coagulation Systems in a process that is entirely dépendent on MASP-2. B y inference, MASP2 blocking antibodies may prove efficacious in mitigating cases of excessive systemic coagulation, e.g., disseminated intravascular coagulation, which is one of the halhnarks leading to mortality in major trauma cases.
EXAMPLE 15
This Example provides results generated using a localized Schwartzman reaction model of disseminated intravascular coagulation (DIC) in MASP-2 -/- déficient and |
MASP-2 +/+ sufficient mice to evaluate the rôle of lectin pathway in DIC. j i i
174
B ackground/Rationale :
As described supra, blockade of MASP-2 inhibits lectin pathway activation and reduces the génération of both anaphylatoxins C3a and C5a. C3a anaphylatoxins can be shown to be potent platelet aggregators in vitro, but their involvement in vivo is less well 5 defined and the release of platelet substances and plasmin in wound repair may only secondarily involve complément C3. In this Example, the rôle of the lectin pathway was analyzed in MASP-2 (-/-) and WT (+/+) mice in order to address whether prolonged élévation of C3 activation is necessary to generate disseminated intravascular coagulation.
Methods:
The MASP-2 (-/-) mice used in this study were generated as described in Example 1 and backcrossed for at least 10 générations with C57B1/6.
The localized Schwartzman reaction model was used in this experiment. The localized Schwartzman reaction (LSR) is a lipopolysaccharide (LPS) -induced response 15 with well-characterized contributions from cellular and humoral éléments of the innate immune System. Dépendent of the LSR on complément is well established (Polak, L., et al., Nature 223:138-739 (1969); Fong J.S. et al., J Exp Med 134:642-655 (1971)). In the LSR model, the mice were primed for 4 hours with TNF alpha (500 ng, intrascrotal), then the mice were anaesthetized and prepared for intravital microscopy of the cremaster 20 muscle. Networks of post-capillary venules (15-60 pm diameter) with good blood flow (1-4 mm/s) were selected for observation. Animais were treated with fluorescent antibodies to selectively label neutrophils, or platelets. The network of vessels was sequentially scanned and images of ail vessels were digitally recorded of later analysis. After recording the basal State of the microcirculation, mice received a single intravenous 25 injection of LPS (100 pg), either alone or with the agents listed below. The same network of vessels was then scanned every 10 minutes for 1 hour. Spécifie accumulation of fluorophores was identified by subtraction of background fluorescence and enhanced by thresholding the image. The magnitude of reactions was measured from recorded images. The primary measure of Schwartzman reactions was aggregate data.
The studies compared the MASP-2 +/+ sufficient, or wild type, mice exposed to either a known complément pathway depletory agent, cobra venom factor (CVF), or a terminal pathway inhibitor (C5aR antagonist). The results (FIGURE 16A) demonstrate
175 that CVF as well as a C5aR antagonist both prevented the appearance of aggregates in the vasculature. In addition, the MASP-2 -/- déficient mice (FIGURE 16B) also demonstrated complété inhibition of the localized Schwartzman reaction, supporting lectin pathway involvement. These results clearly demonstrate the rôle of MASP-2 in DIC génération and support the use of MASP-2 inhibitors for the treatment and prévention of DIC.
EXAMPLE 16
This Example describes the analysis of MASP-2 (-/-) mice in a Murine Rénal Transplantation Model.
BackgroundZRationale:
The rôle of MASP-2 in the functional outcome of kidney transplantation was assessed using a mouse model.
Methods:
The functional outcome of kidney transplantation was assessed using a single kidney isograft into uninephrecomized récipient mice, with six WT (+/+) transplant récipients (B6), and six MASP-2 (-/-) transplant récipients. To assess the function of the transplanted kidney, the remaining native kidney was removed from the récipient 5 days after transplantation, and rénal function was assessed 24 hours later by measurement of blood urea nitrogen (BUN) levels.
Results:
FIGURE 17 graphically illustrâtes the blood urea nitrogen (BUN) levels of the kidney at 6 days post kidney transplant in the WT (+/+) récipients and the MASP-2 (-/-) récipients. As shown in FIGURE 17, strongly elevated BUN levels were observed in the WT (+/+) (B6) transplant récipients (normal BUN levels in mice are < 5 mM), indicating rénal failure. In contrast, MASP-2 (-/-) isograft récipient mice showed substantially lower BUN levels, suggesting improved rénal function. It is noted that these results were obtained using grafts from WT (+/+) kidney donors, suggesting that the absence of a functional lectin pathway in the transplant récipient alone is sufficient to achieve a therapeutic benefit.
Taken together, these results indicate that transient inhibition of the lectin pathway via MASP-2 inhibition provides a method of reducing morbidity and delayed
Ο 176 graft function in rénal transplantation, and that this approach is likely to be useful in other transplant settings.
EXAMPLE 17
This Example demonstrates that MASP-2 (-/-) mice are résistant to septic shock in a Murine Polymicrobial Septic Peritonitis Model.
Background/Rationale :
To evaluate the potential effects of MASP-2 (-/-) in infection, the cecal ligation and puncture (CLP) model, a model of polymicrobial septic peritonitis was evaluated. 10 This model is thought to most accurately mimic the course of human septic peritonitis. The cecal ligation and puncture (CLP) model is a model in which the cecum is ligated and punctured by a needle, leading to continuons leakage of the bacteria into the abdominal cavity which reach the blood through the lymph drainage and are then distributed into ail the abdominal organs, leading to multi-organ failure and septic shock 15 (Eskandari et al., J Immunol 148(9):2124-2730 (1992)). The CLP model mimics the course of sepsis observed in patients and induces an early hyper-inflammatory response followed by a pronounced hypo-inflammatory phase. During this phase, the animais are highly sensitive to bacterial challenges (Wichterman et al., J. Surg. Res. 29(2): 189-201 (1980)).
Methods:
The mortality of polymicrobial infection using the cecal ligation and puncture (CLP) model was measured in WT (+/+) (n=18) and MASP-2 (-/-) (n=16) mice. Briefly described, MASP-2 déficient mice and their wild-type littermates were anaesthetized and the cecum was exteriorized and ligated 30% above the distal end. After that, the cecum 25 was punctured once with a needle of 0.4 mm diameter. The cecum was then replaced into the abdominal cavity and the skin was closed with clamps. The survival of the mice subjected to CLP was monitored over a period of 14 days after CLP. A peritoneal lavage was collected in mice 16 hours post CLP to measure bacterial load. Serial dilutions of the peritoneal lavage were prepared in PBS and inoculated in Mueller Hinton plates with 30 subséquent incubation at 37°C under anaérobie conditions for 24 hours after which bacterial load was determined.
177
The TNF-alpha cytokine response to the bacterial infection was also measured in the WT (+/+) and MASP-2 (-/-) mice 16 hours after CLP in lungs and spleens via quantitative real time polymerase chain reaction (qRT-PCR). The sérum level of TNFalpha 16 hours after CLP in the WT (+/+) and MASP-2 (-/-) mice was also quantified by 5 sandwich ELISA.
Results:
FIGURE 18 graphically illustrâtes the percentage survival of the CLP treated animais as a function of the days after the CLP procedure. As shown in FIGURE 18, the lectin pathway deficiency in the MASP-2 (-/-) mice does not increase the mortality of 10 mice after polymicrobial infection using the cecal ligation and puncture model as compared to WT (+/+) mice. However, as shown in FIGURE 19, MASP-2 (-/-) mice showed a significantly higher bacterial load (approximately a 1000-fold increase in bacterial numbers) in peritoneal lavage after CLP when compared to their WT (+/+) littermates. These results indicate that MASP-2 (-/-) déficient mice are résistant to septic 15 shock. The reduced bacterial clearance in MASP-2 déficient mice in this model may be due to an impaired C3b mediated phagocytosis, as it was demonstrated that C3 déposition is MASP-2 dépendent.
It was determined that the TNF-alpha cytokine response to the bacterial infection was not elevated in the MASP-2 (-/-) mice as compared to the WT (+/+) Controls (data 20 not shown). It was also determined that there was a significantly higher sérum concentration of TNF-alpha in WT (+/+) mice 16 hours after CLP in contrast to MASP-2 (-/-) mice, where the sérum level of TNF-alpha remained nearly unaltered. These results suggest that the intense inflammatory response to the septic condition was tempered in MASP-2 (-/-) mice and allowed the animais to survive in the présence of higher bacterial 25 counts.
Taken together, these results demonstrate the potential deleterious effects of lectin pathway complément activation in the case of septicemia and the increased mortality in patients with overwhelming sepsis. These results further demonstrate that MASP-2 deficiency modulâtes the inflammatory immune response and reduces the expression 30 levels of inflammatory mediators during sepsis. Therefore, it is believed that inhibition of MASP-2 (-/-) by administration of inhibitory monoclonal antibodies against MASP-2 would be effective to reduce the inflammatory response in a subject suffering from septic shock.
EXAMPLE 18
This Example describes analysis of MASP-2 (-/-) mice in a Murine Intranasal
Infectivity Model.
B ackground/Ration ale:
Pseudomonas aeruginosa is a Gram négative opportunistic human bacterial pathogen that causes a wide range of infections, particularly in immune-compromised 10 individuals. It is a major source of acquired nosocomial infections, in particular hospîtalacquired pneumonia. It is also responsible for significant morbidity and mortality in cystic fibrosis (CF) patients. P. aeruginosa pulmonary infection is characterized by strong neutropliil recruitment and significant lung inflammation resulting in extensive tissue damage (Palankî M.S. et al., J. Med. Chem 57:1546-1559 (2008)).
In this Example, a study was undertaken to détermine whether the removal of the lectin pathway in MASP-2 (-/-) mice increases the susceptibility of the mice to bacterial infections.
Methods:
Twenty-two WT (+/+) mice, twenty-two MASP-2 (-/-) mice, and eleven C3 (-/-) 20 mice were challenged with intranasal administration of P. aeruginosa bacterial strain. The mice were monitored over the six days post-infection and Kaplan-Mayer plots were constructed showing percent survival.
Results:
FIGURE 20 is a Kaplan-Mayer plot of the percent survival of WT (+/+), MASP25 2 (-/-) or C3 (-/-) mice six days post-infection. As shown in FIGURE 20, no différences were observed in the MASP-2 (-/-) mice versus the WT (+/+) mice. However, removal of the classical (Clq) pathway in the C3 (-/-) mice resulted in a severe susceptibility to bacterial infection. These results demonstrate that MASP-2 inhibition does not increase susceptibility to bacterial infection, indicating that it is possible to reduce undesirable 30 inflammatory complications in trauma patients by inhibiting MASP-2 without compromising the patient's ability to fight infections using the classical complément pathway.
179
EXAMPLE 19
This Example describes the pharmacodynamie analysis of représentative high affinity anti-MASP-2 Fab2 antibodies that were identified as described in Example 10.
Background/Rationale:
As described in Example 10, in order to identify high-affinity antibodies that block the rat lectin pathway, rat MASP-2 protein was utilized to pan a phage display library. This library was designed to provide for high immunological divers ity and was constructed using entirely human immunoglobin gene sequences. As described in 10 Example 10, approximately 250 individual phage clones were identified that bound with high affinity to the rat MASP-2 protein by ELISA screening. Sequencing of these clones identified 50 unique MASP-2 antibody encoding phage. Fab2 protein was expressed from these clones, purified and analyzed for MASP-2 binding affinity and lectin complément pathway functional inhibition.
As shown in TABLE 6 of Example 10, 17 anti-MASP-2 Fab2s with functional blocking activity were identified as a resuit of this analysis (a 34% hit rate for blocking antibodies). Functional inhibition of the lectin complément pathway by Fab2s was apparent at the level of C4 déposition, which is a direct measure of C4 cleavage by MASP-2. Importantly, inhibition was equally évident when C3 convertase activity was 20 assessed, demonstrating functional blockade of the lectin complément pathway. The 17 MASP-2 blocking Fab2s identified as described in Example 10 potently inhibit C3 convertase formation with IC5Q values equal to or less than 10 nM. Eight of the 17 Fab2s identified hâve IC50 values in the sub-nanomolar range. Furthermore, ail 17 of the MASP-2 blocking Fab2s gave essentially complété inhibition of the C3 convertase 25 formation in the lectin pathway C3 convertase assay, as shown in FIGURES 8A-C, and summarized in TABLE 6 of Example 10. Moreover, each of the 17 blocking anti-MASP2 Fab2s shown in TABLE 6 potently inhibit C3b génération (>95%), thus demonstrating the specificity of this assay for lectin pathway C3 convertase.
Rat IgG2c and mouse IgG2a full-length antibody isotype variants were derived 30 from Fab2 #11. This Example describes the in vivo characterization of these isotypes for pharmacodynamie parameters.
180
Methods:
As described in Example 10, rat MASP-2 protein was utilized to pan a Fab phage display library, from which Fab2#ll was identified. Rat IgG2c and mouse IgG2a fulllength antibody isotype variants were derived from Fab2 #11. Both rat IgG2c and mouse IgG2a full length antibody isotypes were characterized in vivo for pharmacodynamie parameters as follows.
In vivo study in mice:
A pharmacodynamie study was carried out in mice to investigate tire effect of anti-MASP-2 antibody dosing on the plasma lectin pathway activity in vivo. In this study, C4 déposition was measured ex vivo in a lectin pathway assay at varions time points following subeutaneous (sc) and intraperitoneal (ip) administration of 0.3 mg/kg or 1.0 mg/kg of the mouse anti-MASP-2 MoAb (mouse IgG2a full-length antibody isotype derived from Fab2#ll).
FIGURE 21 graphically illustrâtes lectin pathway spécifie C4b déposition, measured ex vivo in undiluted sérum samples taken from mice (n=3 mice/group) at varions time points after subeutaneous dosing of either 0.3 mg/kg or 1.0 mg/kg of the mouse anti-MASP-2 MoAb. Sérum samples from mice collected prior to antibody dosing served as négative Controls (100% activity), while sérum supplemented in vitro with 100 nM of the same blocking anti-MASP-2 antibody was used as a positive control (0% activity).
The results shown in FIGURE 21 demonstrate a rapid and complété inhibition of C4b déposition following subeutaneous administration of 1.0 mg/kg dose of mouse antiMASP-2 MoAb. A partial inhibition of C4b déposition was seen following subeutaneous administration of 0.3 mg/kg dose of mouse anti-MASP-2 MoAb.
The time course of lectin pathway recovery was followed for three weeks following a single ip administration of mouse anti-MASP-2 MoAb at 0.6 mg/kg in mice. As shown in FIGURE 22, a précipitons drop in lectin pathway activity occurred post antibody dosing followed by complété lectin pathway inhibition that lasted for about 7 days after ip administration. Slow restoration of lectin
These results demonstrate that the mouse anti-MASP-2 Moab derived from Fab2 #11 inhibits the lectin pathway of mice in a dose-responsive manner when delivered systemically.
181
EXAMPLE 20
This Example describes analysis of the mouse anti-MASP-2 Moab derived from Fab2 #11 for efficacy in a mouse model for age-related macular degeneration.
Background/Rationale:
As described in Example 10, rat MASP-2 protein was utilized to pan a Fab phage display library, from which Fab2#ll was identified as a functionally active antibody. Full length antibodies of the rat IgG2c and mouse IgG2a isotypes were generated from Fab2 #11. The full length anti-MASP-2 antibody of the mouse IgG2a isotype was 10 characterized for pharmacodynamie parameters as described in Example 19. hi this Example, the mouse anti-MASP-2 full-length antibody derived from Fab2 #11 was analyzed in the mouse model of age-related macular degeneration (AMD), described by Bora P.S. et al, J Immunol 774:491-497 (2005).
Methods:
The mouse IgG2a full-length anti-MASP-2 antibody isotype derived from Fab2 #11 as described in Example 19, was tested in the mouse model of age-related macular degeneration (AMD) as described in Example 13 with the following modifications.
Administration of mouse-anti-MASP-2 MoAbs
Two different doses (0.3 mg/kg and 1.0 mg/kg) of mouse anti-MASP-2 MoAb 20 along with an isotype control Mo Ab treatment were injected ip into WT (+/+) mice (n= 8 mice per group) 16 hours prior to CNV induction
Induction of choroidal neovascularization (CNV)
The induction of choroidal neovascularization (CNV) and measurement of the volume of CNV was carried out using laser photocoagulation as described in Example 13.
Results:
FIGURE 23 graphically illustrâtes the CNV area measured at 7 days post laser injury in mice treated with either isotype control MoAb, or mouse anti-MASP-2 MoAb (0.3 mg/kg and 1.0 mg/kg). As shown in FIGURE 23, in the mice pre-treated with 1.0 mg/kg anti-MASP-2 MoAb, a statistically signîficant (p <0.01) approximately 50% 30 réduction in CNV was observed seven days post-laser treatment. As further shown in FIGURE 23, it was observed that a 0.3 mg/kg dose of anti-MASP-2 MoAb was not efficacious in reducing CNV. It is noted that the 0.3 mg/kg dose of anti-MASP-2 Mo Ab
182 was shown to hâve a partial and transient inhibition of C4b déposition following subcutaneous administration, as described in. Example 19 and shown in FIGURE 21.
The results described in this Example demonstrate that blockade of MASP-2 with an inhibitor, such as anti-MASP-2 MoAb, has a preventative and/or therapeutic effect in 5 the treatment of maculai- degeneration. It is noted that these results are consistent with the results observed in the study carried out in the MASP-2 (-/-) mice, described in Example 13, in which a 30% réduction in the CNV 7 days post-laser treatment was observed in MASP-2 (-/-) mice in comparison to the wild-type control mice. Moreover, the results in this Example further demonstrate that systemically delivered anti-MASP-2 10 antibody provides local therapeutic benefit in the eye, thereby highlighting the potential for a systemic route of administration to treat AMD patients. In summary, these results provide evidence supporting the use of MASP-2 MoAb in the treatment of AMD.
EX AMPLE 21
This Example demonstrates that MASP-2 déficient mice are protected from
Neisseria meningitidis induced mortality after infection with N. meningitidis and hâve enhanced clearance of bacteraemia as compared to wild type control mice.
Rationale: Neisseria meningitidis is a heterotrophic gram-negative diplococcal bacterium known for its rôle in meningitis and other forms of meningococcal disease 20 such as meningococcemia. N. meningitidis is a major cause of morbidity and mortality during childhood. Severe complications include septicaemia, Waterhouse-Friderichsen syndrome, adrenal insufficiency and disseminated intravascular coagulation (DIC). See e.g., Rintala E. et al., Critical Care Medicine 28(7):2373-2378 (2000). In this Example, the rôle of the lectin pathway was analyzed in MASP-2 (-/-) and WT (+/+) mice in order 25 to address whether MASP-2 déficient mice would be susceptible to N. meningitidis induced mortality.
Methods:
MASP-2 knockout mice were generated as described in Example 1 and backcrossed for at least 10 générations with C57B1/6. 10 week old MASP-2 KO mice 30 (n=10) and wild type C57/B6 mice (n=10) were innoculated by intravenous injection with either a dosage of 5xl08 cfu/100 μΐ, 2xl08 cfu/100 μΐ or 3xl07 cfu/100 μΐ of Neisseria meningitidis Serogroup A Z2491 in 400 mg/kg iron dextran. Survival of the mice after
183 infection was monitored over a 72 hour time period. Blood samples were taken from the mice at hourly intervals after infection and analyzed to déterminé the sérum level (log cfu/ml) of N. meningitidis in order to verify infection and détermine the rate of clearance of the bacteria from the sérum.
Results:
FIGURE 24A graphically illustrâtes the percent survival of MASP-2 KO and WT mice after administration of an infective dose of 5xl08/100 pl cfu N. meningitidis. As shown in FIGURE 24A, after infection with the highest dose of 5x108/100 pl cfu N. meningitidis, 100% of the MASP-2 KO mice survived throughout the 72 hour period after infection. In contrast, only 20% of the WT mice were still alive 24 hours after infection. These results demonstrate that MASP-2 déficient mice are protected from N. meningitidis induced mortality.
FIGURE 24B graphically illustrâtes the log cfu/ml of N. meningitidis recovered at different time points in blood samples taken from the MASP-2 KO and WT mice infected with 5xl08 cfu/100 pl N. meningitidis. As shown in FIGURE 24B, in WT mice the level of N. meningitidis in tire blood reached a peak of about 6.5 log cfu/ml at 24 hours after infection and dropped to zéro by 48 hours after infection. In contrast, in the MASP-2 KO mice, the level of N. meningitidis reached a peak of about 3.5 log cfu/ml at 6 hours after infection and dropped to zéro by 36 hours after infection.
FIGURE 25A graphically illustrâtes the percent survival of MASP-2 KO and WT mice after infection with 2xl08 cfu/100 pl N. meningitidis. As shown in FIGURE 25A, after infection with the dose of 2xl08 cfu/100 pl N. meningitidis, 100% of the MASP-2 KO mice survived throughout the 72 hour period after infection. In contrast, only 80% of the WT mice were still alive 24 hours after infection. Consistent with the results shown in FIGURE 24A, these results further demonstrate that MASP-2 déficient mice aie protected from N. meningitidis induced mortality.
FIGURE 25B graphically illustrâtes the log cfu/ml of N. meningitidis recovered at different time points in blood samples taken from the WT mice infected with 2xl08 cfu/100 pl N. meningitidis. As shown in FIGURE 25B, the level of N. meningitidis in the blood of WT mice infected with 2x108 cfu reached a peak of about 4 log cfu/ml at 12 hours after infection and dropped to zéro by 24 hours after infection. FIGURE 25C
184 graphically illustrâtes the log cfu/ml of N. meningitidis recovered at different time points in blood samples taken from the MASP-2 KO mice infected with 2xl08 cfu/100 μΐ M meningitidis. As shown in FIGURE 25C, the level of N. meningitidis in the blood of MASP-2 KO mice infected with 2xl08 cfu reached a peak level of about 3.5 log cfu/ml at 5 2 hours after infection and dropped to zéro at 3 hours after infection. Consistent with the results shown in FIGURE 24B, these results demonstrate that although the MASP-2 KO mice were infected with the same dose of N. meningitidis as the WT mice, the MASP-2 KO mice hâve enhanced clearance of bacteraemia as compared to WT.
The percent survival of MASP-2 KO and WT mice after infection with the lowest 10 dose of 3xl07 cfu/100 μΐ N. meningitidis was 100% at the 72 hour time period (data not shown).
Discussion
These results show that MASP-2 déficient mice are protected from N. meningitidis induced mortality and hâve enhanced clearance of bacteraemia as compared 15 to the WT mice. Therefore, in view of these results, it is expected that therapeutic application of MASP-2 inhibitors, such as MASP-2 MoAb, would be expected to be efficacious to treat, prevent or mitigate the effects of infection with N. meningitidis bacteria (i.e., sepsis and DIC). Further, these results indicate that therapeutic application of MASP-2 inhibitors, such as MASP-2 MoAb would not prédisposé a subject to an 20 increased risk to contract N. meningitidis infections.
EXAMPLE 22
This Example describes the discovery of novel lectin pathway mediated and MASP-2 dépendent C4-bypass activation of complément C3.
Rationale:
The principal therapeutic benefit of utilizing inhibitors of complément activation to limit myocardial ischemia/reperfusion injury (MIRI) was convincingly demonstrated in an experimental rat model of myocardial infarction two décades ago: Recombinant sCRl, a soluble truncated dérivative of the cell surface complément receptor type-1 30 (CRI), was given intravenously and its effect assessed in a rat in vivo model of MIRI. Treatment with sCRl reduced infarct volume by more than 40% (Weisman, H.F., et al.,
185
Science 249:146-151 (1990)). The therapeutic potential of this recombinant inhibitor was subsequently demonstrated in a clinical trial showing that the administration of sCRl in patients with MI preveuted contractile failure in the post-ischemic heart (Shandelya, S., et al., Circulation 87:536-546 (1993)). The primary mechanism leading to the activation of 5 complément in ischémie tissue, however, has not been ultimately defined, mainly due to the lack of appropriate experimental models, the limited understanding of the molecular processes that lead to complément activation of oxygen-deprived cells, and the cross-talk and synergisms between the different complément activation pathways.
As a fondamental component of the immune response, the complément System 10 provides protection against invading microorganisms through both antibody-dependent and -independent mechanisms. It orchestrâtes many cellular and humoral interactions within the immune response, including chemotaxis, phagocytosis, cell adhesion, and Bcell différentiation. Three different pathways initiate the complément cascade: the classical pathway, the alternative pathway, and the lectin pathway. The classical pathway 15 récognition subcomponent Clq binds to a variety of targets - most prominently immune complexes - to initiate the step-wise activation of associated serine proteases, Clr and Cls, providing a major mechanism for pathogen and immune complex clearance following engagement by the adaptive immune System. Binding of Clq to immune complexes couverts the Clr zymogen dimer into its active form to cleave and thereby 20 activate Cls. Cls translates Clq binding into complément activation in two cleavage steps: It first converts C4 into C4a and C4b and then cleaves C4b-bound C2 to form the C3 convertase C4b2a. This complex converts the abundant plasma component C3 into C3a and C3b. Accumulation of C3b in close proximity of the C4b2a complex shifts the substrate specificity for C3 to C5 to form the C5 convertase C4b2a(C3b)n. The C3 and 25 C5 convertase complexes generated via classical pathway activation are identical to those generated through the lectin pathway activation route. In the alternative pathway, spontaneous low-level hydrolysis of component C3 results in déposition of protein fragments onto cell surfaces, triggering complément activation on foreign cells, while cell-associated regulatory proteins on host tissues avert activation, thus preventing self30 damage. Like the alternative pathway, the lectin pathway may be activated in the absence of immune complexes. Activation is initiated by the binding of a multi-molecular lectin pathway activation complex to Pathogen-Associated Molecular Patterns (PAMPs),
186 mainly carbohydrate structures présent on bacterial, fungal or viral pathogens or aberrant glycosylation patterns on apoptotic, necrotic, malignant or oxygen-deprived cells (Collard, C.D., et al., Am. J. Pathol. 756:1549-1556 (2000); Walport, M.J., N. Engl. J. Med. 344:1058-1066 (2001); Schwaeble, W., et al., Immunobiology 205:455-466 (2002);
and Fujita, T., Nat. Rev. Immunol. 2:346-353 (2002)).
Mannan-binding lectin (MBL) was the first carbohydrate récognition subcomponent shown to form complexes with a group of novel serine proteases, named MBL-associated Serine Proteases (MASPs) and numbered according to the sequence of their discovery (i.e., MASP-1, MASP-2 and MASP-3). In man, lectin pathway activation 10 complexes can be formed with four alternative carbohydrate récognition subcomponents with different carbohydrate binding specificities, i.e., MBL 2, and three different members of the ficolin family, namely L-Ficolin, H-ficolin and M-ficolin and MASPs. Two forms of MBL, MBL A and MBL C, and ficolin-A form lectin activation pathway complexes with MASPs in mouse and rat plasma. We hâve previously cloned and 15 characterised MASP-2 and an additional truncated MASP-2 gene product of 19 kDa, termed MApl9 or sMAP, in human, mouse and rat (Thiel, S., et al., Nature 386:506-510 (1997);. Stover, C.M., et al., J. Immunol. 762:3481-3490 (1999); Takahashi, M., et al., Int. Immunol. 77:859-863 (1999); and Stover, C.M., et al., J. Immunol. 763:6848-6859 (1999)). MApl9/ sMAP is devoid of protease activity, but may regulate lectin pathway 20 activation by competing for the binding of MASPs to carbohydrate récognition complexes (Iwaki, D. et al., J. Immunol. 777:8626-8632 (2006)).
There is evidence suggesting that of the three MASPs, only MASP-2 is required to translate binding of the lectin pathway récognition complexes into complément activation (Thiel, S., et al. (1997); Vorup-Jensen, T., et al., J. Immunol. 765:2093-2100 25 (2000); Thiel, S., et al., J. Immunol. Ι65:%Τ&-$&Ί (2000); Rossi, V., et al., J. Biol. Chem.
276:40880-40887 (2001)). This conclusion is underlined by the phenotype of a most recently described mouse strain déficient in MASP-1 and MASP-3. Apart from a delay in the onset of lectin pathway mediated complément activation in vitro -MASP-1/3 déficient mice retain lectin pathway functional activity. Reconstitution of MASP-1 and 30 MASP-3 déficient sérum with recombinant MASP-1 overcomes this delay in lectin pathway activation implying that MASP-1 may facilitate MASP-2 activation (Takahashi, M., et al., J. Immunol. 780:6132-6138 (2008)). A most recent study has shown that
187
MASP-1 (and probably also MASP-3) are required to couvert the alternative pathway activation enzyme Factor D from its zymogen form into its enzymatically active form (Takahashi, M., et al., J. Exp. Med. 207:29-31 (2010)). The physiological importance of this process is underlined by the absence of alternative pathway functional activity in 5 plasma of MASP-1/3 déficient mice.
The recently generated mouse strains with combined targeted deficiencies of the lectin pathway carbohydrate récognition subcomponents MBL A and MBL C may still initiate lectin pathway activation via the remaining murine lectin pathway récognition subcomponent ficolin A (Takahashi, K., et al., Microbes Infect. 4:113-184 (2002)). The 10 absence of any residual lectin pathway functional activity in MASP-2 déficient mice delivers a conclusive model to study the rôle of this effector arm of irmate humoral immunîty in health and disease.
The availability of C4 and MASP-2 déficient mouse strains allowed us to define a novel lectin pathway spécifie, but MASP-2 dépendent, C4-bypass activation route of 15 complément C3. The essential contribution of this novel lectin pathway mediated C4bypass activation route towards post-ischemic tissue loss is underlined by the prominent protective phenotype of MASP-2 deficiency in MIRI while C4-deficient mice tested in the same model show no protection.
In this Example, we describe a novel lectin pathway mediated and MASP-2 20 dépendent C4-bypass activation of complément C3. The physiological relevance of this new activation route is established by the protective phenotype of MASP-2 deficiency in an experimental model of myocardial ischemia/reperfusion injury (MIRI), where C4 déficient animais were not protected.
Methods:
MASP-2 déficient mice show no gross abnormalities. MASP-2 déficient mice were generated as described in Example 1. Both heterozygous (+/‘) and homozygous (’Λ) MASP-2 déficient mice are healthy and fertile, and show no gross abnormalities. Their life expectancy is similar to that of their WT littermates (>18 months). Prior to studying the phenotype of these mice in experimental models of disease, our MASP-27· line was 30 backcrossed for eleven générations onto a C57BL/6 background. The total absence of MASP-2 mRNA was confirmed by Northern blotting of poly A+ selected liver RNA
188 préparations, while the 1.2kb mRNA encoding MApl9 or sMAP (a truncated alternative splicing product of the MASP2 gene) is abundantly expressed.
qRT-PCR analysis using primer pairs spécifie for either the coding sequence for the serine protease domain of MASP-2 (B chain) or the remainder of the coding sequence for the A-chain showed that no B chain encoding mRNA is détectable in MASP-2 ~l~ mice while the abundance of the disrupted A chain mRNA transcript was significantly increased. Likewise, the abundance of MApl9/sMAP encoding mRNA is increased in MASP-2 +/_ and MASP-2 'Λ mice. Plasma MASP-2 levels, determined by ELISA for 5 animais of each génotype, were 300ng/ml for WT Controls (range 260-330ng/ml),
360ng/ml for heterozygous mice (range 330-395ng/ml) and undetectable inMASP-2 mice. Using qRT-PCR, mRNA expression profiles were established demonstrating that MASP-2'/'mice express mRNA for MBL A, MBL C, ficolin A, MASP-1, MASP-3, Clq, ClrA, ClsA, Factor B, Factor D, C4, and C3 at an abundance similar to that of their MASP-2 sufficient littermates (data not shown).
Plasma C3 levels of MASP-2_/· (n=8) and MASP-2+/+ (n=7) littermates were measured using a commercially available mouse C3 ELISA kit (Kamiya, Biomédical, Seattle, WA). C3 levels of MASP-2 déficient mice (average 0.84 mg/ml, +/- 0.34) were similar to those of the WT Controls (average 0.92, +/- 0.37).
Results:
MASP-2 is essentiai for lectin pathway functional activity.
As described in Example 2 and shown in FIGURE 5, the in vitro analyses of MASP-2'Aplasma showed a total absence of lectin pathway functional activity on activating Mannan- and Zymosan-coated surfaces for the activation of C4. Likewise, neither lectin pathway-dependent C4 nor C3 cleavage was détectable in MASP-2’Aplasma 25 on surfaces coated with N-acetyl glucosamine, which binds and triggers activation via MBL A, MBL C and ficolin A (data not shown).
The analyses of sera and plasma of MASP-2-/-mice clearly demonstrated that MASP-2 is essentially required to activate complément via the lectin pathway. The total deficiency of lectin pathway functional activity, however, leaves the other complément 30 activation pathways intact: MASP-2-/-plasma can still activate complément via the classical (FIGURE 26A) and the alternative pathway (FIGURE 26B). In FIGURE 26A and 26B, the symbol symbol indicates sérum from WT (MASP-2 (+/+)); the
189 symbol · indicates sérum from WT (Clq depleted); the symbol indicates sérum from MASP-2 (-/-); and the symbol Δ indicates sérum from MASP-2 (-/-) (Clq depleted).
FIGURE 26A graphically illustrâtes that MASP-2-/- mice retain a functional classical pathway: C3b déposition was assayed on microtiter plates coated with i mm une complexes (generated in situ by coating with BSA then adding goat anti-BSA IgG). FIGURE 26B graphically illustrâtes MASP-2 déficient mice retain a functional alternative pathway: C3b déposition was assayed on Zymosan coated microtiter plates under conditions that permit only alternative pathway activation (buffer containing Mg2+ 10 and EGTA). Results shown in FIGURE 26A and FIGURE 26B are means of duplicates and are typical of three independent experiments. Same symbols for plasma sources were used throughout. These results show that a functional alternative pathway is présent in MASP-2 déficient mice, as evidenced in the results shown in FIGURE 26B under experimental conditions designed to directly trigger the alternative pathway, while 15 inactivating both the classical pathway and lectin pathway.
The lectin pathway of complément activation critically contributes to inflammatory tissue loss in myocardial ischemia/reperfusion injury (MIRI).
In order to study the contribution of lectin pathway functional activity to MIRI, we compared MASP-2“/'mice and WT littermate Controls in a model of MIRI following 20 transient lîgation and reperfusion of the left anterior descending branch of the coronary artery (LAD). The presence or absence of complément C4 has no impact on the degree of ischémie tissue loss in MIRI. We assessed the impact of C4 deficiency on infarct sizes following experimental MIRI. As shown in FIGURE 27A and FIGURE 27B, identical infarct sizes were observed in both C4-deficient mice and their WT littermates. FIGURE 25 27A graphically illustrâtes MIRI-induced tissue loss following LAD ligation and reperfusion in C4-/- mice (n=6) and matching WT littermate Controls (n=7). FIGURE 27B graphically illustrâtes INF as a function of AAR, clearly demonstrating that C4-/mice are as susceptible to MIRI as their WT Controls (dashed line).
These results demonstrate that C4 déficient mice are not protected from MIRI. 30 This resuit was unexpected, as it is in conflict with the widely accepted view that the major C4 activation fragment, C4b, is an essential component of the classical and the lectin pathway C3 convertase C4b2a. We therefore assessed whether a residual lectin
190 pathway spécifie activation of complément C3 can be detected in C4-déficient mouse and human plasma.
The lectin pathway can activate complément C3 in absence of C4 via a novel MASP-2 dépendent C4-bypass activation route.
Encouraged by historical reports indicating the existence of a C4-bypass activation route in C4-deficient guinea pig sérum (May, J.E., and M. Frank, J. Immunol. 777:1671-1677 (1973)), we analyzed whether C4-deficient mice may hâve residual classical or lectin pathway functional activity and monitored activation of C3 under pathway-spécifie assay conditions that exclude contributions of the alternative pathway.
C3b déposition was assayed on Mannan-coated microtiter plates using re-calcified plasma at plasma concentrations prohibitive for alternative pathway activation (1.25% and below). While no cleavage of C3 was détectable in C4-deficient plasma tested for classical pathway activation (data not shown), a strong residual C3 cleavage activity was observed in C4-deficient mouse plasma when initiating complément activation via the lectin pathway. The lectin pathway dependence is demonstrated by compétitive inhibition of C3 cleavage following preincubation of C4-deficient plasma dilutions with soluble Mannan (see FIGURE 28A). As shown in FIGURE 28A-D, MASP-2 dépendent activation of C3 was observed in the absence of C4. FIGURE 28A graphically illustrâtes C3b déposition by C4+/+ (crosses) and C4-/- (open circles) mouse plasma. Pre20 incubating the C4-/- plasma with excess (1 pg/ml) fluid-phase Mannan prior to the assay completely inhibits C3 déposition (filled circles). Results are typical of 3 independent experiments. FIGURE 28B graphically illustrâtes the results of an experiment in which wild-type, MASP-2 déficient (open squares) and C4-/-mouse plasma (1%) was mixed with various concentrations of anti-rat MASP-2 mAbMll (abscissa) and C3b déposition assayed on Mannan-coated plates. Results are means (± SD) of 4 assays (duplicates of 2 of each type of plasma). FIGURE 28C graphically illustrâtes the results of an experiment in which Human plasma: pooled NHS (crosses), C4-/- plasma (open circles) and C4-/plasma pre-incubated with 1 pg/ml Mannan (filled circles). Results are représentative of three independent experiments. FIGURE 28D graphically illustrâtes that inhibition of
C3b déposition in C4 sufficient and C4 déficient human plasma (1%) by anti-human MASP-2 mAbH3 (Means ± SD of triplicates). As shown in FIGURE 28B, no lectin
191 pathway-dependent C3 activation was detected in MASP-2-/-plasma assayed in parallel, ùnplying that this C4-bypass activation route of C3 is MASP-2 dépendent.
To further corroborate these findings, we established a sériés of reconibinant inhibitory mAbs isolated from phage display antibody libraries by affinity screening 5 against recombinant human and rat MASP-2A (where the serine residue of the active protease domain was replaced by an alanine residue by site-directed mutagenesis to prevent autolytic dégradation of the antigen). Recombinant antibodies against MASP-2 (AbH3 and AbMll) were isolated from Combinatorial Antibody Libraries (Knappik, A., et al., J. Mol. Biol. 296:57-86 (2000)), using recombinant human and rat MASP-2A as 10 antigens (Chen, C.B. and Wallis, J. Biol. Chem. 276:25894-25902 (2001)). An anti-rat Fab2 fragment that potently inhibited lectin pathway-mediated activation of C4 and C3 in mouse plasma (IC50-1 nM) was converted to a full-length IgG2a antibody. Polyclonal anti-murine MASP-2A antiserum was raised in rats. These tools allowed us to confirm MASP-2 dependency of this novel lectin pathway spécifie C4-bypass activation route of 15 C3, as further described below.
As shown in FIGURE 28B, M211, an inhibitory monoclonal antibody which selectively binds to mouse and rat MASP-2 inhibited the C4-bypass activation of C3 in C4-deficient mouse as well as C3 activation of WT mouse plasma via the lectin pathway in a concentration dépendent fashion with similar IC50 values. Ail assays were carried 20 out at high plasma dilutions rendering the alternative pathway activation route dysfunctional (with the highest plasma concentration being 1.25%).
In order to investigate the presence of an analogous lectin pathway spécifie C4bypass activation of C3 in humans, we analyzed the plasma of a donor with an inherited deficiency of both human C4 genes (Le., C4A and C4B), resulting in total absence of C4 25 (Yang, Y., et al., J. Immunol. 773:2803-2814 (2004)). FIGURE 28C shows that this patient's plasma efficiently activâtes C3 in high plasma dilutions (rendering the alternative activation pathway dysfunctional). The lectin pathway spécifie mode of C3 activation on Mannan-coated plates is demonstrated in murine C4-deficient plasma (FIGURE 28A) and human C4 déficient plasma (FIGURE 28C) by adding excess 30 concentrations of fluid-phase Mannan. The MASP-2 dependence of this activation mechanism of C3 in human C4-deficient plasma was assessed using AbH3, a monoclonal antibody that specifically binds to human MASP-2 and ablates MASP-2 functional
192 activity. As shown in FIGURE 28D, AbH3 inhibited the déposition of C3b (and C3dg) in both C4-sufficient and C4-deficient human plasma with comparable potency.
In order to assess a possible rôle of other complément components in the C4bypass activation of C3, we tested plasma of MASP-l/3-/-and Bf/C2-/-mice alongside 5 MASP-2-/-, C4-Z- and Clq-/- plasma (as Controls) under both lectin pathway spécifie and classical pathway spécifie assay conditions. The relative amount of C3 cleavage was plotted against the amount of C3 deposited when using WT plasma.
FIGURE 29A graphically illustrâtes a comparative analysis of C3 convertase activity in plasma from varions complément déficient mouse strains tested either under 10 lectin activation pathway or classical activation pathway spécifie assay conditions. Diluted plasma samples (1%) of WT mice (n=6), MASP-2-/-mice (n=4), MASP-1/3-/mice (n=2), C4-/- mice (n=8), C4/MASP-1/3-/- mice (n=8), Bf/C2-/- (n=2) and Clq-/mice (n=2) were tested in parallel. Reconstitution of Bf/C2-/- plasma with 2.5pg/ml recombinant rat C2 (Bf/C2-/- +C2) restored C3b déposition. Results are means (±SD).
**p<0.01 (compared to WT plasma). As shown in FIGURE 29A, substantial C3 déposition is seen in C4-/- plasma tested under lectin pathway spécifie assay conditions, but not under classical pathway spécifie conditions. Again, no C3 déposition was seen in MASP-2 déficient plasma via the lectin pathway activation route, while the same plasma deposited C3 via the classical pathway. hi MASP-1/3-/- plasma, C3 déposition occurred in both lectin and classical pathway spécifie assay conditions. No C3 déposition was seen in plasma with a combined deficiency of C4 and MASP-1/3, either using lectin pathway or classical pathway spécifie conditions. No C3 déposition is détectable in C2/Bf-/- plasma, either via the lectin pathway, or via the classical pathway. Reconstitution of C2/Bf-/- mouse plasma with recombinant C2, however, restored both lectin pathway and classical pathway-mediated C3 cleavage. The assay conditions were validated using Clq-/- plasma.
FIGURE 29B graphically illustrâtes time-resolved kinetics of C3 convertase activity in plasma from varions complément déficient mouse strains WT, fB-/-, C4-/-, MASP-1/3-/-, and MASP-2-/-plasma, tested under lectin activation pathway spécifie 30 assay conditions (1% plasma, results are typical of three independent experiments). As shown in FIGURE 29B, while no C3 cleavage was seen in MASP-2-/-plasma, fB-/plasma cleaved C3 with similar kinetics to the WT plasma. A significant delay in the
193 lectin pathway-dependent conversion of C3 to C3b (and C3dg) was seen in C4-/-as well as in MASP-1/3 déficient plasma. This delay of C3 activation in MASP-1/3-/- plasma was recently shown to be MASP-1, rather than MASP-3 dépendent (Takahashi, M., et al., J. Immunol. 780:6132-6138 (2008)).
Discussion:
The results described in this Ex ample strongly suggest that MASP-2 functional activity is essential for the activation of C3 via the lectin pathway both in presence and absence of C4. Furthermore, C2 and MASP-1 are required for this novel lectin pathway spécifie C4-bypass activation route of C3 to work. The comparative analysis of lectin 10 pathway functional activity in MASP-2-/-as well as C4-/- plasma revealed the existence of a previously unrecognized C4-mdependent, but MASP-2-dependent activation route of complément C3 and showed that C3 can be activated in a lectin pathway-dependent mode in total absence of C4. While the detailed molecular composition and the sequence of activation events of this novel MASP-2 dépendent C3 convertase remains to be 15 elucidated, our results imply that this C4-bypass activation route additionally requires the presence of complément C2 as well as MASP-1. The loss of lectin pathway-mediated C3 cleavage activity in plasma of mice with combined C4 and MASP-1/3 deficiency may be explained by a most recently described rôle of MASP-1 to enhance MASP-2 dépendent complément activation through direct cleavage and activation of MASP-2 (Takahashi, 20 M., et al., J. Immunol. 780:6132-6138 (2008)). Likewise, MASP-1 may aid MASP-2 functional activity through its ability to cleave C2 (Moller-Kristensen, et al., Int. Immunol. 79:141-149 (2007)). Both activities may explain the reduced rate by which MASP-1/3 déficient plasma cleaves C3 via the lectin activation pathway and why MASP1 may be required to sustain C3 conversion via the C4-bypass activation route.
The inability of C2/fB-/- plasma to activate C3 via the lectin pathway was shown to be C2-dependent as the addition of recombinant rat C2 to C2/fB-/- plasma restored the ability of the reconstituted plasma to activate C3 on Mannan-coated plates.
The finding that C4 deficiency specifically disrupts the classical complément activation pathway while the lectin pathway retains a physiologically critical level of C3 30 convertase activity via a MASP-2 dépendent C4-bypass activation route calls for a reassessment of the rôle of the lectin pathway in various disease models, including experimental 8. pneumoniae infection (Brown, J. S., et al., Proc. Natl. Acad. Sci. U. S. A.
194
99:16969-16974 (2002); Experimental Allergie Encephalomyelitis (Boos, L.A., et al., Glia 49:158-160 (2005); and models of C3 dépendent murine liver régénération (Clark, A., et al., Mol. Immunol. 45:3125-3132 (2008)). The latter group demonstrated that C4deficient mice can activate C3 in an alternative pathway independent fashion as in vivo 5 inhibition of the alternative pathway by an antibody-mediated déplétion of factor B functional activity did not effect C3 cleavage-dependent liver régénération in C4-/- mice (Clark, A., et al. (2008)). This lectin pathway mediated C4-bypass activation route of C3 may also explain the lack of a protective phenotype of C4 deficiency in our model of MIRI as well as in a previously described model of rénal allograft rejection (Lin, T., et 10 al., Am. J. Pathol. 768:1241-1248 (2006)). In contrast, our recent results hâve independently demonstrated a signifïcant protective phenotype of MASP-2-/-mice in models of rénal transplantation (Farrar, C.A., et al., Mol. Immunol. 46:2832 (2009)).
In summary, the results of this Example support the view that MASP-2 dépendent C4-bypass activation of C3 is a physiologically relevant mechanism that may be 15 important under conditions where availability of C4 is limiting C3 activation.
EXAMPLE 23
This Example describes activation of C3 b y thrombin substrates and C3 déposition on mannan in WT (+/+), MASP-2 (-/-), Fil (-/-), F11/C4 (-/-) and C4 (-/-) 20 mice.
Rationale:
As described in Example 14, it was determined that thrombin activation can occur following lectin pathway activation under physiological conditions, and demonstrates the extent of MASP-2 involvement. C3 plays a central rôle in the activation 25 of complément System. C3 activation is required for both classical and alternative complément activation pathways. An experiment was carried ont to détermine whether C3 is activated by thrombin substrates.
Methods:
C3 Activation by thrombin substrates
Activation of C3 was measured in the presence of the following activated forms of thrombin substrates; human FCXIa, human FVIIa, bovine FXa, human FXa, human activated protein C, and human thrombin. C3 was incubated with the varions thrombin
195 substrates, dieu separated under reducing conditions on 10% SDS-polyacrylamide gels. After electrophoretic transfer using cellulose membrane, the membrane was incubated with monoclonal biotin-coupled rat anti-mouse C3, detected with a streptavidin-HRP kit and developed using ECL reagent.
Results:
Activation of C3 involves cleavage of the intact a-chain into the truncated a' chain and soluble C3a (not shown in FIGURE 30). FIGURE 30 shows the results of a Western blot analysis on the activation of human C3 by thrombin substrates, wherein the uncleaved C3 alpha chain, and the activation product a' chain are shown by arrows. As 10 shown in FIGURE 30, incubation of C3 with the activated forms of human clotting factor XI and factor X, as well as activated bovine clotting factor X, can cleave C3 in vitro in the absence of any complément proteases.
C3 déposition on mannan
C3 déposition assays were carried out on sérum samples obtained from WT, 15 MASP-2 (-/-), Fl 1(-/-), Fl 1(-/-)/04(-/-) and C4(-/-). Fil is the gene encoding coagulation factor XL To measure C3 activation, microtiter plates were coated with mannan (1 pg/well), then adding sheep anti-HSA sérum (2 pg/ml) in TBS/tween/Ca2+. Plates were blocked with 0.1% HSA in TBS and washed as above. Plasma samples were diluted in 4 mM barbital, 145 mM NaCl, 2 mM CaCh, 1 mM MgCh, pH 7.4, added to the 20 plates and incubated for 1.5 h at 37°C. After washing, bound C3b was detected using rabbit anti-human C3c (Dako), followed by alkaline phosphatase-conjugated goat antirabbit IgG and pNPP.
Results:
FIGURE 31 shows the results of the C3 déposition assay on sérum samples 25 obtained from WT, MASP-2 (-/-), Fll(-/-), Fl 1(-/-)/04 (-/-) and 04 (-/-). As shown in FIGURE 31, there is a functional lectin pathway even in the complété absence of 04. As further shown in FIGURE 31, this novel lectin pathway dépendent complément activation requires coagulation factor XL
Discussion:
Prior to the results obtained in this experiment, it was believed by those in the art that the lectin pathway of complément required C4 for activity. Hence, data from C4 knockout mice (and C4 déficient humans) were interpreted with the assumption that such
196 organisais were lectin pathway déficient (in addition to classical pathway deficiency). The présent results demonstrate that this notion is false. Thus, conclusions of past studies suggesting that die lectin pathway was not important in certain disease settings based on the phenotype of C4 déficient animais may be false. The data described in this Example also show that in the physiological context of whole sérum the lectin pathway can activate components of the coagulation cascade. Thus, it is demonstrated tirât there is cross-talk between complément and coagulation involving MASP-2.
EXAMPLE 24
This Example describes methods to assess the effect of an anti-MASP-2 antibody on lysis of red blood cells from blood samples obtained from Paroxysmal nocturnal hemoglobinuria (PNH) patients. .
Background/Rationale :
Paroxysmal nocturnal hemoglobinuria (PNH), also referred to as MarchiafavaMicheli syndrome, is an acquired, potentially life-threatening disease of the blood, characterized by complement-induced intravascular hemolytic anémia. The hallmark of PNH is chronic intravascular hemolysis that is a conséquence of unregulated activation of the alternative pathway of complément. Lindorfer, M.A., et al., Blood 775(11) (2010). Anémia in PNH is due to destruction of red blood cells in the bloodstream. Symptoms of PNH include red urine, due to appearance of hemoglobin in the urine, and thrombosis. PNH may develop on its own, referred to as primary PNH or in the context of other bone marrow disorders such as aplastic anémia, referred to as secondary PNH. Treatment for PNH includes blood transfusion for anémia, anticoagulation for thrombosis and the use of the monoclonal antibody eculizumab (Soliris), which protects blood cells against immune destruction by inhibiting the complément System (Hillmen P. et al., N Engl. J. Med. 556(6):552-9 (2004)). However, a significant portion of PNH patients treated with eculizumab are left with clinically significant immune-mediated hemolytic anémia because the antibody does not block activation of the alternative pathway of complément.
197
This Example describes methods to assess the effect of an anti-MASP-2 antibody on lysis of red blood cells from blood samples obtained from PNH patients (not treated with Soliris) that are incubated with ABO-matched acidified normal human sérum.
Methods:
Reagents:
Erythrocytes from normal donors and from patients suffering from PNH (not treated with Soliris) are obtained by venipuncture, and prepared as described in Wilcox, L.A., et aL, Blood 75:820-829 (1991), hereby incorporated herein by 10 reference. Anti-MASP-2 antibodies -with functional blocking activity of the lectin pathway may be generated as described in Example 10.
Hemolysis Analysis:
The method for determining the effect of anti-MASP-2 antibodies on the ability to block hemolysis of érythrocytes from PNH patients is carried out using the 15 methods described in Lindorfer, M.A., et al., Blood 75(11):2283-91 (2010) and Wilcox, L.A., et al., Blood 75:820-829 (1991), both référencés hereby incorporated herein by reference. As described in Lindorfer et al., érythrocytes from PNH patient samples are centrifuged, the buffy coat is aspirated and the cells are washed in gelatin veronal buffer (GVB) before each experiment. The érythrocytes are tested for susceptibility to 20 APC-mediated lysis as follows. ABO-matched normal human sera are diluted with GVB containing 0.15 mM CaC12 and 0.5 mM MgC12 (GVB+2) and acidified to pH 6.4 (acidified NHS, aNHS) and used to reconstitute the érythrocytes to a hematocrit of 1.6% in 50% aNHS. The mixtures are then incubated at 37BC, and after 1 hour, the érythrocytes are pelleted by centrifugation. The optical density of an aliquot of the 25 recovered supernate is measured at 405 nM and used to calculate the percent lysis. Samples reconstituted in acidified serum-EDTA are processed similarly and used to define background noncomplement-mediated lysis (typically less than 3%). Complété lysis (100%) is determined after incubating the érythrocytes in distilled water.
198
In order to détermine the effect of anti-MASP-2 antibodies on hemolysis of PNH érythrocytes, érythrocytes from PNH patients are incubated in aNHS in the presence of incrémental concentrations of the anti-MASP-2 antibodies, and the presence/amount of hemolysis is subsequently quantified.
In view of the fact that anti-MASP-2 antibodies bave been shown to block subséquent activation of the alternative complément pathway, it is expected that antiMASP-2 antibodies will be effective in blocking alternative pathway-mediated hemolysis of PNH érythrocytes, and will be useful as a therapeutic to treat patients suffering from PNH.
EXAMPLE 25
This Example describes methods to assess the effect of an anti-MASP-2 blocking antibody on complément activation by cryoglobulins in blood samples obtained from patients suffering from cryoglobulinemia.
Background/Rationale:
Cryoglobulinemia is characterized by the presence of cryoglobulins in the sérum. Cryoglobulins are single or mixed immunoglobulins (typically IgM antibodies) that undergo réversible aggregation at low températures. Aggregation leads to classical pathway complément activation and inflammation in vascular beds, particularly in the 20 periphery. Clinical présentations of cryoglobulinemia include vasculitis and glomerulonephritis.
Cryoglobulinemia may be classified as follows based on cryoglobulin composition: Type I cryoglobulinemia, or simple cryoglobulinemia, is the resuit of a monoclonal immunoglobulin, usually immunoglobulin M (IgM); Types II and III 25 cryoglobulinemia (mixed cryoglobulinemia) contain rheumatoid factors (RFs), which aie usually IgM in complexes with the Fc portion of polyclonal IgG.
Conditions associated with cryoglobulinemia include hepatitis C infection, lymphoproliférative disorders and other autoimmune diseases. Cryoglobulin-containing immune complexes resuit in a clinical syndrome of systemic inflammation, possibly due 30 to their abiiity to activate complément. While IgG immune complexes normally activate
199 the classical pathway of complément, IgM containing complexes can also activate complément via the lectin pathway (Zhang, M., et al., Mol Immunol 44(1-3):103-110 (2007) and Zhang. M„ et al., J. Immunol. 777(7):4727-34 (2006)).
Immunohistochemical studies hâve further demonstrated the cryoglobulin 5 immune complexes contain components of the lectin pathway, and biopsies from patients with cryoglobulinémie glomerulonephritis showed immunohistochemical evidence of lectin pathway activation in situ (Ohsawa, I., et al., Clin Immunol 707(1):59-66 (2001)). These results suggest that the lectin pathway may contribute to inflammation and adverse outcomes in cryoglobulemic diseases.
Methods:
The method for determining the effect of anti-MASP-2 antibodies on the ability to block the adverse effects of Cryoglobulinemia is carried out using the assay for fluid phase C3 conversion as described in Ng Y.C. et al., Arthritis andRheumatism 57(1):99-107 (1988), hereby incorporated herein by reference. As described in Ng et 15 al., in essential mixed cryoglobulinemia (EMC), monoclonal rheumatoid factor (mRF), usually IgM, complexes with polyclonal IgG to form the characteristic cryoprecipitate immune complexes (IC) (type II cryoglobulin). Immunoglobulins and C3 hâve been demonstrated in vessel walls in affected tissues such as skin, nerve and kidney. As described in Ng et al., 125I-labeled mRF is added to sérum (normal human sérum and 20 sérum obtained from patients suffering from cryoglobulinemia), incubated at 379C, and binding to érythrocytes is measured.
Fluid phase C3 conversion is determined in sérum (normal human sérum and sérum obtained from patients suffering from cryoglobulinemia) in the presence or absence of the following IC: BSA-anti BSA, mRF, mRF plus IgG, or cryoglobulins, in 25 the presence or absence of anti-MASP-2 antibodies. The fixation of C3 and C4 to IC is measured using a coprécipitation assay with F(ab')2 anti-C3 and F(ab')2 anti-C4.
In view of the fact that anti-MASP-2 antibodies hâve been shown to block activation of the lectin pathway it is expected that anti-MASP-2 antibodies will be effective in blocking complément mediated adverse effects associated with
200 cryoglobulinemia, and will be useful as a therapeutic to treat patients suffering from cryoglobulinemia.
EXAMPLE 26
This Example describes methods to assess the effect of an anti-MASP-2 antibody on blood samples obtained from patients with Cold Agglutinin Disease, which manifests as anémia.
Background/Rationale:
Cold Agglutinin Disease (CAD), is a type of autoimmune hemolytic anémia. Cold agglutinins antibodies (usually IgM) are activated by cold températures and bind to and aggregate red blood cells. The cold agglutinin antibodies combine with complément and attack the antigen on the surface of red blood cells. This leads to opsoniation of red blood cells (hemolysis) which triggers their clearance by the réticuloendothélial System. The température at which the agglutination takes place varies from patient to patient.
CAD manifests as anémia. When the rate of destruction of red blood cell destruction exceeds the capacity of the boue marrow to produce an adéquate number of oxygen-carrying cells, then anémia occurs. CAD can be caused by an underlying disease or disorder, referred to as Secondary CAD, such as an infections disease (mycoplasma pneumonia, mumps, mononucleosis), lymphoproliférative disease (lymphoma, chronic lymphocytic leukemia), or connective tissue disorder. Primary CAD patients are considered to hâve a low grade lymphoproliférative bone marrow disorder. Both primary and secondary CAD are acquired conditions.
Methods:
Reagents:
Erythrocytes from normal donors and from patients suffering from CAD are obtained by venipuncture. Anti-MASP-2 antibodies with functional blocking activity of the lectin pathway may be generated as described in Example 10.
The effect of anti-MASP-2 antibodies to block cold aggultinin-niediated activation of the lectin pathway may be determined as follows. Erythrocytes from blood group I positive patients are sensitized with cold aggultinins (i.e., IgM antibodies), in the presence or absence of anti-MASP-2 antibodies. The érythrocytes are then tested for the
201 ability to activate the lectin pathway by measuring C3 binding.
In view of the fact that anti-MASP-2 antibodies hâve been shown to block activation of the lectin pathway, it is expected that anti-MASP-2 antibodies will be effective in blocking complément mediated adverse effects associated with Cold 5 Agglutinin Disease, and will be useful as a therapeutic to treat patients suffering from Cold Agglutinin Disease.
EXAMPLE 27
This Example describes methods to assess the effect of an anti-MASP-2 antibody 10 on lysis of red blood cells in blood samples obtained from mice with atypical hemolytic urémie syndrome (aHUS).
Background/Rationale:
Atypical hemolytic urémie syndrome (aHUS) is characterized by hemolytic anémia, thrombocytopenia, and rénal failure caused by platelet thrombi in the 15 microcirculation of the kidney and other organs. aHUS is associated with defective complément régulation and can be either sporadic or familial. aHUS is associated with mutations in genes coding for complément activation, including complément factor H, membrane cofactor B and factor I, and well as complément factor H-related 1 (CFHR1) and complément factor H-related 3 (CFHR3). Zipfel, P.F., et al., PloS Genetics 5(3):e41 20 (2007). This Example describes methods to assess the effect of an anti-MASP-2 antibody on lysis of red blood cells from blood samples obtained from aHUS mice.
Methods:
The effect of anti-MASP-2 antibodies to treat aHUS may be determined in a mouse model of this disease in which the endogenouse mouse fH gene has been replaced 25 with a human homologue encoding a mutant form of fH frequently found in aHUS patients. See Pickering M.C. et al., J. Exp. Med. 204(6):1249-1256 (2007), hereby incorporated herein by reference. As described in Pickering et al., such mice develop an aHUS like pathology. In order to assess the effect of an anti-MASP-2 antibody for the treatment of aHUS, anti-MASP-2 antibodies are administered to the mutant aHUS mice 30 and lysis of red blood cells obtained from anti-MASP-2 ab treated and untreated Controls is compared. In view of the fact that anti-MASP-2 antibodies hâve been shown to block
202 activation of the lectin pathway it is expected that anti-MASP-2 antibodies will be effective in blocking lysis of red blood cells in manunalian subjects suffering from aHUS.
EX AMPLE 28
This Example describes methods to assess the effect of an anti-MASP-2 antibody for the treatment of glaucoma.
Rationale/Background:
It has been shown that uncontrolled complément activation contributes to the progression of dégénérative injury to retinal ganglion cells (RGCs), their synapses and axons in glaucoma. See Tezel G. et al., Invest Ophthalmol Vis Sci 57:5071-5082 (2010). For example, histopathologie studies of human tissues and in vivo studies using different animal models hâve demonstrated that complément components, including Clq and C3, are synthesized and terminal complément complex is formed in the glaucomatous retina (see Stasi K. et al., Invest Ophthalmol Vis Sci 47:1024-1029 (2006), Kuehn M.H. et al.,
Exp Eye Res 55:620-628 (2006)). As further described in Kuehn M.H. et al., Experimental Eye Research 87:^9-95 (2008), complément synthesis and déposition is induced by retinal I/R and the disruption of the complément cascade delays RGC degeneration. In this study, mice carrying a targeted disruption of the complément component C3 were found to exhibit delayed RGC degeneration after transient retinal I/R L when compared to normal animais.
Methods:
The method for determining the effect of anti-MASP-2 antibodies on RGC degeneration is carried ont in an animal model of retinal ER as described in Kuehn M.H. et al., Experimental Eye Research 57:89-95 (2008), hereby incorporated herein by reference. As described in Kuehn et al., retinal ischemia is induced by anesthetizing thei
T animais, then inserting a 30-gauge needle connected to a réservoir containing phosphate[ buffered saline through the comea into the anterior chamber of the eye. The salinej réservoir is then elevated to yield an intraocular pressure of 104 mmHg, sufficient toi completely prevent circulation through the retinal vasculature. Elevated intraocular ischemia is confirmed by blanching of the iris and retina and ischemia is maintained for| minutes in the left eye only; the right eye serves as a control and does not receive
203 cannulation. Mice are then euthanized either 1 or 3 weeks after the ischémie insult. AntiMASP-2 antibodies are administered to the mice either locally to the eye or systemically to assess the effect of an anti-MASP antibody administered prior to ischémie insult.
Immunohistochemistry of the eyes is carried out using antibodies against Clq and C3 to detect complément déposition. Optic nerve damage can also be assessed using standard électron microscopy methods. Quantitation of surviving retinal RGCs is performed using gamma synuclein labelîng.
Results:
As described in Kuehn et al., in normal control mice, transient retinal ischemia results in degenerative changes of the optic nerve and retinal deposits of Clq and C3 détectable by immunohistochemistry. In contrast, C3 déficient mice displayed a marked réduction in axonal degeneration, exhibiting only minor levels of optic nerve damage 1 week after induction. Based on these results, it is expected that similar results would be observed when this assay is carried out in a MASP-2 knockout mouse, and when anti-MASP-2 antibodies are administered to a normal mouse prior to ischémie insult.
EXAMPLE 29
This Example demonstrates that a MASP-2 inhibitor, such as an anti-MASP-2 antibody, is effective for the treatment of radiation exposure and/or for the treatment, amelioration or prévention of acute radiation syndrome.
Rationale:
Exposure to high doses of ionizing radiation causes mortality b y two main mechanisms: toxicity to the bone marrow and gastrointestinal syndrome. Bone marrow toxicity results in a drop in ail hématologie cells, predisposing the organism to death by infection and hemorrhage. The gastro intestinal syndrome is more severe and is driven by a loss of intestinal barrier function due to disintegration of the gut épithélial layer and a loss of intestinal endocrine function. This leads to sepsis and associated systemic inflammatory response syndrome which can resuit in death.
204
The lectin pathway of complément is an innate immune mechanism that initiâtes inflammation in response to tissue injury and exposure to foreign surfaces (i.e., bacteria). Blockade of this pathway leads to better outcomes in mouse models of ischémie intestinal tissue injury or septic shock. It is hypothesized that the lectin pathway may trigger excessive and harmful inflammation in response to radiation-induced tissue injury. Blockade of the lectin pathway may thus reduce secondary injury and increase survival following acute radiation exposure.
The objective of the study carried ont as described in this Example was to assess the effect of lectin pathway blockade on survival in a mouse model of radiation injury by administering anti-murine MASP-2 antibodies.
Methods and Materials:
Materials. The test articles used in this study were (i) a high affinity anti-murine MASP-2 antibody (mAbMll) and (ii) a high affinity anti-human MASP-2 antibody (mAbH6) that block the MASP-2 protein component of the lectin complément pathway which were produced in transfected mammalian cells. Dosing concentrations were 1 mg/kg of anti-murine MASP-2 antibody (mAbMll), 5mg/kg of anti-human MASP-2 antibody (mAbH6), or stérile saline. For each dosing session, an adéquate volume of fresh dosing solutions were prepared.
Animais. Young adult male Swiss-Webster mice were obtained from Harlan Laboratories (Houston, TX). Animais were housed in solid-bottom cages with Alpha-Dri bedding and provîded certified PMI 5002 Rodent Diet (Animal Specialties, Inc., Hubbard OR) and water ad libitum. Température was monitored and the animal holding room operated with a 12 hour light/12 hour dark light cycle.
Irradiation. After a 2-week acclimation in the facility, mice were irradiated at 6.5 and 7.0 Gy by whole-body exposure in groups of 10 at a dose rate of 0.78 Gy/min using a Therapax X-RAD 320 system equipped with a 320-kV high stabilîty X-ray generator, métal ceramic X-ray tube, variable x-ray beam collimator and fil ter (Précision X-ray Incorporated, East Haven, CT). Dose levels were selected based on prior studies conducted with the same strain of mice indicating the LD50/30 was between 6.5 and 7.0 Gy (data not shown).
Drug Formulation and Administration. The appropriate volume of concentrated stock solutions were diluted with ice cold saline to préparé dosing solutions of 0.2 mg/ml
205 anti-murine MASP-2 antibody (mAbMll) or 0.5 mg/ml anti-human MASP-2 antibody (mAbH6) according to protocol. Administration of anti-MASP-2 antibody mAbMl 1 and mAbH6 was via IP injection using a 25-gauge needle base on animal weight to deliver 1 mg/kg mAbMll, 5mg/kg mAbH6, or saline vehicle.
Study Design. Mice were randomly assigned to the groups as described in
Table 8. Body weight and température were measured and recorded daily. Mice in Groups 7, 11 and 13 were sacrificed at post-irradiation day 7 and blood collected by cardiac puncture under deep anesthésia. Surviving animais at post-irradiation day 30 were sacrificed in the same manner and blood collected. Plasma was prepared from 10 collected blood samples according to protocol and returned to Sponsor for analysis.
TABLE 8: Study Groups
Group ID | N | Irradiation Level (Gy) | Treatment | Dose Schedule |
1 | 20 | 6.5 | Vehicle | 18 hr prior to irradiation, 2 hr post irradiation, weekly booster |
2 | 20 | 6.5 | anti-murine MASP-2 ab (mAbMll) | 18 hr prior to irradiation only |
3 | 20 | 6.5 | anti-murine MASP-2 ab (mAbMll) | 18 hr prior to irradiation, 2 hr post irradiation, weekly booster |
4 | 20 | 6.5 | anti-murine MASP-2 ab (mAbMll) | 2 hr post irradiation, weekly booster |
5 | 20 | 6.5 | anti-human MASP-2 ab (mAbH6) | 18 hr prior to irradiation, 2 hr post irradiation, weekly booster |
6 | 20 | 7.0 | Vehicle | 18 hr prior to irradiation, 2 hr post irradiation, weekly booster |
7 | 5 | 7.0 | Vehicle | 2 hr post irradiation only |
8 | 20 | 7.0 | anti-murine MASP-2 ab | 18 hr prior to irradiation only |
206
Group ID | N | Irradiation Level (Gy) | Treatment | Dose Schedule |
(mAbMll) | ||||
9 | 20 | 7.0 | anti-murine MASP-2 ab (mAbMll) | 18 hr prior to irradiation, 2 hr post irradiation, weekly booster |
10 | 20 | 7.0 | anti-murine MASP-2 ab (mAbMll) | 2 hr post irradiation, weekly booster |
11 | 5 | 7.0 | anti-murine MASP-2 ab (mAbMll) | 2 hr post irradiation only |
12 | 20 | 7.0 | anti-human MASP-2 ab (mAbH6) | 18 hr prior to irradiation, 2 hr post irradiation, weekly booster |
13 | 5 | None | None | None |
Statistical Analysis. Kaplan-Meier survival curves were generated and used to compare mean survival time between treatment groups using log-Rank and Wilcoxon methods. Averages with standard déviations, or means with standard error of the mean are reported. Statistical comparisons were made using a two-tailed unpaired t-test between controlled irradiated animais and individual treatment groups.
Results
Kaplan-Meier survival plots for 7.0 and 6.5 Gy exposure groups are provided in FIGURES 32A and 32B, respectively, and summarized below in Table 9. Overall, treatment with anti-murine MASP-2 ab (mAbMll) pre-irradiation increased the survival of irradiated mice compared to vehicle treated irradiated control animais at both 6.5 (20% increase) and 7.0 Gy (30% increase) exposure levels. At the 6.5 Gy exposure level, postirradiation treatment with anti-murine MASP-2 ab resulted in a modest increase in survival (15%) compared to vehicle control irradiated animais.
In comparison, ail treated animais at the 7.0 Gy exposure level showed an increase in survival compared to vehicle treated irradiated control animais. The greatest change in survival occurred in animais receiving mAbH6, with a 45% increase compared to control animais. Further, at the 7.0 Gy exposure level, mortalities in the mAbH6
207 treated group first occurred at post-irradiation day 15 compared to post-irradiation day 8 for vehicle treated irradiated control animais, an increase of 7 days over control animais. Mean time to mortality for mice receiving mAbH6 (27.3 ± 1.3 days) was significantly increased (p = 0.0087) compared to control animais (20.7 ± 2.0 days) at the 7.0 Gy 5 expo sure level.
The percent change in body weight compared to pre-irradiation day (day -1) was recorded throughout the study. A transient weight loss occurred in ail irradiated animais, with no evidence of differential changes due to mAbMl 1 or mAbH6 treatment compared to Controls (data not shown). At study termination, ail surviving animais showed an 10 increase in body weight from starting (day -1) body weight.
TABLE 9: Survival rates of test animais exposed to radiation
Test Group | Exposure Level | Survival (%) | Time to Death (Mean ± S EM, Day) | First/Last Death (Day) |
Control Irradiation | 6.5 Gy | 65% | 24.0 ± 2.0 | 9/16 |
mAbMll preexposure | 6.5 Gy | 85% | 27.7 ± 1.5 | 13/17 |
mAbMll pre + post-exposure | 6.5 Gy | 65 % | 24.0 ± 2.0 | 9/15 |
mAbMll postexposure | 6.5 Gy | 80% | 26.3 ± 1.9 | 9/13 |
mAbH6 pre+postexposure | 6.5 Gy | 65% | 24.6 ± 1.9 | 9/19 |
Control irraditation | 7.0 Gy | 35 % | 20.7 ± 2.0 | 8/17 |
mAbMll preexposure | 7.0 Gy | 65 % | 23.0 ± 2.3 | 7/13 |
mAbMll pre + post-exposure | 7.0 Gy | 55 % | 21.6 ±2.2 | 7/16 |
mAbMll postexposure | 7.0 Gy | 70% | 24.3 ±2.1 | 9/14 |
mAbH6 pre+postexposure | 7.0 Gy | 80% | 27.3 ± 1.3* | 15/20 |
*p = 0.0087 by two-tailed unpaired t-test between controlled irradiated animais and treatment group at the same irradiation exposure level.
208
Discussion
Acute radiation syndrome consists of three defined subsyndromes: hematopoietic, gastrointestinal, and cerebrovascular. The syndrome observed dépends on the radiation dose, with the hematopoietic effects observed in humans with significant partial or 5 whole-body radiation exposures exceeding 1 Gy. The hematopoietic syndrome is characterized by severe dépréssion of bone-marrow function leading to pancytopenia with changes in blood counts, red and white blood cells, and platelets occurring concomitant with damage to the immune System. As nadir occurs, with few neutrophîls and platelets présent in peripheral blood, neutropenia, fever, complications of sepsis and 10 uncontrollable hemorrhage lead to death.
In the présent study, administration of mAbH6 was found to increase survivability of whole-body x-ray irradiation in Swiss-Webster male mice irradiated at 7.0 Gy. Notably, at the 7.0 Gy exposure level, 80% of the animais receiving mAbH6 survived to 30 days compared to 35% of vehicle treated control irradiated animais. Importantly, the 15 first day of death in this treated group did not occur until post-irradiation day 15, a 7-day increase over that observed in vehicle treated control irradiated animais. Curiously, at the lower X-ray exposure (6.5 Gy), administration of mAbH6 did not appear to impact survivability or delay in mortality compared to vehicle treated control irradiated animais. There could be multiple reasons for this différence in response between exposure levels, 20 although vérification of any hypothesis may require additional studies, including intérim sample collection for microbiological culture and hematological parameters. One explanation may simply be that the number of animais assîgned to groups may hâve precluded seeing any subtle treatment-related différences. For example, with groups sizes of n=20, the différence in survival between 65% (mAbH6 at 6.5 Gy exposure) and 25 80% (mAbH6 at 7.0 Gy exposure) is 3 animais. On the other hand, the différence between 35% (vehicle control at 7.0 Gy exposure) and 80% (mAbH6 at 7.0 Gy exposure) is 9 animais, and provides sound evidence of a treatment-related différence.
These results demonstrate that anti-MASP-2 antibodies are effective in treating a mammalian subject at risk for, or suffering from the detrimental effects of acute radiation 30 syndrome.
EXAMPLE 30 i
209
This Example demonstrates that MASP-2 déficient mice are protected from Neisseria meningitidis induced mortality after infection with either N. meningitidis serogroup A or Neisseria meningitidis serogroup B.
Methods:
MASP-2 knockout mice (MASP-2 KO mice) were generated as described in Example 1. 10-week-old MASP-2 KO mice (n=10) and wild-type (WT) C57/BL6 mice (n=10) were inoculated by intraperitoneal (i.p.) injection with a dosage of 2.6 x 107 CFU of Neisseria meningitidis serogroup A Z2491 in a volume of 100 μΐ. The infective dose was adminîstered to mice in conjunction with iron dextran at a final concentration of 400 mg/kg. Survival of the mice after infection was monitored over a 72-hour time period.
In a separate experiment, 10-week-old MASP-2 KO mice (n=10) and wild-type C57/BL6 mice (n=10) were inoculated by i.p. injection with a dosage of 6 x 106 CFU of Neisseria meningitidis serogroup B strain MC58 in a volume of 100 μΐ. The infective dose was adminîstered to mice in conjunction with iron dextran at a final dose of 400 mg/kg. Survival of the mice after infection was monitored over a 72-hour time period. An illness score was also determined for the WT and MASP-2 KO mice during the 72-hour time period after infection, based on the illness scoring parameters described below in TABLE 10, which is based on the scheme of Fransen et al. (2010) with slight modifications.
_______TABLE 10: Illness Scoring associated with clinical signs in infected mice
Signs | Score |
Normal | 0 |
Slightly ruffled fur | 1 |
Ruffled fur, slow and sticky eyes | 2 |
Ruffled fur, léthargie and eyes shut | 3 |
Ver y sick and no movement after stimulation | 4 |
Dead | 5 |
210 ί
Blood samples were taken from the mice at hourly intervals after infection and analyzed to détermine the sérum level (log cfu/mL) of N. meningitidis in order to verify infection and déterminé the rate of clearance of the bacteria from the sérum.
Results:
FIGURE 33 is a Kaplan-Meyer plot graphically illustrating the percent survival of MASP-2 KO and WT mice after administration of an infective dose of 2.6 x 107 cfu of N. meningitidis serogroup A Z2491. As shown in FIGURE 33, 100% of the MASP-2 KO mice survived throughout the 72-hour period after infection. In contrast, only 80% of the WT mice (p=0.012) were still alive 24 hours after infection, and only 50% of the WT mice were still alive at 72 hours after infection. These results démonstrate that MASP-2deficient mice are protected from N. meningitidis serogroup A Z2491-induced mortality.
FIGURE 34 is a Kaplan-Meyer plot graphically illustrating the percent survival i of MASP-2 KO and WT mice after administration of an infective dose of 6 x 106 cfu of ’ i N. meningitidis serogroup B strain MC58. As shown in FIGURE 34, 90% of the MASP15 2 KO mice survived throughout the 72-hour period after infection. In contrast, only 20% of the WT mice (p=0.0022) were still alive 24 hours after infection. These results demonstrate that MASP-2-deficient mice are protected from N. meningitidis serogroup B strain MC58-induced mortality.
FIGURE 35 graphically illustrâtes the log cfu/mL of N. meningitidis serogroup B strain MC58 recovered at different time points in blood samples taken from the MASP-2 KO and WT mice after i.p. infection with 6x106 cfu of W meningitidis serogroup B strain MC58 (n=3 at different time points for both groups of mice). The results are expressed as Means±SEM. As shown in FIGURE 35, in WT mice the level of N. meningitidis in the blood reached a peak of about 6.0 log cfu/mL at 24 hours after infection and dropped to about 4.0 log cfu/mL by 36 hours after infection. In contrast, in the MASP-2 KO mice, the level of N. meningitidis reached a peak of about 4.0 log cfu/mL at 12 hours after infection and dropped to about 1.0 log cfu/mL by 36 hours after infection (the Symbol indicates p<0.05; the Symbol ** indicates p=0.0043). These results demonstrate that although the MASP-2 KO mice were infected with the same dose of N. meningitidis serogroup B strain MC58 as the WT mice, the MASP-2 KO mice hâve enhanced clearance of bacteraemia as compared to WT.
i i i i
211
FIGURE 36 graphically illustrâtes the average illness score of MASP-2 KO and WT mice at 3, 6, 12 and 24 hours after infection with 6x10^ cfu of N. meningitidis serogroup B strain MC58. As shown in FIGURE 36, the MASP-2-déficient mice showed high résistance to the infection, with much lower illness scores at 6 hours 5 (symbol indicates p=0.0411), 12 hours (symbol ** indicates p=0.0049) and 24 hours (symbol indicates p=0.0049) after infection, as compared to WT mice. The results in FIGURE 36 are expressed as means±SEM.
In summary, the results in this Example demonstrate that MASP-2-deficient mice are protected from Neisseria meningitidesAn&iceA mortality after infection with either N.
meningitidis serogroup A or N. meningitidis serogroup B.
EX AMPLE 31
This Example demonstrates that the administration of anti-MASP-2 antibody after infection with N. meningitidis increases the survival of mice înfected with N. 15 meningitidis.
Background/Rationale :
As described in Example 10, rat MASP-2 protein was utilized to pan a Fab phage display library, from which Fab2 #11 was identified as a functionally active antibody. Full-length antibodies of the rat IgG2c and mouse IgG2a isotypes were generated from 20 Fab2 #11. The full-length anti-MASP-2 antibody of the mouse IgG2a isotype was characterized for pharmacodynamie parameters (as described in Example 19).
In this Example, the mouse anti-MASP-2 full-length antibody derived from Fab2 #11 was analyzed in the mouse model of N. meningitidis infection.
Methods:
The mouse IgG2a full-length anti-MASP-2 antibody isotype derived from Fab2 #11, generated as described above, was tested in the mouse model of N. meningitidis infection as follows. ’
Administration of mouse-anti-MASP-2 Monoclonal antibodies (MoAb) after infection
9-week-old C57/BL6 Charles River mice were treated with inhibitory mouse antiMASP-2 antibody (1.0 mg/kg) (n=12) or control isotype antibody (n=10) at 3 hours after i.p. injection with a high dose (4x106 cfu) of N. meningitidis serogroup B strain MC58.
212
Results:
FIGURE 37 is a Kaplan-Meyer plot graphically illustrating the percent survival of mice after administration of an infective dose of 4x106 cfu of N. meningitidis serogroup B strain MC58, followed by administration 3 hours post-infection of either 5 inhibitory anti-MASP-2 antibody (1.0 mg/kg) or control isotype antibody. As shown in FIGURE 37, 90% of tire mice treated with anti-MASP-2 antibody survived throughout the 72-hour period after infection. In contrast, only 50% of the mice treated with isotype control antibody survived throughout the 72-hour period after infection. The symbol indicates p=0.0301, as determined by comparison of the two survival curves.
These results demonstrate that administration of anti-MASP-2 antibody is effective to treat and improve survival in subjects infected with N. meningitidis.
As demonstrated herein, the use of anti-MASP-2 antibody in the treatment of a subject infected with N. meningitidis is effective when administered within 3 hours postinfection, and is expected to be effective within 24 hours to 48 hours after infection. 15 Meningococcal disease (either meningococcemia or meningitis) is a medical emergency, and therapy will typically be initiated immediately if meningococcal disease is suspected (i.e., before N. meningitidis is positively identified as the etiological agent).
In view of the results in the MASP-2 KO mouse demonstrated in EXAMPLE 30, it is believed that administration of anti-MASP-2 antibody prior to infection with N. 20 meningitidis would also be effective to prevent or ameliorate the severity of infection.
EXAMPLE 32
This Example demonstrates that administration of anti-MASP-2 antibody is 25 effective to treat N. meningitidis infection in human sérum.
Rationale:
Patients with decreased sérum levels of functional MBL display increased susceptibility to récurrent bacterial and fungal infections (Kilpatrick et al., Biochim Biophys Acta 1572:401-413 (2002)). It is known that N. meningitidis is recognized by
MBL, and it has been shown that MBL-deficient sera do not lyse Neisseria.
In view of the results described in Examples 30 and 31, a sériés of experiments were carried ont to détermine the efficacy of administration of anti-MASP-2 antibody to
213 treat N. meningitidis infection m complement-deficient and control human sera.
Experiments were carried out in a high concentration of sérum (20%) in order to préservé the complément pathway.
Methods:
1. Sérum bactericidal activity in varions complement-deficient human sera and in human sera treated with human anti-MASP-2 antibody
The following complement-deficient human sera and control human sera were used in this experiment:
______TABLE 11: Human sera samples tested (as shown in FIGURE 38)
Sample | Sérum type |
A | Normal human sera (NHS) + human anti-MASP-2 Ab |
B | NHS + isotype control Ab |
C | MBL human sérum |
D | NHS |
E | Heat-Inactivated (HI) NHS__ |
A recombinant antibody against human MASP-2 was isolated from a Combinatorial Antibody Library (Knappik, A., et al., J. Mol. Biol. 296:57-86 (2000)), using recombinant human MASP-2A as an antigen (Chen, C.B. and Wallis, J. Biol. Chem. 27(5:25894-25902 (2001)). An antî-human scFv fragment that potently inhibited lectin pathway-mediated activation of C4 and C3 in human plasma (IC50-20 nM) was identified and converted to a full-length human IgG4 antibody.
N. meningitidis serogroup B-MC58 was incubated with the different sera show in TABLE 11, each at a sérum concentration of 20%, with or without the addition of inhibitory human anti-MASP-2 antibody (3 μ g in 100 μΐ total volume) at 37 °C with shaking. Samples were taken at the following time points: 0-, 30-, 60- and 90-minute intervals, plated out and then viable counts were determined. Heat-inactivated human sérum was used as a négative control.
Results:
FIGURE 38 graphically illustrâtes the log cfu/mL of viable counts of N. meningitidis serogroup B-MC58 recovered at different time points in the human sera
214 samples shown in TABLE 11. TABLE 12 provides the Student’s t-test results for
FIGURE 38.
TABLE 12: Student’s t-test Results for FIGURE 38 (time point 60 minutes)
Mean Diff. (Log) | Significant? P<0.05? | P value summary | |
AvsB | -0.3678 | Yes | ***(0.0002) |
A vs C | -1.1053 | Yes | ***(p<0.0001) |
AvsD | -0.2111 | Yes | **(0.0012) |
CvsD | 1.9 | Yes | ***(p<0.0001) |
As shown in FIGURE 38 and TABLE 12, complement-dependent killing of N. meningitidis in human 20% sérum was significantly enhanced by the addition of the human anti-MASP-2 inhibitory antibody.
2. Complement-dependent killing of N. meningitidis in 20% (v/v) mouse sera 10 déficient of MASP-2.
The following complement-deficient mouse sera and control mouse sera were used in this experiment:
TABLE 13: Mouse sera samples tested (as shown in FIGURE 39)
Sample | Sérum Type |
A | WT |
B | MASP-2 -/- |
C | MBL A/C -/- |
D | WT heat-inactivated (HIS) |
N. meningitidis serogroup B-MC58 was incubated with different complement15 déficient mouse sera, each at a sérum concentration of 20%, at 37°C with shaking.
Samples were taken at the following time points: 0-, 15-, 30-, 60-, 90- and 120-minute intervals, plated out and then viable counts were determined. Heat-inactivated human sérum was used as a négative control.
Results:
215
FIGURE 39 graphically illustrâtes tire log cfu/mL of viable counts of N. meningitidis serogroup B-MC58 recovered at different time points in the mouse sera samples shown in TABLE 13. As shown in FIGURE 39, the MASP-2 -/- mouse sera hâve a higher level of bactericidal activity for N. meningitidis than WT mouse sera. The symbol ** indicates p=0.0058, the symbol *** indicates p=0.001. TABLE 14 provides the Student's t-test results for FIGURE 39.
TABLE 14: Studenf s t-test Results for FIGURE 39
Comparison | Time point | Mean Diff. (LOG) | Significant? (p<0.05)? | P value summary |
A vs. B | 60 min. | 0.39 | yes | ** (0.0058) |
A vs. B | 90 min. | 0.6741 | yes___________ | *** (0.001) |
In summary, the results in this Example demonstrate that MASP-2 -/- sera has a higher level of bactericidal activity for N. meningitidis than WT sera.
EXAMPLE 33
This Example demonstrates the inhibitory effect of MASP-2 deficiency on lysis of red blood cells from blood samples obtained from a mouse model of paroxysmal nocturnal hemoglobinuria (PNH).
Background/Rationale :
Paroxysmal nocturnal hemoglobinuria (PNH), also referred to as Marchiafava20 Micheli syndrome, is an acquired, potentially life-threatening disease of the blood, characterized by complement-induced intravascular hemolytic anémia. The hallmark of PNH is the chronic complement-mediated intravascular hemolysis that is a conséquence of unregulated activation of the alternative pathway of complément due to the absence of the complément regulators CD55 and CD59 on PNH érythrocytes, 25 with subséquent hemoglobinuria and anémia. Lindorfer, M.A., et al., Blood 775(11) (2010), Risitano, A.M, Mini-Reviews in Médicinal Chemistry, 11:528-535 (2011).
θ 216
Anémia in PNH is due to destruction of red blood cells in the bloodstream. Symptoms of PNH include red urine, due to appearance of hemoglobin in the urine, back pain, fatigue, shortness of breath and thrombosis. PNH may develop on its own, referred to as primary PNH or in the context of other bone marrow disorders such as aplastic anémia, referred to as secondary PNH. Treatment for PNH includes blood transfusion for anémia, anticoagulation for thrombosis and the use of the monoclonal antibody eculizumab (Soliris®), which protects blood cells against immune destruction by inhibiting the complément System (Hillmen P. et al., A/ Engl.
J. Med. 556(6):552-9 (2004)). Eculizumab (Soliris®) is a humanized monoclonal antibody that targets the complément component C5, blocking its cleavage by C5 convertases, thereby preventing the production of C5a and the assembly of the MAC. Treatment of PNH patients with eculizumab has resulted in a réduction of intravascular hemolysis, as measured by lactate dehydrogenase (LDH), leading to hemoglobin stabilization and transfusion îndependence in about half of the patients (Hillmen P, et al., Mini-Reviews in Médicinal Chemistry, vol 11(6) (2011)). While nearly ail patients undergoing therapy with eculizumab achieve normal or almost normal LDH levels (due to control of intravascular hemolysis), only about one third of the patients reach a hemoglobin value above llgr/dL, and the remaining patients on eculizumab continue to exhibit moderate to severe (f.e.,transfusion-dependent) anémia, in about equal proportions (Risitano A.M. et al., Blood 113:4094-100 (2009)).
As described in Risitano et al., Mini-Reviews in Médicinal Chemistry 11:528-535 (2011), it was demonstrated that PNH patients on eculizumab contained C3 fragments bound to a substantial portion of their PNH érythrocytes (while untreated patients did not), leading to the conclusion that membrane-bound C3 fragments work as opsonins on PNH érythrocytes, resulting in their entrapment in the réticuloendothélial cells through spécifie C3 receptors and subséquent extravascular hemolysis. Therefore, therapeutic strategies in addition to the use of eculizumab are needed for those patients developing C3 fragment-mediated extravascular hemolysis
217 because they continue to require red cell transfusions.
This Example describes methods to assess the effect of MASP-2- déficient sérum and sérum treated with MASP-2 inhibitory agent on lysis of red blood cells from blood samples obtained from a mouse model of PNH and demonstrates the efficacy of MASP-2 inhibition to treat subjects suffering from PNH, and also supports the use of inhibitors of MASP-2 to ameliorate the effects of C3 fragment-mediated extravascular hemolysis in PNH subjects undergoing therapy with a C5 inhibitor such as eculizumab.
Methods:
PNH animal model:
Blood samples were obtained from gene-targeted mice with deficiencies of Crry and C3 (Crry/C3-/-) and CD55/CD59-deficient mice. These mice are missing the respective surface complément regulators and their érythrocytes are, therefore, susceptible to spontaneous complément autolysis as are PNH human blood cells.
In order to sensitize these érythrocytes even more, these cells were used with and without coating by mannan and then tested for hemolysis in WT C56/BL6 plasma, MBL null plasma, MASP-2 -/- plasma, human NHS, human MBL -/- plasma, and NHS treated with human anti-MASP-2 antibody.
1. Hemolysis assay ofCrry/C3 and CD55/CD59 double-deficient murine érythrocytes in
MASP-2-deficient/depleted sera and Controls
Day 1. Préparation of murine RBC (± mannan coating)
Materials included: fresh mouse blood, BBS/Mg2+/Ca2+ (4.4 mM barbituric acid,
1.8 mM sodium barbitone, 145 mM NaCl, pH7.4, 5mM Mg2+, 5mM Ca2+), chromium chloride, CrCh-ôHzO (0.5mg/mL in BBS/Mg2+/Ca2+) and mannan, 100 pg/mL in BBS /Mg2+/Ca2+.
Whole blood (2mL) was spun down for 1-2 min at 2000xg in a refrigerated centrifuge at 4°C. The plasma and buffy coat were aspirated off. The sample was then 30 washed three times by re-suspending the RBC pellet in 2 mL ice-cold
218
BBS/gelatin/Mg2+/Ca2+ and repeating centrifugation step. After the third wash, the pellet was re-suspended in 4mL BBS/Mg2+/Ca2+. A 2 mL aliquot of the RBC was set aside as an uncoated control. To the remaîning 2 mL, 2 mL CrC13 and 2 mL mannan were added and the sample was incubated with gentle mixing at room température for 5 5 minutes. The reaction was terminated by adding 7.5mL BBS/gelatin/Mg2+/Ca2+. The sample was spun down as above, re-suspended in 2 mL BBS/gelatin/Mg2+/Ca2+ and washed a further two times as above, then stored at 4°C.
Day 2. Hemolysis assay
Materials included BBS/gelatin/Mg2+/Ca2+ (as above), test sera, 96-well round10 bottomed and flat-bottomed plates and a spectrophotometer that reads 96-well plates at 410-414 nm.
The concentration of the RBC was first determined and the cells were adjusted to 109/mL, and stored at this concentration. Before use, the assay buffer was diluted to 108/mL, and then lOOul per well was used. Hemolysis was measured at 410-414 nm 15 (allowing for greater sensitivity then 541nm). Dilutions of test sera were prepared in icecold BBS/gelatin/Mg2+/Ca2+. lOOpl of each sérum dilution was pipetted into roundbottomed plate (see plate layout). lOOpl of appropriately diluted RBC préparation was added (i.e., 108 /mL) (see plate layout), incubated at 37°C for about 1 hour, and observed for lysis. (The plates may be photographed at this point.) The plate was then spun down 20 at maximum speed for 5 minutes. lOOpl was aspirated of the fluid-phase, transferred to flat-bottom plates, and the OD was recorded at 410-414 nm. The RBC pellets were retained (these can be subsequently lysed with water to obtain an inverse resuit).
Experiment #1:
Fresh blood was obtained from CD55/CD59 double-deficient mice and blood of 25 Crry/C3 double-deficient mice and érythrocytes were prepared as described in detail in the above protocol. The cells were split and half of the cells were coated with mannan and the other half were left untreated, adjusting the final concentration to Ix 108 per mL, of which 100 μΐ was used in the hemolysis assay, which was carried out as described above.
Results of Experiment #1: The lectin pathway is involved in érythrocyte lysis in the PNH animal model
219
In an initial experiment, it was determined that non-coated WT mouse érythrocytes were not lysed in any mouse sérum. It was further determined that mannancoated Crry-/- mouse érythrocytes were slowly lysed (more than 3 hours at 37 degrees) in WT mouse sérum, but they were not lysed in MBL null sérum. (Data not shown).
It was determined that mannan-coated Crry-/- mouse érythrocytes were rapidly lysed in human sérum but not in heat-inactivated NHS. Importantly, mannan-coated Crry-/- mouse érythrocytes were lysed in NHS diluted down to 1/640 (i.e., 1/40, 1/80, 1/160, 1/320 and 1/640 dilutions ail lysed). (Data not shown). In this dilution, the alternative pathway does not work (AP functîonal activity is significantly reduced below 10 8% sérum concentration).
Conclusions from Experiment #1
Mannan-coated Crry-/- mouse érythrocytes are very well lysed in highly diluted human sérum with MBL but not in that without MBL. The efficient lysis in every sérum concentration tested implies that the alternative pathway is not involved or needed for this 15 lysis. The inability of MBL-deficient mouse sérum and human sérum to lyse the mannan-coated Crry-/- mouse érythrocytes indicates that the classical pathway also has nothing to do with the lysis observed. As lectin pathway récognition molécules are required (i.e., MBL), this lysis is mediated by the lectin pathway.
Experiment #2:
Fresh blood was obtained from the Crry/C3 and CD55/CD59 double-deficient mice and mannan-coated Crry-/- mouse érythrocytes were analyzed in the haemolysis assay as described above in the presence of the following human sérum: MBL null; WT; NHS pretreated with human anti-MASP-2 antibody; and heat-inactivated NHS as a control.
Results of Experiment #2: MASP-2 inhibitors prevent érythrocyte lysis in the
PNH animal model
With the Mannan-coated Crry-/- mouse érythrocytes, NHS was incubated in the dilutions diluted down to 1/640 (i.e., 1/40, 1/80, 1/160, 1/320 and 1/640), human MBL-/serum, NHS pretreated with anti-MASP-2 mAb, and heat-inactivated NHS as a control.
The ELISA microtiter plate was spun down and the non-lysed érythrocytes were collected on the bottom of the round-well plate. The supernatant of each well was
220 collected and the amount of hemoglobin released from the lysed érythrocytes was measured by reading the OD415 nm in an ELIS A reader.
In the control heat-inactivated NHS (négative control), as expected, no lysis was observed. MBL-/- human sérum lysed mannan-coated mouse érythrocytes at 1/8 and
1/16 dilutions. Anti-MASP-2-antibody-pretreated NHS lysed mannan-coated mouse érythrocytes at 1/8 and 1/16 dilutions while WT human sérum lysed mannan-coated mouse érythrocytes down to dilutions of 1/32.
FIGURE 40 graphically illustrâtes hemolysis (as measured by hemoglobin release of lysed mouse érythrocytes (Cryy/C3-/-) into the supernatant measured by photometry) 10 of mannan-coated murine érythrocytes by human sérum over a range of sérum concentrations in sérum from heat-inactivated (HI) NHS, MBL-/-, NHS pretreated with anti-MASP-2 antibody, and NHS control.
From the results shown in FIGURE 40, it is demonstrated that MASP-2 inhibition with anti-MASP-2 antibody significantly shifted the CH50 and inhibited complement15 mediated lysis of sensitized érythrocytes with déficient protection from autologous complément activation.
Experiment #3
Fresh blood obtained from the Crry/C3 and CD55/CD59 double-déficient mice in non-coated Crry-/- mouse érythrocytes was analyzed in the hemolysis assay as described 20 above in the presence of the following sérum: MBL -/-; WT sera; NHS pretreated with human anti-MASP-2 antibody and heat-inactivated NHS as a control.
Results:
FIGURE 41 graphically illustrâtes hemolysis (as measured by hemoglobin release of lysed WT mouse érythrocytes into the supernatant measured by photometry) of non25 coated murine érythrocytes by human sérum over a range of sérum concentrations in sérum from heat inactivated (HI) NHS, MBL-/-, NHS pretreated with anti-MASP-2 antibody, and NHS control. As shown in FIGURE 41, it is demonstrated that inhibiting MASP-2 inhibits complement-mediated lysis of non-sensitized WT mouse érythrocytes.
FIGURE 42 graphically illustrâtes hemolysis (as measured by hemoglobin release 30 of lysed mouse érythrocytes (CD55/59 -/-) into the supernatant measured by photometry) of non-coated murine érythrocytes by human sérum over a range of sérum concentration
221 in sérum from heat-inactivated (HI) NHS, MBL-/-, NHS pretreated with anti-MASP-2 antibody, and NHS control.
TABLE 12: CHso values expressed as sérum concentrations
Sérum | WT | CD55/59 -/- |
Heat-inactivated NHS | No lysis | No lysis |
MBL AO/XX donor (MBL déficient) | 7.2% | 2.1% |
NHS + anti-MASP-2 antibody | 5.4% | 1.5% |
NHS | 3.1% | 0.73% |
Note: “CHso” is the point at which complément mediated hemolysis reaches 50%.
In summary, the results in this Example demonstrate that inhibiting MASP-2 inhibits complement-mediated lysis of sensitized and non-sensitized érythrocytes with déficient protection from autologous complément activation. Therefore, MASP-2 10 inhibitors may be used to treat subjects suffering from PNH, and may also be used to ameliorate (i.e., inhibit, prevent or reduce the severity of) extravascular hemolysis in PNH patients undergoing treatment with a C5 inhibitor such as eculizumab (Soliris®).
EXAMPLE 34
This Example describes a follow on study to the study described above in Example 29, providing further evidence confirming that a MASP-2 inhibitor, such as a MASP-2 antibody, is effective for the treatment of radiation exposure and/or for the treatment, amelioration or prévention of acute radiation syndrome.
Rationale: In the initial study described in Example 29, it was demonstrated that preirradiation treatment with an anti-MASP-2 antibody in mice increased the survival of irradiated mice as compared to vehicle treated irradiated control animais at both 6.5 Gy and 7.0 Gy exposure levels. It was further demonstrated in Example 29 that at the 6.5 Gy
222 .
exposure level, post-irradiation treatment with anti-MASP-2 antibody resulted in a modest increase in survival as compared to vehicle control irradiated animais. This Example describes a second radiation study that was camed ont to confirm the results of the first study.
Methods:
Design of Study A:
Swiss Webster mice (n=50) were exposed to ionizing radiation (8.0 Gy). The effect of anti-MASP-2 antibody therapy (mAbH6 5mg/kg), administered 18 hours before and 2 hours after radiation exposure, and weekly thereafter, on mortality was assessed.
Results of Study A:
As shown in FIGURE 43, it was determined that administration of the anti-MASP-2 antibody mAbH6 increased survival in mice exposed to 8.0 Gy, with an adjusted médian survival rate increased from 4 to 6 days as compared to mice that received vehicle control, and a mortality reduced by 12% when compared to mice that received vehicle control (log-rank test, p=0.040).
Design of Study B:
Swiss Webster mice (n=50) were exposed to ionizing radiation (8.0 Gy) in the following groups (I: vehicle) saline control; (II: low) anti-MASP-2 antibody mAbH6 (5 mg/kg) 20 administered 18 hours before irradiation and 2 hours after irradiation; (III: high) mAbH6 (10 mg/kg) administered 18 hours before irradiation and 2 hours post irradiation; and (IVhigh post) mAbH6 (lOmg/kg) administered 2 hours post irradiation only.
Results of Study B:
Administration of anti-MASP-2 antibody pre- and post-irradiation adjusted the mean 25 survival from 4 to 5 days in comparison to animais that received vehicle control.
Mortality in the anti-MASP-2 antibody-treated mice was reduced by 6-12% in comparison to vehicle control mice. It is further noted that no significant detrimental treatment effects were observed (data not shown).
In summary, the results shown in this Example are consistent with the results 30 shown in Example 29 and further demonstrate that anti-MASP-2 antibodies are effective in treating a mammalian subject at risk for, or suffering from the detrimental effects of acute radiation syndrome.
223
EXAMPLE 35
This study investigates the effect of MASP-2-deficiency in a mouse model of LPS (lipopolysaccharide)-induced thrombosis.
Rationale:
Hemolytic urémie syndrome (HUS), which is caused by Shiga toxin-producing E. coli infection, is the leading cause of acute rénal failure in children. In this Example, a Schwaitzman model of LPS-induced thrombosis (microvascular coagulation) was carried ont in MASP-2-/- (KO) mice to détermine whether MASP-2 inhibition is effective to inhibit or prevent the formation of intravascular thrombi.
Methods:
MASP-2-/- (n=9) and WT (n=10) mice were analyzed in a Schwarztman model of LPS-induced thrombosis (microvascular coagulation), Mice were administered Serratia LPS and thrombus formation was monitored over time. A comparison of the incidence of microthromi and LPS-induced microvascular coagulation was carried ont.
Results:
Notably, ail MASP-2 -/- mice tested (9/9) did not form intravascular thrombi after Serratia LPS administration. In contrast, microthrombi were detected in 7 of 10 of the WT mice tested in parallel (p=0.0031, Fischer’s exact). As shown in FIGURE 44, the time to onset of microvascular occlusion following LPS infection was measured in MASP-2-/- and WT mice, showing the percentage of WT mice with thrombus formation measured over 60 minutes, with thrombus formation detected as early as about 15 minutes. Up to 80% of the WT mice demonstrated thrombus formation at 60 minutes. In contrast, as shown in FIGURE 44, noue of the MASP-2 -/- had thrombus formation at 60 minutes (log rank: p=0.0005).
These results demonstrate that MASP-2 inhibition is protective against the development of intravascular thrombi in an HUS model.
EXAMPLE 36
This Example describes the effect of anti-MASP-2 antibodies in a mouse model of HUS using intraperitoneal co-injection of purified Shiga toxin 2 (STX2) plus LPS.
Background:
224
A mouse model of HUS was developed using intraperitoneal co-injection of purified Shiga toxin 2 (STX2) plus LPS. Biochemical and microarray analysis of mouse kidneys revealed the STX2 plus LPS challenge to be distinct from the effects of either agent alone. Blood and sérum analysis of these mice showed neutrophilia, 5 thrombocytopenia, red cell hemolysis, and increased sérum créatinine and blood. urea nitrogen. In addition, histologie analysis and électron microscopy of mouse kidneys demonstrated glomerular fibrin déposition, red cell congestion, microthrorabi formation, and glomerular ultrastructural changes. It was established that this model of HUS induces ail clinical symptoms of human HUS pathology in C57BL/6 mice including 10 thrombocytopenia, hemolytic anémia, and rénal failure that define the human disease. (J.
Immunol 187(1):172-80 (2011))
Methods:
C57BL/6 female mice that weighed between 18 to 20 g were purchased from Charles River Laboratories and divided in to 2 groups (5 mice in each group). One group 15 of mice was pretreated by intraperitoneal (i.p.) injection with the recombinant antiMASP-2 antibody mAbMll (100 pg per mouse; corresponding to a final concentration of 5 mg/kg body weight) diluted in a total volume of 150 μΐ saline. The control group received saline without any antibody. Six hours aller i.p injection of anti-MASP-2 antibody mAbMll, ail mice received a combined i.p. injection of a sublethal dose (3 20 pg/animal; corresponding to 150 pg/kg body weight) of LPS of Serratia marcescens (L6136; Sigma-Aldrich, St. Louis, MO) and a dose of 4.5 ng/animal (corresponding to 225 ng/kg) of STX2 (two times the LD50 dose) in a total volume of 150 μΐ. Saline injection was used for control.
Survival of the mice was monitored every 6 hours after dosing. Mice were culled 25 as soon as they reached the léthargie stage of HUS pathology. After 36 hours, ail mice were culled and both kidneys were removed for immunohistochemistry and scanning électron microscopy. Blood samples were taken at the end of the experiment by cardiac puncture. Sérum was separated and kept frozen at -80°C for measuring BUN and sérum Créatinine levels in both treated and control groups.
Immunohistochemistry
225
One-third of each mouse kidney was fixed m 4% paraformaldéhyde for 24 h, processed, and embedded in paraiTin. Three-micron-lhick sections were eut and placed onto charged slides for subséquent stainîng with H & E staîn.
Electron Microscopy
The middle section of the kidneys was eut into blocks of approximately 1 to 2 mm3, and fixed ovemight at 4°C in 2.5% glutaraldehyde in Ix PBS. The fixed tissue subsequently was processed by the Universîty of Leicester Electron Microscopy Facility
Cryostat sections
The other third of the kidneys was, eut into blocks approximately 1 to 2 mm3 and snap frozen in liquid nitrogen and kept at -80°C for cryostat sections and mRNA analysis.
Results:
FIGURE 45 graphically illustrâtes the percent survival of saline-treated control mice (n=5) and anti-MASP-2 antibody-treated mice (n=5) in. the STX/LPS-induced model over time (hours). Notably, as shown in FIGURE 45, ail of the control mice died by 42 hours. In sharp contrast, 100 % of the anti-MASP-2 antibody-treated mice survived throughout the time course of the experiment. Consistent with tire results shown in FIGURE 45, it was observed that ail the untreated mice that either died or had to be culled with signs of severe disease had significant glomerular injuries, while the glomeruli of ail anti-MASP-2-treated mice looked normal (data not shown). These results demonstrate that MASP-2 inhibitors, such as anti-MASP-2 antibodies, may be used to treat subjects suffering from, or at risk for developing a thrombotic microangiopathy (TMA), such as hemolytic urémie syndrome (HUS), atypical HUS (aHUS), or thrombotic thrombocytopénie purpura (TTP).
EXAMPLE 37
This Example describes the effect of MASP-2 deficiency and MASP-2 inhibition in a murine FITC-dextran/light induced endothélial cell injury model of thrombosis.
BackgiOund/Rationale: As demonstrated in Examples 35 and 36, MASP-2 deficiency (MASP-2 KO) and MASP-2 inhibition (via administration of an inhibitory MASP-2 antibody) protects mice in a model of typical HUS, wherease ail control mice exposed to STX and LPS developed severe HUS and became moribund or died within 48 hours. For example, as shown in FIGURE 54, ail mice treated with a MASP-2 inhibitory
226 antibody and then exposed to STX and LPS survived (Fisher s exact p<0.01; N=5). Thus, anti-MASP-2 therapy protects mice in this model of HUS.
The following experiments were carried out to analzye the effect of MASP-2 deficiency and MASP-2 inhibition in a fluorescein isothiocyanate (FITC)-dextraninduced endothélial cell injury model of thrombotic microangiopathy (TMA) in order to demonstrate further the benefit of MASP-2 inhibitors for the treatment of HUS, aHUS, TTP, and TMA’s with other étiologies.
Methods:
Intravital microscopy
Mice were prepared for intravital microscopy as described by Frommhold et al., BMC Immunology 12:56-68, 2011. Briefly, mice were anesthetized with intraperitoneal (i.p.) injection of ketamine (125 mg/kg bodyweight, Ketanest, Pfitzer GmbH, Karlsruhe, Germany) and xylazine (12.5 mg/kg body weight; Rompun, Bayer, Leverkusen, Germany) and placed on a heating pad to maintain body température at 37°C. Intravital microscopy was conducted on an upright microscope (Leica, Wetzlar, Germany) with a saline immersion objective (SW 40/0.75 numerical aperture, Zeiss, Jena, Germany). To ease breathing, mice were intubated using PE 90 tubing (Becton Dickson and Company, Sparks, MD, USA). The left carotid artery was cannuled with PE10 tubing (Becton Dickson and Company, Sparks, MD, USA) for blood sampling and systemic monoclonal antibody (mAb) administration.
Cremaster muscle préparation
The surgical préparation of the cremaster muscle for intravital microscopy was performed as described by Sperandio et al., Blood, 97:3812-3819, 2001. Briefly, the scrotum was opened and the cremaster muscle mobilized. After longitudinal incision and spreading of the muscle over a cover glass, the epididymis and testis were moved and pinned to the side, giving full microscopie access to the cremaster muscle microcirculation. Cremaster muscle venules were recorded via a CCD caméra (CF8/1; Kappa, Gleichen, Germany) on a Panasonic S-VHS recorder. The cremaster muscle was superfused with thermo-controlled (35°C bicarbonate-buffered saline) as previously described by Frommhold et al., BMC Immunology 12:56-68, 20112011.
Light excitation FITC dextran injury model
227
A controlled, light-dose-dependent vascular injury of the endothélium of cremaster muscle venules and artérioles was induced b y light excitation of photo toxic (FITC)-dextran (Cat. No. FD150S, Sigma Aldrich, Poole, U.K.). This procedure initiâtes localized thrombosis. As a phototoxic reagent, 60 pL of a 10% w/v solution of FITC5 dextran was injected through the left carotid artery access and allowed to spread homogenously throughout the circulating blood for 10 minutes. After selecting a wellperfused venule, halogen light of low to midrange intensity (800-1500) was focused on the vessel of interest to induce FITC-dextran fluorescence and mild to moderate phototoxicity to the endothélial surface in order to stimulate thrombosis in a reproducible, 10 controlled manner. The necessary phototoxic light intensity for the excitation of FITCdextran was generated using a halogen lamp (12V, 100W, Zeiss, Oberkochen, Germany). The phototoxicity resulting from light-induced excitation of the fluorochrome requires a threshold of light intensity and/or duration of illumination and is caused by either direct heating of the endothélial surface or by génération of reactive oxygen radicals as 15 described by Steinbauer et al., Langenbecks Arch Surg 385:290-298, 2000.
The intensity of the light applied to each vessel was measured for adjustment by a wavelength-correcting diode detector for low power measurements (Labmaster LM-2, Cohérent, Auburn, USA). Off-line analysis of video scans was performed by means of a computer assisted microcirculation analyzing System (CAMAS, Dr. Zeintl, Heidelberg) 20 and red blood cell velocity was measured as described by Zeintl et al., Int J Microcirc Clin Exp, 8(3):293-302, 2000.
Application of monoclonal anti-human MASP-2 inhibitory antibody (mAbH6) and vehicle control prior to induction of thrombosis
Using a blinded study design, 9-week-old male C57BL/6 WT littermate mice 25 were given i.p. injections of either the recombinant monoclonal human MASP-2 antibody (mAbH6), an inhibitor of MASP-2 functional activity (given at a final concentration of lOmg/kg body weight), or the same quantity of an isotype control antibody (without MASP-2 inhibitory activity) 16 hours before the phototoxic induction of thrombosis in the cremaster model of intravital microscopy. One hour prior to thrombosis induction, a 30 second dose of either mAbH6 or the control antibody was given. MASP-2 knockout (KO) mice were also evaluated in this model.
228 mAbHo (estabhshed against recombinant human MASP-2) is a potent inhibitor of human MASP-2 functional activity, which cross-reacts with, binds to and inhibits mouse MASP-2 but with lower affinity due to its species specificity (data not shown). In order to compensate for the lower affinity of mAbH6 to mouse MASP-2, mAbH6 was given at a high concentration (lOmg/kg body weight) to overcome the variation in species specificity, and the lesser affinity for mouse MASP-2, to provide effective blockade of murine MASP-2 functional activity under in vivo conditions.
In this blinded study, the time required for each individual venuole tested (sélection criteria were by comparable diameters and blood flow velocity) to fully occlude was recorded.
The percentage of mice with microvascular occlusion, the time of onset, and the time to occlusion were evaluated over a 60-minute observation period using intravital microscopy video recordings.
Results:
FIGURE 46 graphically illustrâtes, as a function of time after injury induction, the percentage of mice with microvascular occlusion in the FITC/Dextran UV model after treatment with isotype control or human MASP-2 antibody mAbH6 (lOmg/kg) dosed at 16 hours and 1 hour prior to injection of FITC/Dextran. As shown in FIGURE 46, 85% of the wild-type mice receiving the isotype control antibody occluded within 30 minutes or less, whereas only 19% of the wild-type mice pre-treated with the human MASP-2 antibody (mAbH6) occluded within the same time period, and the time to occlusion was delayed in the mice that did eventually occlude in the human MASP-2 antibody-treated group. It is further noted that three of the MASP-2 mAbH6 treated mice did not occlude at ail within the 60-minute observation period (i.e., were protected from thrombotic occlusion).
FIGURE 47 graphically illustrâtes the occlusion time in minutes for mice treated with the human MASP-2 antibody (mAbH6) and the isotype control antibody. The data are reported as scatter-dots with mean values (horizontal bars) and standard error bars (vertical bars). This figure shows the occlusion time in the mice where occlusion was observable. Thus, the three MASP-2 antibody-treated mice that did not occlude during the 60 minute observation period were not included in this analysis (there was no control treated mouse that did not occlude). The statistical test used for analysis was the unpaired
229 t test; wherein the Symbol indicates p=0.0129. As shown in FIGURE 47, in the four MASP-2 antibody (mAbH6)-treated mice that occluded, treatment with MASP-2 antibody significantly increased the venous occlusion time in the FITC-dextran/lightinduced endothélial cell injury model of thrombosis with low light intensity (800-1500) as compared to the mice treated with the isotype control antibody. The average of the full occlusion time of the isotype control was 19.75 minutes, while the average of the full occlusion time for the MASP-2 antibody treated group was 32.5 minutes.
FIGURE 48 graphically illustrâtes the time until occlusion in minutes for wildtype mice, MASP-2 KO mice, and wild-type mice pre-treated with human MASP-2 antibody (mAbH6) administered i.p. at lOmg/kg 16 hours before, and then administered again i.v.l hour prior to the induction of thrombosis in the FITC-dextran/light-induced endothélial cell injury model of thrombosis with low light intensity (800-1500). Only the animais that occluded were included in FIGURE 48; n=2 for wild-type mice receiving isotype control antibody; n=2 for MASP-2 KO; and n=4 for wild-type mice receiving human MASP-2 antibody (mAbH6). The Symbol indicates p<0.01. As shown in FIGURE 48, MASP-2 deficiency and MASP-2 inhibition (mAbH6 at lOmg/kg) increased the venous occlusion time in the FITC-dextran/light-induced endothélial cell injury model of thrombosis with low light intensity (800-1500).
Conclusions:
The results in this Example further demonstrate that a MASP-2 inhibitory agent that blocks the lectin pathway (e.g., antibodies that block MASP-2 function), inhibits microvascular coagulation and thrombosis, the hallmarks of multiple microangiopathic disorders, in a mouse model of TMA. Therefore, it is expected that administration of a MASP-2 inhibitory agent, such as a MASP-2 inhibitory antibody, will be an effective therapy in patients suffering from HUS, aHUS, TTP, or other microangiopathic disorders and provide protection from microvascular coagulation and thrombosis.
EXAMPLE 38
This Example describes a study demonstrating that human MASP-2 inhibitory antibody (mAbH6) has no effect on platelet function in platelet-rich human plasma.
Background/Rationale: As described in Example 37, it was demonstrated that MASP-2
inhibition with human MASP-2 inhibitory antibody (mAbH6) increased the venons occlusion time in the FITC-dextran/light-induced endothélial cell injury model of thrombosis. The following experiment was carried out to déterminé whether the MASP-2 inhibitory antibody (mAbH6) has an effect on platelet function.
Methods: The effect of human mAbH6 MASP-2 antibody was tested on ADP-induced aggregation of platelets as follows. Human MASP-2 mAbH6 at a concentration of either 1 pg/ml or 0.1 pg/ml was added in a 40 pL solution to 360 pL of freshly prepared platelet-rich human plasma. An isotype control antibody was used as the négative control. After adding the antibodies to the plasma, platelet activation was induced by 10 adding ADP at a final concentration of 2 pM. The assay was started by stirring the solutions with a small magnet in the 1 mL cuvette. Platelet aggregation was measured in a two-channel Chrono-log Platelet Aggregometer Model 700 Whole Blood/Optical LumiAggregometer.
Results:
The percent aggregation in the solutions was measured over a time period of five minutes. The results are shown below in TABLE 13.
TABLE 13: Platelet Aggregation over a time period of five minutes.
Antibody | Amplitude (percent aggregation) | Slope (percent aggregation over time) |
MASP-2 antibody (mAbH6) (1 pg/ml) | 46% | 59 |
Isotype control antibody (1 pg/ml) | 49% | 64 |
MASP-2 antibody (mAbH6) (0.1 pg/ml) | 52% | 63 |
Isotype control antibody | 46% | 59 |
231 (0.1 gg/inl)
As shown above in TABLE 13, no significant différence was observed between the aggregation of the ADP-induced platelets treated with the control antibody or the MASP-2 mAbH6 antibody. These results demonstrate that the human MASP-2 antibody (mAbH6) has no effect on platelet function. Therefore, the results described in Example 37 demonstrating that MASP-2 inhibition with human MASP-2 inhibitory antibody (mAbH6) increased the venous occlusion time in the FITC-dextran/light-induced endothélial cell injury model of thrombosis, were not due to an effect of mAbH6 on platelet function. Thus, MASP-2 inhibition prevents thrombosis without directly impacting platelet function, revealing a therapeutic mechanism that is distinct from existing anti-thrombotic agents.
EXAMPLE 39
This Example describes the effect of MASP-2 inhibition on thrombus formation and vessel occlusion in a murine model of TMA.
B ackground/Rationale : The lectin pathway plays a dominant rôle in activating the complément System in settings of endothélial cell stress or injury. This activation is amplified rapidly by the alternative pathway, which is dysregulated in many patients presenting with aHUS. Preventing the activation of MASP-2 and the lectin pathway is thus expected to hait the sequence of enzymatic reactions that lead to the formation of the membrane attack complex, platelet activation, and leukocyte recruitment. This effect limits tissue damage.
In addition, MASP-2 has Factor Xa-like activity and cleaves prothrombin to form thrombin. This MASP-2-driven activation of the coagulation System may imbalance hemostasis and resuit in the pathology of TMA. Thus, inhibition of MASP-2 using a MASP-2 inhibîtor, such as a MASP-2 inhibitory antibody that blocks activation of the complément and coagulation Systems is expected to improve outcomes in aHUS and other TMA-related conditions.
As described in Example 37, it was demonstrated that MASP-2 inhibition with human MASP-2 inhibitory antibody (mAbH6) increased the venous occlusion time in the FITCdextran/light-induced endothélial cell injury model of thrombosis. In this model of TMA,
232 mice were sensîtized by IV injection of FITC- dextran, followed by localized photoactivation of the FITC- dextran in the microvasculature of the mouse cremaster muscle (Thorlacius H et al., Eur J Clin. Invest 30(9):804-10, 2000; Agero et al., Toxicon 50(5):698-706, 2007).
The following experiment was carried out to détermine whether the MASP-2 inhibitory antibody (mAbH6) has a dose-response effect on thrombus formation and vessel occlusion in a murine model of TMA.
Methods: Localized thrombosis was induced by photo-activation of fluorescein isothîocyanate-labeled dextran (FITC-dextran) in the microvasculature of the cremaster 10 muscle of C57 Bl/6 mice and intravital microscopy was used to measure onset of thrombus formation and vessel occlusion using methods described in Example 37, with the following modifications. Groups of mice were dosed with mAbH6 (2mg/kg, 10 mg/kg or 20 mg/kg) or isotype control antibody (20 mg/kg) were administered by intravenous (iv) injection one hour before TMA induction. The time to onset of thrombus 15 formation and time to complété vessel occlusion were recorded. Video playback analysis of intravital microscopy images recorded over 30 to 60 minutes was used to evaluate vessel size, blood flow velocity, light intensity, rate of onset of thrombus formation as équivalent of platelet adhesion, time to onset of thrombus formation, rate of total vessel occlusion and time until total vessel occlusion. Statistical analysis was conducted using 20 SigmaPlot vl2.0.
Results:
Initiation of Thrombus Formation
FIGURE 49 is a Kaplan-Meier plot showing the percentage of mice with thrombi as a function of time in FITC-Dextran induced thrombotic microangiopathy in mice treated 25 with increasing doses of human MASP-2 inhibitory antibody (mAbH6 at 2 mg/kg, lOmg/kg or 20 mg/kg) or an isotype control antibody. As shown in FIGURE 49, initiation of thrombus formation was delayed in the mAbH6-treated mice in a dosedependent manner relative to the control-treated mice.
FIGURE 50 graphically illustrâtes the médian time to onset (minutes) of thrombus 30 formation as a function of mAbH6 dose (*p<0.01 compared to control). As shown in FIGURE 50, the médian time to onset of thrombus formation increased with increasing doses of mAbH6 from 6.8 minutes in the control group to 17.7 minutes in the 20 mg/kg
233 mAbH6 treated group (p<0.01). The underlying experimental data and statistical analysis are provided in TABLES 14 and 15.
The time to onset of thrombus formation in individual mice recorded based on évaluation of the videographic recording is detailed below in TABLE 14.
234
TABLE 14: Time to Onset of Thrombus Formation After Light Dye-induced Injury
Control Treatment | mAbH6 Treatment | |||
Time to Onset (minutes) | Control | 2 mg/kg | 10 mg/kg | 20 mg/kg |
6.07 | 5.93 | 12.75 | 10.00 | |
1.07 | 6.95 | 2.53 | 10.33 | |
8.00 | 8.92 | 14.00 | 21.00 | |
2.40 | 11.92 | 3.05 | 11.50 | |
8.48 | 12.75 | 8.00 | 19.00 | |
4.00 | 12.53 | 8.17 | 10.37 | |
4.00 | . 15.83 | 22.65 | ||
7.83 | 11.70 | 16.37 | ||
6.83 | 50.67 | 21.75* | ||
15.00 | 32.25* | |||
15.67 |
* vessels did not show onset during the indicated observation period
The statistical analysis compaiïng time to onset of occlusion between control and mAbH6 treated animais is shown below in TABLE 15.
235
TABLE 15: Time to Onset: data from FITC Dex dose response study
Statistic | Control | mAbH6 (2 mg/kg) | mAbH6 (10 mg/kg) | mAbH6 (20 mg/kg) |
Number of events/number of animais (%) | 11/11 (100%) | 6/6 (100%) | 9/9 (100%) | 8/10 (80.0%) |
Médian time (minutes) (95% CI) | 6.8 (2.4, 8.5) | 10.4 (5.9,12.8) | 11.7 (2.5, 15.8) | 17.7 (10.0, 22.7) |
Wilcoxon p-value* | 0.2364 | 0.1963 | 0.0016 | |
Event=Time to onset observed Médian (minutes) and its 95% CI were based on Kaplan-Meier estimate NE=not estimable *p-values were adjusted by Dunnett-Hsu multiple comparison |
Microvascular Occlusion
FIGURE 51 is a Kaplan-Meier plot showing the percentage of mice with microvascular 5 occlusion as a function of time in FETC-Dextran induced thrombotic microangiopathy in mice treated with increasing doses of human MASP-2 inhibitory antibody (mAbH6 at 2 mg/kg, lOmg/kg or 20mg/kg) or an isotype control antibody. As shown in FIGURE 51, complété microvascular occlusion was delayed in the mAbH6 treated groups as compared to the control mice.
FIGURE 52 graphically illustrâtes the médian time to microvascular occlusion as a function of mAbH6 dose (*p<0.05 compared to control). As shown in FIGURE 52, the médian time to complété microvascular occlusion increased from 23.3 minutes in the control group to 38.6 minutes in tire 2mg/kg mAbH6 treated group (p<0.05). Doses of 10 mg/kg or 20 mg/kg of mAbH6 performed similarly (médian time for complété microvascular occlusion was 40.3 and 38 minutes, respectively) to the 2 mg/kg mAbH6
236 treated group, The underlying experimental data and statistical analysis are provided in TABLES 16 and 17,
The time to complété vessel occlusion in individual mice recorded based on primary évaluation of the videographic recording is detailed below in TABLE 16.
TABLE 16: Time to Complété Occlusion After Light Dye-Induced Injury
Control Treatment | mAbH6 Treatment | |||
Time to Occlusion (minutes) | Control | 2 mg/kg | 10 mg/kg | 20 mg/kg |
37.50 | 42.3 | 30.92 | 38.00 | |
29.07 | 21.91 | 17.53 | 28.00 | |
27.12 | 24.4 | 51.38 | 40.58 | |
19.38 | 31.38 | 36.88 | 33.00 | |
19.55 | 61.17* | 26.83 | 39.10 | |
18.00 | 61.55* | 40.28 | 32.03 | |
16.50 | 55.83 | 38.53 | ||
23.33 | 71.93* | 21.75* | ||
14.83 | 98.22* | 32.25* | ||
30* | 33.17* | |||
61.8* |
*vessels did not completely occlude during the indicated observation period.
The statistical analysis comparing time to complété occlusion between control and mAbH6 treated animais is shown below in TABLE 17.
237
TABLE 17: Time to Complété Microvascular Occlusion: data from FITC Dex dose response study
Statistic | Control | mAbH6 (2 mg/kg) | mAbH6 (10 mg/kg) | mAbHô (20 mg/kg) |
Number of events/number of animais (%) | 9/11 (81.8%) | 4/6 (66.7%) | 7/9 (77.8%) | 7/10 (70.0%) |
Médian time (minutes) (95% CI) | 23.3 (16.5,37.5) | 36.8 (21.9, NE) | 40.3 (17.5, NE) | 38.0 (28.0, 40.6) |
Wilcoxon p-value* | 0.0456 | 0.0285 | 0.0260 | |
Event=Time to occlusion observed Médian (minutes) and its 95% CI were based on Kaplan-Meier estimate NE=not estimable *p-values were adjusted by Dunnett-Hsu multiple comparison |
Summary
As summarized in TABLE 18, the initiation of thrombus formation was delayed in the mAbH6 treated mice in a dose-dependent manner relative to the control-treated mice (médian time to onset 10.4 to 17.7 minutes vs 6.8 minutes). The médian time to complété occlusion was significantly delayed in ail mAbH6-treated groups relative to the controltreated groups (Table 18).
238
TABLE 18: Médian Time to Onset of Thrombus Formation and Complété Occlusion
Control | mAbH6 (2 mg/kg) | niAbH6 (10 mg/kg) | mAbH6 (20 mg/kg) | |
Médian# time to onset of thrombus formation (minutes) | 6.8 | 10.4 | 11.7 | 17.7* |
Médian# time to complété microvascular occlusion (minutes) | 23.3 | 36.8* | 40.3* | 38.0* |
#Median values are based on Kaplan-Meier estimate |
*p<0.05 compared to control (Wilcoson adjusted by Dunnett-Hsu for multiple 5 comparisons)
These results demonstrate that mAbH6, a human monoclonal antibody that binds to MASP-2 and blocks the lectin pathway of the complément System, reduced microvascular thrombosis in a dose-dependent manner in an experimental mouse model of TMA. Therefore, it is expected that administration of a MASP-2 inhibitory agent, 10 such as a MASP-2 inhibitory antibody, will be an effective therapy in patients suffering from HUS, aHUS, TTP, or other microangiopathic disorders such as other TM As including catastrophic antiphospholipid syndrome (CAPS), systemic Degos disease, and TM As secondary to cancer, cancer chemo therapy and transplantation and pro vide protection from microvascular coagulation and thrombosis.
EXAMPLE 40
239
This Example describes the identification, using phage display, of fully human scFv antibodies that bind to MASP-2 and inhibit lectin-mediated complément activation while leaving the classical (Clq-dependent) pathway and the alternative pathway components of the immune System intact.
OverView:
Fully human, high-affinity MASP-2 antibodies were identified by screening a phage display library. The variable light and heavy chain fragments of the antibodies were isolated in both a scFv format and in a full-length IgG format. The human MASP-2 antibodies are useful for inhibiting cellular injury associated with lectin pathwaymediated alternative complément pathway activation while leaving the classical (Clq-dependent) pathway component of the immune System intact. In some embodiments, the subject MASP-2 inhibitory antibodies hâve the following characteristics: (a) high affinity for human MASP-2 (e.g., a KD of 10 nM or less), and (b) inhibit MASP-2-dependent complément activity m 90% human sérum with an TC5Q of 30 nM or less.
Methods:
Expression of full-length catalytically inactive MASP-2:
The full-length cDNA sequence of human MASP-2 (SEQ ID NO: 4), encoding the human MASP-2 polypeptide with leader sequence (SEQ ID NO:5) was subcloned into the mammalian expression vector pCI-Neo (Promega), which drives eukaryotic expression under the control of the CMV enhancer/promoter région (described in Kaufman R.J. et al., Nucleic Acids Research 79:4485-90, 1991; Kaufman, Methods in Enzymology, 185:531-66 (1991)).
In order to generate catalytically inactive human MASP-2A protein, site-directed mutagenesis was carried out as described in US2007/0172483, hereby incorporated herein by référencé. The PCR products were purified after agarose gel electrophoresis and band préparation and single adenosine overlaps were generated using a standard tailing procedure. The adenosine-tailed MASP-2A was then cloned into the pGEM-T easy vector and transformed into E. coli. The human MASP-2A was further subcloned into either of the mammalian expression vectors pED or pCI-Neo.
240
The MASP-2A expression construct described above was transfected into DXB1 cells using the standard calcium phosphate transfection procedure (Maniatis et al., 1989). MASP-2A was produced in serum-free medium to ensure that préparations were not contaminated with other sérum proteins. Media was harvested from confluent cells every second day (four times in total). The level of recombinant MASP-2A averaged approximately 1.5 mg/liter of culture medium. The MASP-2A (Ser-Ala mutant described above) was purified b y affinity chromatography on MBP-A-agarose columns
MASP-2A ELIS A on ScFv Candidate Clones identified by panning/scFv conversion and filter screening
A phage display library of human immunoglobulin light- and heavy-chain variable région sequences was subjected to antigen panning followed by automated antibody screening and sélection to identify high-affinity scFv antibodies to human MASP-2 protein. Three rounds of panning the scFv phage library against HIS-tagged or biotin-tagged MASP-2A were carried out. The third round of panning was eluted first with MBL and then with TEA (alkaline). To monitor the spécifie enrichment of phages display ing scFv fragments against the target MASP-2 A, a polyclonal phage ELIS A against immobilized MASP-2A was carried out. The scFv genes from panning round 3 were cloned into a pHOG expression vector and run in a small-scale filter screening to look for spécifie clones against MASP-2A.
Bacterial colonies containing plasmids encoding scFv fragments from the third round of panning were picked, gridded onto nitrocellulose membranes and grown ovemight on non-inducing medium to produce master plates. A total of 18,000 colonies were picked and analyzed from the third panning round, half from the compétitive elution and half from the subséquent TEA elution. Panning of the scFv phagemid library against MASP-2A followed by scFv conversion and a filter screen yielded 137 positive clones. 108/137 clones were positive in an ELISA assay for MASP-2 binding (data not shown), of which 45 clones were further analyzed for the ability to block MASP-2 activity in normal human sérum.
Assay to Measure Inhibition of Formation of Lectin Pathway C3 Convertase
A functional assay that measures inhibition of lectin pathway C3 convertase formation was used to evaluate the blocking activity of the MASP-2 scFv candidate clones. MASP-2 serine protease activity is required in order to generate the two protein
241 components (C4b, C2a) that comprise the lectin pathway C3 convertase. Therefore, a MASP-2 scFv that inhibits MASP-2 functional activity (i.e., a blocking MASP-2 scFv), will inhibit de novo formation of lectin pathway C3 convertase. C3 contains an unusual and highly reactive thioester group as part of its structure. Upon cleavage of C3 by C3 5 convertase in this assay, the thioester group on C3b can form a covalent bond with hydroxyl or amino groups on macromolecules immobilized on the bottom of the plastic wells via ester or amide linkages, thus facilitating détection of C3b in the ELISA assay.
Yeast mannan is a known activator of the lectin pathway. In the following method to measure formation of C3 convertase, plastic wells coated with mannan were 10 incubated with diluted human sérum to activate the lectin pathway. The wells were then washed and assayed for C3b immobilized onto the wells using standard ELISA methods. The amount of C3b generated in this assay is a direct reflection of the de novo formation of lectin pathway C3 convertase. MASP-2 scFv clones at selected concentrations were tested in this assay for their ability to inhibit C3 convertase formation and conséquent 15 C3b génération.
Methods:
The 45 candidate clones identified as described above were expressed, purified and diluted to the same stock concentration, which was again diluted in Ca++ and Mg++ containing GVB buffer (4.0 mM barbital, 141 mM NaCl, 1.0 mM MgC12, 2.0 mM CaCl2, 20 0.1% gelatin, pH 7.4) to assure that ail clones had the same amount of buffer. The scFv clones were each tested in triplicate at the concentration of 2 pg/mL. The positive control was OMS 100 Fab2 and was tested at 0.4 pg/mL. C3c formation was monitored in the presence and absence of the scFv/IgG clones.
Mannan was diluted to a concentration of 20 pg/mL (1 pg/well) in 50mM 25 carbonate buffer (15mM Na2CO3 + 35mM NaHCO3 + 1.5 mM NaN3), pH 9.5 and coated on an ELISA plate overnight at 4°C. The next day, the mannan-coated plates were washed 3 times with 200 pl PBS. 100 pl of 1% HSA blocking solution was then added to the wells and incubated for 1 hour at room température. The plates were washed 3 times with 200 pl PBS, and stored on ice with 200 pl PBS until addition of the samples.
Normal human sérum was diluted to 0.5% in CaMgGVB buffer, and scFv clones or the OMS 100 Fab2 positive control were added in triplicates at 0.01 pg/mL; 1 pg/mL
242 (only OMSIOO control) and 10 pg/rnL to this buffer and preincubated 45 minutes on ice before addition to the blocked ELISA plate. The reaction was initiated by incubation for one hour at 37°C and was stopped by transferring the plates to an ice bath. C3b déposition was detected with a Rabbit α-Mouse C3c antibody followed by Goat a-Rabbit
HRP. The négative control was buffer without antibody (no antibody = maximum C3b déposition), and the positive control was buffer with EDTA (no C3b déposition). The background was determined by carrying out the same assay except that the wells were mannan-free. The background signal against plates without mannan was subtracted from the signais in the mannan-containing wells. A cut-off criterion was set at half of the 10 activity of an irrelevant scFv clone (VZV) and buffer alone.
Results: Based on the cut-off criterion, a total of 13 clones were found to block the activity of MASP-2. Ail 13 clones producing > 50% pathway suppression were selected and sequenced, yielding 10 unique clones. Ail ten clones were found to hâve the same light chain subclass, λ3, but three different heavy chain subclasses: VH2, VH3 and 15 VH6. In the functional assay, five out of the ten candidate scFv clones gave IC50 nM values less than the 25 nM target criteria using 0.5% human sérum.
To identify antibodies with improved potency, the three mother scFv clones, identified as described above, were subjected to light-chain shuffling. This process involved the génération of a combinatorial library consisting of the VH of each of the 20 mother clones paired up with a library of naïve, human lambda light chains (VL) derived from six healthy donors. This library was then screened for scFv clones with improved binding affinity and/or functionaiity.
TABLE 19: Comparison of functional potency in IC5Q (nM) of the lead daughter 25 clones and their respective mother clones (ail in scFv format)
scFv clone | 1% human sérum C3 assay (ICjq nM) | 90% human sérum C3 assay (IC50nM) | 90% human sérum C4 assay (IC50nM) |
17D20mc | 38 | nd | nd |
17D20m_d3521Nll | 26 | >1000 | 140 |
17N16mc | 68 | nd | nd |
243
17N16m dl7N9
230
Presented below are the heavy-chain variable région (VH) sequences for the mother clones and daughter clones shown above in TABLE 19.
The Kabat CDRs (31-35 (Hl), 50-65 (H2) and 95-107 (H3)) aie bolded; and the Chothia CDRs (26-32 (Hl), 52-56 (H2) and 95-101 (H3)) are underlined.
17D20 35VH-21N11VL heavy chain variable région (VH) (SEQ ID NO:67, encoded by SEQ ID NO:66)
OVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIROPPGKALEW LAHIFSSDEKSYRTSLKSRLTISKDTSKNOVVLTMTNMDPVDTATYYCARIRRG GIDYWGQGTLVTVSS d!7N9 heavy chain variable région (VH) (SEQ ID NO:68)
OVQLOQSGPGLVKPSOTLSLTCAISGDSVSSTSAAWNWIROSPSRGLEWLGRTY YRSKWYNDYAVSVKSRITINPDTSKNOFSLOLNSVTPEDTAVYYCARDFFGVPF DIWGQGTMVTVSS
Presented below are the light-chain variable région (VL) sequences for the mother clones and daughter clones.
The Kabat CDRs (24-34 (Ll); 50-56 (L2); and 89-97 (L3) are bolded; and the Chothia CDRs (24-34 (Ll); 50-56 (L2) and 89-97 (L3) are underlined. These régions are the same whether numbered by the Kabat or Chothia System.
17D20m d3521Nll light chain variable région (VL) (SEQ ID NO:7Q, encoded by SEQ ID NO:69)
OPVLTQPPSLSVSPGOTASITCSGEKLGDKYAYWYOOKPGOSPVLVMYO DKQRPSGIPERFSGSNSGNTATLTISGTOAMDEADYYCOAWDSSTAVFGGGTKL TVL
17N16m d!7N9 light chain variable région (VL) (SEQ ID NO:71)
244
SYELIOPPSVSVAPGOTATITCAGDNLGKKRVHWYOQRPGOAPVLVIYD DSDRPSGIPDRFSASNSGNTATLTITRGEAGDEADYYCQVWDIATDHVVFGGGT KLTVLAAAGSEQKLISE
The MASP-2 antibodies OMSIOO and MoAb_d3521NllVL, (comprising a heavy 5 chain variable région set forth as SEQ ID NO:67 and a light chain variable région set forth as SEQ ID NO:70, also referred to as “OMS646” and “mAbH6”), which hâve both been demonstrated to bind to human MASP-2 with high affinity and hâve the ability to block functîonal complément activity, were analyzed with regard to epitope binding by dot blot analysis, The results show that OMS646 and OMSIOO antibodies are highly 10 spécifie for MASP-2 and do not bind to MASP-1/3, Neither antibody bound to MApl9 nor to MASP-2 fragments that did not contain the CCP1 domain of MASP-2, leading to the conclusion that the binding sites encompass CCP1.
The MASP-2 antibody OMS646 was determined to avidly bind to recombinant MASP-2 (Kd 60-250pM) with >5000 fold selectivity when compared to Cls, Clr or 15 MASP-1 (see TABLE 20 below):
TABLE 20: Affinity and Specificity of OMS646 MASP-2 antibody-MASP-2 interaction as assessed by solid phase ELISA studies
Antigen | Kd (pM) |
MASP-1 | >500,000 |
MASP-2 | 62±23* |
MASP-3 | >500,000 |
Purified human Clr | >500,000 |
Purified human Cls | -500,000 |
*Mean±SD; n=12
OMS646 specifically blocks lectin-dependent activation of terminal complément components
Methods:
The effect of OMS646 on membrane attack complex (MAC) déposition was 25 analyzed using pathway-specific conditions for the lectin pathway, the classical pathway
245 and the alternative pathway. For this purpose, the Wieslab Comp300 complément screening kit (Wieslab, Lund, Sweden) was used following the manufacturer’s instructions.
Results:
FIGURE 53A graphically illustrâtes the level of MAC déposition in the presence or absence of anti-MASP-2 antibody (OMS646) under lectin pathway-specific assay conditions. FIGURE 53B graphically illustrâtes the level of MAC déposition in the presence or absence of anti-MASP-2 antibody (OMS646) under classical pathwayspecific assay conditions. FIGURE 53C graphically illustrâtes the level of MAC 10 déposition in the presence or absence of anti-MASP-2 antibody (OMS646) under alternative pathway-specific assay conditions.
As shown in FIGURE 53A, OMS646 blocks lectin pathway-mediated activation of MAC déposition with an IC50 value of approximately InM. However, OMS646 had no effect on MAC déposition generated from classical pathway-mediated activation 15 (FIGURE 53B) or from alternative pathway-mediated activation (FIGURE 53C).
Pharmacokinetics and Pharmacodynamies of OMS646 following Intravenous (IV) or Subeutaneous (SC) Administration to Mice
The pharmacokinetics (PK) and pharmacodynamies (PD) of OMS646 were 20 evaluated in a 28 day single dose PK/PD study in mice. The study tested dose levels of 5mg/kg and 15mg/kg of OMS646 administered subcutaneously (SC), as well as a dose level of 5mg/kg OMS646 administered intravenously (IV).
With regard to the PK profile of OMS646, FIGURE 54 graphically illustrâtes the OMS646 concentration (mean of n=3 animals/groups) as a function of time after 25 administration of OMS646 at the indicated dose. As shown in FIGURE 54, at 5mg/kg SC, OMS646 reached the maximal plasma concentration of 5-6 ug/mL approximately 1-2 days after dosing. The bioavailability of OMS646 at 5 mg/kg SC was approximately 60%. As further shown in FIGURE 54, at 15 mg/kg SC, OMS646 reached a maximal plasma concentration of 10-12 ug/mL approximately 1 to 2 days after dosing. For ail 30 groups, the OMS646 was cleared slowly from systemic circulation with a terminal halflife of approximately 8-10 days. The profile of OMS646 is typical for human antibodies in mice.
246
The PD activity of OMS646 is graphically illustrated in FIGURES 55A and 55B. FIGURES 55A and 55B show the PD response (drop in systemic lectin pathway activity) for each mouse in the 5mg/kg IV (FIGURE 55A) and 5mg/kg SC (FIGURE 55B) groups. The dashed line indicates the baseline of the assay (maximal inhibition; naïve mouse 5 sérum spiked in vitro with excess OMS646 prior to assay). As shown in FIGURE 55A, following IV administration of 5mg/kg of OMS646, systemic lectin pathway activity immediately dropped to near undetectable levels, and lectin pathway activity showed only a modest recovery over the 28 day observation period. As shown in FIGURE 55B, in mice dosed with 5mg/kg of OMS646 SC, time-dependent inhibition of lectin pathway 10 activity was observed. Lectin pathway activity dropped to near-undetectable levels within 24 hours of drug administration and remained at low levels for at least 7 days. Lectin pathway activity gradually increased with time, but did not revert to pre-dose levels within the 28 day observation period. The lectin pathway activity versus time profile observed after administration of 15mg/kg SC was similar to the 5 mg/kg SC dose 15 (data not shown), indicating saturation of the PD endpoint. The data further indicated that weekly doses of 5mg/kg of OMS646, administered either IV or SC, is sufficient to achieve continuons suppression of systemic lectin pathway activity in mice.
EXAMPLE 41
This Example demonstrates that a MASP-2 inhibitory antibody (OMS646) inhibits aHUS serum-induced complément C5b-9 déposition on the surface of activated human microvascular endothélial cells (HMEC-1) after exposure to sérum from patients with atypical hemolytic urémie syndrome (aHUS) obtained during the acute phase and the remission phase of the disease.
B ackground/Rationale: The following study was carried out to analyze aHUS serum-induced complément C5b-9 déposition on the surface of activated HMEC-1 cells after exposure to aHUS patient sérum obtained (1) during the acute phase and (2) during the remission phase of the disease in the presence or absence of OMS646, a MASP-2 antibody that specifically binds to MASP-2 and inhibits lectin pathway activation.
Methods:
Patients: Four patients with aHUS, studied both during the acute phase of the disease and in remission, were selected for this study among those included in the
247
International Registry of HUS/TTP and genotyped by the Laboratory of Immunology and Genetics of Transplantation and Rare Diseases of the Mario Negri Institute. One aHUS patient had a heterozygous p.R1210C complément factor H (CFH) mutation and one had anti-CFH autoantibodies, while no mutation or antibodies to CFH were found in the other 5 two aHUS patients.
Tables 21 and 22 summarize the results of screening for complément gene mutations and anti-CFH autoantibodies in the four aHUS patients analyzed in this study along with clinical and biochemical data measured either during the acute phase or at remission.
TABLE 21: Clinical Parameters of the four aHUS patients in this study
Case No. | Mutation or antiCFH Ab | Disease phase | Platelets (150400*103/μ1) | LDH (266-500 IU/1) | Hemoglobin (14-18g/dl) | s-Creatinine (0.55- 1.25mg/dl) |
#1 | no mutations, no anti-CFH Ab | acute | 31,000 | 1396 | 12.9 | 2.37 |
remission | 267,000 | n.a. | 11.5 | 3.76 | ||
#2 | CF77-R1210C | acute | 46,000 | 1962 | 7 | 5.7 |
remission | 268,000 | 440 | 13.4 | 7.24 | ||
#3 | anti-CFH Ab | acute | 40,000 | 3362 | 9.5 | 1.77 |
remission | 27.1,000 | 338 | 8.8 | 0.84 | ||
#4 | no mutations, no anti-CFH Ab | acute | 83,000 | 1219 | 7.8 | 6.8 |
remission | 222,000 | 495 | 12.2 | 13 |
Vote: n.a. = not available
TABLE 22: Complément Parameters of the four aHUS patients in this study
Case No. | Mutation of antiCFH Ab | Disease phase | Sérum C3 (83-180 mg/dl) | Plasma SC5b-9 (127-400 ng/ml) |
#1 | no mutations, no anti-CFH Ab | acute | 51 | 69 |
remission | n.a. | 117 | ||
#2 | CEH-R1210C | acute | 79 | 421 |
remission | 119 | 233 | ||
#3 | anti-CFH Ab | acute | 58 | 653 |
remission | 149 | 591 | ||
#4 | no mutations, no anti-CFH Ab | acute | 108 | n.a. |
remission | n.a. | n.a. |
Experimental Methods: Cells from a human microvascular endothélial cell line (HMEC-1) of dermal origin were plated on glass slides and used when confluent.
Confluent HMEC-1 cells were activated with 10 μΜ ADP (adenosine diphosphate) for 10
248 minutes and then incubated for four hours with sérum from the four aHUS patients described above in Tables 23 and 24 collected either during the acute phase of the disease, or from the same aHUS patients at remission, or from 4 healthy control subjects. The sérum was diluted 1:2 with test medium (HBSS with 0.5% BSA) in the presence or 5 in the absence of a MASP-2 inhibitory antibody, OMS646 (100 pg/mL), generated as described above in Example 40, or in the presence of soluble complément receptor 1 (sCRl) (150 pg/mL), as a positive control of complément inhibition. At the end of the incubation step, the HMEC-1 cells were treated with rabbit anti-human complément C5b9 followed by FITC-conjugated secondary antibody. In each experiment, sérum from one 10 healthy control was tested in parallel with aHUS patient sérum (acute phase and remission). A confocal inverted laser microscope was used for acquisition of the fluorescent staining on the endothélial cell surface. Fifteen fields per sample were acquired and the area occupied by the fluorescent staining was evaluated by automatic edge détection using built~in spécifie fonctions of the software Image J and expressed as 15 pixel2 per field analyzed. The fields showing the lowest and the highest values were excluded from calculation.
For the statistical analysis (one-way ANOVA followed by Tukey’s test for multiple comparisons) results in pixel2 of the 13 fields considered in each experimental condition for each patient and control were used.
Results:
The results of the complément déposition analysis with the sera from the four aHUS patients are summarized below in Table 23A, and the results with the sera from the four healthy subjects are summarized below in Table 23B.
TABLE 23A: Effect of complément inhibitors on aHUS serum-induced C5b-9 déposition 25 on ADP-activated HMEC-1 cells
aHUS Patient # | aHUS acute phase | aHUS rémission phase | ||||
untreated | +sCRl | +OMS646 | untreated | +sCRl | +OMS646 | |
Patient #1 (no mutation, no anti- CFHab) | 5076 ±562° | 551 ±80* | 3312 ±422** | 4507 ± 533° | 598±101 § | 1650 ±223§ |
249
Patient #2 (CFH- R1210C) | 5103 ±648° | 497 ±67* | 2435 ± 394* | 3705 ± 570° | 420 ± 65§ | 2151±250§§§ |
Patient #3 (anti-CFH ab) | 3322 + 421° | 353 ±64* | 2582 ±479 | 6790 ±901° | 660 ± 83§ | 2077 ± 35 3 § |
Patient #4 (no mutations, no antiCFH ab) | 4267 ±488° | 205 ± 34* | 2369 ± 265** | 5032 ± 594° | 182 ± 29§ | 3290±552§§ |
TABLE 23Β: Effect of complément inhibitors on sera from four healthy control subjects (not suffering from aHUS) on C5b-9 déposition on ADP-activated HMEC-1 cells
Healthy Control Subject # | Untreated | -f-sCRl | +OMS646 |
Control Subject #1 (assayed in parallel with aHUS subject #1) | 481 ±66 | 375 + 43 | 213 ±57 |
Control Subject #2 (assayed in parallel with aHUS subject #2) | 651 ±61 | 240 ± 33 | 490 ± 69 |
Control Subject #3 (assayed in parallel with aHUS subject #3) | 602 ± 83 | 234 ± 35 | 717±109 |
Control Subject #4 (assayed in parallel with aHUS subject #4) | 370 ± 53 | 144 ± 20 | 313 ±36 |
For Tables 23A and 23B: Data are mean ± SE. °P<0.001 vs control; *P<0.001, **P<0.01 vs aHUS acute phase untreated; §P<0.001, §§P<0.01, §§§P<0.05 vs aHUS remission phase untreated.
250
Figure 56 graphically illustrâtes the inhibitory effect of MASP-2 antibody (OMS646) and sCRl on aHUS serum-induced C5b-9 déposition on ADP-activated HMEC-1 cells. In Figure 56, the data are mean ± SE. °P<0.0001 vs control; *P<0.0001 vs aHUS acute phase untreated; ΛΡ<0.0001 vs aHUS acute phase + sCRl; §P<0.0001 vs aHUS rémission phase untreated and #P<0.0001 vs aHUS remission phase + sCRl.
As shown in Table 23A, 23B and Figure 56, ADP-stimulated HMEC-1 cells exposed to sérum from aHUS patients (collected either in the acute phase or in remission) for four hours in static conditions showed an intense déposition of C5b-9 on cell surface as detected by confocal microscopy. By measuring the area covered by C5b-9, a significantly higher amount of C5b-9 déposition was observed on cells exposed to sérum from aHUS patients than on cells exposed to sérum from healthy control subjects, irrespective of whether aHUS sérum was collected in the acute phase or during remission. No différence in serum-induced endothélial C5b-9 deposits was observed between acute phase and rémission.
As further shown in Table 23A, 23B and Figure 56, addition of the MASP-2 antibody OMS646 to aHUS sérum (either obtained from patients during acute phase or in remission) led to a significant réduction of C5b-9 déposition on endothélial cell surface as compared to untreated aHUS sérum. However, the inhibitory effect of OMS646 on C5b-9 déposition was less profound than the effect exerted by the complément pan-înhibitor sCRl. Indeed, a statistically significant différence was observed between aHUS seruminduced C5b-9 deposits in the presence of OMS646 vs. sCRl (Figure 56 and Tables 23A and 23B).
When calculated as a mean of the four aHUS patients, the percentages of réduction of C5b-9 deposits (as compared with C5b-9 deposits induced by the untreated sérum from the same patients taken as 100%) observed in the presence of the complément inhibitors were as follows:
Acute Phase:
sCRl (150 pg/ml): 91% réduction in C5b-9 deposits
OMS646 (100 gg/ml): 40% réduction in C5b-9 deposits
Remission Phase:
251 sCRl (150 μ§/ιη1): 91% réduction in C5b-9 deposits
OMS646 (100 ftg/ml): 54% réduction in C5b-9 deposits
Conclusion: The results described in this Example demonstrate that the lectin pathway of complément is stünulated b y actîvated micro vascular endothélial cells and that this stimulation is a significant driver for the exaggerated complément activation response characteristic of aHUS. It is also demonstrated that this stimulation of the lectin pathway and resulting exaggerated complément activation response occurs both during the acute phase and in clinical remission of aHUS. Moreover, this finding does not appear to be limited to any particular' complément defect associated with aHUS. As further demonstrated in this Example, sélective inhibition of the lectin pathway with a MASP-2 inhibitory antibody such as OMS646 reduces complément déposition in aHUS patients with diverse étiologies.
EXAMPLE 42
This Example demonstrates that a MASP-2 inhibitory antibody (OMS646) inhibits aHUS serum-induced platelet aggregation and thrombus formation on the surface of activated human microvascular endothélial cells (HMEC-1) after exposure to aHUS patient sérum obtained during (1) the acute phase and (2) the rémission phase of aHUS.
Methods:
Patients: Three patients (patients #1, #2 and #4 as described in Tables 21, 22, 23A and 23B in Example 41) with aHUS (one patient had a heterozygous p.R1210C CFH mutation, while no mutation or anti-CFH antibodies were found in the other two patients) were studied both during the acute phase of the disease and in remission. The patients were selected for this study among those included in the International Registry of HUS/TTP and genotyped by the Laboratory of Immunology and Genetics of Transplantation and Rare Diseases of the Mario Negri Institute. Five healthy subjects were also selected as blood donors for perfusion experiments.
Methods: Confluent HMEC-1 cells were activated with 10 μΜ ADP for 10 minutes and then were incubated for three hours with sera from three aHUS patients (patients #1, 2 and 4 described in Example 41) collected during the acute phase of the disease or from the same patients at remission, or with control sera from healthy subjects.
252
The sérum was diluted 1:2 with test medium (HBSS with 0.5% BSA), in the presence or in the absence of a MASP-2 inhibitory antibody, OMS646 (100 pg/mL), generated as described in Example 40; or with sCRl (150 pg/mL), as a positive control of complément inhibition. For patients #1 and #2 additional wells were incubated with sera (from acute phase and remission) diluted 1:2 with test medium containing 100 pg/mL of irrelevant isotype control antibody or with 20 pg/mL of OMS646 (for the latter, case #1 was tested only in remission and case #2 both during the acute phase and at remission).
At the end of the incubation step, HMEC-1 cells were perfused in a flow chamber with heparinized whole blood (10 Ul/mL) obtained from healthy subjects (containing the fluorescent dye mepacrine that labels platelets) at the shear stress encountered in the microcirculation (60 dynes/cm2, three minutes). After three minutes of perfusion, the endothelial-cell monolayers were fixed in acetone. Fifteen images per sample of platelet thrombî on the endothélial cell surface were acquired by confocal inverted laser microscope, and areas occupied by thrombi were evaluated using Image J software. The fields showing the loweest and the highest values were excluded from calculation.
For statistical analysis (one-way ANOVA followed by Tukey’s test for multiple comparisons), results in pixel2 of the 13 fields considered in each experimental condition for each patient and control were used.
Results:
The results of the thrombus formation experiments with the sera from the three aHUS patients are summarized below in Table 24A, and the results with the sera from the five healthy subjects are summarized below in Table 24B.
TABLE 24A: Effect of complément inhibitors on aHUS serum-induced thrombus formation (pixel2±SE) on ADP-activated HMEC-1 Cells
Experimental conditions | Disease phase | aHUS Case #1 thrombus formation (pixel2±SE) (no mutation, no anti-CFH ab) | aHUS Case #2 thrombus formation (pixel2±SE) (CFH-R1210C) | aHUS Case #4 thrombus formation (pixel2±SE) (no mutations, no anti-CFH ab) |
untreated | acute | 5499 ±600 | 22320 ±1273° | 10291±1362° |
253
remission | 6468 ±1012° | 3387 ±443° | 17676± 1106° | |
+sCRl (150 pg/mL) | acute | 4311 ±676 | 5539 ±578* | 5336±1214*** |
remission | 573±316§ | 977 ±102§ | 2544 ± 498§ | |
+OMS646 (20 pg/mL) | acute | not determined | 6974 ± 556* | not determined |
remission | 832 ±150§ | 1224±252§ | not determined | |
+OMS646 (100 pg/mL) | acute | 3705 ± 777 | 9913 ±984* | 2836 ±509* |
remission | 3321 ±945§§§ | 733 ±102§ | 1700+321§ | |
+ irrelevant isotype control antibody (100 pg/mL) | acute | 5995 ± 725 | 18655 ±1699 | not determined |
remission | 10885±1380 | 2711 ±371 | not determined |
TABLE 24B: Effect of complément inhibitors on sera from five healthy control subjects (not suffering from aHUS) in the thrombus formation (pixel2±SE) assay on ADP-activated HMEC-1 Cells
Experimental conditions | Control #1 thrombus formation (pixel2±SE) | Control #2 thrombus formation (pixel2±SE) | Control #3 thrombus formation (pixelz±SE) | Control #4 thrombus formation (pixel2±SE) | Control #5 thrombus formation (pixel2±SE) |
untreated | 2880±510 | 1046 ±172 | 1144 ±193 | 735 ±124 | 2811 +609 |
+sCRl (150 pg/mL) | 5192 + 637 | 1527 ±153 | 1198±138 | 2239 ± 243 | 2384 ±410 |
+OMS646 (100 pg/mL) | 7637 ± 888 | 1036 ±175 | 731 ±203 | 2000 ± 356 | 7177 ± 1477 |
254
+irrelevant isotype control antibody (100 pg/mL | 6325 ± 697 | 1024 ± 235 | 399 ± 82 | 45269 | not determined |
Assayed in parallel with sérum from aHUS subject | #1 (acute phase sérum) | #1 (remission phase sérum) | #2 (acute phase sérum) | #2 (remission phase sérum) | #5 (acute and remission phase sérum) |
For Tables 24A and 24B: Data are mean ± SE. °P<0.001 vs control; *P<0.001, ***p<0.05 vs aHUS acute phase untreated; §P<0.001, §§§P<0.05 vs aHUS remission phase untreated.
Figure 57 graphically illustrâtes the effect of MASP-2 antibody (OMS646) and 5 sCRl on aHUS serum-induced thrombus formation on ADP-activated HMEC-1 cells. In Figure 57, the data shown are mean ± SE. °P<0.0001, °°P<0.01 vs control; *P<0.0001, **P<0.01 vs aHUS acute phase untreated; §P<0.0001 vs aHUS remission phase untreated.
As shown in Table 24A and Figure 57, a marked increase in the area covered by 10 thrombi was observed on HMEC-1 cells treated with aHUS sérum, collected either during acute phase or at remission, in comparison to cells exposed to sérum from healthy control subjects (Table 24B and Figure 57). As shown in Figure 57 and Table 24A, OMS646 (at both 100 pg/ml and 20 pg/ml) showed a partial inhibition of thrombus formation on cells pre-exposed to aHUS sérum taken during the acute phase. The anti-thrombogenic effect 15 was comparable between the two different doses of OMS646 and was not different from the effect of sCRl (Figure 57 and Table 24A). Addition of the irrelevant isotype control antibody had no inhibitory effect on aHUS-serum-induced thrombus formation.
As further shown in Figure 57 and Table 24A, the inhibitory effect of OMS646 was even more évident on aHUS sérum collected during remission phase. Indeed, the 20 addition of OMS646, at both 100 pg/ml and 20 pg/ml doses, to aHUS patient sérum collected at remission resulted in a nearly complété inhibition of thrombus formation, simîlar to that observed with the addition of sCRl. The irrelevant isotype control antibody showed no significant inhibitory effect.
255
When calculâted as a mean of the three aHUS patients, the percentages of réduction of the HMEC-1 surface covered by thrombi deposits (as compared with thrombus area induced by the untreated sera from the same patients taken as 100%) recorded with the complément inhibitors were as follows:
Acute Phase:
sCRl (150 pg/ml): 60% réduction
OMS646 (100 pg/ml): 57% réduction
OMS646 (20 μg/ml): 45% réduction
Remission Phase:
sCRl (150 μg/ml): 85% réduction
OMS646 (100 μg/ml): 79% réduction
OMS646 (20 μg/ml): 89% réduction
Discussion of Results:
The results in this Example demonstrate that a MASP-2 inhibitory antibody, such as OMS646 (generated as described in Example 40), has a strong inhibitory effect on aHUS serum-induced thrombus formation on HMEC-1 cells. Surprisingly, the inhibitory effect of OMS646 on thrombus formation was greater than its effect on C5b-9 deposits 20 induced on HMEC-1 (as described in Example 41). It is also surprising that the addition of OMS646, at both 100 pg/ml and 20 pg/ml doses, to aHUS patient sérum collected at remission resulted in nearly a complété inhibition of thrombus formation. Another surprîsing finding is the observation that OMS646, in both the acute phase and in remission, was as effective as the positive control sCRl, which is a broad and almost 25 complété inhibitor of the complément System (Weisman H. et al., Science 249:146-151, 1990; Lazar H. et al., Circulation 100:1438-1442,1999).
It is noted that the control sérum from healthy subjects also induced a modest thrombus formation on HMEC-1 cells. We did not observe a consistent inhibitory effect on control sérum induced thrombus formation with either OMS646 or with sCRl. While 30 not wishing to be bound by any particular theory, it is believed that the control-induced thrombi do not dépend upon complément, as supported by very low C5b-9 deposits
256 observed on HMEC-1 incubated with control sérum (see Example 41).
Conclusion:
In conclusion, the observed anti-thrombotic effect of a MASP-2 inhibitory antibody, such as OMS646, appears substantîally greater than one would hâve expected based on the inhibitory effect of OMS646 on C5b-9 déposition observed in this experimental System (as described in Example 41 and shown in Figure 56). For example, as described in Gastoldi et al., Immunobiology 217:1129-1222 Abstract 48 (2012) entitled “C5a/C5aR interaction médiates complément activation and thrombosis on endothélial cells in atypical hemolytic urémie syndrome (aHUS),” it was determined that addition of a C5 antibody inhibiting C5b-9 deposits (60% réduction) limited thrombus formation on HMEC-1 to a comparable extent (60% réduction). In contrast, the MASP-2 inhibitory antibody (OMS646 at 100 pg/mL) inhibited C5b-9 deposits with mean values of (acute phase = 40% réduction; remission phase = 54% réduction); and inhibited thrombus formation at a substantîally higher percent (acute phase = 57% réduction; remission phase = 79% réduction). In comparison, OMS646 inhibited complément déposition at a lower percentage than did the positive control complément inhibitor (sCRl at 150 pg/mL, acute phase inhibition of C5b-9 déposition = 91% réduction; remission phase = 91% réduction) yet was equally effective as the sCRl positive control in inhibiting thrombus formation (sCRl at 150 pg/mL, acute phase = 60% réduction; remission phase = 85% réduction). These results demonstrate that a MASP-2 inhibitory antibody (e.g., OMS646) is surprisingly effective at inhibiting thrombus formation in sérum obtained from aHUS subjects both in the acute phase and remission phase.
In accordance with the foregoing, in one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from, or at risk for developing, a thrombotic microangiopathy (TMA) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complément activation. In one embodiment, the TMA is selected from the group consisting of hemolytic urémie syndrome (HUS), thrombotic thrombocytopénie purpura (TTP) and atypical hemolytic urémie syndrome (aHUS). In one embodiment, the TMA is aHUS. In one embodiment, the composition is administered to an aHUS patient during the acute phase of the disease. In one embodiment, the composition is administered to an aHUS patient during the remission phase (i.e., in a
257 subject that has recovered or partially recovered from an épisode of acute phase aHUS, such remission evidenced, for example, by increased platelet count and/or reduced sérum LDH concentrations, for example as described in Loirat C et al., Orphanet Journal of Rare Diseases 6:60, 2011, hereby incorporated herein by reference).
In one embodiment, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a KD of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC50 of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM 10 or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab’, F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation, and/or wherein the antibody does not substantially inhibit the classical 15 pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the alternative pathway. hi one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the classical pathway or the alternative pathway (i.e., inhibits the lectin pathway while leaving the classical and alternative complément 20 pathways intact).
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from a TMA such as aHUS (acute or rémission phase), by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at 25 least 95% up to 99%, as compared to untreated sérum. I11 some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from aHUS at a level of at least 20 percent or greater, (such as at least 30%, at least 40%, at least 50%) more than the inhibitory effect on C5b-9 déposition in sérum.
In one embodiment, the MASP-2 inhibitory antibody inhibits thrombus formation 30 in sérum from an aHUS patient in remission phase by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such
258 as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum. In some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum in an aHUS patient in remission phase at a level of at least 20 percent or greater, (such as at least 30%, at least 40%, at least 50%) more than the inhibitory effect on C5b-9 déposition in sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the subject via an intravenous cathéter or other cathéter delivery method.
In one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from a TMA comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavychain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDRL1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a lightchain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In one embodiment, the TMA is selected from the group consisting of atypical hemolytic urémie syndrome (aHUS) (either acute or remission phase), HUS and TTP. In one embodiment, the subject is in acute phase of aHUS. In one embodiment, the subject is in remission phase of aHUS.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises
259 administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
hi some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, tliat specifically recognizes at least part of an epitope on human MASP-2 recognized by reference antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70. Compétition between binding members may be assayed easily in vitro, for example using ELISA and/or by tagging a spécifie reporter molécule to one binding member which can be detected in the presence of other untagged binding member(s), to enable identification of spécifie binding members which bind the same epitope or an overlapping epitope. Thus, there is presently provided a spécifie antibody or antigenbinding fragment thereof, comprising a human antibody antigen-binding site, which competes with reference antibody OMS646 for binding to human MASP-2.
EX AMPLE 43
This Example demonstrates tliat a human MASP-2 inhibitory antibody (OMS646) is able to inhibit TMA patient plasma-mediated induction of apoptosis in primary human microvascular endothélial cells (MVECs) of dermal origin.
B ackground/Rationale :
The pathophysiology of TMA is known to involve an endothélial cell injury induced by various factors that is followed by occlusions of small vessels (e.g., small artérioles and capillaries) by platelet plugs and/or fibrin thrombi (Hirt-Minkowsk P. et al., Nephron Clin Pract 114:c219-c235, 2010; Goldberg RJ. et al., Am J Kidney Dis 56(6):1168-1174, 2010). It has been shown that MVECs undergo apoptotic injury when exposed in vitro to plasma from patients with TMA-related disorders (see Stefanescu et al., Blood Vol 112 (2):340-349, 2008; Mitra D. et al., Blood 89:1224-1234, 1997). Apoptotic injury associated with TMAs has been documented in MVEC obtained from tissue biopsies (skin, bone, marrow, spleen, kidney, ileum) of such patients. It has also been shown that apoptotic insults to MVECs reduces the levels of membrane-bound
260 complément regulatory proteins in MVECs (see e.g., Mold & Morris, Immunology 102:359-364, 2001; Christmas et al., Immunology 119:522, 2006).
A positive feedback loop involving terminal complément components is believed to be involved in the pathophysiology of TMAs including atypical hemolytic-uremic 5 syndrome (aHUS), and TMAs associated with catastrophic antiphospholipid syndrome (CAPS), Degos disease, and TMAs secondary to cancer, cancer chemotherapy, autoimmunity and transplantation, each of these conditions are known or thought to be responsive to anti-C5 therapy with the mAb eculizumab (Chapin J. et al., Brit. J. Hematol 157:772-774, 2012; Tsai et al., BrJHaematol 162(4):558-559, 2013); Magro C. M. et al., 10 Journal ofRare Diseases 8:185, 2013).
The following experiment was carried out to analyze the ability of human MASP2 inhibitory antibody (OMS646) to block TMA patient plasma-mediated induction of apoptosis in primary human dermal MVECs in plasma samples obtained from patients suffering from aHUS, ADAMTS13 deficiency-related thrombotic thrombocytopénie 15 purpura (TTP), CAPS and systemic Degos disease, as well as TMAs secondary to cancer, transplantation, auto immune disease and chemotherapy.
Methods:
An in vitro assay was carried out to analyze the efficacy of a MASP-2 inhibitory antibody (OMS646) to block TMA patient plasma-mediated induction of apoptosis in 20 primary human MVECs of dermal origin as described in Stefanescu R. et al., Blood Vol 112 (2):340-349, 2008, which is hereby incorporated herein by référencé. The plasma samples used in this assay were obtained from a collection of healthy control subjects and from individuals with either acute-phase or convalescent thrombotic microangiopathies. The presence of micro angiopathy in the TMA patients was assessed by detecting 25 schistocytes on a peripheral blood smear. In addition, TTP was diagnosed as described in Stefanescu R. et al., Blood Vol 112 (2):340-349, 2008.
Endothélial Cell (EC) Culture
As described in Stefanescu et al., primary human MVECs of dermal origin were purchased from ScienCell Research Labs (San Diego, CA). MVECs expressed CD34 up 30 through passages 5 and 6 (Blood 89:1224-1234, 1997). The MVECs were maintained in polystyrène flasks coated with 0.1% gelatin in water in ECM1001 medium (ScienCell Research Labs) containing endothélial cell growth supplément, penicillin, streptomycin
261 and 15% fêtai bovine sérum. Ail MVECs were used in passages 2 to 6. Subcultures involved a 5 to 10 minute exposure to 0.25% trypsin-EDTA.
Apoptosis Assay
Représentative primary human MVECs of dermal origin known to be susceptible to TTP/HUS plasma-induced apoptosis were washed with phosphate buffered saline (PBS) and plated in chambers of 12-well plates, coated with 0.1% gelatin in water at 0.15xl06 viable cells/mL. The plated MVEC cells were starved in complété media for 24 hours then exposed to varying concentrations (2% to 20% v/v) of TMA patient plasma samples or healthy donor plasma for 18 hours in the presence or absence of MASP-2 mAb OMS646 (150 pg/mL) and the cells were then harvested by trypsinization. Each TMA patient sample was analyzed in duplicate. The degree of plasma-mediated apoptosis was assessed using propidium iodide (PI) staining, with >5 xlO3 cells analyzed in a cytofluorograph and A0 peaks defined by computer software (MCycle Av, Phoenix Flow Systems, San Diego, CA). Enzyme-linked immunosorbent assay (ELISA)-based quantitation of cytoplasmic histone-associated DNA fragments from cell lysate was also performed as per the manufacturer’s directions (Roche Diagnostics, Mannheim, Germany).
Results:
The results of the TMA patient plasma-induced MVEC apoptosis assay in the presence of MASP-2 mAb (OMS646) are shown below in Table 25.
Table 25: TMA patient plasma tested on primary human MVEC of dermal origin in the presence of MASP-2 mAb (OMS646)
Subject # | Age/ Sex | Clinical Diagnosis (TMA) and other conditions | MASP-2 ng/ml | Diagnosis based on Cre/LDH | C5a | sC5- b9 | ADAM S Activity | Diagnosis based on ADAMS activity | protection with OMS646 |
#2 | 41/f | TTP | 174 | TTP | 34.42 | 772 | 30% | aHUS | responder |
#3 | 52/f | TTP | 150 | TTP | 48.32 | 1399 | 70% | aHUS | non- |
262
Subject # | Age/ Sex | Clinical Diagnosis (TMA) and other conditions | MASP-2 ng/ml | Diagnosis based on Cre/LDH |
#4 | 20/ m | TTP | 224 | TTP |
#10 | 60/f | TTP | 175,4 | TTP |
#11 | 59/f | TTP | 144.9 | TTP |
#13 | 49/f | HUS, Cancer, TTP | 142.8 | TTP |
#42 | 27/ m | TTP | 341.5 | TTP |
#46 | 25/f | TTP, Degos, SLE | 225.11 | TTP |
#48 | 53/f | TTP, SLE, nephritis s/p rénal transplan t | 788,5 | aHUS |
#49 | 64/f | TTP, APLAs, CVA | 494,5 | |
#51 | 25/f | aHUS, APLAs | 313.1 | TTP |
#52 | 56/f | aHUS, SLE | 333.1 | TTP |
#53 | 56/f | aHUS | 189.9 | Remissio |
C5a | sC5b9 | ADAM S Activity | Diagnosis based on ADAMS activity | protection with OMS646 |
responder | ||||
36.9 | 1187 | <10% | TTP | responder |
49.5 | 4406 | 64% | aHUS | nonresponder |
40,3 | 1352 | <10% | TTP | nonresponder |
48.6 | 3843 | 86% | aHUS | nonresponder |
100.0 | 5332 | <5% | TTP | nonresponder |
53.9 | 3426 | ND | ND | responder |
31.2 | 1066 | 66% | aHUS | responder |
35.4 | 2100 | ND | ND | responder |
26.8 | 1595 | 23% | aHUS | responder |
18.9 | 1103 | 97% | aHUS | nonresponder |
28.69 | 344 | 74% | aHUS | non- |
263
Subject # | Age/ Sex | Clinical Diagnosis (TMA) . and other conditions | MASP-2 ng/ml | Diagnosis based on Cre/LDH | C5a | sC5- b9 | ADAM S Activity | Diagnosis based on ADAMS activity | protection with OMS646 |
remission | nTT'P | responder |
Abbreviations used in Table 25:
“APLAs” = antiphospholipid antibodies, associated with Catastrophic antiphospholipid syndrome (CAPS).
“S LE” = systemic lupus erythematosus “CVA” = cerebrovascular accident (stroke)
Consistent with the results reported in Stefanescu R. et al., Blood Vol 112 (2):340349, 2008, significant apoptosis was observed for primary MVECs of dermal origin in the presence of the thirteen TMA patient plasma samples in the absence of MASP-2 antibody. Control plasma samples from healthy human subjects were run in parallel and did not induce apoptosis in the MVECs (data not shown). As shown in Table 25, the MASP-2 inhibitory mAb (OMS646) inhibited TMA patient plasma-mediated induction of apoptosis in primary MVECs (“responders” in Table 25) in 6 of the 13 patient plasma samples tested (46%). In particular, it is noted that MASP-2 inhibitory mAb (OMS646) inhibited apoptosis in plasma obtained from patients suffering from aHUS, TTP, Degos disease, S LE, transplant, and APLAs (CAPS). With regard to the seven patient samples tested in this assay in which the MASP-2 mAb did not block apoptosis (“non-responders” in Table 25), it is noted that apoptosis can be induced by several pathways, not ail of which are complément dépendent. For example, as noted in Stefanescu R. et al., Blood Vol 112 (2):340-349, 2008, apoptosis in an EC assay is dépendent on the basal EC activation State which is influenced by plasma factors which may play a rôle in determining the level of insult required to induce apoptosis. As further noted in Stefanescu R. et al., additional factors capable of modulating apoptosis may be présent in the TMA patient plasma, such as cytokines and varions components of the complément System. Therefore, due to these complicating factors, it is not surprising that the MASP-2
264 antibody did not show a blocking effect in ail of the plasma samples that exhibited TMAplasma induced apoptosis.
Further in this regard, it is noted that a similar analysis was carried out using TMA-plasma induced apoptosis assay with the anti-C5 antibody eculizumab and very similar results were observed (see Chapin et al., Blood (ASH Annual Meeting Abstracts): Abstract #3342, 120: 2012). Clinical efficacy of eculizumab, a highly successful commercial product, appears greater than the efficacy demonstrated in this model, suggesting that this in vitro model may underestimate the clinical potential of complément inhibitory drugs.
These results demonstrate that a MASP-2 inhibitory antibody such as OMS646 is effective at inhibiting TMA-plasma-induced apoptosis in plasma obtained from patients suffering from a TMA such as aHUS, TTP, Degos disease, SLE, transplant, and APLAs (CAPS). It is known that endothélial damage and apoptosis play a key rôle in the pathology of TMAs such as idiopathic TTP and sporadic HUS (Kim et al., Microvascular Research vol 62(2):83-93, 2001). As described in Dang et al., apoptosis was demonstrated in the splenic red pulp of TTP patients but not in healthy control subjects (Dang et al., Blood 93(4):1264-1270,1999). Evidence of apoptosis has also been observed in rénal glomerular cells of MVEC origin in an HUS patient (Arends M. J. et al., Hum Pathol 20:89, 1989). Therefore, it is expected that administration of a MASP-2 inhibitory agent, such as a MASP-2 inhibitory antibody (e.g., OMS646) will be an effective therapy in patients suffering from a TMA such as aHUS, TTPor other microangiopathic disorder such as other TMAs including CAPS, systemic Degos disease, and a TMA secondary to cancer; a TMA secondary to chemotherapy, or a TMA secondary to transplantation.
In accordance with the foregoing, in one embodiment, the invention provides a method of inhibiting endothélial cell damage and/or endothélial cell apoptosis, and/or thrombus formation in a subject suffering from, or at risk for developing, a thrombotic microangiopathy (TMA) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2dependent complément activation. In one embodiment, the TMA is selected from the group consisting of atypical hemolytic urémie syndrome (aHUS), thrombotic thrombocytopénie purpura (TTP) and hemolytic urémie syndrome (HUS). hr one
265 embodiment, the TMA is aHUS. In one embodiment, the composition is administered to an aHUS patient during the acute phase of the disease. In one embodiment, the composition is administered to an aHUS patient during the remission phase (i.e., in a subject that has recovered or partially recovered from an épisode of acute phase aHUS, such rémission evidenced, for example, b y increased platelet count and/or reduced sérum LDH concentrations, for example as described in Loirat C et al., Orphanet Journal of Rare Diseases 6:60, 2011, hereby incorporated herein by reference).
In one embodiment, the subject is suffering from, or at risk for developing a TMA that is (i) a TMA secondary to cancer; (ii) a TMA secondary to chemotherapy; or (iii) a TMA secondary to transplantation (e.g., organ transplantation, such as kidney transplantation or allogeneic hematopoietic stem cell transplantation). In one embodiment, the subject is suffering from, or at risk for developing Upshaw-Schulman Syndrome (USS). In one embodiment, the subject is suffering from, or at risk for developing Degos disease. In one embodiment, the subject is suffering from, or at risk for developing Catastrophic Antiphospholipid Syndrome (CAPS).
In accordance with any of the disclosed embodiments herein, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a Kp of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5Q of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC5Q of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation, and/or wherein the antibody does not substantially inhibit the classical pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the alternative pathway. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the classical pathway (i.e., inhibits the lectin pathway while leaving the classical complément pathway intact).
266
In one embodiment, the MASP-2 inhibitory antibody inhibits plasma induced MVEC apoptosis in sérum from a subject suffering from a TMA such as aHUS (acute or rémission phase), hemolytic urémie syndrome (HUS), thrombotic thrombocytopénie purpura (TTP), a TMA secondary to cancer; a TMA secondary to chemotherapy; a TMA 5 secondary to transplantation (e.g., organ transplantation, such as kidney transplantation or allogeneîc hematopoietic stem cell transplantation), or in sérum from a subject suffering from Upshaw-Schulman Syndrome (USS), or in sérum from a subject suffering from Degos disease, or in a subject suffering from Catastrophic Antiphospholipid Syndrome (CAPS), wherein the plasma induced MVEC apoptosis is inhibited by at least 5%, such as 10 at least 10%, such as at least 20%, such as at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, such as at least 80% such as at least 85%, such as at least 90%, such as at least 95% up to 99%, as compared to untreated sérum. In some embodiments, the MASP-2 inhibitory antibody inhibits thrombus formation in sérum from a subject suffering from a TMA (e.g., such as aHUS (acute or 15 remission phase), hemolytic urémie syndrome (HUS), thrombotic thrombocytopénie purpura (TTP), a TMA secondary to cancer; a TMA secondary to chemotherapy; a TMA secondary to transplantation (e.g., organ transplantation, such as kidney transplantation or allogeneîc hematopoietic stem cell transplantation), or in sérum from a subject suffering from Upshaw-Schulman Syndrome (USS), or in sérum from a subject suffering from 20 Degos disease, or in a subject suffering from Catastrophic Antiphospholipid Syndrome (CAPS)), at a level of at least 20 percent or greater, (such as at least 30%, at least 40%, at least 50%) more than the inhibitory effect on C5b~9 déposition in sérum.
In one embodiment, the MASP-2 inhibitory antibody is administered to the subject via an intravenous cathéter or other cathéter delivery method.
In one embodiment, the invention provides a method of inhibiting thrombus formation in a subject suffering from a TMA (such as aHUS (acute or remission phase), hemolytic urémie syndrome (HUS), thrombotic thrombocytopénie purpura (TTP), a TMA secondary to cancer; a TMA secondary to chemotherapy; a TMA secondary to transplantation (e.g., organ transplantation, such as kidney transplantation or allogeneîc 30 hematopoietic stem cell transplantation), or in sérum from a subject suffering from Upshaw-Schulman Syndrome (USS), or in sérum from a subject suffering from Degos disease, or in a subject suffering from Catastrophic Antiphospholipid Syndrome (CAPS)),
267 comprising administering to the subject a composition comprising an amount of a MASP2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavychain variable région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the 5 amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-102 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDR-L1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the 10 amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 15 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In one embodiment, the subject is suffering from a TMA selected from the group consisting of a TMA secondary to cancer; a TMA secondary to chemotherapy; a TMA secondary to transplantation (e.g., organ transplantation, such as kidney transplantation or allogeneic hematopoietic stem cell transplantation), Upshaw-Schulman Syndrome (USS), 20 Degos disease, and Catastrophic Antiphospholipid Syndrome (CAPS).
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67. In some embodiments, the method comprises 25 administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment 30 thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by référencé antibody OMS646 comprising a heavy-chain variable région as
268 set forth m SEQ ID NO: 67 and a light-chain variable région as set forth in SEQ ID NO:70.
EXAMPLE 44
This Example describes the initial results of an ongoing Phase 2 Clinical Trial to Evaluate the Safety and Clinical Efficacy of a fully human monoclonal MASP-2 inhibitory antibody in Adults with Thrombotic Microangiopathies (TMAs).
Background: TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thiOmbi (clots) - aggregations of platelets — in the microcirculation of the body’s organs, most commonly the kidney and brain.
Methods:
The first stage of an open-label Phase 2 clinical trial was carried out in subjects with primary atypical hemolytic urémie syndrome (aHUS), plasma therapy-resistant aHUS and thrombotic thrombocytopénie purpura (TTP). This Phase 2 clinical trial has no placebo arm given the life-threatening nature of the disease.
The subjects were âge >18 at screening and were only included in this study if they had a dîagnosis of one of the following TMAs:
Primary aHUS, diagnosed clinically and having ADAMTS13 activity > 10% in plasma. Patients are eligible with or without a documented complément mutation or anti-CFH antibody. Patients are categorized according to their response to plasma therapy (plasma exchange or plasma infusion):
o Plasma therapy-resistant aHUS patients, for purposes of this study, meet ail of the following:
(a) screening platelet count < 150,000/pL despite at least four plasma therapy treatments prior to screening;
(b) evidence of microangiopathic hemolysis (presence of schistocytes, sérum lactate dehydrogenase (LDH) > upper lirait of normal (ULN), haptoglobin < LLN); and (c) sérum créatinine > ULN.
o Chrome plasma therapy-responsive aHUS patients (plasma therapysensitive) must require at least once-per-week plasma therapy for four weeks before first dose of OMS646 with sérum créatinine > ULN.
i i
i
I
I i
269
2) TTP defined as having ail of the following:
o Platelet count < 150,000/pL:
o Evidence of microangiopathic hemolysis (presence of schistocytes, sérum LDH > ULN, or haptoglobin < LLN); and o ADAMTS13 activity < 10% during the current épisode of TTP or historically.
Note: Subjects were excluded from the study if they had eculizumab therapy within three months prior to screening. The criteria for a patient qualîfyîng as plasma therapyrésistant were for purposes of determining eligibility in this study. In further aspects of the invention, a plasma therapy-resistant patient to be treated with a MASP-2 inhibitor was previously treated with plasma therapy at least once and after such plasma therapy treatment still had one or more clinical markers of aHUS that were not adequately reduced or eliminated b y such plasma therapy treatment.
The monoclonal antibody used in this study, OMS646, is a fully human IgG4 mAb directed against human MASP-2. As demonstrated in Example 40, OMS646 avidly binds to recombinant MASP-2 (apparent equilibrium dissociation constant in the range of 100 pM) and exhibits greater than 5,000-fold selectivity over the homologous proteins Cl s, Clr, and MASP-1. In functional assays, OMS646 inhibits the human lectin pathway with nanomolar potency (concentration leading to 50% inhibition [IC50] of approximately 3 nM) but has no significant effect on the classical pathway. OMS646 administered either by intravenous (IV) or subeutaneous (SC) injection to mice, non-human primates, and humans resulted in high plasma concentrations that were associated with suppression of lectin pathway activation in an ex vivo assay. As further described in Example 42, OMS646 treatment reduced C5b-9 déposition and thrombus formation in in vitro models of TMA and thrombus formation in a mouse model of TMA, thus demonstrating that OMS646 has therapeutic utility.
In this study, the OMS646 drug substance was provided at a concentration of 100 mg/mL, which was further diluted for IV administration. The appropriate calculated volume of OMS646 100 mg/mL injection solution was withdrawn from the vial using a
270 syringe for dose préparation. The infusion bag was adminîstered within four hours of préparation.
In Stage 1 of the study, OMS646 was adminîstered to escalating dose cohorts of three subjects per cohort. Each subject in Stage 1 received four weekly doses of OMS646 5 as shown below in TABLE 26.
TABLE 26: Dosing Schedule For Stage 1
Stage, Cohort | Number of | |
Subjects | OMS646 Dose (mg/kg) | |
1, Cohort 1 | 3 | 0.675, weekly x 4 |
1, Cohort 2 | 3 | 2.0, weekly x 4 |
1, Cohort 3 | 3 | 4.0, weekly x 4 |
Stage 1 Study Design Schematic
Treatment Period
The diluted study drug was infused intravenously over a 30-minute period.
Primary End points
The co-primary endpoints were:
Safety as assessed by AEs, vital signs, ECGs, and clinical laboratory tests
271 • Clinical activity as assessed by change in platelet count
Secondary Endpoints
The secondary endpoints were:
• TMA clinical activity o Sérum LDH o Sérum haptoglobin o Hemoglobîn o Sérum créatinine o TMA-related symptoms o Need for plasma therapy (plasma exchange or plasma infusion) o Need for dialysis
Allowed Concomitant Thérapies • Plasma therapy-resistant aHUS - plasma therapy during OMS646 treatment was allowed if the investigator considered it to be medically indicated.
• Chronic plasma therapy-responsive aHUS - investigators were advised that plasma therapy should be continued untîl there was a sign of improvement in TMA, e.g., increase in platelet count, decrease in LDH, increase in haptoglobin, increase in hemoglobîn, decrease in créatinine, at which time the investigator was advised to consider withholding plasma therapy and monitoring TMA parameters to assess whether plasma therapy can be discontinued.
• TTP - plasma therapy was allowed if the investigator considered it to be medically indicated.
• Investigators were advised that rénal dialysis therapy should be managed according to standard of care.
• Eculizumab was not administered during the study.
272
Results:
The first cohort of subjects consisted of three aHUS patients treated with the lowest dose of OMS646. Improvements were observed across TMA disease markers in ail patients m this study cohort. Platelet count, sérum lactate dehydrogenase (LDH) and sérum haptoglobîn were measured as markers of disease activity. When compared to baseline levels, platelet counts improved in ail patients. Sérum LDH levels remained normal in one patient, substantially decreased to close to the normal range in another and remained elevated in the tliird. Haptoglobîn improved in two patients, normalizing in one. Créatinine levels in the one patient with independent rénal function also improved.
As designed, three patients were treated in the second, mid-dose cohort of this clinical trial. Two patients hâve plasma therapy-resistant aHUS and one patient has thrombotic thrombocytopénie purpura (TTP). Both patients with aHUS were on rénal dialysis prior to and at the time of study enrollment. In the second or mid-dose cohort, the two patients with plasma therapy-resistant aHUS demonstrated:
• 47% increase in mean platelet count, resulting in both patients having counts in the normal range • 86% decrease in mean schiztocyte count, with schistocytes disappearing in one patient • 71% increase in mean haptoglobîn with both patients reaching the normal range during treatment, one slipping slightly below normal at one week following the last dose • 5% decrease in the mean levels of LDH, with levels in both patients remainîng slightly elevated above normal range.
The mid-dose-cohort patient with TTP required repeated plasma infusion therapy prior to entering the study. Laboratory parameters did not show consistent improvement, but the patient did not require plasma therapy while on treatment with OMS646, nor, to date, since completion of treatment.
The drug was well tolerated by ail patients throughout the treatment period. Based on the positive data from the second or mid-dose cohort, the third or high-dose cohort was initiated and an aHUS patient has already completed the study treatment
273 period. The data referenced for ail patients include measures to one week following the last dose.
The first patient in the third (high-dose) cohort - a plasma therapy-resistant aHUS patient with additional complicating disorders including hepatitis C, cryoglobulinemia and lymphoma - has also completed treatment with OMS646. Prior to OMS646 treatment, the patient required repeated dialysis. Throughout treatment and following completion of the OMS646 course, to date the patient has remained off dialysis. Hematological and rénal parameters showed:
• 63% improvement in platelet count, returning to normal levels • 100% decrease in shistocytes • Haptoglobin increased from an undetectable level and normalized • 43% decrease in LDH, resulting in a level just slightly above normal • 24% réduction in créatinine level
As in the first and second cohorts, the drug was well tolerated.
The primary endpoint in this open-label Phase 2 clinical trial is change in platelet count. Platelet counts in ail three aHUS patients in the mid- and high-dose cohorts (two in the mid-dose and one in the high-dose cohort) retumed to normal, with a statistically significant mean increase from baseline of approximately 68,000 platelets/mL (p=0.0055).
In summary, the data obtained so far from this Phase 2 clinical trial show efficacy of OMS646 in patients with primary aHUS, plasma-therapy résistant aHUS and in patients with TTP.
In accordance with the foregoing, in one embodiment, the invention provides a method of treating a subject suffering from plasma therapy-resistant aHUS comprising administerîng to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complément activation. In some embodiments, the method further comprises the step of identifying a subject suffering from plasma therapy-resistant aHUS prior to administerîng to the subject a composition comprising a MASP-2 inhibitory antibody.
274
In accordance with any of the disclosed embodiments herein, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a KD of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5Q of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC5Q of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein tire IgG4 molécule comprises a S228P mutation. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the classical pathway (i.e., inhibits the lectin pathway while leaving the classical complément pathway intact).
In one embodiment, the MASP-2 inhibitory antibody is administered in an amount effective to improve at least one or more clinical parameters associated with aHUS such as an increase in platelet count, a decrease in LDH, an increase in haptoglobin, an increase in hemoglobin, and/or a decrease in créatinine.
In some embodiments, the method comprises administering a MASP-2 inhibitory antibody to a subject suffering from plasma therapy-resistant aHUS via a cathéter (e.g., intravenously) for a first time period (e.g., at least one day to a week or two weeks) followed by administering a MASP-2 inhibitory antibody to the subject subcutaneously for a second time period (e.g., a chronîc phase of at least two weeks or longer). In some embodiments, the administration in the first and/or second time period occurs in the absence of plasma therapy. In some embodiments, the administration in the first and/or second time period occurs in the presence of plasma therapy.
In some embodiments, the method comprises administering a MASP-2 inhibitory antibody, to a subject suffering from plasma therapy-resistant aHUS either intravenously, intramuscularly, or preferably, subcutaneously. Treatment may be chronic and administered daily to monthly, but preferably every two weeks. The MASP-2 inhibitory antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
275
In one embodiment, the method comprises treating a subject suffering from plasma therapy-resistant aHUS comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavy-chain
CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65 of SEQ ID >
NO:67; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-107 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDRL1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and ii) a light10 chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID N0:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ
1.5 ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67 and a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by référencé antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
I i i
EXAMPLE 45 |
This Example describes additional results obtained in the ongoing Phase 2 i
Clinical trial to evaluate the Safety and Clinical Efficacy of a fully human monoclonal
276
MASP-2 inhibitory antibody in Adults with Thrombotic Microangiopathies (TMAs) described in Example 44.
Background: As described in Example 44, TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) - aggregations 5 of platelets - in the microcirculation of the body’s organs, most commonly the kidney and brain. As described herein, transplantation-associated TMA (TA-TMA) is a devastating syndrome that can occur in transplant patients, such as hematopoietic stem cell transplant (HSCT) récipients. This Example describes the initial results of the Phase 2 Clinical trial 10 to evaluate the safety and clinical efficacy of a fully human monoclonal MASP-2 inhibitory antibody in a patient suffering from hematopoietic stem cell transplant-related TMA.
Methods:
As described in Example 44, the Phase 2 TMA trial consista of a three-level dose15 ranging stage, followed by a fixed-dose stage of the MASP-2 inhibitory antibody OMS646. As further described in Example 44, positive results were obtained from aHUS patents and one TTP patient, with consistent and robust improvement in efficacy measures. As in the low-dose cohort, OMS646 was well tolerated by ail patients in the mid- and high-dose cohorts throughout the treatment period. Preclinical toxicity studîes 20 hâve been completed and demonstrated no safety concems, allowing chronic dosing in clinical trials.
As described in Example 44, data from the OMS646 Phase 2 TMA clinical trial were obtained from aHUS and TTP patients. Dosing has now been completed for an additional hematopoietic stem cell transplant-related TMA patient in the high-dose cohort 25 using the methods described in Example 44. This is a patient with a history of lymphoma for which he undcrwent hematopoietic stem cell transplant. His post-transplant course has been complicated by a number of life-threatening disorders, including platelet transfusion-requiring TMA. Despite transfusions, his stem cell transplant-related TMA persisted and he was enrolled in the OMS646 Phase 2 Trial.
Results:
Following the four-week dosing period (high-dose cohort) as described in Example 44, the patient with stem cell transplant-related TMA demonstrated:
277 • Platelet count quadrupled, resulting in a platelet count of more than 100,000;
• Haptoglobin level more than doubled and was normal;
• Plasma lactate dehydrogenase level, a measure of damage within blood vessels, decreased by 35% but was still above normal;
• Shistocyte count remained at only one.
Throughout dosing with OMS646 and since completing OMS646 treatment, the patient has not requîred any platelet transfusions or plasmapheresis.
In summary, the data obtained so far from this Phase 2 clinical trial (as described in Example 44 and in this Example) show efficacy of OMS646 in patients with primary aHUS, plasma-therapy résistant aHUS, TTP and in a patient with TMA associated with hematopoietic stem cell transplant.
In accordance with the foregoing, in one embodiment, the invention provides a method of treating a human subject suffering from a TMA associated with hematopoietic stem cell transplant comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complément activation. In one embodiment, the subject is suffering from a TMA associated with hematopoietic stem cell transplant that is résistant to treatment with platelet transfusions and/or plasmapheresis. In one embodiment, the method further comprises identifying a human subject suffering from a TMA associated with hematopoietic stem cell transplant that is résistant to treatment with platelet transfusions and/or plasmapheresis prior to the step of administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2dependent complément activation.
In accordance with any of the disclosed embodiments herein, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a KD of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5Q of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC5q of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and
Ο
278
F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not 5 substantially inhibit the classical pathway (i.e., inhibits the lectin pathway while leaving the classical complément pathway intact).
In one embodiment, the MASP-2 inhibitory antibody is administered in an amount effective to improve at least one or more clinical parameters associated with TMA associated with hematopoietic stem cell transplant, such as an increase in platelet count 10 (e.g., at least double, at least triple, at least quadruple the platelet count prior to treatment), an increase in haptoglobin, and/or a decrease in lactate dehydrogenase.
In some embodiments, the method comprises administering a MASP-2 inhibitory antibody to a subject suffering from TMA associated with hematopoietic stem cell transplant via a cathéter (e.g., intravenously) for a first time period (e.g., at least one day 15 to a week or two weeks) followed by administering a MASP-2 inhibitory antibody to the subject subcutaneously for a second time period (e.g., a chronic phase of at least two weeks or longer). In some embodiments, the administration in the first and/or second time period occurs in the absence of plasma therapy. In some embodiments, the administration in the first and/or second time period occurs in the presence of plasma 20 therapy.
In some embodiments, the method comprises administering a MASP-2 inhibitory antibody to a subject suffering from TMA associated with hematopoietic stem cell transplant either intravenously, intramuscularly, or preferably, subcutaneously. Treatment may be chronic and administered daily to monthly, but preferably every two 25 weeks. The MASP-2 inhibitory antibody may be administered alone, or in combination with a C5 inhibitor, such as eculizamab.
In one embodiment, the method comprises treating a subject suffering from TMA associated with hematopoietic stem cell transplant comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen 30 binding fragment thereof, comprising (I) (a) a heavy-chain variable région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO:67; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence from 50-65
279 of SEQ ID NO:67; and ni) a heavy-chain CDR-H3 comprising the amino acid sequence from 95-107 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a lightchain CDR-L1 comprising the amino acid sequence from 24-34 of SEQ ID NO:70; and iî) a light-chain CDR-L2 comprising the amino acid sequence from 50-56 of SEQ ID NO:70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67 and a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by reference antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
EXAMPLE 46
This Example describes additional results obtained in the ongoing Phase 2 Clinical trial to evaluate the Safety and Clinical Efficacy of a fully human monoclonal MASP-2 inhibitory antibody in adults with Thrombotic Microangiopathies (TMAs) described in Examples 44 and 45.
Background: As described in Example 45, transplantation-associated TMA (TATMA) is a devastating syndrome that can occur in transplant patients, such as hematopoietic stem cell transplant (HSCT) récipients. Hematopoietic stem cell transplant-associated TMA (HSCT-TMA) is a life-threatening complication that is
Ο
280 triggered by endothélial injury. The kidney is the most commonly affected organ, though HSCT-TMA can be a multi-system disease that also involves the lung, bowel, heart and brain. The occurrence of even mild TMA is associated with long-term rénal impairment. Development of post-allogeneic HSCT-associated TMA differs in frequency based on 5 varying diagnostic criteria and conditioning and graft-versus-host disease prophylaxis regimens, with calcineurin inhibitors being the most frequent drugs implicated (Ho VT et al., Biol Blood Marrow Transplant, 11(8):571-5, 2005). Modification of the immunosuppressive calcineurin inhibitor regimen may resuit in improvement of the TMA in some patients within a few weeks of the réduction or discontinuation of calcineurin 10 inhibitor administration.
TMA is a potentially life-threatening complication of HSCT and is currently managed largely by amelioration of inciting factors including avoidance of immunosuppressive agents (e.g., calcineurin inhibitors) and treatment of ongoing infections, as well as suppoitive measures such as hemodialysis. Although many HSCT15 TMA patients respond well to réduction or discontinuation of immunosuppressive agents, there is a subset of patients that hâve persistent HSCT-TMA despite conservative treatment measures (i.e., the TMA did not respond to réduction or discontinuation of immunosuppressives). Patients who do not respond to these conservative treatment measures hâve poor prognosis. Plasma exchange has not shown efficacy and no other 20 therapy is approved.
Example 45 describes the initial positive results of the Phase 2 Clinical trial to evaluate the safety and clinical efficacy of a fully human monoclonal MASP-2 inhibitory antibody (OMS646) in a patient suffering from persistent hematopoietic stem cell transplant-related TMA (HSCT-TMA). This Example describes additional results of the 25 ongoing Phase 2 Clinical trial to evaluate the safety and clinical efficacy of OMS646 in three additional subjects suffering from persistent HSCT-TMA résistant to conservative treatment measures.
Methods:
As described in Example 44, the Phase 2 TMA trial consists of a three-level dose30 ranging stage, followed by a fixed-dose stage of the MASP-2 inhibitory antibody OMS646. OMS646 was well tolerated by ail patients in the low, mid and high-dose
281 cohorts throughout the treatment period. Preclinical toxicity studies hâve been completed and demonstrated no safety concems, allowing chronic dosing in clinical trials.
The Phase 2 TMA trial üicludes subjects suffering from persistent HSCTassociated TMA résistant to conservative treatment measures, which is defined, for the purposes of this study, as having ail of the following at least two weeks following réduction or discontinuation of immunosuppression agent (e.g., calcineurin inhibitor treatment) or at least 30 days after transplant:
- Thrombocytopenia (Platelet count < 150,000/pL); and
- Evidence of microangiopathic hemolytic anémia (presence of schistocytes, sérum lactate dehydro gênas e (LDH) > upper limit of normal (ULN), or haptoglobin < lower limit of normal (LLN).
Allowed Concomitant Thérapies for HSCT-associated TMA • Plasma therapy during OMS646 treatment is allowed if the investigator considers it medically indicated. Patients given plasma therapy could receive additional half doses of OMS646.
• Investigators were advised that rénal dialysis therapy should be managed according to standard of care.
• Eculizumab was not administered during the study.
The ongoing TMA study includes subjects suffering from persistent HSCT-TMA that is résistant to standard treatment measures (i.e., persistent TMA at least two weeks after réduction or discontinuation of calcineurin inhibitor treatment).
As described in Example 45, dosing was completed for a patient suffering from persistent HSCT-TMA (patient #1) in the high dose cohort (4 mg/kg OMS646 administered IV once a week for four weeks) using the methods described in Example 44.
Dosing has now been completed for an additional 4 patients suffering from persistent HSCT-TMA, as described below.
Patient #1 (described in Example 44) was treated for four weeks with OMS646 (4mg/kg IV once weekly);
282
Patients #2 and #3 were treated for eight weeks with OMS646 (4mg/kg IV once weekly);
Patients #4 and #5 were treated with OMS646 (4mg/kg IV once weekly) for two and three weeks, respectively. Patients #4 and #5 withdrew from the study after two and 5 three weeks, respectively, did not respond to treatment and deteriorated. It is noted that one of these patients had markedly elevated créatinine at the time of study admission.
Results:
Five patients with persistent HSCT-TMA were emolled in this study. Ail subjects 10 were adults and received HSCT for hematological malignancies. FIGURES 58, 59 and 60 provide the change from baseline in TMA variables after treatment with MASP-2 inhibitory antibody OMS646. These figures provide data on ail five patients, two of whom discontinued the study after 2-3 weeks, with one subsequently relapsing and the other receiving palliative care. As noted in FIGURES 58, 59 and 60, the last possible 15 treatment given occurred at week 7.
FIGURE 58 graphically illustrâtes the mean change in platelet count from baseline over time (weeks) in subjects suffering from persistent hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) after treatment with MASP-2 inhibitory antibody (OMS646).
FIGURE 59 graphically illustrâtes the mean change in LDH from baseline over time (weeks) in subjects suffering from persistent (HSCT-TMA) after treatment with MASP-2 inhibitory antibody (OMS646).
FIGURE 60 graphically illustrâtes the mean change in haptoglobin from baseline over time (weeks) in subjects suffering from persistent (HSCT-TMA) after treatment with 25 MASP-2 inhibitory antibody (OMS646).
As shown in FIGURES 59 and 60, statistically significant improvement in LDH and haptoglobin were observed during treatment. As shown in FIGURE 58, platelet count improved but did not reach statistical significance in this small number of patients. Of the three patients who completed treatment, one did not show improvement in 30 créatinine but was receiving concomitant nephrotoxic agents. Créatinine improved or remained normal in the other two patients. On extended follow up, one patient
283 experienced graft failure and is awaiting a second transplant. The other two patients remain stable.
Despite potentially confounding effects of médications associated with bone marrow suppression and nephrotoxicity in two of the subjects, bénéficiai treatment effects 5 with OMS646 were observed in three of the subjects suffering from persistent HSCTTMA (one of which is described in Example 45) and further described below. Notably, treatment effects in each of the three responders were initially seen after approximately three weeks of treatment with OMS646.
Patient #1 (treated for 4 weeks as described in Example 45). Briefly summarized, 10 the platelet count quadrupled, resulting in a platelet count of more than 100,000/pL; the haptoglobin level more than doubled and was normal; the plasma lactate dehydrogenase level decreased by 35% but was still above normal; and the shistocyte count remained at only one.
Patient #2 (treated for 8 weeks): the platelet count did not respond to treatment, 15 although the patient also suffered from marrow suppression secondary to concurrent treatment with valganciclovi and later graft failure; the plasma lactate dehydrogenase level decreased from 712 U/L to as low as 256 U/L; the haptoglobin level increased from undetectable levels to as high as 250 mg/dL.
Patient #3 (treated for 8 weeks): the platelet count increased from 13,500/pL to 20 133,000/pL; the plasma lactate dehydrogenase level decreased from 537 to 225 U/L, the haptoglobin level increased from undetectable levels to as high as 181 mg/dL.
Summary of Results:
For the three patients suffering from persistent HSCT-associated TMA who completed dosing with OMS646, the data demonstrate a strong and consistent efficacy 25 signal. Statistically signifïcant improvements in LDH and haptoglobin were observed during treatment. Platelet counts improved but did not reach statistical significance in this small number of patients. Of the three patients who completed treatment, one did not show an improvement in créatinine but was receiving concomitant nephrotoxic agents. Créatinine improved or remained normal in the other two patients.
Conclusions:
OMS646 improved TMA markers in patients suffering from persistent HSCTTMA who had not responded to conservative treatment measures. The HSCT-TMA
284 patients treated with OMS646 represent some of the most difficult to treat, thereby demonstratîng clinical evidence of a therapeutic effect of OMS646 in patients with highrisk persistent HSCT-TMA despite conservative treatment measures.
In accordance with the foregoing, in one embodiment, the invention provides a 5 method of treating a human subject suffering from a TMA associated with hematopoietic stem cell transplant comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complément activation. In one embodiment, the subject is suffering from persistent TMA associated with hematopoietic stem cell transplant that is résistant to conservative treatment measures. In one embodiment, the method further comprises identifying a human subject suffering from persistent TMA associated with hematopoietic stem cell transplant that is résistant to conservative treatment measures prior to the step of administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complément activation.
In accordance with any of the disclosed embodiments herein, the MASP-2 inhibitory antibody exhibits at least one or more of the following characteristics: said antibody binds human MASP-2 with a KD of 10 nM or less, said antibody binds an epitope in the CCP1 domain of MASP-2, said antibody inhibits C3b déposition in an in vitro assay in 1% human sérum at an IC5() of 10 nM or less, said antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM or less, wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab', F(ab)2 and F(ab')2 wherein the antibody is a single-chain molécule, wherein said antibody is an IgG2 molécule, wherein said antibody is an IgGl molécule, wherein said antibody is an IgG4 molécule, wherein the IgG4 molécule comprises a S228P mutation. In one embodiment, the antibody binds to MASP-2 and selectively inhibits the lectin pathway and does not substantially inhibit the classical pathway (i.e., inhibits the lectin pathway while leaving the classical complément pathway intact).
In one embodiment, the MASP-2 inhibitory antibody is administered in an amount effective to improve at least one or more clinical parameters associated with TMA 30 associated with hematopoietic stem cell transplant, such as an increase in platelet count
Ο ' 285 (e.g., at least double, at least triple, at least quadruple the platelet count prior to treatment), an increase in haptoglobin, and/or a decrease in lactate dehydrogenase.
In some embodiments, the method comprises administering a MASP-2 inhibitory antibody to a subject suffering from TMA associated with hematopoietic stem cell 5 transplant via a cathéter (e.g., intravenously) for a first time period (e.g., at least one day to a week or two weeks or three weeks or four weeks or longer) followed by administering a MASP-2 inhibitory antibody to the subject subcutaneously for a second time period (e.g., a chronic phase of at least two weeks or longer). In some embodiments, the administration in the first and/or second time period occurs in the absence of plasma therapy. In some embodiments, the administration in the first and/or second time period occurs in the presence of plasma therapy.
In some embodiments, the method comprises administering a MASP-2 inhibitory antibody to a subject suffering from TMA associated with hematopoietic stem cell transplant either intravenously, intramuscularly, or subcutaneously. Treatment may be 15 chronic and adminîstered daily to monthly, but preferably every at least every two weeks, or at least once a week, such as twice a week or three times a week. The MASP-2 inhibitory antibody may be adminîstered alone, or in combination with a C5 inhibitor, such as eculizamab.
In one embodiment, the method comprises treating a subject suffering from persistent TMA associated with hematopoietic stem cell transplant comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding fragment thereof, comprising a heavy chain variable région comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable région comprising CDR-L1, CDR-L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO:70. In some embodiments, the composition comprises a MASP-2 inhibitory antibody comprising (a) a heavy-chain variable région comprising: i) a heavy-chain CDR-H1 comprising the amino acid sequence from 31-35 of SEQ ID NO: 67; and ii) a heavy-chain CDR-H2 comprising the i .I amino acid sequence from 50-65 of SEQ ID NO:67; and iii) a heavy-chain CDR-H3!
comprising the amino acid sequence from 95-107 of SEQ ID NO:67 and b) a light-chain variable région comprising: i) a light-chain CDR-L1 comprising the amino acid sequence| from 24-34 of SEQ ID NO:70; and ii) a light-chain CDR-L2 comprising the amino acid
286 sequence from 50-56 of SEQ ID NO;70; and iii) a light-chain CDR-L3 comprising the amino acid sequence from 89-97 of SEQ ID NO:70, or (II) a variant thereof comprising a heavy-chain variable région with at least 90% identity to SEQ ID NO:67 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at 5 least 98%, at least 99% identity to SEQ ID NO:67) and a light-chain variable région with at least 90% identity (e.g,, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identity to SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen binding 10 fragment thereof, comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67 and a light-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:70.
In some embodiments, the method comprises administering to the subject a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment 15 thereof, that specifically recognizes at least part of an epitope on human MASP-2 recognized by reference antibody OMS646 comprising a heavy-chain variable région as set forth in SEQ ID NO:67 and a light-chain variable région as set forth in SEQ ID NO:70.
In some embodiments, the method comprises administering to a subject suffering 20 from, or at risk for developing TMA associated with HS CT, including a subject suffering from persistent TMA associated with hematopoietic stem cell transplant that is résistant to conservative treatment measures, a composition comprising a MASP-2 inhibitory antibody, or antigen binding fragment thereof comprising a heavy-chain variable région comprising the amino acid sequence set forth as SEQ ID NO:67 and a light-chain 25 variable région comprising the amino acid sequence set forth as SEQ ID NO:70 in a dosage from 1 mg/kg to 10 mg/kg (i.e., 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg or 10 mg/kg) at least once weekly (such as at least twice weekly or at least three times weekly) for a period of at least 3 weeks, or for at least 4 weeks, or for at least 5 weeks, or for at least 6 weeks, or for at least 7 weeks, or for at 30 least 8 weeks.
287
While illustrative embodiments hâve been illustrated and described, it will be appreciated that varions changes can be made therein without departing from the spirit and scope of the invention.
Claims (11)
- CLA1MSThe embodiments of the invention in which an exclusive property or privilège is claimed are defined as foliows:1. A composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dépendent complément activation for use in a method of treating a human subject suffering from persistent TMA associated with hematopoietic stem cell transplant (HSCT-TMA).
- 2. Use of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof in the manufacture of a composition for treating a human subject suffering from persistent TMA associated with hematopoietic stem cell transplant (HSCT-TMA), wherein the composition comprises an amount of the MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit MASP-2-dependent complément activation.
- 3. The composition for use of Claim 1 or the use of Claim 2, wherein the MASP-2 inhibitory antibody is a monoclonal antibody, or fragment thereof that specifically binds to human MASP-2.
- 4. The composition for use of Claim 1 or the use of Claim 2, wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody, and a human antibody.
- 5. The composition for use of Claim 1 or the use of Claim 2, wherein the MASP-2 inhibitory antibody does not substantially inhibit the classical pathway.
- 6. The composition for use of Claim 1 or the use of Claim 2, wherein the MASP-2 inhibitory antibody inhibits C3b déposition in 90% human sérum with an IC50 of 30 nM or less.
- 7. The composition for use of Claim 1 or the use of Claim 2, wherein the MASP-2 inhibitory antibody is delivered to the subject systemîcally.I289
- 8. The composition for use of Claim 1 or the use of Claim 2, wherein the subject has previously undergone, or is currently undergoing, treatment with a humanized anti-C5 antibody or antigen-binding fragment thereof.
- 9. The composition for use of Claim 1 or the use of Claim 2, wherein the MASP-2 5 inhibitory antibody or antigen-binding fragment thereof is for administration in an amount effective to improve at least one or more of the following clinical parameters associated with persistent TMA associated with hematopoietic stem cell transplant: (i) an increase in platelet count (e.g., at least double, at least triple, at least quadruple the platelet count prior to treatment)); (ii) an increase in haptoglobin; (iii) a decrease in 10 lactate dehydrogenase (LDH); and/or (iv) a decrease in créatinine.
- 10. The composition for use of Claim 1 or the use of Claim 2, wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof, comprises a heavy chain variable région comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable région comprising CDR-L1, CDR-
- 15 L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO:70.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/252,814 | 2015-11-09 | ||
US62/406,726 | 2016-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18664A true OA18664A (en) | 2019-04-08 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020203748B2 (en) | Methods for treating conditions associated with MASP-2 dependent complement activation | |
US11981749B2 (en) | Methods for treating conditions associated with MASP-2 dependent complement activation | |
US20240076409A1 (en) | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | |
US11896621B2 (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
US20240218080A1 (en) | Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant | |
OA18664A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
OA19494A (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant. | |
OA18663A (en) | Staged zone heating of hydrocarbons bearing materials |